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Natural products play an important role in drug discovery. Numerous life 
saving medicine and medical breakthrough have been associated and 
intrinsically linked to natural products. Today, half of the drugs approved for 
marketing are of natural origin or derived from natural products. Currently, 
less than 10% of world biodiversity has been explored for medicinal purposes. 
Many more biologically active compounds from nature have yet to be 
discovered and developed into useful drugs for the treatment of various 
diseases. In this thesis, the synthesis and biological evaluation of analogues of 
two natural products are presented. 
 
In Chapter 2, the synthesis and biological evaluation of phosphoglycolipid 
PGL1 analogues are described. The synthetic route towards PGL1 was 
successfully established and a library consisting of 21 analogues was prepared. 
The analogues were initially evaluated for their immunostimulation activity. 
However, no positive results were obtained. This could be due to various 
factors such as incorrect chiral centre of the glycerol moiety or incorrect fatty 
acid chains (length and branching). The analogues were then evaluated for 
their inhibition activity agains TNF- and IL-6 instead. Two of the analogues, 
PGL1j and PGL1s showed significant inhibition against IL-6. 
 
In Chapter 3, the synthesis of  andrographolide probes as well as Activity 
Based Protein Profiling (ABPP) of potential andrographolide targets are 
described. The probes were designed based on previous structure-activity 
viii 
 
relationship study and anti-inflammatory mechanism of andrographolide. 
Protein profiling and subsequent target validation confirmed p50 as the protein 
target in HepG2 cell. Pull down/LC-MS/MS analysis identified NAMPT as 
one of the potential targets in A549 cell. The fluorophore containing probes 
were successfully utilized in live cell imaging which produced fluorescent 
signal upon reacting with the targets. The imaging result were also consistent 
with the pull down and Western blot analysis. 
 
Finally, the synthesis and biological evaluation of andrographolide 
analogues for inhibition of NF-B are described in Chapter 4. The synthesis 
involved modification of the lactone ring of andrographolide. Biological 
evaluation revealed that one of the analogues, 4-7c showed a concentration-
dependent inhibition of NF-B in A549 cell.  
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CHAPTER 1. INTRODUCTION 
 
 
1.1   Overview 
Natural products play an important role in drug discovery. Numerous life 
saving medicines and medical breakthroughs have been associated and 
intrinsically linked to natural products. These compounds are particularly 
evident in the development of treatment for infectious diseases, cancers, 
hypercholesterolemia and immunological disorders.1  
 
 Humans have utilized natural products for medicinal purposes for 
thousands of years. The earliest records can be traced back to as early as 2900 
– 2600 BC,2 which documented the use of approximately 1000 plant-derived 
substances in Mesopotamia,3 In addition, ancient civilizations such as the 
Chinese, Egyptian, Indians, Greeks and Romans were reputed for their use of 
mostly plant based natural products for the treatment of various diseases and 
illneses.4 Natural products continue to inspire the development of therapeutic 
treatment today. This is demonstrated by number of approved anti-cancer 
drugs (Figure 1.1),5 From 1981 to 2010, up to 50% of the approved drugs were 
natural products or of natural product origin.  
 
Despite their abundance in nature, currently only less than 10% of the 
world’s biodiversity has been explored for their potential therapeutic 
applications.6 The nature pool thus presents many exciting opportunities for 





Figure 1.1.  Approved Anticancer Drugs, 1981 – 2010.5 (“B”: biological, 
usually large protein, “N”: natural product, “NB”: natural product “Botanical”, 
“ND”: derived from Natural product, usually semi-synthetic, “S”: totally 
synthetic drug, “S*”: made by total synthesis, natural product pharmacophore, 
“NM”: natural product mimic, “v”: vaccine. 
 
1.2   Definition, Classification and Sources of Natural Products 
There are different ways in which a natural product can be defined. The 
general definition of a natural product is a substance isolated from a living 
organism in nature. In the organic chemistry context, natural products are 
purified organic compounds, which are produced by the pathways of primary 
or secondary metabolism.7 For a medicinal chemist, natural product means 
secondary metabolites produced by a living organism.8 
 
Although there is no universal classification available due to the highly 
diverse structure, function and biosynthesis, natural products are generally 
categorized into the following classes: terpenoids and steroids, nonribosomal 
3 
 
polypeptides, alkaloids, enzyme cofactors, fatty acids and polyketides (Figure 
1.2).9 The following are the descriptions (Table 1.1)9 for the different classes 
of natural products:  
CLASS DESCRIPTION EXAMPLE 
Terpenoid a class of natural product, which 
contains isoprene (2-methyl-1,3-
butadiene) unit as the basic 
building block 
 
Steroid A modified terpenoid, which has 








synthesized by nonribosomal 
peptide synthetases without direct 
RNA transcription 
 
Alkaloids a class of natural product, which 






non-protein component of 
enzymes which is usually 
inorganic ions or small organic 
molecules 
  
Fatty Acids carboxylic acids that contain long 
hydrocarbon chain (saturated or 
unsaturated). 
  
Polyketides a class of natural product, which 




























































Figure 1.2.  Classification of Natural Products.9  
 
Natural products can be extracted from various sources including plants, 
microbes, marine species, venoms and toxins. An example of a clinically 
useful drug derived from plants is paclitaxel (Figure 1.3). It was isolated from 
the Pacific yew tree Taxus brevifolia in 1971 by Wall and Wani.10 This 
anticancer compound was subsequently developed commercially by Bristol-
Myers Squibb (BMS) and sold under the trademark name Taxol. Paclitaxel is 
used to treat a large variety of cancers such as lung, ovarian, breast, head and 
neck. The anticancer property of paclitaxel is related to its ability to bind to 
the beta-tubulin subunits of microtubules.11 This binding process results in the 
inhibition of cell division and eventually cell death, which serves to kill the 
rapidly dividing tumor cells. 
 
Another natural product derived from plant origin is artemisinin 1-2 
(Figure 1.4).  This compound was isolated from the leaves of Artemesia 
annua. Artemesia has been used as traditional Chinese medicine for over 2000 
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years.12 Today, it is used primarily as an antimalarial drug. The endo-peroxide 
functionality of this compound was reported to be essential for its biological 
activity.13 The antimalarial effect of artemisinin originates from its ability to 
modify protein synthesis within the malaria parasite, Plasmodium 
falciparum.14 
 
                                
Figure 1.3. Structure of paclitaxel 1-1 
 
            
Figure 1.4. Structure of artemisinin 1-2 
 
Microorganisms represent another valuable source for discovering 
pharmacologically active natural products. One of the most well-known 
natural products of this origin is penicillin 1-3 (Figure 1.5). Penicillin belongs 
to a group of antibiotics, which were isolated from the fungus Penicillium 
notatum.15 This discovery had led to the Nobel Prize in Medicine or 




























importantly, many lives have been saved as a result of using penicillin to treat 
bacterial infections, which caused very serious diseases decades ago. 
Penicillin exerts its antibiotic activity by specifically inhibiting transpeptidase, 
the enzyme which catalyzes the final steps in cell wall biosynthesis of 
bacteria.16,17 This results in the degradation of the cell wall which eventually 
leads to bacterial cell death. 
 
           
Figure 1.5. Structure of penicillin 1-3. 
 
In addition to plants and microorganisms, natural products with promising 
pharmacological activities can also be derived from marine sources. One such 
compound is bryostatin 1-418 (Figure 1.6), a group of macrolide lactones 
isolated from Bugula Neritina. It was reported to possess potent in vitro 
activity against various cancer cell lines.19 Recently, bryostatin was subjected 
to clinical trials for the treatment of Alzheimer’s disease.20 Bryostatin exerts 
its biological effect by modulating protein kinase C (PKC) activity.21 
 
Natural products with potential therapeutic value can also be derived from 
venoms and toxins. This is illustrated by captopril 1-5 (Figure 1.7), a peptide 
based drug, which has been approved by US Food and Drug Administration to 
be used for the treatment of hypertension. Captopril was synthesized in 1975 













compound isolated from the venom of Brazilian viper.  The lead compound 
was a nonapeptide (termed teprotide 1-6) (Figure 1.8) which was reported to 
possess the ability to inhibit angiotensin converting enzyme (ACE).23 
 
 







Captopril 1-5  
Figure 1.7. Structure of captopril 1-5. 
 
As of 2005, 200,000 natural compounds from various sources have been 
identified24. This represents only a minute fraction of what nature has to offer. 
Many more biological active natural products have yet to be discovered and 














































teprotide 1-6  
 
Figure 1.8. Structure of teprotide 1-6. 
 
1.3 Natural Products with Anti-inflammatory Activity 
Inflammation is the protective response towards noxious stimuli and 
conditions such as infection, tissue injury and irritants.25 The word 
inflammation is derived from the Latin word “inflammare” meaning to set on 
fire.26 The Roman, Celsus (1st century AD) described four cardinal signs of 
inflammation: rubor (redness), tumor (swelling), calor (heat) and dolor 
(pain).27 He was also known to use the extract of willow leaves to relieve 
inflammation. 
 
Inflammation can be classified into two broad types: acute and chronic 
inflammation.28 Acute inflammation involves a short-term response and 
usually results in healing. Chronic inflammation, on the other hand, involves 
prolonged, dysregulated and maladaptive response. Chronic inflammation has 
been linked to various diseases such as cancers, asthma, arthritis, stroke, 




The causes/initiators of inflammation can also be divided into two types: 
exogenous and endogenous.28 Exogenous inducers consist of microbial and 
non-microbial inducers. Microbial inducers can be further classified into 
pathogen-associated molecular patterns (PAMPs) and virulence factors.  
PAMPs are distinctive molecular structures shared by pathogens, which are 
recognized by pattern recognition receptor (PRRs) at the surface of the cells.30 
Lipopolysaccharide (LPS) is an example of the molecules recognized by 
PRRs. Others include bacterial carbohydrates, nucleic acids (bacterial or viral 
DNA and RNA), lipoproteins, peptidoglycans and phospholipids.30 Virulence 
factors, on the other hand, are not detected directly by dedicated receptor. 
Instead, the inflammatory responses are triggered by the adverse effects 
caused by the virulence factors. Non-microbial inducers include irritants, 
allergens, toxic compounds and foreign bodies.31 Endogenous inducers are 
signals produced by the cell in the event of damage, stress or malfunction.  
 
The mechanism28 of acute inflammation involves recognition of 
inflammatory inducers by macrophages (a type of white blood cells).  This is 
followed by the release of cytokines, lipid messengers and other inflammatory 
mediators. The mediators then act on the blood vessel to facilitate the 
migration of leukocytes (neutrophils) into the tissue. The neutrophils attempt 
to eliminate the offending agents by releasing reactive oxygen species (ROS), 
reactive nitrogen species and elastase.32 After the elimination of the 
inflammatory inducer, a resolution of inflammation and tissue repair take 




The inflammation process involves various signaling pathways, receptors, 
mediators and enzymes. In particular, two signaling pathways, arachidonic 
acid33 and NF-B pathway,34,35 have been linked to the development of 
various diseases.36-41 Compounds with anti-inflammatory properties are often 
designed and developed based on their potential inhibitory effect on these 
pathways. These drugs target the receptors, mediators and enzymes involved. 
 
Salicin 1-7 (Figure 1.9) is one of the natural products that possess anti-
inflammatory property. It is the active ingredient found in the willow bark, 
which was used by Greek physican Hippocrates in ~400 BC to treat 
inflammation and fever.1 Other natural products (Figure 1.9) which exhibit 
anti-inflammatory activity include curcumin 1-8, resveratrol 1-9, andalusol 1-
10, parthenolide 1-11, etc. Curcumin is the major component of the spice 
turmeric, which is widely used in Asia for flavoring. Curcumin was reported 
to inhibit NF-B activation in a concentration-dependent manner.42 This 
natural product has been subjected to clinical trials for the treatment of 
Alzheimer disease.43 Resveratrol is a phenolic compound that is commonly 
present in the skin of grapes and red wines. Resveratrol exerts its anti-
inflammatory activity by inhibiting NF-B DNA-binding activity.44 Andalusol 
and parthenolide are natural products belonging to the terpenoid class which 
have also been reported to inhibit NF-B.45,46 The ability of parthenolide in 
inhibiting NF-B proved to be useful in increasing the sensitivity of cancer 
cells towards chemotherapeutic drugs. This is evidenced by its ability to 





Figure 1.9. Examples of natural products with anti-inflammatory activity48-51 
 
In addition to the natural products mentioned above, numerous terpenoids, 
polyphenols, lignans and marine natural products were reported to possess 
anti-inflammatory activity.48-51 
 
The advancement of structural characterization techniques such as NMR 
spectroscopy, Mass Spectroscopy, X-Ray diffraction, etc., empowers scientists 
and researchers to further search for therapeutically useful compounds from 
natural sources. Progress made in the field of chemical synthesis also enables 
medicinal chemist to synthesize, develop and modify these compounds to suit 






























1.4 Synthesis of Natural Product and Analogues 
The process of harvesting natural products from their natural sources can 
be tedious, time consuming, expensive and resource inefficient. A perfect 
example to highlight this difficulty is paclitaxel. To prepare one dosage of this 
drug, an entire yew tree would have to be sacrificed in order to obtain 
sufficient quantities of this compound. Large scale extraction of yew tree bark 
is thus unsustainable and may even result in species extinction. In addition, the 
number of structural analogues and chemical diversity that can be obtained 
from natural sources are also limited. Since living organisms produce natural 
products for their own physiological purposes, the chemical structures may be 
deficient in certain pharmacological properties and require fine tuning for 
better drug efficacy. Hence, there is a need for alternative means to obtain 
natural products and their analogues. This can be accomplished by chemical 
synthesis. 
 
Natural products can be constructed in the laboratory starting from simple 
building blocks. This synthetic methodology, otherwise known as total 
synthesis, usually involves many reaction steps. The pharmacophore of a 
molecule can often be identified via total synthesis of the natural product. 
With the identification of the pharmacophore, a medicinal chemist can then 
synthesize analogues that are less complex and with better biological activity 
compared to the original natural products. This methodology is called 
“diverted total synthesis” (DTS), a term introduced by Danishefsky. An 
example of DTS is illustrated by the synthesis of migrastatin ether.52 
Migrastatin ether (Figure 1.10) is a simpler analogue of the natural product 
13 
 
migrastatin. The total synthesis of migrastatin led to the discovery that the 
glutarimide side chain as well as the ,-unsaturated lactone moiety were not 
essential for its anticancer property.53,54 The simplified analogue, migrastatin 
ether, was indeed able to inhibit migration of breast cancer cells in a 
concentration dependent manner.52  
 
 
Figure 1.10. Diverted Total Synthesis of Migrastatin Ether.52 
 
In cases where the natural product cannot be isolated in sufficient 
quantities and total synthesis is not feasible due to high complexity of the 
molecule, a hybrid approach is utilized. Semisynthesis of the target molecule 
is applied by utilising the biosynthetic precursor of the corresponding natural 
product. This methodology is illustrated by the semisynthesis of paclitaxel 
from 10-deacetylbaccatin III (Figure 1.11).55-57 The precursor, 10-
deacetylbaccatin III, can be isolated in significant quantity (10 times greater 
than paclitaxel) from the renewable needles of the European Yew, Taxus 
baccata L (Taxaceae). This semisynthesis approach is, therefore, a better 
























Figure 1.11. Semi-synthesis of Paclitaxel55 
 
1.5 Purpose of Research Work in this Thesis 
Nature has provided us with therapeutically useful compounds for 
thousands of years. Today, half of the drugs approved for marketing are of 
natural origin or derived from natural products. Currently, less than 10% of 
world biodiversity has been explored for medicinal purposes. Many more 
biologically active compounds from nature have yet to be discovered and 
developed into useful drugs for the treatment of various diseases. Of particular 
importance is the development of drugs for the treatment of inflammation, 
especially chronic inflammation, which has been linked to various debilitating 
diseases such as cancer, asthma, cardiovascular diseases, diabetes, etc. The 
aim of this thesis is to develop two different classes of natural products for the 
study of their immunostimulation as well as anti-inflammatory activity. In 
addition, different probes will be developed to identify the cellular targets of a 
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CHAPTER 2. SYNTHESIS AND BIOLOGICAL EVALUATION OF 
PHOSPHOGLYCOLIPID PGL1 ANALOGUES 
 
2.1 Introduction 
Lipopolysaccharide (LPS) is a major structural constituent of the outer 
membrane of Gram-negative bacteria.1 LPS is also known as endotoxin and is 
responsible for causing immune response in diverse eukaryotic species 
including humans. The function of LPS in Gram-negative bacteria is 




Figure 2.1. General structure of Gram-negative LPS.2 
 
The general structure of a LPS molecule consists of three parts: O-
polysaccharide chain, core and lipid A (Figure 2.1).2 Lipid A is the 
hydrophobic part of the molecule and is responsible for the toxic effect of 
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Gram-negative bacteria.3 Lipid A is covalently attached to the core section of 
the molecule. The core section can be divided into inner core and outer core. 
The inner core contains sugars such as 3-deoxy-D-manno-octulosonic acid 
(Kdo) and L-glycero-D-manno heptose (Hep). The sugar constituents of the 
outer core are hexoses and hexosamines. The O-polysaccharide unit is a 
polymer of repeating saccharide units (hexoses) which is attached to the outer 
core. 
 
In mammalians, LPS is recognized by toll-like receptor 4 (TLR4).4 This 
recognition activates intracellular signaling cascades that induce the 
expression of genes involved in the inflammatory response. TLR4 is present 
on the surface of immune cells such as neutrophils, macrophages, monocytes 
and dendritic cells.5 The lipid A of different bacteria species varies in terms of 
number and length of the fatty acids. The length and number of fatty acids of 
lipid A are essential for TLR signaling in humans.6 The lipid A of E. coli 
which consists of two phosphate groups and six acyl chains (12 to 14 carbons) 
are well recognized by human TLR.7 Some Gram-negative pathogens are able 
to modify the structure of lipid A to avoid detection by human TLR.8-10 In 
addition to TLR, caspase 11 and caspase 4 have recently been identified as the 
new LPS cytoplasmic receptor.11 The identification of these receptors is 







Figure 2.2. Structure of Lipid A of E. coli.6 
 
Some species of Gram-negative bacteria do not contain LPS on their outer 
membrane. Instead, glycosphingolipids, glycolipids or phosphoglycolipids are 
found on the outer membrane of these bacteria. Sphingomonas is an example 
of Gram-negative bacteria, which lacks LPS but contains glycosphingolipids. 
The glycosphingolipids of spingomonas (Figure 2.3) are recognized by natural 
killer T (NKT) cells which activates the host immune response.12  
 
           















































In 2006, two new phosphoglycolipids were isolated from thermophilic 
bacteria Thermus oshimai NTU-063, Thermus Thermophilus NTU-077, 
Meiothermus ruber NTU-124 and Meiothermus taiwanensis NTU-220.13 The 
structures of these two phosphoglycolipids were determined by spectroscopic 
and chemical analyses.13 The two phosphoglycolipids are 2’-O-(1,2-diacyl-sn-
glycero-3-phospho)-3’-O-(-N-acetyl-glucosaminyl)-N glyceroyl alkylamine 
(PGL1) and 2’-O-(2-acylalkyldio-1-O-phospho)-3’-O-(-N-









































The phosphoglycolipids were isolated as inseparable mixtures of 
PGL1/PGL2. In addition, the isolated phosphoglycolipids also contained 
mixture of heterogeneous fatty acid chains (in terms of chain length and 
branching variations). Different bacterial strains produced phosphoglycolipids 
with different PGL1/PGL2 ratio as well as different fatty acid composition. 
These variations in PGL1/PGL2 ratio and fatty acid composition were also 
observed when the same bacteria strain was grown at different temperature. 
 
Biological studies revealed that one of the phosphoglycolipids, PGL1 
possessed immunomodulatory functions.14 PGL1 was reported to stimulate 
proIL-1 production in human THP-1 monocytes and blood-isolated primary 
monocytes. Furthermore, the PGL1/PGL2 mixtures from different bacteria 
species showed different potency of proIL-1 stimulation. In fact, 
phosphoglycolipids from two bacterial strains (T. thermophilus and M. ruber) 
failed to stimulate the proIL-1 production. This was probably due to variation 
in the fatty acid composition of different bacterial strains. These findings 
highlighted the importance of the fatty acid constituents of PGL1 for proIL-1 
induction. In addition, it was reported that PGL1 with C-15 fatty acid as the 
major component was the most active in stimulating proIL-1 production.  
 
Biological evaluation also indicated that the induction of proIL-1 by 
PGL1 was independent of TLR. Hence, unlike LPS, the receptor for PGL1 
remains unknown. In order to facilitate further biological study, which aims to 
identify this receptor as well as to evaluate the effect of different fatty acid 
compositions, pure PGL1 with homogenous fatty acid chains is required. 
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Since PGL1 obtained via isolation from thermophilic bacteria could not be 
separated from PLG2 using general chromatographic method, chemical 
synthesis will be an attractive alternative to obtain pure PGL1. Herein, we 
report the synthesis and biological evaluation of PGL1 analogues. 
 
2.2   Results and Discussions 





















































































The retrosynthetic analysis of phosphoglycolipid PGL1 is shown in 
Scheme 2.1. Structural elucidation13 of the PGL1/PGL2 mixtures identified 
the chiral center present in the glycerate as R configuration.  The chiral center 
of the glycerol moiety, however, remains unknown. For the synthesis of the 
analogues, we decided to fix this chiral center as S configuration.  
 
Disconnection of PGL1 results in 2 fragments: glycolipid 2-1 and H-
phosphonate 2-2. Glycolipid 2-1 is further disconnected to give glycosyl donor 
2-3 and glycerate 2-4 which is derived from (S)-solketal and primary amine. 
H-phosphonate 2-2 is disconnected to give carboxylic acid 2-6 and glycerol 2-
5 which is derived from (R)-solketal. 
 
In order to evaluate the effect of fatty acid chain length and branching 
pattern on the proIL-1 stimulation as well as to identify optimum length of 
fatty acid chain for receptor binding, the following targets were planned for 
the analogues synthesis: analogues having 8 carbons to 17 carbons fatty acids 
and analogues with linear, iso, ante-iso and t-butyl fatty acids. 
 
2.2.2   Synthesis of Glycosyl Donor 2-3 
Synthesis of glycosyl donor 2-3 involved converting the anomeric alcohol 
into a suitable leaving group and protecting the other three hydroxyls moieties 
with orthogonal protecting groups. It is important to ensure that the protecting 
group for the three hydroxyls is stable when subjected to subsequent reactions 
conditions and at the same time easily removed during the final deprotection 
step. An appropriate choice for this protecting group would be the benzyl 
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ether, which can be removed by hydrogenation. A typical glycosyl donor 
would have a good leaving group on the anomeric position. Glycosylation is 
an important step in carbohydrate synthesis. Numerous glycosyl donors with a 
wide variety of reactivities have been developed.15 For our glycosylation, we 
decided to prepare two glycosyl donors, thioglycoside 2-3a and 
trichloroacetimidate 2-3b. These two glycosyl donors have been widely used 
and proven to be effective for glycosylation reaction.15 
 
N-acetylglucosamine was acetylated with acetic anhydride to give 2-11 
(Scheme 2.2).  Subsequent reaction with thiophenol in the presence of Lewis 
acid BF3.OEt2 under microwave irradiation furnished thioglycoside 2-12. 
Removal of the acetyl protecting groups was achieved with sodium methoxide 
to give 2-13. Glycosyl donor 2-3a was obtained following protection of the 
alcohols as benzyl ether. It is interesting to note that the electron donating 
group (thiophenol) at the anomeric position prefers to be in the equatorial 
position due to steric reason while an electron withdrawing group (acetate) 
prefers to be in the axial position due to the anomeric effect. 
 
 

















































The synthesis of glycosyl donor 2-3b was modified from a procedure 
reported earlier.16 Anomeric deprotection of 2-11 was achieved by the use of 
methylamine to furnish 2-14 (Scheme 2.3). The anomeric alcohol was then 
protected with TBDMS to give 2-15. Removal of the acetyl protecting group 
was achieved following reaction with sodium methoxide to obtain 2-16. The 
free alcohols were deprotonated by sodium hydride and reacted with benzyl 
bromide to give benzylated sugar 2-17. Deprotection of TBDMS was achieved 
by reaction with TBAF to yield 2-18. Subsequent reaction with 











































































2.2.3   Synthesis of glycerate 2-4 
Three primary amines having different alkyl chain length were used as the 
building blocks for the synthesis of glycerate 2-4. These primary amines were 
synthesized from alkyl bromide or alcohol starting materials (Scheme 2.4 & 
Scheme 2.5). Depending on the starting material, Gabriel17 or Mitsunobu18 
reaction was used to introduce the phathalimide functionality into the alkyl 






















2-19 2-20a  z = 11 (96%)
2-20b  z = 15 (90%)
hydrazine, reflux,
 2 h
THF : EtOH (1 : 1)
H2N (CH2)zCH3
2-7a z = 11 (98%)









2-24d 2-20d  (80%)
hydrazine, reflux,
 2 h








Scheme 2.6. Synthesis of glycerate 2-4. 
 
We next proceeded with the synthesis of glycerate 2-4 as shown in 
Scheme 2.6. Alcohol 2-8 was oxidized with a mild oxidizing method,19 
employing TEMPO and BAIB, to afford carboxylic acid 2-21. Carboxylic acid 
2-21 was coupled with amine 2-7 using CDI as the coupling agent to afford 
amide 2-22 (Table 2.1). Deprotection of the diol was achieved by using 
aqueous hydrochloric acid to afford glycerate 2-4 (Table 2.2). 
 
Analogues of 2-22 z R3 yield (%) 
a 11 CH3 76 
b 15 CH3 80 
c 14 CH(CH3)2 70 
 
Table 2.1. Analogues of 2-22. 
 
 
Analogues of 2-4 z  R3 yield (%) 
a 11 CH3 94 
b 15 CH3 90 
c 14 CH(CH3)2 92 
 
Table 2.2. Analogues of 2-4. 
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2.2.4   Synthesis of H-phosphonate 2-2 
Carboxylic acids having a variety of alkyl chain length were synthesized 
from the corresponding bromo alcohol starting materials (Scheme 2.7). In 
order to create diversity, different types of branch were also introduced to the 
chain end of the carboxylic acid. This was achieved by coupling20 bromo 
alcohol 2-23 with a Grignard reagent in the presence of Li2CuCl4 to afford 
alcohol 2-24 (Table 2.3). Oxidation was performed with PDC21 to give 




Scheme 2.7. Synthesis of carboxylic acid 2-6. 
 
Analogues of 2-24 x  R yield (%) 
a 11 CH(CH3)2 95 
b 12 CH(CH3)2 90 
c 13 CH(CH3)2 89 
d 14 CH(CH3)2 92 
e 10 C(CH3)3 88 
f 11 C(CH3)3 87 
g 12 C(CH3)3 89 
h 10 CH(CH3)(CH2CH3) 80 
i 11 CH(CH3)(CH2CH3) 82 
j 12 CH(CH3)(CH2CH3) 85 
 













PDC, r.t., 12 h
DMF
HOOC-(CH2)x-1-R
2-24 (80-95%) 2-6 (65-75%)
31 
 
Analogues of 2-6 x  R yield (%) 
a 11 CH(CH3)2 67 
b 12 CH(CH3)2 70 
c 13 CH(CH3)2 65 
d 14 CH(CH3)2 65 
e 10 C(CH3)3 68 
f 11 C(CH3)3 69 
g 12 C(CH3)3 72 
h 10 CH(CH3)(CH2CH3) 73 
i 11 CH(CH3)(CH2CH3) 70 
j 12 CH(CH3)(CH2CH3) 67 
k 7 CH3 75 
l 9 CH3 73 
m 11 CH3 72 
n 13 CH3 72 
o 15 CH3 70 
p 16 CH3 74 
q 19 CH3 69 
 






Scheme 2.8. Synthesis of phospholipid 2-2. 
 
The synthesis of H-phosphonate 2-2 is shown in Scheme 2.8. The primary 
alcohol of (R)-solketal was protected as benzyl ether to give 2-25. This was 
followed by removal of the acetal using aqueous hydrochloric acid in 
acetonitrile to afford diol 2-5. Regioselective esterification of the primary 
alcohol was achieved by using DCC as coupling agent to yield monoester 2-
26. The DCC and DMAP were added at 0oC followed by stirring at this 
temperature for 1 h before warming up the reaction mixture to room 
temperature. This regioselective esterification was done according to 
literature.22 Monoester 2-26 was subjected to further Steglich23 esterification 
to afford diester 2-27. For analogues of diester 2-27 (Table 2.5) with identical 
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lipid tails (R1 = R2, x =y) on both alcohols, regioselective esterification step 
was omitted. Instead, diol 2-5 was directly subjected to Steglich esterification 
to obtain diester 2-27. Deprotection of the benzyl ether was achieved by 
hydrogenation in the presence of Pd/C catalyst and ethanol/acetic acid solvent 
mixture to obtain 2-28 (Table 2.6). The use of other solvents such as 
methanol, ethanol and THF did not give satisfactory result, as the reaction 
could not proceed to completion even after stirring for 24 h. The alcohol of 2-
28 was then reacted with PCl3 in the presence of imidazole and triethylamine 




x R1 y R2 yield (%) 
a 13 CH(CH3)2 11 CH(CH3)2 77 
b 13 CH(CH3)2 12 CH(CH3)2 79 
c 13 CH(CH3)2 13 CH(CH3)2 83 
d 13 CH(CH3)2 9 C(CH3)3 81 
e 13 CH(CH3)2 10 C(CH3)3 80 
f 13 CH(CH3)2 11 C(CH3)3 85 
g 13 CH(CH3)2 9 CH(CH3)(CH2CH3) 76 
h 13 CH(CH3)2 10 CH(CH3)(CH2CH3) 79 
i 13 CH(CH3)2 11 CH(CH3)(CH2CH3) 75 
j 13 CH(CH3)2 8 CH3 80 
k 13 CH(CH3)2 10 CH3 81 
l 13 CH(CH3)2 12 CH3 82 
m 13 CH(CH3)2 18 CH3 85 
n 10 CH(CH3)2 10 CH(CH3)2 85 
o 11 CH(CH3)2 11 CH(CH3)2 83 
p 12 CH(CH3)2 12 CH(CH3)2 81 
q 6 CH3 6 CH3 84 
r 10 CH3 10 CH3 79 
s 12 CH3 12 CH3 80 
t 14 CH3 14 CH3 85 
u 15 CH3 15 CH3 81 





x R1 y R2 yield (%) 
a 13 CH(CH3)2 11 CH(CH3)2 87 
b 13 CH(CH3)2 12 CH(CH3)2 89 
c 13 CH(CH3)2 13 CH(CH3)2 83 
d 13 CH(CH3)2 9 C(CH3)3 91 
e 13 CH(CH3)2 10 C(CH3)3 90 
f 13 CH(CH3)2 11 C(CH3)3 95 
g 13 CH(CH3)2 9 CH(CH3)(CH2CH3) 88 
h 13 CH(CH3)2 10 CH(CH3)(CH2CH3) 87 
i 13 CH(CH3)2 11 CH(CH3)(CH2CH3) 85 
j 13 CH(CH3)2 8 CH3 88 
k 13 CH(CH3)2 10 CH3 91 
l 13 CH(CH3)2 12 CH3 92 
m 13 CH(CH3)2 18 CH3 85 
n 10 CH(CH3)2 10 CH(CH3)2 85 
o 11 CH(CH3)2 11 CH(CH3)2 89 
p 12 CH(CH3)2 12 CH(CH3)2 94 
q 6 CH3 6 CH3 93 
r 10 CH3 10 CH3 95 
s 12 CH3 12 CH3 93 
t 14 CH3 14 CH3 88 
u 15 CH3 15 CH3 90 





of  2-2 
x R1 y R2 yield (%) 
a 13 CH(CH3)2 11 CH(CH3)2 68 
b 13 CH(CH3)2 12 CH(CH3)2 70 
c 13 CH(CH3)2 13 CH(CH3)2 73 
d 13 CH(CH3)2 9 C(CH3)3 72 
e 13 CH(CH3)2 10 C(CH3)3 67 
f 13 CH(CH3)2 11 C(CH3)3 65 
g 13 CH(CH3)2 9 CH(CH3)(CH2CH3) 66 
h 13 CH(CH3)2 10 CH(CH3)(CH2CH3) 73 
i 13 CH(CH3)2 11 CH(CH3)(CH2CH3) 75 
j 13 CH(CH3)2 8 CH3 65 
k 13 CH(CH3)2 10 CH3 68 
l 13 CH(CH3)2 12 CH3 67 
m 13 CH(CH3)2 18 CH3 70 
n 10 CH(CH3)2 10 CH(CH3)2 73 
o 11 CH(CH3)2 11 CH(CH3)2 71 
p 12 CH(CH3)2 12 CH(CH3)2 69 
q 6 CH3 6 CH3 75 
r 10 CH3 10 CH3 75 
s 12 CH3 12 CH3 73 
t 14 CH3 14 CH3 72 
u 15 CH3 15 CH3 74 
Table 2.7. Analogues of 2-2. 
 
HSQC and HMBC spectroscopy were performed to confirm that the ester 
moiety was indeed attached to the primary alcohol of monoester 2-26 (Figure 
2.5). The overlapped HSQC/HMBC spectra are shown in Figures 2.6 and 2.7. 
On the vertical axis of the spectrum, DEPT-135 was used instead of normal 
13C. This is useful for differentiating carbon with odd or even number of 
protons attached to it.  The chemical shift of protons Ha is in the region of 3-4 
ppm due to its proximity to the electronegative oxygen atom. However, there 
are five other protons, two Hb, two Hc  and one Hd with chemical shifts that fall 
within the same region as well. The peak that belongs to protons Hc can be 
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easily identified due to the HMBC correlation with the benzene carbons at 
~125 ppm (Figure 2.7). Hence, the singlet at ~4.6 ppm belongs to protons Hc. 
From the HSQC, the chemical shift of the carbon at which protons Hc are 
attached to is ~74 ppm. Protons Hb have HMBC correlation with this carbon 
(where protons Hc are attached) while protons Ha do not. Therefore, the 
multiplet at ~3.5 ppm belongs to protons Hb. From HSQC, the multiplet at 
~4.05 ppm belongs to proton Hd. This is because this multiplet shows a 
correlation with the carbon (~69 ppm) that has a positive peak in DEPT-135, 
thus indicating that an odd number of proton is attached (figure 2.6). So far the 
peaks belonging to protons Hb, Hc and Hd have been identified. This leaves us 
with one multiplet at ~4.2 pm and this peak is assigned to protons Ha. Finally, 
the HMBC correlation between protons Ha and the ester carbonyl carbon at 

















Figure 2.6. Overlapped HSQC/HMBC Spectrum (zoom in) of compound 2-
26; Blue nodes represent HSQC, red nodes represent HMBC. 
 
 
Figure 2.7. Overlapped HSQC/HMBC Spectrum of compound 2-26; Blue 





2.2.5   Synthesis of glycolipid 2-29 and 2-35 
Glycosylation was first attempted with glycosyl donor 2-3a (Scheme 2.9) 
employing NIS/TfOH as promoter. However, no product was obtained using 
this method. The same result was obtained when TMSOTf was used as the 
promoter (Table 2.8). Glycosylation with glycosyl donor 2-3b (Scheme 2.10) 




Scheme 2.9. Glycosylation of glycosyl donor 2-3a. 
 
 
Entry Promoter Yield/% 
1 NIS, TfOH - 
2 TMSOTf - 
 





Scheme 2.10. Glycosylation of glycosyl donor 2-3b. 
39 
 
Entry Promoter Solvent Temperature/oC Yield/% 
1 TMSOTf DCM 25 - 
2 TMSOTf DCM 0 - 
3 TMSOTf DCM -40 - 
4 TMSOTf MeCN -40 - 
5 BF3.OEt2 MeCN -40 - 
6 ZnBr2 DCM 25 - 
 









The unsuccessful glycosylation attempt prompted us to modify our 
synthetic route. We suspected that the acceptor 2-4a was not reactive enough 
for the glycosylation reaction.  Hence, in our modified synthetic route, alcohol 
2-9 was used as the acceptor instead. Glycosyl donor 2-3b, which is more 
reactive due to anomeric effect was selected for the glycosylation reaction. 
The reaction was carried out at 0oC with TMSOTf as promoter to furnish 2-30 
(Scheme 3.11). Only the -product was obtained via this glycosylation 
reaction. Removal of the acetal protecting group was achieved using aqueous 
hydrochloric acid in acetonitrile to give 2-31. Selective protection of the 
primary alcohol was done using bulky trityl protecting group to afford 2-32.24 
This was followed by protection of the secondary alcohol as acetate to yield 2-
33. In-situ deprotection of trityl and oxidation25 was achieved by using 
CrO3/H5IO6 to afford 2-34. Compound 2-34 was finally coupled with amine 2-
7a using EDC as coupling agent to yield 2-35. 
 
So far only the -product was obtained from the glycosylation of glycosyl 
donor 2-3b with alcohol 2-9. Although subsequent reactions furnished 
glycolipid 2-35, the modified synthetic route was too linear. A more 
convergent synthetic strategy is preferred to generate a library of analogues. In 
addition, a glycosylation strategy that produces the  glycosyl product is 
required. 
 
The mechanism of the glycosylation of N-acetylglucosamine donor is 
shown in Scheme 2.12.26 Oxocarbenium intermediate 2-45 is formed 
following addition of promoter. This oxocarbenium is stabilized by the 
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coordination of the carbonyl oxygen of the neighboring N-acetyl group to 
form 2-46. This five-membered ring intermediate blocks off the axial face and 
therefore a reactive alcohol nucleophile can only undergo stereoselective 
equatorial attack to give product 2-47. When a less reactive alcohol is used as 
an acceptor, oxazoline 2-48 is mainly formed instead of product 2-47. In 
addition to that, 1,2-elimination product 2-49 is also formed, although to a 
lesser extent. This could be the explanation for the absence of the 
glycosylation product when alcohol 2-4 was used as an acceptor. Since 
alcohol 2-4 has an additional carbonyl group attached next to the secondary 
alcohol, it is less reactive compared to alcohol 2-9. 
 
 
Scheme 2.12. Glycosylation mechanism of glycosyl donor with participating 
neighboring group.26 
 
In order to obtain the -glycosylated product, a glycosyl donor with a 
non-participating group at C2 was synthesized. A suitable precursor for the 
acetamide moiety at C2 would be an azide, which could be converted back to 














































2.2.6   Synthesis of glycosyl donor 2-41 
There are several diazo transfer reagents which are commonly used for 
the conversion of amine to azide. These include trifluoromethanesulfonyl 
(triflyl) azide27, imidazole-1-sulfonyl azide28, nonafluorobutanesulfonyl 
(nonaflyl) azide29 and benzotriazol-1-sulfonyl azide30. Since a library of 
analogues had to be generated, a large scale preparation was involved in our 
synthesis of the sugar fragment. For this purpose, imidazole-1-sulfonyl azide 
was selected as the diazo-transfer reagent because it was relatively safer to be 
prepared and stored compared to the other diazo transfer reagents mentioned 





Scheme 2.13. Synthesis of diazo transfer reagent 2-36.28 
 
Next we proceeded with the synthesis of glycosyl donor 2-41 (Scheme 
2.14).  D-glucosamine hydrochloride 2-37 was reacted with the diazo-transfer 
reagent 2-36 in the presence of potassium carbonate and copper sulfate 
followed by acetylation with acetic anhydride to afford azide 2-38.28 
Subsequent reaction with thiophenol in the presence of the Lewis acid 
BF3.OEt2 under microwave irradiation furnished 2-39. Removal of acetyl 









oC to r.t., 12 h
2) imidazole, 0oC to r.t., 2 h
43 
 
alcohols were protected as benzyl ether to yield glycosyl donor 2-41. Gylcosyl 




Scheme 2.14. Synthesis of glycosyl donor 2-41. 
 
2.2.7   Synthesis of PGL1 analogues 
Following the successful synthesis of glycosyl donor 2-41, we carried on 
with the synthesis of PGL1 and analogues (Scheme 2.15). Glycosyl donor 2-
41 was reacted with glycerate 2-4 to afford 2-42. Solvent plays an important 
role in influencing the stereochemical outcome of the glycosylation reaction 
involving C2 non-participating gylcosyl donor.31 As shown in Scheme 2.16, 
ether-type solvents such as diethyl ether usually produced cis-glycosides 
stereoselectively. This is because an equatorial oxonium ion type intermediate 
2-51 is formed preferentially when ether is used as solvent. Axial attack on 
intermediate 2-51 then takes place to form the axial glycoside 2-52. On the 
other hand, when nitrile-type solvents, such as acetonitrile are used at low 
temperature, the opposite stereoselectivity is observed. Equatorial glycoside 2-
54 is formed via equatorial attack on nitrilium ion 2-53. Hence, diethyl ether 








1) 2-36, K2CO3, 
    CuSO4.5H2O,
    MeOH, r.t., 2 h
2) Ac2O, pyridine, 






































- product. Glycosylation product 2-42 was obtained with -anomer as the 
major product (/ = 3 : 1).  An initial attempt to convert the azido group of 2-
42 into an amine using Staudinger32 reaction did not give satisfactory result. 
This was mainly due to difficulty in separating the resulting amine from the 
triphenylphosphine oxide which was formed as the side product. An 
alternative method33 involving direct conversion of azido to acetamide was 
then employed. Thioacetic acid was reacted with glycolipid 2-42 to afford N-
acetyl glucosamine derivative 2-1. Effort to couple 2-1 with phospholipid 2-2 
using pivaloyl chloride34 as coupling agent failed to provide the desired 
product. The coupling was only successful when the reaction was carried out 
in the presence of CCl3CN and pyridine under microwave irradiation 
condition.35 This was followed by oxidation of the H-phosphonate with iodine 
to furnish 2-43 (Table 2.10). The final step involved exchanging of the 
triethylammonium cation against sodium using DOWEX 50 X 4 (Na+) resin 
and removal of the benzyl ether protecting group using hydrogenation to 














































x R1 y R2 z R3 
yield 
(%) 
a 13 CH(CH3)2 11 CH(CH3)2 14 CH(CH3)2 71 
b 13 CH(CH3)2 12 CH(CH3)2 14 CH(CH3)2 73 
c 13 CH(CH3)2 13 CH(CH3)2 14 CH(CH3)2 70 
d 13 CH(CH3)2 9 C(CH3)3 14 CH(CH3)2 72 
e 13 CH(CH3)2 10 C(CH3)3 14 CH(CH3)2 73 
f 13 CH(CH3)2 11 C(CH3)3 14 CH(CH3)2 72 
g 13 CH(CH3)2 9 CH(CH3)(CH2CH3) 14 CH(CH3)2 73 
h 13 CH(CH3)2 10 CH(CH3)(CH2CH3) 14 CH(CH3)2 74 
i 13 CH(CH3)2 11 CH(CH3)(CH2CH3) 14 CH(CH3)2 73 
j 13 CH(CH3)2 8 CH3 14 CH(CH3)2 75 
k 13 CH(CH3)2 10 CH3 14 CH(CH3)2 71 
l 13 CH(CH3)2 12 CH3 14 CH(CH3)2 73 
m 13 CH(CH3)2 18 CH3 14 CH(CH3)2 72 
n 10 CH(CH3)2 10 CH(CH3)2 15 CH3 72 
o 11 CH(CH3)2 11 CH(CH3)2 15 CH3 71 
p 12 CH(CH3)2 12 CH(CH3)2 15 CH3 70 
q 6 CH3 6 CH3 15 CH3 75 
r 10 CH3 10 CH3 15 CH3 75 
s 12 CH3 12 CH3 15 CH3 73 
t 14 CH3 14 CH3 15 CH3 74 
u 15 CH3 15 CH3 15 CH3 72 
 














x R1 y R2 z R3 
yield  
(%) 
a 13 CH(CH3)2 11 CH(CH3)2 14 CH(CH3)2 89 
b 13 CH(CH3)2 12 CH(CH3)2 14 CH(CH3)2 90 
c 13 CH(CH3)2 13 CH(CH3)2 14 CH(CH3)2 87 
d 13 CH(CH3)2 9 C(CH3)3 14 CH(CH3)2 88 
e 13 CH(CH3)2 10 C(CH3)3 14 CH(CH3)2 89 
f 13 CH(CH3)2 11 C(CH3)3 14 CH(CH3)2 88 
g 13 CH(CH3)2 9 CH(CH3)(CH2CH3) 14 CH(CH3)2 85 
h 13 CH(CH3)2 10 CH(CH3)(CH2CH3) 14 CH(CH3)2 85 
i 13 CH(CH3)2 11 CH(CH3)(CH2CH3) 14 CH(CH3)2 86 
j 13 CH(CH3)2 8 CH3 14 CH(CH3)2 87 
k 13 CH(CH3)2 10 CH3 14 CH(CH3)2 89 
l 13 CH(CH3)2 12 CH3 14 CH(CH3)2 88 
m 13 CH(CH3)2 18 CH3 14 CH(CH3)2 87 
n 10 CH(CH3)2 10 CH(CH3)2 15 CH3 87 
o 11 CH(CH3)2 11 CH(CH3)2 15 CH3 86 
p 12 CH(CH3)2 12 CH(CH3)2 15 CH3 85 
q 6 CH3 6 CH3 15 CH3 90 
r 10 CH3 10 CH3 15 CH3 87 
s 12 CH3 12 CH3 15 CH3 88 
t 14 CH3 14 CH3 15 CH3 87 
u 15 CH3 15 CH3 15 CH3 89 
 
Table 2.11. Analogues of PGL1 (please refer to scheme 2.15 for structural 
formula). 
 
HSQC and HMBC were carried out to confirm the structure of 2-42 
(Figure 2.8). From the HSQC correlation (Figure 2.9), the doublet at ~4.9 ppm 
was identified to be the anomeric proton. As shown in Figure 2.10, an -
glycoside product has a dihedral angle of ~80o while the -glycoside anomer 
has dihedral angle of ~180o. According to Karplus equation36, the anomeric 
proton of an -glycoside would have a smaller coupling constant compared to 
the  anomer. The coupling constant of this doublet was calculated to be 3.5 




Figure 2.8. HMBC correlation of compound 2-42 (proton Hd). 
 
 




















































In order to confirm that the primary alcohol of diol 2-4 is attached to the 
anomeric carbon of 2-41, protons Hd have to be identified. The chemical shift 
of protons Hd fall in the range of ~3.5 to 4.9 ppm. There are, however, 
fourteen other protons (belonging to the benzyl and carbohydrate backbone) 
having chemical shifts that fall within the same range. HMBC correlations 
(Figure 2.11) of protons Hd and the carbon of the amide carbonyl were used to 
identify the peak belonging to protons Hd. From the correlation, the doublet of 
doublet at ~ 3.75 and 3.95 ppm were identified as the two protons of Hd. Since 
there are HMBC correlations (Figure 2.12) between the anomeric carbon and 
the two protons of Hd, the structure of 2-42  was confirmed. 
 





Figure 2.12. HMBC spectrum of 2-42; Correlation between Hd and anomeric 
carbon. 
 
2.3   Biological Resultsa 
aThis project was carried out in collaboration with Prof. Wu Shih-Hsiung 
(Institute of Biological Chemistry , Academia Sinica, Taiwan) and Prof. Hua 
Kuo-Feng (Department of Biotechnology and Animal Science, National Ilan 
University, Taiwan). Hence the biological experiments were performed by 
Prof Wu’s research fellow, Dr. Yang Feng Ling. 
 
The synthesized analogues were evaluated for their ability to stimulate 
proIL-1 production. However, no positive result was obtained. This could be 
due to several factors such as incorrect stereochemistry at the chiral center of 
the glycerol moiety. Other possible causes could be an incorrect length or 
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branching pattern of one or more alkyl chains of the three fatty acids. For the 
future directions, analogues with S configuration (of the glycerol moiety) will 
be synthesized to evaluate their proIL-1 stimulation. 
 
Instead of simply disposing the analogues, we decided to evaluate the 
analogues for other potential anti-inflammatory activity instead. Hence, the 
synthesized analogues (Table 2.11) were tested for their ability to inhibit TNF-
 and IL-6. The cytotoxicity of the analogues in J774A.1 macrophages was 
evaluated with AlamarBlue® assay kit. As can be seen from Table 2.12 and 
Table 2.13, at concentrations of 12.5 M and 3.125 M the analogues were 
not cytotoxic towards the cell line. Using these two concentrations, the 
analogues were evaluated for their inhibitory activity against TNF- and IL-6. 
As shown in Table 2.14 and Table 2.15, compound PGL1j and PGL1s 
showed significant inhibition against IL-6. These two compounds may serve 




Sample concentration (μM) 
Analogues of 
PGL1a 
12.5 25 50 100 200 
PGL1b 79±2b 75±5 75±4 66±5 70±5 
PGL1c 81±5 76±6 62±8 38±7 18±9 
PGL1f 68±9 67±5 62±7 61±6 56±1 
PGL1h 76±3 74±1 54±2 42±2 21±3 
PGL1j 79±8 49±1 32±5 33±6 41±5 
PGL1l 68±3 63±1 60±1 55±2 46±2 
PGL1m 80±3 74±7 73±6 60±6 44±4 
PGL1o 85±2 81±1 68±1 47±1 27±2 
PGL1q 80±1 74±1 53±3 28±3 12±5 
PGL1r 78±2 74±3 60±5 36±1 16±7 
PGL1s 75±3 62±3 35±1 23±1 8±1 
PGL1t 80±1 73±3 60±5 43±7 18±8 
PGL1u 79±1 69±4 78±2 71±4 48±3 
a J774A.1 macrophages were incubated for 24 h with or without tested sample or DMSO 
(vehicle control), then the cell viability was measured by AlamarBlue® assay kit. 
b The cell viability are expressed as the mean ± SD (% of control) for three separate 
experiments. 
 
Table 2.12. Cytotoxicity of PGL1 analogues (concentration of 12.5 M to 
200M) in J774A.1 macrophages. 
 
 
          Sample concentration (µM) 
Analogues of 
PGL1a 
3.125 6.25 12.5 25 50 100 200 
PGL1a 80±3b 73±4 69±1 64±6 64±5 55±5 19±9 
PGL1d 78±2 71±1 68±4 59±3 67±4 57±4 38±4 
PGL1e 75±2 69±2 73±1 62±1 63±1 51±1 57±6 
PGL1g 88±6 78±4 68±4 66±1 69±2 63±6 63±2 
PGL1i 74±7 67±2 60±2 59±2 49±3 43±3 51±2 
PGL1k 71±2 68±1 61±4 53±5 45±6 35±7 16±10 
PGL1n 77±3 76±5 76±1 67±2 54±4 34±5 11±5 
PGL1p 75±4 74±2 71±4 67±4 58±4 38±3 15±5 
a J774A.1 macrophages were incubated for 24 h with or without tested sample or DMSO 
(vehicle control), then the cell viability was measured by AlamarBlue® assay kit. 
b The cell viability are expressed as the mean ± SD (% of control) for three separate 
experiments. 
 
Table 2.13. Cytotoxicity of PGL1 analogues (concentration of 3.25 M to 






IL-6 (pg/ml)b TNF-α (pg/ml)b 
Control N.D.c N.D.c 
DMSO + LPS 2.1±0.18 9.29±3.47 
PGL1b + LPS 0.35±0.061 7.87±0.44 
PGL1c + LPS 0.26±0.077 4.79±0.64 
PGL1f + LPS 0.21±0.044 6.82±0.51 
PGL1h + LPS 0.43±0.034 5.15±0.55 
PGL1j + LPS N.D. 3.38±1.61 
PGL1l + LPS 0.43±0.042 6.20±0.90 
 PGL1m + LPS 0.41±0.091 7.88±3.45 
PGL1o + LPS 0.16±0.057 2.57±0.99 
  PGL1q + LPS  0.42±0.098 2.96±0.90 
PGL1r + LPS 0.21±0.051 6.90±0.72 
PGL1s + LPS 0.079±0.015 3.70±0.90 
PGL1t + LPS 0.58±0.083 3.63±1.32 
PGL1u + LPS 0.66±0.10 6.06±0.36 
a J774A.1 macrophages were incubated for 30 min with or without tested 
sample (12.5 µM) or DMSO (vehicle), then for 6 h with or without 1 µg/ml 
of LPS in the continued presence or absence of tested sample, and then IL-
6 and TNF-α in the culture medium were measured by ELISA. 
b The data are expressed as the (mean ± SD)x103 for three separate 
experiments.  
c N.D. means non detectable. 
 
Table 2.14. Inhibition of TNF- and IL-6 by PGL1 analogues (at 







Control N.D.c N.D.c 
DMSO + LPS 2.09±0.18 9.29±3.47 
PGL1a + LPS 0.49±0.021 5.62±0.46 
PGL1d + LPS 0.59±0.12 4.06±0.66 
PGL1e + LPS 0.43±0.096 3.65±0.24 
PGL1g + LPS 0.25±0.17 4.53±0.91 
PGL1i + LPS 0.52±0.098 4.95±0.63 
PGL1k + LPS 0.61±0.059 5.43±0.34 
PGL1n + LPS 0.40±0.014 5.25±0.87 
PGL1p + LPS 0.71±0.091 5.89±0.36 
a J774A.1 macrophages were incubated for 30 min with or without tested 
sample (3.125 µM) or DMSO (vehicle), then for 6 h with or without 1 
µg/ml of LPS in the continued presence or absence of tested sample, and 
then IL-6 and TNF-α in the culture medium were measured by ELISA. 
b The data are expressed as the (mean ± SD) x103 for three separate 
experiments. 
c N.D. means non detectable. 
Table 2.15. Inhibition of TNF- and IL-6 by PGL1 analogues (at 
concentration of 3.25 µM)) in J774A.1 macrophages. 
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2.4   Conclusion 
The synthetic route towards phosphoglycolipid PGL1 has been 
successfully established. Using this methodology, a library consisting of 
twenty-one analogues was obtained. Biological studies revealed that the 
analogues did not stimulate proIL-1 production in J774A.1 macrophages. 
Instead, two of the analogues PGL1j and PGL1s showed potential anti-
inflammatory activity by inhibition of IL-6. This current result lays a 
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CHAPTER 3. SYNTHESIS OF PROBES FOR ACTIVITY-BASED 
PROTEIN PROFILING OF POTENTIAL CELLULAR TARGETS OF 
ANDROGRAPHOLIDE 
 
3.1   Introduction 
Activity-based protein profiling (ABPP) is a powerful tool that makes use 
of chemical probes to study protein targets in the cell. ABPP was pioneered by 
Cravatt and Bogyo and has been used extensively in drug discovery1,2 and 
target validation3-5 processes. ABPP utilizes small molecule probes that form 
covalent interaction with their protein targets. A typical ABPP probe contains 
two main components: a reactive group and a reporter tag (Figure 3.1).6 The 
reactive group is normally an electrophilic moiety that reacts with the 
nucleophilic residue of an enzyme. Another type of reactive group includes a 
photoreactive group, which is capable of forming a covalent interaction with 
the protein target following UV irradiation. A reporter tag is another essential 
part of ABPP probes, which aids target characterization. Examples of 
commonly used reporter tags include fluorophores and biotin. In addition, 
some ABPP probes also contain a binding group which functions to direct the 
reactive group into the active site of an enzyme. 
 
The labeled proteins are analyzed by either gel electrophoresis (Figure 
3.2) or LC-MS. The former involves resolving the labeled proteins by 
polyacrylamide gel electrophoresis (PAGE) followed by in gel fluorescence 
visualization. Often, a combination of both analytical methods is used to 














A major disadvantage of using reporter tags such as fluorophores or biotin 
is their large size, which may affect the cell permeability and original 
biological activities of an inhibitor or natural product. Furthermore, 
preparative scale synthesis of the probes is not feasible due to the high cost of 
biotin and fluorophores. 
 
The solution to this problem involves replacing these bulky fluorophores 
or biotin with a small alkyne or azide group (“tag-free” probes).7 After the 
proteins have been labeled by the probes, bio-orthogonal chemical reaction are 
then applied to attach the fluorophores or biotin which are necessary for target 
visualization and subsequent analysis (figure 3.3).  By definition, a bio-
orthogonal reaction should not interfere with the native biochemical processes 
that occur inside the living systems.8 Two well established bio-orthogonal 
reactions are the Cu(I)-catalyzed Huisgen’s [3+2] azide-alkyne cycloaddition9 
and the Staudinger ligation.10 
 
 
Figure 3.3. Tag-free ABPP using bio-orthogonal reactions.7 
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The cellular targets of several natural products have been successfully 
investigated using the ABPP approach.11-14 An example is the natural product, 
parthenolide (previously mentioned in Chapter 1), that was reported to exhibit 
anti-inflammatory activity (through inhibition of NF-B).15 In order to study 
the biological targets of this natural product, Crews et al synthesized 
biotinylated parthenolide (Figure 3.4) as the probe.11 The ABPP revealed that 
IB kinase is the protein target of parthenolide. IB kinase is a protein that is 
involved in the activation of NF-B. Further mass spectroscopy analysis of the 
labeled protein indicated that the biological activity of parthenolide was 




Figure 3.4. ABPP of parthenolide using biotinylated derivative.11  
 
Andrographolide is a major bioactive diterpenoid lactone isolated from 
Andrographis paniculata.16 It has been used extensively as traditional 

















been associated with a wide range of biological activities such as anticancer17, 
anti-inflammatory18, antibacteria19 and antihepatotoxicity.20 The structural 
features of andrographolide (Figure 3.5) include a five-membered lactone ring, 
three hydroxyls (one allylic C-14, one primary C-19 and one secondary C-3) 
and two double bonds (one of the double bonds C-12(13) is a Michael 
acceptor). 
 
Since its discovery and isolation in 1911 by Gorter21, many synthetic 
derivatives of andrographolide with varying biological activities have been 
reported. Until recently, however, very few studies22 focused on identifying 
the cellular targets of this natural product. The wide range and interesting 
biological activities of andrographolide motivated us to investigate and reveal 
its cellular targets. The biological activities (eg. anti-inflammatory23) of 
andrographolide have been reported to originate from Michael addition by the 
nucleophilic residue of protein targets on its ,-unsaturated lactone moiety. 
The covalent interaction between andrographolide and its targets facilitates 
protein identification by ABPP approach. Herein, we describe the synthesis of 
andrographolide probes and the ABPP of its potential targets. 
 
 



















3.2   Results and Discussions 
3.2.1   Design of probes 
Previous structure-activity relationship studies24-28 revealed that the ,-
unsaturated lactone moiety of andrographolide was essential for its biological 
activity. Earlier studies29-31 also indicated that converting the hydroxyls into 
ester derivatives did not affect the pharmacological properties of 
andrographolide. Based on these studies, we proceeded with the design of our 
probes. As mentioned previously, a reactive group is an essential component 
of an ABPP probe, which typically forms covalent interactions with the 
protein targets. For our probes, the ,-unsaturated lactone moiety of 
andrographolide functions as the reactive group. By taking advantage of the 
bio-orthogonal Cu(I)-catalyzed Huisgen’s [3+2] azide-alkyne cycloaddition9, 
we decided to adopt the “tag-free” ABPP approach. As such, a small alkyne 
handle was included into the design of our probes. The alkyne handle was 
introduced into andrographolide by attaching it to the ester group at C-3, C-19 
or C-14. This resulted in three different probes: AP1, AP2 and AP3 (Figure 
3.6). In addition, compound NC1 which lacks the Michael acceptor was 
designed as the negative control. The design of the probes involved minor 
changes to the structure of andrographolide. These conservative modifications 





Figure 3.6. Structures of andrographolide probes. 
One of the mechanisms of the anti-inflammatory effect of 
andrographolide is linked to the inhibition of NF-B23. This is achieved by the 
formation of a covalent adduct with reduced cysteine 62 of p50, thus 
preventing the NF-B oligonucleotide from binding to nuclear proteins, 
therefore, inhibiting transcriptional activity. The proposed mechanism 
involves nucleophilic attack of the thiol moiety of the cysteine on the ,-
unsaturated lactone (Michael acceptor) of andrographolide (Scheme 3.1).  The 
enolate then tautomerizes back into the carbonyl form with the release of a 
water molecule.   
 

























































The mechanism mentioned above inspired us to design a series of probes 
(Figure 3.7) containing fluorophore at C-14 position of andrographolide. A 
leaving group attached to the C-14 position of andrographolide would undergo 
the same elimination process during the formation of the covalent adduct with 
potential targets. After the release of the carbamate moiety from the probes 
through nucleophilic attack, the fluorophore would be generated following a 
simple decarboxylation process (Scheme 3.2). Hence, these probes were 
















































































Scheme 3.2. Proposed mechanism of self-reporting property of probe APNP. 
 
A one-photon dye (7-amino-4-methylcoumarin) was utilized as the 
fluorophore in APCM (Figure 3.7) while 6-acetyl-2-naphthylamine, a two-
photon dye, was the fluorophore in APNP (Figure 3.7). Several advantages 
are offered by two-photon (2P) fluorescence microscopy compared to 
conventional one-photon (1P) imaging techniques. These include increased 
penetration depth, lower tissue autofluorescence and self-absorption, reduced 
photodamage and photobleaching.32 This technique is therefore particularly 
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Compounds AP1CM, AP1NP, AP2CM and AP2NP which contain both 
the fluorophore and alkyne handle were designed to demonstrate both self-
reporting activity via live cell imaging as well as protein targets identification 
using pull down and mass spectrometry.  
 
All of the probes are envisioned to be cell permeable because they are 
derived from a natural product. They are therefore applicable for direct in situ 
cell-based screening. 
 
3.2.2   Synthesis of probes 
The synthesis of AP1 and AP2 is shown is Scheme 3.3. The diol of 
andrographolide (AP) was protected as isopropylidine to yield 3-1. The 
hydroxyl at C-14 was then protected with TBDMS33 to obtain 3-2 followed by 
hydrolysis of the isopropylidine acetal with trifluoroacetic acid to afford diol 
3-3. Selective protection34 of the primary alcohol of 3-3 with TBDMS 
afforded compound 3-4. Subsequent esterification of the secondary alcohol 
employing the well-established Steglich35 method gave 3-5. Common 
deprotection of TBDMS using mild acidic conditions36-40 did not give a 
satisfactory result. Deprotection was however, achieved by cerium (IV) 
ammonium nitrate (CAN),41 which produced both AP1 and AP2 in similar 
yield. AP1 was probably generated during the deprotection through acyl 

























































































The synthesis of AP3 is shown in Scheme 3.4. Esterification of the C-14 
hydroxyl of 3-1 gave 3-6. The esterification was slightly modified from 
normal Steglich reaction. The esterification had to be done in the absence of 
DMAP, which would otherwise cause the elimination of the ester group.  
Acetyl deprotection employing an acetic acid water mixture afforded AP3 in 
good yield.  
 
 
Scheme 3.4. Synthesis of AP3. 
 
Scheme 3.5 shows the synthesis of NC1. Reduction of the conjugated 
double bond24 was achieved with sodium borohydride to afford 3-7. The 
hydroxyl at C-14 was then protected with TBDMS33 to give 3-8. This was 
followed by acetal deprotection with trifluoroacetic acid to give diol 3-9. 
Subsequent Steglich esterification35 afforded 3-10. Deprotection of TBDMS 


































Scheme 3.5. Synthesis of NC1. 
 
The synthesis of both APCM and APNP (Scheme 3.6) was achieved by 
converting the corresponding aromatic amine to isocyanate42 using 
triphosgene. The resulting isocyanate was then reacted with 3-1 to afford 3-11. 
Deprotection of the acetal was achieved with trifluoroacetic acid to yield 





























































Scheme 3.6. Synthesis of APCM and APNP. 
 
Synthesis of AP1CM and AP1NP (Scheme 3.7) was achieved by reacting 
AP1 with the isocyanates, which were formed in situ by reacting the 
corresponding aromatic amines with triphosgene.42 
 
 
Scheme 3.7. Synthesis of AP1CM and AP1NP. 
Ar-NH2
1) triphosgene
    NaHCO3 : DCM (1:1),
    r.t., 30 min
2) 3-1, Et3N, DCM, r.t.,












3-11a, APCM Ar =
3-11b, APNP Ar =
O
OO























    NaHCO3 : DCM (1:1),
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The synthesis of AP2CM and AP2NP is shown in Scheme 3.8. Selective 
protection of the primary alcohol34 of AP was achieved using TBDMS and 
pyridine as solvent to give 3-12. The allylic alcohol was then protected with 
THP43 to afford compound 3-13. Steglich esterification35 with hexynoic acid 
gave 3-14, which was then subjected to THP removal with ethanedithiol44 to 
give 3-15. The hydroxyl group was reacted with the isocyanate42 to afford 3-
16. Removal of TBDMS with cerium (IV) ammonium nitrate yielded AP2CM 
and AP2NP. 41 
 
3.3.   Biological Resultsa 
aThis project was carried out in collaboration with Prof. Yao Shao Qin 
(Department of Chemistry, NUS). Hence the biological experiments were 
performed by Prof Yao’s research fellow, Dr. Li Lin and Prof. Yao’s Honours 
student Sun Chenyang. 
 
3.3.1. Cell Proliferation Assay and Western Blot Analysis of STAT 3 
Phosphorylation in HepG2 cell line. 
The anti-proliferation activity of the probes and wild type 
andrographolide against HepG2 cells (a human hepatocellular liver carcinoma 
cell line) was examined using the XTT assay. All of the compounds showed a 
concentration dependent inhibition of cancer cell proliferation. The IC50 
values of each compounds were determined and compared with the wild type 
andrographolide which was reported to be 40μM. The IC50 of the probes did 
not differ significantly from the wild type andrographolide (Figure 3.8). This 
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indicates that the conservative modification applied on andrographolide does 
not change its native biological activities.  
 
Figure 3.8. Cell proliferation assay of andrographolide and probes. 
 
Andrographolide was previously reported to inhibit the constitutive 
phosphorylation of STAT3 in a dose and time dependent manner, without 
altering the overall STAT3 protein level.45 STAT3 is a protein that is involved 
in the signaling pathway within the cells in response to inflammation.46 In 
order to further prove that AP1 (which will be used for the majority of the 
subsequent labeling and pull down experiments) retains the same biological 
activity as andrographolide, Western blot was carried out with different 
concentrations of AP1. From Figure 3.9, it can be clearly seen that the overall 
STAT3 protein level remains unchanged while the pSTAT3 protein level 
decreases with increasing concentration of AP1. 
 
These two experiments show that the introduction of an alkyne handle at 
the C-3 and C-9 positions of andrographolide as well as the introduction of 
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Figure 3.9. Western blot analysis of STAT3 phosphorylation in HepG2 cell. 
 
 
3.3.2.   In situ protein profiling in HepG2 cell line with AP1 
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Both time and concentration dependent in situ labeling were performed 
with live HepG2 cells. The concentration dependent experiment was 
conducted by incubating varying concentrations of AP1 for 3 hours, while the 
time dependent experiment was achieved by incubating 10M of AP1 for 
different time intervals. From Figure 3.10, it can be observed that there is an 
increase in fluorescence intensity with increasing both concentration and time. 
An intense band slightly below 55kDa can be observed from this labeling 
experiment. This indicates that the protein was covalently labeled by the 
probe. Judging from the molecular weight, p50 is the most likely candidate 
and the identity of the protein was validated by Western blot. These two 
experiments also indicate the optimized condition for the subsequent labeling 
experiment, which is incubating 10M of probes for 3 hours. 
 











































































































































































































































































































































Figure 3.11. shows the in situ protein profiling of all the alkyne 
containing probes as well as andrographolide in HepG2 cell. As expected, 
wild type andrographolide, which does not have the alkyne handle, did not 
give any fluorescence signal. The same result was observed for NC1, which 
lacks the Michael acceptor. All of the probes except AP3 showed an intense 
fluorescent band slightly below 55kDa. The lack of this fluorescent band for 
AP3 was expected because of the loss of the alkyne handle following the 
nucleophilic attack of the protein targets. This result further validates 
previously reported mechanism whereby the hydroxyl at C-14 of 
andrographolide was eliminated after nucleophilic attack by the cysteine 
residue of p50. Probes with an alkyne handle at C-14 are therefore unsuitable 
to be used for ABPP of cellular targets of andrographolide. 
 
3.3.4.   In situ protein profiling by AP1 in different cell lines 
 
                         
                               













































The results of in situ protein profiling by AP1 in different cancer cell lines 
are shown in Figure 3.12. All the cell lines except A549 gave similar profile 
whereby there was an intense band slightly below 55 kDa. The profile in A549 
was different from all the other cell lines in which there was an intense band 
slightly above 55 kDa. This indicates that the target protein covalently labeled 
by the probe in A549 cell is different from those in HepG2, HeLa, CNE1 and 
the rest of the cell lines.  
 
3.3.5.   Pull down and Target Validation 
The identity of the protein labeled by the probes in HepG2 cell was 
validated by Western blot analysis. The labeled proteins (by AP1) were first 
enriched by avidin-agarose beads and then subjected to SDS-PAGE gel. The 
Western blot analysis was carried out with p50 antibody to detect the presence 
of p50 protein, which was suspected as the potential target in HepG2 cell 
following the profiling experiment. From Figure 3.13, it can be seen that there 
is an intense band corresponding to the p50 protein. The Western blot analysis 
confirmed that p50 is indeed the protein labeled by the probes in HepG2 cell. 
 
BF  DMSO PD PR                     BF DMSO PD PR 
 FL             Anti-P50 
Figure 3.13. In-gel fluorescence scanning and Western blot analysis (anti p50) 




An initial attempt to validate the identity of the protein labeled by AP1 in 
A549 cell by Western blot analysis using various antibodies did not give any 
positive result (Figure 3.14). 
 
 BF  DMSO PD  PR                                            BF  DMSO PD  PR               
 FL                            Anti-P50  
 PR  BF   DMSO  PD                                      PR  BF  DMSO PD   
                               
  
          
                                Anti-Tubulin                                           Anti-PDI 
 
Figure 3.14. In-gel fluorescence scanning and Western blot analysis (anti-p50, 
anti-tubulin, anti-PDI) of A549 cell. BF = before pull down, PD = after pull 
down. 
 
The labeled proteomes in A549 cell were then subjected to pull-down/LC-
MS/MS analysis for identification of labeled protein targets. The resulting 
candidate proteins are listed in Table 3.1. The process to validate the identity 






Protein Mass (in Da) Protein Score emPaI 
NAMPT 55772 277 0.68 
ALDH1B1 57626 219 0.35 
ENDOD1 55723 245 0.31 
ADCK4 60773 221 0.30 
GSR 56791 214 0.30 
CYP4F11 60848 128 0.21 
UGP2 57940 57 0.14 
SARS2 58602 99 0.14 
LPCAT2 60797 47 0.07 
SMARCD3 55210 61 0.06 
CYP24A1 59408 59 0.06 
CYP1B1 61263 60 0.05 
PDP1 61586 56 0.05 
CCDC151 63926 34 0.05 
 















Figure 3.15. Concentration (reacted for 3 h) and time (with 1M of GSH) 




Fluorescence enzymatic assay (time and concentration dependent) was 
carried out to determine the self-reporting activity of APCM.  The positive 
control consisted of coumarin dye, which is known to emit an intense 
fluorescence signal at the excitation wavelength of 450 nm. The negative 
control comprised of only APCM without any GSH (glutathione) added. From 
Figure 3.15, it can be seen that negligible fluorescence signal was observed 
when no GSH was added to APCM. This was because without nucleophile 
(GSH), no Michael addition took place and the fluorophore was not released. 
The fluorescence intensity increased with increasing concentration of the 













Figure 3.16. Fluorescence activated cell sorting of live HepG2 cell incubated 
with APCM and APNP; wildtype = andrographolide. 
 
Wildtype 1uM APNP 5uM APNP 20uM APNP 
Wildtype 1uM APCM 5uM APCM 20uM APCM 
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Fluorescence-activated cell sorting (FACS) experiments were carried out 
with live cells (HepG2) to determine the in situ self-reporting activity of 
APCM and APNP. From Figure 3.16, it can be observed that there is an 
increase in the fluorescence intensity with increasing concentration of both 
APCM and APNP. This concentration dependent increase in fluorescence 
intensity indicates that the fluorophore-containing probe reacted with the 
potential target and subsequently released the fluorophore, resulting in the 
fluorescence signal. 
 
The two experiments mentioned above proved that the fluorophore 
containing probes APCM and APNP are indeed capable of generating a 
fluorescence signal upon reacting with the targets in the cell. They are 
therefore suitable to be used as self-reporting probes. 
 
 
3.3.7.   Cellular imaging with APNP, AP1NP and AP2NP 
In order to demonstrate the utility of the cell-permeable probes for 
potential cellular imaging of andrographolide targets, fluorescence microscopy 
was performed to visualize the probe-treated cells (Figure 3.17). Live HepG2 
and A549 cells were treated with APNP, AP1NP and AP2NP independently. 
DMSO was used as the negative control in this experiment. As expected, a 
fluorescence signal was observed at a wavelength of 500 nm for all the probes. 
This was due to the Michael addition of the protein target which resulted in 
the release of the fluorophore. At 600 nm, the fluorescence signal was not 





Figure 3.17. One-photon excited fluorescence images of HepG2 (a) and A549 
(b) cells upon treatment with APNP, AP1NP and AP2NP (10.0 µM). AAN: 
probe (ex/em = 405 nm/500 ~ 550 nm); TMR: tri-functional probe (ex/em = 
543 nm/565 ~ 600 nm); NU: nuclear tracker (ex/em = 405 nm/420 ~ 460 nm); 
Merged: merged image of (panel 2 and 3); DMSO: background control; 




It can be observed that for HepG2 cell, the fluorescence signal was 
originating from the nucleus. This is consistent with the pull down experiment 
which confirmed that p50 was the target in HepG2 cell. P50 is a subunit of 
NF-B which is active in the nucleus. In addition, the fluorescence signal 
distribution in the cell membrane was also observed. This is probably due to 
the reaction between the probes and gluthathione, which is distributed 
throughout the cells. For A549 cell, the fluorescent was mainly distributed in 
the cytosol. This result is in accordance with the pull-down/LC-MS/MS 
analysis which identified NAMPT as one of the potential targets. NAMPT is 
known to be located in the cytoplasm of the cell. 
 
3.4   Conclusion 
The probes for ABPP of potential cellular targets of andrographolide have 
been successfully synthesized.  Analysis of the anti-proliferation activity and 
inhibition of STAT3 phosphorylation in HepG2 cell showed that the probes 
were able to retain the native biological activities of androgapholide. All of the 
probes except AP3 were able to generate a fluorescent band in the profiling 
experiment. This result is consistent with the previously reported mechanism 
in which the alkyne handle (located at C-14 of andrographolide) in AP3 was 
eliminated as a result of the Michael addition of the protein target. The protein 
profiling by AP1 in various cancer cell lines (HepG2, Hela, CNE1) revealed 
an intense fluorescent band slightly below 55 kDa. Subsequent pull down and 
Western blot validation confirmed p50 protein as the target. In A549 cell, a 
different profile was obtained in which there was an intense band slightly 
above 55 kDa. Pull-down/LC-MS/MS analysis identified NAMPT as one of 
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the potential targets. Attempts to confirm the identity of this protein with 
Western blot are currently underway.  Lastly, all the fluorophore containing 
probes were found to be able to emit a fluorescence signal upon reacting with 
the target protein. This indicates that they indeed possess self-reporting 
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CHAPTER 4: SYNTHESIS AND BIOLOGICAL EVALUATION OF 
ANDROGRAPHOLIDE ANALOGUES AS POTENTIAL INHIBITORS OF 
NF-B. 
 
4.1   Introduction 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a 
transcription factor that is involved in the regulation of a wide variety of genes 
including inflammation, immune response and apoptosis.1 NF-κB complexes are 
normally made up of heterodimer of p50 and p65. Typical stimuli which trigger the 
activation of NF-κB include cytokines, oxidized LDL free radicals, ultraviolet 
irradiation, stress, bacterial and viral antigens.2-4 
 
An inactive NF-κB is located in the cytoplasm and bound to its inhibitory protein 
IκB (Figure 4.1). Activation of NF-κB (canonical/classical)2 involves stimulation by 
inflammatory cytokines such as tumor necrosis factor (TNF) or pathogens. The 
stimulation involves binding of a ligand (eg. TNF or LPS) to a cell surface receptor 
(eg. TNF receptor or Toll-like receptor). This triggers the recruitment of adaptor 
proteins (TRAF, tumor necrosis factor receptor-associated factor) to the cytoplasmic 
region of the receptor. The adaptor proteins then recruit IKK complex (IKK or 
NEMO, IKK and IKK), which results in the accumulation of molecules at the 
receptor. Following this, IKK complex is activated and IKK carries out the 
phosphorylation of IκB proteins resulting in their degradation. The released NF-κB 
dimers then translocate into the nucleus, bind to DNA and carry out the transcription 





Figure 4.1. Activation pathway (canonical) of NF-B.2 
 
Dysregulation of NF-κB has been linked to numerous chronic inflammatory 
diseases such as asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid 
arthritis and cancer.5-9 The development of compounds that inhibit the activation of 
NF-κB, thus represents a promising approach for the treatment of these diseases. This 
is supported by the understanding of the NF-κB activation mechanism described 
earlier. These compound were usually designed by targeting the proteins that are 
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involved in its activation cascade. Several natural products have been reported to 
possess inhibitory activity against NF-κB. The inhibition of NF-κB by natural 
products involves a few mechanisms.10 Parthenolide was reported to inhibit NF-κB by 
forming a covalent adduct with cysteine 179 of IKK.11 Recently, Withaferin A 
(Figure 4.2) was reported to inhibit NF-κB via the same mechanism as parthenolide.12 
Andrographolide, on the other hand, inhibits NF-κB through a different mechanism. It 
was reported that andrographolide forms a covalent bond with the reduced cysteine 62 




Figure 4.2. Different natural products that inhibit NF-κB.  
 
The majority of synthetic derivatives of andrographolide have been obtained by 
modifications of the hydroxyl group.14-17 In addition, derivatives which lack C-14 
hydroxyl (as a result of elimination) were reported to exhibit similar or improved 
potency compared to andrographolide.18-20 We are interested to investigate the effect 
of modifying the lactone moiety of andrographolide on its anti-inflammatory activity. 
Herein, we report the synthesis of andrographolide analogues and their inhibitory 
























4.2   Results and Discussion 
4.2.1   Synthesis of Analogues 
 
 
Scheme 4.1. Synthesis of 4-1a and 4-1b. 
 
Compound 3-1, the key intermediate used for the synthesis of ABPP probes 
described earlier in chapter 3, was used as the starting material for the analogues 
synthesis. The synthesis involved ozonolysis of 3-1 to afford aldehyde 4-1a (Scheme 
4.1) and a minor product from incomplete ozonolysis of 3-1, compound 4-1b, in 16% 
yield. Condensation reactions were then employed to functionalize 4-1a and 4-1b into 





























4-2a R = H
4-2b R = CH3
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4-3b R = CH3 (40%)
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Analogues 4-5 were synthesized by Wittig olefination of aldehyde 4-1 with 4-3 
(Scheme 4.3). Ylides 4-3 were obtained from the corresponding -bromo ester 
starting materials (Scheme 4.2). Nucleophilic substitution of 4-2 with 
triphenylphosphine under microwave irradiation generated the Wittig salts, which 
upon deprotonation of the acidic -hydrogen with sodium hydroxide furnished the 
ylides.21 The ylides were then condensed with aldehyde 4-1 by stirring in 
dichloromethane for 12 h at room temperature (Schemes 4.3 and 4.4). Subsequent 
removal of the acetonide protecting group was achieved by using Amberlyst 15, an 
acidic resin.  
 
 







4-1a  X = O
4-1b  X = CH2








4-4a  X = O     R = H     (83%)
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4-6a X = S (68%)




















4-7a X = S (74%)











Andrographolide analogues that contain rhodanine, thiazolidinedione and 
oxindole moieties were reported to possess moderate anti-cancer activity against a 
variety of cancer cell lines.22 We are interested to study the inhibitory activity of these 
analogues against NF-B.  The analogues were synthesized according to the reported 
protocol.22 Knoevenagel condensation of 4-1a with rhodanine, thiazolidinedione or 
oxindole followed by deprotection of the isopropylidine acetal with Amberlyst 15 









































Figure 4.3. X-ray crystal structure of 4-10. 
 
Synthesis of 4-11 is shown in Scheme 4.6. The -hydrogen of N-
methylpyrrolidine, 4-8 was subjected to deprotonation by LDA. The resulting 
carbanion underwent nucleophilic attack on diphenylmethylsilyl chloride to furnish 
intermediate 4-9. This intermediate was condensed with aldehyde 4-1a (Peterson 
olefination) to give compound 4-10. Subsequent deprotection of the diol furnished 
analogue 4-11. X-ray crystallography analysis (Figure 4.3) of 4-10, indicated that the 
double bond (C-12 C-13) has a Z-conformation.  
 
 

















The synthesis of analogue 4-12 is shown in Scheme 4.7. The synthetic protocol 
was adapted from literature.23 Andrographolide was reacted with acetic anhydride in 
the presence of pyridine at r.t. for 12 h to afford 4-12. 
 
4.2.2   Biological Resultsa 
aThis project was carried out in a collaboration with Assoc Prof. Fred Wong 
(Department of Pharmacology, NUS). Hence the biological experiment were 
performed by Assoc Prof Wong’s graduate student, Ms. Loh Xin Yi. 
 
The inhibitory activity of androgapholide and its analogues against NF-B were 
evaluated using the SEAP reporter assay (Figure 4.4, Figure 4.5, Figure 4.6 and 
Figure 4.7).24 A549 cells were transfected with the pNF-κB/SEAP plasmid and 
induced with TNF-α. As shown in Figure 4.6, concentration-dependent as well as 
significant inhibition at concentration of 30M were observed for andrographolide. 
Compound 4-12 (C-14 hydroxyl removed via elimination as acetate) also showed 
significant inhibition at three different concentrations used (Figure 4.7). Analogues 
that lack C-14 alcohol (4-5a, 4-5b, 4-5c and 4-5d) did not show any inhibition 
activity (Figure 4.4 and Figure 4.5). The same result was observed when the lactone 
ring was replaced by an acyclic ester (4-5e). Analogues with rhodanine (4-7a) and 
thiazolidinone (4-7b) appeared to inhibit NF-κB. However, this inhibition, which was 
only observed at concentration of 100M, could be a false hit as reported by 
literature.25 In addition, the analogue with a lactam ring (4-11, C-12-C13double bond 
Z configuration) also did not show inhibition activity. Of all the analogues tested, 
only 4-7c showed encouraging results. This analogue inhibited NF-κB in a 
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concentration-dependent manner (Figure 4.5). The inhibitory activity of this 
compound, however, was not as potent as andrographolide. 
 
Next, the cytotoxicity of andrographoide, 4-7c and 4-12 were evaluated using 
flow cytometry. Both andrographolide and compound 4-12 were cytotoxic towards 
A549 cell (Figure 4.8). The cytotoxicity of compound 4-12 was significantly higher 
compared to andrographolide. This high cytotoxicity of 4-12 could have contributed 
to the strong inhibition of SEAP reporter assay. Compound 4-7c, on the other hand, 
was not cytotoxic as indicated by the flow cytometric analysis. Hence, this compound, 
which showed concentration-dependent NF-κB inhibition has the potential to be 
further developed into anti-inflammatory agent.  
 
 
Figure 4.4. SEAP reporter assay (inhibition of NF-B) for 4-5b, 4-5d, 4-5e, 4-7b.  
 










Figure 4.6. SEAP reporter assay (inhibition of NF-B) for andrographolide. 
 










Figure 4.8. Flow cytometric analysis of cytotoxicity of andrographolide, 4-7c and 4-






4.3   Conclusion 
The analogues of andrographolide for the inhibition of NF-κB have been 
successfully synthesized. Biological evaluation revealed that both 4-7c and 4-12 
showed inhibition against NF-κB. Significant inhibition was observed for 4-12 even 
at low concentration (10M). Compound 4-12, however, was highly toxic towards 
A549 cells. The inhibition activity against NF-κB observed for this analogue could 
likely be due to its high toxicity against the cancer cells. This analogue is therefore 
not suitable for the treatment of inflammatory diseases.  It could be used as a potential 
lead for the development of anti-cancer drugs. However, the cytotoxicity of this 
compound against normal cell lines needs to be determined. Compound 4-7c inhibited 
NF-κB in a dose-dependent manner. The potency of 4-7c was, however, not as good 
as andrographolide. Further modification on compound 4-7c needs to be carried out to 
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Appendix A. Experimental Procedures and Characterization Data for 
Compounds 2 
General Procedures. All chemical reagents and solvents were obtained 
from Sigma Aldrich, Merck, Alfa Aesar, or Fluka and were used without 
further purification. The microwave-assisted reactions were performed using 
the Biotage Initiator microwave synthesizer. Analytical TLC was carried out 
on precoated silica plates (Merck silica gel 60, F254) and visualized with UV 
light or stained with phosphomolybdic acid (PMA) stain. Flash column 
chromatography was performed with silica (Merck, 70-230 mesh). 1H NMR 
and 13C NMR spectra were measured on a Bruker ACF 300 or AMX 500 
Fourier transform spectrometer. Chemical shifts were reported in parts per 
million (δ) relative to the internal standard of tetramethylsilane (TMS). The 
signals observed were described as follows: s (singlet), d (doublet), t (triplet), 
q (quartet), dd (doublet of doublets), m (multiplet). The number of protons (n) 
for a given resonance was indicated as nH. Mass spectra were performed on a 
Finnigan/MAT LCQ mass spectrometer under electron spray ionization (ESI) 
or electron impact (EI) techniques. 
 
Synthesis of 3-acetamido-6-(acetoxymethyl)tetrahydro-2H-pyran-2,4,5-
triyl triacetate (2-11). To a solution of N-acetyl-D-glucosamine (2.50 g, 
11.25 mmol) in pyridine (4.2 mL) were added acetic anhydride (7.0 mL, 74.25 
mmol) and DMAP (34 mg, 0.28 mmol). The reaction mixture was stirred at 
room temperature for 12 h. After that, the reaction mixture was diluted with 
dichloromethane and washed with 3M HCl followed by saturated NaHCO3 
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and brine. The organic layer was dried over MgSO4, filtered and concentrated 
to give 2-11 (4.38 g, 94%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
6.16 (d, J = 3.7 Hz, 1H), 5.61 (d, J = 9.0 Hz, 1H), 5.26 – 5.16 (m, 2H), 4.51 – 
4.41 (m, 1H), 4.23 (dd, J = 12.5, 4.1 Hz, 1H), 4.05 (dd, J = 12.5, 2.4 Hz, 1H), 
3.98 (ddd, J = 9.7, 3.8, 2.4 Hz, 1H), 2.18 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 
2.03 (s, 3H), 1.92 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.68, 170.63, 
169.90, 169.04, 168.56, 90.67, 70.66, 69.69, 67.50, 61.52, 51.05, 22.98, 20.86, 
20.66, 20.63, 20.50.  HRMS (ESI, M + Na) calcd. for  C16H23NNaO10, 
412.1214; found 412.1218. 
 
Synthesis of 5-acetamido-2-(acetoxymethyl)-6-(phenylthio)tetrahydro-
2H-pyran-3,4-diyl diacetate (2-12). To a solution of 2-11 (4 g, 10.30 mmol) 
in dichloromethane (21 mL) were added BF3.OEt2 (1.65 mL, 13.39 mmol) and 
PhSH (3.15 mL, 30.90 mmol). The reaction mixture was then microwave 
irradiated at 110oC for 20 min (Warning! Pressure of more than 5 bars was 
generated). After that, the reaction mixture was diluted with dichloromethane 
and washed with sat NaHCO3 and brine. The organic layer was dried over 
MgSO4, filtered and concentrated. The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-12 (3.40 g, 74%) as a 
brownish solid. 1H NMR (500 MHz, CDCl3) δ 7.43 – 7.42 (m, 2H), 7.23 – 
7.21 (m, 3H), 5.99 (d, 1H, J = 7.55 Hz), 5.18 (t, 1H, J = 9.5 Hz), 4.97 (t, 1H, J 
= 9.45 Hz), 4.82 (d, 1H, J = 10.75 Hz), 4.15 – 4.08 (m, 2H), 4.01 – 95 (m, 
1H), 3.69 – 3.67 (m, 1H), 1.99 (s, 1H), 1.95 (s, 1H), 1.92 (s, 1H), 1.91 (s, 1H). 
13C NMR (125 MHz, CDCl3) δ 170.9, 170.5, 170.1, 169.3, 132.5, 132.3, 
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128.8, 127.9, 86.5, 75.6, 73.7, 68.5, 62.4, 53.2, 23.2, 20.7, 20.6, 20.5. HRMS 
(ESI, M + Na): calcd. for C20H25NNaO8S 462.1199; found 462.1190. 
 
Synthesis of N-(4,5-dihydroxy-6-(hydroxymethyl)-2-
(phenylthio)tetrahydro-2H-pyran-3-yl)acetamide(2-13). To a solution of 2-
12 (2 g, 4.55 mmol) in methanol (16 mL) was added NaOMe (74 mg, 1.36 
mmol). The reaction mixture was stirred at room temperature for 10 min. After 
that, the reaction mixture was concentrated and the crude mixture was purified 
by flash chromatography (ethyl acetate : hexane = 1 : 3 to dichloromethane : 
methanol = 95 : 5) to give 2-13 (1.13 g, 79%) as a brownish solid. 1H NMR 
(500 MHz, DMSO) δ  7.84 (d, 1H, J = 8.8 Hz), 7.40 (d, 2H, J = 7.55 Hz), 7.29 
(t, 2H, J = 7.55), 7.20 (t, 1H, J = 6.9 Hz), 5.09 (s, 2H), 4.75 (d, 1H, J = 10.1 
Hz), 4.60 (s, 1H), 3.71 (d, 1H, J = 11.35 Hz), 3.63 – 3.57 (m, 1H), 3.48 – 3.44 
(m, 1H), 3.36 – 3.32 (m, 1H), 3.22 – 3.13 (m, 2H), 1.82 (s, 3H). 13C NMR 
(125 MHz, DMSO) δ  169.0, 135.7, 128.8, 128.8, 126.1, 86.2, 81.1, 75.4, 70.3, 




(phenylthio)tetrahydro-2H-pyran-3-yl)acetamide (2-3a). To a solution of 
2-13 (1 g, 3.19 mmol) in anhydrous dimethylformamide (7 mL) at 0oC were 
added sodium hydride (60%; 0.42 g, 10.53 mmol) portionwise followed by 
addition of benzyl bromide (1.25 mL, 10.53 mmol). The reaction mixture was 
then warmed up to room temperature and stirred for 2 h. After that, the 
reaction mixture was quenched with ice water and diluted with diethyl ether. 
109 
 
The organic layer was washed with water and brine and subsequently dried 
over MgSO4, filtered and concentrated. The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 12) to give 2-3a (1.58 g, 
85%) as a white solid. 1H NMR (500 MHz, CDCl3 ) δ  7.43 – 7.42 (m, 2H), 
7.24 – 7.13 (m, 18H), 5.52 (d, 1H, J = 7.6 Hz), 4.94 (d, 1H, J = 10.1 Hz), 4.75 
– 4.69 (m, 2H), 4.58 – 4.43 (m, 4H), 3.88 (t, 1H, J = 8.85 Hz), 3.71 – 3.53 (m, 
5H), 1.78 (s, 3H). 13C NMR (125 MHz, CDCl3 ) δ  170.2, 138.2, 138.2, 138.0, 
133.3, 131.9, 128.8, 128.5, 128.4, 128.3, 128.1, 127.8, 127.8, 127.8, 127.6, 
127.5, 127.4, 85.6, 82.2, 79.2, 78.5, 74.8, 74.7, 73.4, 69.1, 55.4, 23.5. HRMS 
(ESI, M + Na): calcd. for C35H37NNaO5S 606.2290 ; found 606.2295. 
 
Synthesis of 5-acetamido-2-(acetoxymethyl)-6-hydroxytetrahydro-2H-
pyran-3,4-diyl diacetate (2-14). To a solution of 2-11 (4.10 g, 10.53 mmol) 
in tetrahydrofuran (50 mL) was added MeNH2 in ethanol (33%; 2.62 mL, 
21.10 mmol). The reaction mixture was stirred at room temperature for 3 h. 
After that, the reaction mixture was concentrated and the crude mixture was 
purified by flash chromatography (ethyl acetate : hexane = 4 : 1 to 8 : 1) to 
give 3-14 (2.96 g, 81%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 6.04 
(d, J = 9.0 Hz, 1H), 5.27 (t, J = 10.1 Hz, 1H), 5.22 (s, 1H), 5.10 (t, J = 9.5 Hz, 
1H), 4.25 (td, J = 9.8, 3.1 Hz, 1H), 4.19 (d, J = 9.5 Hz, 2H), 4.14 – 4.06 (m, 
1H), 2.07 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.95 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 171.36, 170.93, 170.61, 169.40, 91.43, 70.96, 68.29, 67.40, 
62.11, 52.34, 23.02, 20.69, 20.66, 20.55. .  HRMS (ESI, M + Na) calcd. for  





butyldimethylsilyloxy)tetrahydro-2H-pyran-3,4-diyl diacetate (2-15). To a 
solution of 2-14 (2.95 g, 8.49 mmol) in anhydrous dimethylformamide (15 
mL) were added TBDMSCl (3.20 g, 21.20 mmol) and imidazole (2.89 g, 
42.40 mmol). The reaction mixture was stirred at room temperature for 2.5 h. 
After that, the reaction mixture was diluted with ethyl acetate and washed with 
water and brine. The organic layer was dried over MgSO4, filtered and 
concentrated. The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 2 : 1) to give 2-15 (3.17 g, 81%) as a white solid. 1H NMR 
(500 MHz, CDCl3) δ 5.44 (d, J = 9.0 Hz, 1H), 5.26 – 5.16 (m, 1H), 5.03 (t, J = 
9.6 Hz, 1H), 4.83 (d, J = 7.9 Hz, 1H), 4.15 (ddd, J = 14.7, 12.1, 4.2 Hz, 2H), 
3.89 – 3.80 (m, 1H), 3.69 (ddd, J = 9.9, 5.8, 2.7 Hz, 1H), 2.06 (s, 3H), 2.02 (s, 
3H), 2.02 (s, 3H), 1.92 (s, 3H), 0.87 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 171.02, 170.62, 169.79, 169.42, 96.13, 72.37, 
71.86, 69.01, 62.53, 56.64, 25.51, 23.30, 20.70, 20.68, 20.62, 17.87, -4.22, -




(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide (2-16). To a solution 
of 2-15 (3.19 g, 6.90 mmol) in methanol (25 mL) was added NaOMe (0.15 g, 
2.76 mmol). The reaction mixture stirred at room temperature for 3 h. After 
that, the reaction mixture was concentrated and the crude mixture was purified 
by flash chromatography (dichloromethane : methanol = 92 : 8) to give 2-16 
(2.13 g, 92%) as a white solid. 1H NMR (500 MHz, MeOD) δ 4.67 (d, J = 8.0 
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Hz, 1H), 3.84 (dd, J = 11.9, 2.4 Hz, 1H), 3.74 – 3.67 (m, 1H), 3.60 (dd, J = 
10.4, 8.0 Hz, 1H), 3.47 (dd, J = 10.3, 8.8 Hz, 1H), 3.39 – 3.33 (m, 1H), 3.26 
(ddd, J = 9.6, 5.3, 2.5 Hz, 1H), 1.96 (s, 3H), 0.89 (s, 9H), 0.13 (s, 3H), 0.11 (s, 
3H). 13C NMR (126 MHz, MeOD) δ 173.37, 97.66, 77.81, 75.56, 72.13, 
62.75, 59.31, 26.09, 23.12, 18.67, -3.93, -5.25. HRMS (ESI, M + Na) calcd. 
for  C14H29NNaO6Si, 358.1656; found 358.1666. 
 
Synthesis of N-(4,5-bis(benzyloxy)-6-(benzyloxymethyl)-2-(tert-
butyldimethylsilyloxy)tetrahydro-2H-pyran-3-yl)acetamide (2-17). To a 
solution of 2-16 (2.60 g, 7.74 mmol) in anhydrous dimethylformamide (30 
mL) at 0oC were added sodium hydride (60%; 1.00 g, 24.70 mmol) 
portionwise followed by addtition of benzyl bromide (3.00 mL, 25.50 mmol). 
The reaction mixture was then warmed up to room temperature and stirred for 
2 h. After that, the reaction mixture was quenched with ice water and diluted 
with diethyl ether. The organic layer was washed with water and brine and 
subsequently dried over MgSO4, filtered and concentrated. The crude mixture 
was purified by flash chromatography (ethyl acetate : hexane = 1 : 4) to give 
2-17 (3.28 g, 70%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.26 
(m, 13H), 7.24 – 7.21 (m, 2H), 5.51 (d, J = 8.1 Hz, 1H), 4.97 (d, J = 7.6 Hz, 
1H), 4.80 (dd, J = 11.2, 8.8 Hz, 2H), 4.60 (ddd, J = 35.1, 24.3, 11.9 Hz, 4H), 
4.08 – 3.97 (m, 1H), 3.70 (d, J = 4.2 Hz, 2H), 3.64 (t, J = 8.9 Hz, 1H), 3.57 – 
3.50 (m, 1H), 3.39 (dd, J = 17.6, 7.9 Hz, 1H), 1.82 (s, 3H), 0.87 (s, 9H), 0.12 
(s, 3H), 0.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.98, 138.58, 138.31, 
138.18, 128.36, 128.34, 128.26, 127.94, 127.79, 127.65, 127.62, 127.56, 
127.43, 95.05, 80.43, 78.68, 74.78, 74.47, 74.34, 73.36, 69.14, 58.93, 25.59, 
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23.49, 17.87, -4.19, -5.31. HRMS (ESI, M + Na) calcd. for  C35H47NNaO6Si, 
628.3065; found 628.3075. 
 
Synthesis of N-(4,5-bis(benzyloxy)-6-(benzyloxymethyl)-2-
hydroxytetrahydro-2H-pyran-3-yl)acetamide (2-18). To a solution of 2-17 
(3.25 g, 5.37 mmol) in tetrahydrofuran (40 mL) was added TBAF (11.30 mL, 
11.30 mmol). The reaction mixture stirred at room temperature for 1 h. After 
that, the reaction mixture was diluted with ethyl acetate and washed with 
water and brine. The organic layer was dried over MgSO4, filtered and 
concentrated. The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 3 : 1 to 1 : 0) to give 2-18 (2.19 g, 83%) as a white solid. 1H 
NMR (500 MHz, DMSO) δ 8.00 (d, J = 9.2 Hz, 1H), 7.35 – 7.25 (m, 13H), 
7.23 – 7.18 (m, 2H), 6.79 (d, J = 3.8 Hz, 1H), 4.93 (t, J = 3.6 Hz, 1H), 4.71 (dt, 
J = 19.6, 7.4 Hz, 3H), 4.50 (dd, J = 25.3, 12.0 Hz, 3H), 3.92 (td, J = 10.1, 3.2 
Hz, 2H), 3.80 – 3.73 (m, 1H), 3.63 (dd, J = 19.3, 7.7 Hz, 2H), 3.50 – 3.42 (m, 
1H), 1.86 (s, 3H). 13C NMR (126 MHz, DMSO) δ 169.20, 138.80, 138.33, 
138.25, 128.20, 128.17, 128.09, 127.66, 127.58, 127.48, 127.47, 127.37, 
127.30, 90.99, 79.80, 78.54, 73.95, 73.93, 72.27, 69.70, 69.08, 53.20, 22.58. 







(2-3b). To a solution of 2-18 (2.18 g, 4.43 mmol) in dichloromethane (75 mL) 
were added DBU (0.33 mL, 2.22 mmol) and CCl3CN (1.61 mL, 17.70 mmol). 
The reaction mixture was stirred at room temperature for 12 h. After that, the 
reaction mixture was concentrated and the crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 1) to give 2-3b (1.97 g, 70%) as 
a yellowish solid. 1H NMR (500 MHz, CDCl3) δ 8.61 (s, 1H), 7.40 – 7.27 (m, 
13H), 7.24 (dd, J = 7.6, 1.6 Hz, 2H), 6.31 (d, J = 3.4 Hz, 1H), 4.88 (dd, J = 
19.5, 11.2 Hz, 2H), 4.77 (d, J = 8.4 Hz, 1H), 4.68 – 4.61 (m, 3H), 4.51 (d, J = 
12.0 Hz, 1H), 4.35 – 4.28 (m, 1H), 3.92 (d, J = 5.8 Hz, 2H), 3.82 (dd, J = 10.7, 
2.2 Hz, 2H), 3.69 (d, J = 10.8 Hz, 1H), 1.69 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 169.72, 160.34, 138.02, 137.91, 137.74, 128.99, 128.69, 128.49, 
128.36, 128.24, 128.21, 127.99, 127.82, 127.66, 95.96, 91.15, 77.86, 77.79, 
75.34, 74.55, 73.95, 73.50, 67.97, 52.14, 23.05. HRMS (ESI, M + Na) calcd. 
for  C31H33Cl3N2NaO6, 657.1296; found 657.1303. 
 
General procedure for the synthesis of 2-20. To a solution of alkyl 
bromide 2-19 (20 mmol) in dimethylsulfoxide (20 mL) were added 
phthalimide (24 mmol) and K2CO3 (48 mmol). The reaction mixture was 
heated to 90oC and stirred for 2 h. After that, the reaction mixture was diluted 
with diethyl ether and washed with water and brine. The organic layer was 
dried over MgSO4, filtered and concentrated. The crude mixture was purified 




2-dodecylisoindoline-1,3-dione (2-20a). The crude mixture was purified 
by flash chromatography (ethyl acetate : hexane = 1 : 30) to give 2-20a (6.04 
g, 96%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.83 (dd, J = 5.4, 3.1 
Hz, 2H), 7.69 (dd, J = 5.4, 3.0 Hz, 2H), 3.72 – 3.62 (m, 2H), 1.72 – 1.60 (m, 
2H), 1.38 – 1.19 (m, 18H), 0.86 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 168.42, 133.77, 132.16, 123.10, 38.05, 31.87, 29.59, 29.57, 29.53, 
29.46, 29.30, 29.16, 28.57, 26.84, 22.65, 14.08. HRMS (EI): calcd. for 
C20H29NO2 315.2198 ; found 315.2193. 
 
2-hexadecylisoindoline-1,3-dione (2-20b). The crude mixture was purified 
by flash chromatography (ethyl acetate : hexane = 1 : 30) to give 2-20b (6.68 
g, 90%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.83 (dd, J = 5.4, 3.0 
Hz, 2H), 7.69 (dd, J = 5.4, 3.0 Hz, 2H), 3.85 – 3.50 (m, 2H), 1.65 (dd, J = 
13.7, 6.4 Hz, 2H), 1.39 – 1.19 (m, 26H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 168.42, 133.77, 132.20, 123.10, 38.07, 31.90, 29.66, 
29.63, 29.60, 29.54, 29.46, 29.33, 29.17, 28.58, 26.85, 22.66, 14.08. HRMS 
(EI): calcd. for C24H37NO2 371.2824 ; found 371.2821. 
 
Synthesis of 2-(15-methylhexadecyl)isoindoline-1,3-dione (2-20d). To a 
solution of 2-19d  (0.84 g, 3.27 mmol) in tetrahydrofuran (6.5 mL) were added 
phthalimide (0.58 g, 3.92 mmol) and PPh3 (1.03 g, 3.92 mmol). The reaction 
mixture was cooled down to 0oC followed by dropwise addition of DIAD 
(0.77 mL, 3.92 mmol). Subsequently the reaction mixture was warmed up to 
room temperature and stirred for 2 h. After that, the reaction mixture was 
concentrated and the crude mixture was purified by flash chromatography 
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(ethyl acetate : hexane = 12 : 1) to give 2-20d (1.01 g, 80%) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 7.83 (dd, J = 5.4, 3.0 Hz, 2H), 7.69 (dd, J = 5.4, 
3.0 Hz, 2H), 3.70 – 3.63 (m, 2H), 1.69 – 1.63 (m, 2H), 1.50 (dt, J = 13.2, 6.6 
Hz, 1H), 1.32 – 1.21 (m, 22H), 1.13 (d, J = 7.2 Hz, 2H), 0.85 (d, J = 6.6 Hz, 
6H). 13C NMR (126 MHz, CDCl3) δ 168.40, 133.76, 132.18, 123.09, 39.03, 
38.05, 29.91, 29.69, 29.65, 29.62, 29.59, 29.54, 29.46, 29.17, 28.57, 27.93, 
27.39, 26.84, 22.62. HRMS (ESI, 2M + Na): calcd. for C50H78N2NaO4 
793.5854 ; found 793.5863. 
 
General procedure for the synthesis of 2-7. To a solution of 2-20  (6 
mmol) in ethanol : tetrahydrofuran (1 : 1; 80 mL) was added hydrazine 
hydrate (90 mmol). The reaction mixture was refluxed for 2 h. After that, the 
reaction mixture was concentrated to remove the solvent. Aqueous NaOH (2.5 
M) was then added to the residue. The aqueous layer was extracted with 
dichloromethane (3x). The combined organic layers were washed with brine, 
dried over MgSO4, filtered and concentrated to afford 2-7. 
 
dodecan-1-amine (2-7a). The product (1.09 g, 98%) was obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 2.68 (t, J = 6.8 Hz, 2H), 1.59 (s, 
2H), 1.43 (dd, J = 13.7, 6.8 Hz, 2H), 1.34 – 1.22 (m, 18H), 0.87 (t, J = 7.0 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 42.16, 33.66, 31.90, 29.66, 29.63, 29.61, 
29.49, 29.34, 26.89, 22.67, 14.10. HRMS (ESI, M + H+): calcd. for C12H28N 





hexadecan-1-amine (2-7b). The product (1.38 g, 95%) was obtained as a 
white solid 1H NMR (500 MHz, MeOD) δ 2.62 (t, J = 7.2 Hz, 2H), 1.52 – 1.42 
(m, 2H), 1.31 (d, J = 12.3 Hz, 26H), 0.91 (t, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, MeOD) δ 42.60, 33.89, 33.12, 30.85, 30.82, 30.80, 30.70, 30.53, 28.10, 
23.78, 14.51. HRMS (ESI, M + H): calcd. for C16H36N 242.2842 ; found 
242.2851. 
 
15-methylhexadecan-1-amine (2-7d). The product (1.46 g, 95%) was 
obtained as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.67 (t, J = 6.3 Hz, 
2H), 1.86 (s, 2H), 1.50 (dd, J = 13.3, 6.7 Hz, 1H), 1.45 – 1.41 (m, 2H), 1.27 – 
1.24 (m, 22H), 1.13 (dd, J = 13.8, 6.6 Hz, 2H), 0.84 (d, J = 6.6 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 39.03, 29.91, 29.69, 29.66, 29.64, 29.60, 29.59, 
29.46, 27.93, 27.38, 26.86, 22.61. HRMS (ESI, M + H): calcd. for C17H38N 
256.2999 ; found 256.3008. 
 
Synthesis of (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid (2-21). To 
a solution of 2-8 (0.97 mL, 7.57 mmol) in acetonitrile : water (1 : 1; 15 mL) 
were added TEMPO (0.24 g, 1.51 mmol) and BAIB (5.36 g, 16.70 mmol). The 
reaction mixture was stirred at room temperature for 1 h. After that, the 
reaction mixture was quenched with 10% aqueous Na2S2O3. The aqueous 
layer was extracted with ethyl acetate (3x). The combined organic layers were 
washed with water and brine, dried over MgSO4, filtered and concentrated. 
The crude mixture was purified by flash chromatography (ethyl acetate : 
hexane = 4 : 1 + 0.5% v/v acetic acid) to give 2-21 (0.61 g, 55%) as a colorless 
viscous oil. 1H NMR (500 MHz, CDCl3) δ 4.62 (dd, J = 7.4, 4.9 Hz, 1H), 4.29 
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(t, J = 8.1 Hz, 1H), 4.18 (dd, J = 8.8, 4.8 Hz, 1H), 1.52 (s, 3H), 1.41 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 175.46, 111.83, 73.58, 67.24, 25.87, 25.22. 
HRMS (ESI, M - H+): calcd. for C6H9O4 145.0506 ; found 145.0508. 
 
General procedure for the synthesis of 2-22. To a solution of 2-21  (1 
mmol) in tetrahydrofuran (6 mL) was added CDI (1.1 mmol). The reaction 
mixture was stirred at room temperature for 1 h. After that, 2-7 (1.1 mmol) 
and DBU (0.5 mmol) were added and the reaction mixture was further stirred 
at room temperature for 12 h. After that, the reaction mixture was concentrated 
and the crude mixture was purified by flash chromatography to give 2-22. 
 
(R)-N-dodecyl-2,2-dimethyl-1,3-dioxolane-4-carboxamide (2-22a). The 
crude mixture was purified by flash chromatography (ethyl acetate : hexane = 
1 : 5) to give 2-22a (0.24 g, 76%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 6.56 (s, 1H), 4.45 – 4.36 (m, 1H), 4.22 (t, J = 7.5 Hz, 1H), 4.03 (dd, 
J = 9.3, 4.7 Hz, 1H), 3.30 – 3.15 (m, 2H), 1.52 – 1.41 (m, 5H), 1.34 (s, 3H), 
1.22 (d, J = 19.3 Hz, 18H), 0.88 – 0.79 (m, 3H). 13C NMR (126 MHz, CDCl3) 
δ 170.90, 110.64, 74.97, 67.66, 38.81, 31.77, 29.49, 29.42, 29.38, 29.20, 
29.10, 26.71, 26.03, 24.91, 22.54, 13.95. HRMS (ESI, M + Na): calcd. for 
C18H35NNaO3 336.2509 ; found 336.2514. 
 
(R)-N-hexadecyl-2,2-dimethyl-1,3-dioxolane-4-carboxamide (2-22b). 
The crude mixture was purified by flash chromatography (ethyl acetate : 
hexane = 1 : 6) to give 2-22b (0.30 g, 80%) as a white solid. 1H NMR (500 
MHz, CDCl3) δ 6.57 (s, 1H), 4.45 (dd, J = 7.5, 5.3 Hz, 1H), 4.31 – 4.23 (m, 
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1H), 4.08 (dd, J = 8.7, 5.3 Hz, 1H), 3.32 – 3.19 (m, 2H), 1.54 – 1.48 (m, 2H), 
1.47 (s, 3H), 1.38 (s, 3H), 1.26 (d, J = 21.7 Hz, 26H), 0.86 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 170.97, 110.74, 75.04, 67.77, 38.89, 31.88, 
29.64, 29.62, 29.59, 29.52, 29.50, 29.48, 29.32, 29.20, 26.80, 26.14, 25.00, 




(2-22c). The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 1 : 6) to give 2-22c (0.27 g, 70%) as a white solid. 1H NMR 
(500 MHz, CDCl3) δ 6.57 (s, 1H), 4.46 (dd, J = 7.6, 5.3 Hz, 1H), 4.27 (dd, J = 
8.7, 7.7 Hz, 1H), 4.08 (dd, J = 8.8, 5.3 Hz, 1H), 3.31 – 3.21 (m, 2H), 1.51 (dd, 
J = 13.2, 6.6 Hz, 3H), 1.48 (s, 3H), 1.38 (s, 3H), 1.26 (d, J = 22.0 Hz, 22H), 
1.14 (dd, J = 13.7, 6.6 Hz, 2H), 0.86 (s, 3H), 0.84 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 170.99, 110.75, 75.05, 67.78, 39.03, 38.91, 29.92, 29.69, 
29.66, 29.63, 29.60, 29.53, 29.51, 29.49, 29.21, 27.94, 27.39, 26.81, 26.15, 
25.01, 22.63. HRMS (ESI, M + Na): calcd. for C23H45NNaO3 406.3297 ; 
found 406.3299. 
 
General procedure for the synthesis of 2-4. To a solution of 2-22 (0.64 
mmol) in acetonitrile (2 mL) was added HCl (3M; 1.5 mmol). The reaction 
mixture was stirred at room temperature for 1 h. After that, the reaction 
mixture was quenched by addition of sat NaHCO3. The aqueous layer was 
then extracted with ethyl acetate (3x). The combined organic layers were dried 




(R)-N-dodecyl-2,3-dihydroxypropanamide (2-4a). 2-4a (0.16 g, 94%) 
was obtained as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.04 (t, J = 5.6 
Hz, 1H), 4.62 (s, 1H), 4.14 (s, 1H), 3.94 (s, 1H), 3.83 (dd, J = 11.3, 3.9 Hz, 
1H), 3.75 (dd, J = 11.2, 5.8 Hz, 1H), 3.30 – 3.18 (m, 2H), 1.55 – 1.45 (m, 2H), 
1.35 – 1.22 (m, 18H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
172.40, 72.47, 64.39, 39.27, 31.88, 29.63, 29.60, 29.53, 29.42, 29.31, 29.28, 
26.90, 22.64, 14.04. HRMS (ESI, M + Na): calcd. for C15H31NNaO3 296.2196 
; found 296.2205. 
 
(R)-N-hexadecyl-2,3-dihydroxypropanamide (2-4b). 2-4b (0.19 g, 90%) 
was obtained as a white solid. 1H NMR (500 MHz, DMSO) δ 7.63 (t, J = 5.1 
Hz, 1H), 5.44 (d, J = 5.3 Hz, 1H), 4.64 (t, J = 5.7 Hz, 1H), 3.84 (dd, J = 8.8, 
5.4 Hz, 1H), 3.57 (dd, J = 10.6, 5.1 Hz, 1H), 3.45 – 3.38 (m, 1H), 3.09 – 3.00 
(m, 2H), 1.42 – 1.35 (m, 2H), 1.23 (s, 26H), 0.85 (t, J = 6.6 Hz, 3H). 13C NMR 
(126 MHz, DMSO) δ 171.80, 73.00, 64.00, 38.11, 31.31, 29.19, 29.07, 29.04, 
28.79, 28.72, 26.35, 22.10, 13.91. . HRMS (ESI, M - H): calcd. for C19H38NO3 
328.2857 ; found 328.2861. 
 
(R)-2,3-dihydroxy-N-(15-methylhexadecyl)propanamide (2-4c). 2-4c 
(0.20 g, 92%) was obtained as a white solid. 1H NMR (500 MHz, DMSO) δ 
7.61 (s, 1H), 5.40 (d, J = 3.4 Hz, 1H), 4.60 (s, 1H), 3.84 (s, 1H), 3.57 (s, 1H), 
3.43 (s, 1H), 3.05 (s, 2H), 1.54 – 1.45 (m, 1H), 1.39 (s, 2H), 1.23 (s, 22H), 
1.13 (s, 2H), 0.84 (d, J = 5.1 Hz, 6H). 13C NMR (126 MHz, DMSO) δ 171.76, 
72.96, 63.97, 38.44, 38.08, 29.27, 29.15, 29.01, 28.74, 27.34, 26.73, 26.31, 
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22.43. HRMS (ESI, M - H): calcd. for C20H40NO3 342.3014 ; found 342.3020. 
 
General procedure for the synthesis of 2-24. To a solution of 2-23 (3.98 
mmol) in tetrahydrofuran (4 mL) at -10oC were added in a dropwise manner 
Grignard reagent (7.96 mmol) and Li2CuCl4 (0.12 mmol). The reaction 
mixture was stirred at -10oC for 1 h. After that, the reaction mixture was 
quenched by addition of sat NH4Cl. The aqueous layer was then extracted with 
ethyl acetate (3x). The combined organic layers were dried over MgSO4, 
filtered and concentrated. The crude mixture was purified by flash 
chromatography to give 2-24. 
 
12-methyltridecan-1-ol (2-24a). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24a (0.81 g, 95%) as 
a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.62 (t, J = 6.7 Hz, 2H), 1.71 (s, 
1H), 1.57 – 1.49 (m, 3H), 1.28 (d, J = 26.9 Hz, 16H), 1.17 – 1.11 (m, 2H), 
0.85 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 63.03, 39.04, 32.76, 
29.92, 29.68, 29.64, 29.59, 29.42, 27.95, 27.39, 25.73, 22.62. HRMS (EI): 
calcd. for C14H30O 214.2297 ; found 214.2302. 
 
13-methyltetradecan-1-ol (2-24b). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24b (0.82 g, 
90%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.63 (t, J = 6.7 Hz, 2H), 
1.62 (s, 1H), 1.57 – 1.48 (m, 3H), 1.35 – 1.24 (m, 18H), 1.16 – 1.12 (m, 2H), 
0.86 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 63.05, 39.05, 32.78, 
29.93, 29.70, 29.66, 29.65, 29.60, 29.58, 29.42, 27.95, 27.40, 25.73, 22.63. 
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HRMS (EI): calcd. for C15H32O 228.2453 ; found 228.2459. 
 
14-methylpentadecan-1-ol (2-24c). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24c (0.86 g, 
89%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.63 (t, J = 6.7 Hz, 2H), 
1.67 (s, 1H), 1.58 – 1.48 (m, 3H), 1.36 – 1.24 (m, 20H), 1.16 – 1.12 (m, 2H), 
0.86 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 63.04, 39.05, 32.77, 
29.93, 29.70, 29.67, 29.64, 29.60, 29.59, 29.42, 27.95, 27.40, 25.73, 22.63. 
HRMS (EI): calcd. for C16H34O 242.2610 ; found 242.2619. 
 
15-methylhexadecan-1-ol (2-24d). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24d (0.94 g, 
92%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.60 (t, J = 6.7 Hz, 2H), 
1.58 – 1.45 (m, 3H), 1.35 – 1.21 (m, 22H), 1.16 – 1.10 (m, 2H), 0.85 (d, J = 
6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 62.89, 39.03, 32.74, 29.92, 29.70, 
29.67, 29.65, 29.64, 29.60, 29.58, 29.42, 27.92, 27.39, 25.73, 22.60. HRMS 
(EI): calcd. for C17H36O 256.2766 ; found 256.2768. 
 
11,11-dimethyldodecan-1-ol (2-24e). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24e (0.75 g, 
88%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.63 (t, J = 6.6 Hz, 2H), 
1.58 – 1.53 (m, 2H), 1.42 (s, 1H), 1.34 – 1.21 (m, 14H), 1.18 – 1.11 (m, 2H), 
0.85 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 63.04, 44.27, 32.80, 30.62, 30.25, 




12,12-dimethyltridecan-1-ol (2-24f). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24f (0.79 g, 
87%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.62 (t, J = 6.7 Hz, 2H), 
1.59 – 1.52 (m, 2H), 1.50 (s, 1H), 1.36 – 1.21 (m, 16H), 1.19 – 1.11 (m, 2H), 
0.85 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 63.02, 44.27, 32.79, 30.62, 30.25, 
29.71, 29.66, 29.59, 29.42, 29.41, 25.73, 24.55. HRMS (EI): calcd. for 
C15H32O 228.2453 ; found 228.2457. 
 
13,13-dimethyltetradecan-1-ol (2-24g). The crude mixture was purified 
by flash chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24g (0.86 g, 
89%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.62 (t, J = 6.7 Hz, 2H), 
1.68 (s, 1H), 1.60 – 1.52 (m, 2H), 1.36 – 1.21 (m, 18H), 1.16 – 1.12 (m, 2H), 
0.85 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 63.02, 44.26, 32.77, 30.63, 30.25, 
29.72, 29.68, 29.65, 29.60, 29.58, 29.41, 25.73, 24.55. HRMS (EI): calcd. for 
C16H34O 242.2610 ; found 242.2617. 
 
11-methyltridecan-1-ol (2-24h). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24h (0.68 g, 80%) as 
a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.62 (t, J = 6.7 Hz, 2H), 1.64 (s, 
1H), 1.55 (dt, J = 13.3, 6.7 Hz, 2H), 1.36 – 1.22 (m, 17H), 1.14 – 1.05 (m, 
2H), 0.89 – 0.79 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 63.02, 36.62, 34.38, 
32.77, 30.00, 29.74, 29.68, 29.60, 29.59, 29.47, 29.42, 27.08, 25.73, 19.19, 





12-methyltetradecan-1-ol (2-24i). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24i (0.75 g, 82%) as 
a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.62 (t, J = 6.7 Hz, 2H), 1.78 (s, 
1H), 1.61 – 1.51 (m, 2H), 1.35 – 1.21 (m, 19H), 1.15 – 1.05 (m, 2H), 0.90 – 
0.81 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 62.97, 36.62, 34.37, 32.76, 
30.00, 29.69, 29.65, 29.59, 29.47, 29.42, 27.08, 25.73, 19.18, 11.35. HRMS 
(EI): calcd. for C15H32O 228.2453 ; found 228.2457. 
 
13-methylpentadecan-1-ol (2-24j). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 8) to give 2-24j (0.82 g, 
85%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.63 (t, J = 6.7 Hz, 2H), 
1.60 – 1.52 (m, 3H), 1.39 – 1.21 (m, 21H), 1.16 – 1.03 (m, 2H), 0.92 – 0.79 
(m, 6H). 13C NMR (126 MHz, CDCl3) δ 63.04, 36.63, 34.38, 32.78, 30.02, 
29.71, 29.67, 29.65, 29.60, 29.59, 29.48, 29.42, 27.09, 25.73, 19.20, 11.38. 
HRMS (EI): calcd. for C16H34O 242.2610 ; found 242.2615. 
 
General procedure for the synthesis of 2-6. To a solution of 2-24  (3.35 
mmol) in dimehtylformamide (15 mL) was added PDC (16.75 mmol). The 
reaction mixture was stirred at room temperature for 12 h. After that, the 
reaction mixture was diluted with water. The aqueous layer was then extracted 
with diethyl ether (3x). The combined organic layers were dried over MgSO4, 
filtered and concentrated. The crude mixture was purified by flash 





12-methyltridecanoic acid (2-6a). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6a (0.51 g, 67%) as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 1.66 – 
1.60 (m, 2H), 1.54 – 1.47 (m, 1H), 1.25 (s, 14H), 1.18 – 1.09 (m, 2H), 0.86 (d, 
J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 180.27, 39.05, 34.09, 29.91, 
29.66, 29.58, 29.43, 29.23, 29.06, 27.96, 27.40, 24.67, 22.64. HRMS (ESI, M 
- H): calcd. for C14H27O2 227.2017 ; found 227.2017. 
 
13-methyltetradecanoic acid (2-6b). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6b (0.57 g, 
70%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.38 (t, J = 7.4 Hz, 2H), 
1.69 – 1.64 (m, 2H), 1.60 – 1.50 (m, 1H), 1.29 (s, 16H), 1.21 – 1.15 (m, 2H), 
0.90 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 179.55, 38.42, 33.64, 
29.30, 29.06, 29.00, 28.96, 28.79, 28.61, 28.43, 27.33, 26.78, 24.06, 22.02. 
HRMS (ESI, M - H): calcd. for C15H29O2 241.2173 ; found 241.2163. 
 
14-methylpentadecanoic acid (2-6c). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6c (0.56 g, 
65%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 
1.66 – 1.60 (m, 2H), 1.56 – 1.47 (m, 1H), 1.36 – 1.23 (m, 18H), 1.19 – 1.13 
(m, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 180.18, 
39.07, 34.07, 29.94, 29.71, 29.66, 29.64, 29.58, 29.43, 29.23, 29.06, 27.97, 





15-methylhexadecanoic acid (2-6d). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6d (0.59 g, 
65%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 
1.66 – 1.60 (m, 2H), 1.54 – 1.49 (m, 1H), 1.34 – 1.24 (m, 20H), 1.19 – 1.10 
(m, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 180.05, 
39.06, 34.05, 29.94, 29.72, 29.68, 29.66, 29.63, 29.58, 29.43, 29.23, 29.06, 
27.97, 27.42, 24.67, 22.65. HRMS (ESI, M - H): calcd. for C17H33O2 269.2486 
; found 269.2489. 
 
 11,11-dimethyldodecanoic acid (2-6e). The crude mixture was purified 
by flash chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6e (0.52 g, 
68%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.35 (t, J = 7.5 Hz, 2H), 
1.68 – 1.60 (m, 2H), 1.33 – 1.23 (m, 12H), 1.17 – 1.12 (m, 2H), 0.86 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 180.24, 44.26, 34.07, 30.58, 30.26, 29.64, 
29.45, 29.42, 29.24, 29.05, 24.67, 24.54. HRMS (ESI, M - H): calcd. for 
C14H27O2 227.2017 ; found 227.2015. 
 
12,12-dimethyltridecanoic acid (2-6f). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6f (0.56 g, 
69%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 
1.68 – 1.60 (m, 2H), 1.26 (t, J = 19.0 Hz, 14H), 1.15 (d, J = 5.7 Hz, 2H), 0.86 
(s, 9H). 13C NMR (126 MHz, CDCl3) δ 180.37, 44.26, 34.09, 30.61, 30.26, 
29.69, 29.60, 29.42, 29.23, 29.05, 24.66, 24.55.HRMS (ESI, M - H): calcd. for 




13,13-dimethyltetradecanoic acid (2-6g). The crude mixture was purified 
by flash chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6g (0.62 g, 
72%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.35 (t, J = 7.5 Hz, 2H), 
1.67 – 1.59 (m, 2H), 1.36 – 1.22 (m, 16H), 1.18 – 1.12 (m, 2H), 0.86 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 180.25, 44.27, 34.07, 30.63, 30.27, 29.71, 
29.65, 29.59, 29.42, 29.23, 29.05, 24.67, 24.56. HRMS (ESI, M - H): calcd. 
for C16H31O2 255.2330 ; found 255.2338. 
 
11-methyltridecanoic acid (2-6h). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6h (0.56 g, 
73%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 
1.68 – 1.58 (m, 2H), 1.36 – 1.23 (m, 15H), 1.16 – 1.05 (m, 2H), 0.89 – 0.80 
(m, 6H). 13C NMR (126 MHz, CDCl3) δ 180.38, 36.63, 34.39, 34.10, 29.97, 
29.62, 29.49, 29.43, 29.24, 29.05, 27.08, 24.67, 19.20, 11.38. HRMS (ESI, M 
- H): calcd. for C14H27O2 227.2017 ; found 227.2015. 
 
12-methyltetradecanoic acid (2-6i). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6i (0.57 g, 
70%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.35 (t, J = 7.5 Hz, 2H), 
1.66 – 1.60 (m, 2H), 1.36 – 1.23 (m, 17H), 1.16 – 1.06 (m, 2H), 0.90 – 0.83 
(m, 6H). 13C NMR (126 MHz, CDCl3) δ 180.13, 36.64, 34.40, 34.06, 30.00, 
29.67, 29.59, 29.50, 29.43, 29.23, 29.06, 27.10, 24.67, 19.21, 11.39. HRMS 





13-methylpentadecanoic acid (2-6j). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6j (0.58 g, 
67%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 
1.68 – 1.59 (m, 2H), 1.35 – 1.24 (m, 19H), 1.16 – 1.06 (m, 2H), 0.89 – 0.82 
(m, 6H). 13C NMR (126 MHz, CDCl3) δ 180.23, 36.64, 34.40, 34.07, 30.02, 
29.70, 29.64, 29.59, 29.49, 29.42, 29.23, 29.05, 27.10, 24.67, 19.21, 11.39. 
HRMS (ESI, M - H): calcd. for C16H31O2 255.2330 ; found 255.2337. 
 
octanoic acid (2-6k). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6k (0.36 g, 75%) as 
a white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 1.68 – 
1.57 (m, 2H), 1.31 –  1.27 (m, 8H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 180.45, 34.11, 31.61, 29.00, 28.88, 24.66, 22.57, 14.01. 
HRMS (ESI, M - H): calcd. for C8H15O2 143.1078 ; found 143.1082. 
 
decanoic acid (2-6l). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6l (0.42 g, 73%) as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 1.66 – 
1.60 (m, 2H), 1.30 – 1.26 (m, 12H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 180.44, 34.09, 31.84, 29.37, 29.23, 29.04, 24.65, 22.64, 14.07. 
HRMS (ESI, M - H): calcd. for C10H19O2 171.1391 ; found 171.1395. 
 
dodecanoic acid (2-6m). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6m (0.48 g, 72%) as 
a white solid. 1H NMR (300 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 1.65 – 
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1.58 (m, 2H), 1.30 – 1.26 (m, 16H), 0.88 (t, J = 6.6 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 180.39, 34.09, 31.89, 29.58, 29.42, 29.32, 29.23, 29.05, 24.66, 
22.67, 14.08. HRMS (ESI, M - H): calcd. for C12H23O2 199.1704 ; found 
199.1707. 
 
tetradecanoic acid (2-6n). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6n (0.55 g, 72%) as 
a white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 1.67 – 
1.58 (m, 2H), 1.30 – 1.26 (m, 20H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 180.29, 34.08, 31.91, 29.66, 29.63, 29.58, 29.42, 29.34, 29.23, 
29.05, 24.66, 22.68, 14.10. HRMS (ESI, M - H): calcd. for C14H27O2 227.2017 
; found 227.2009. 
 
palmitic acid (2-6o). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6o (0.60 g, 70%) as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 1.71 – 
1.58 (m, 2H), 1.38 – 1.22 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 180.35, 34.09, 31.92, 29.69, 29.68, 29.66, 29.65, 29.63, 29.58, 
29.43, 29.36, 29.23, 29.05, 24.67, 22.68, 14.10. HRMS (ESI, M - H): calcd. 
for C16H31O2 255.2330 ; found 255.2328. 
 
heptadecanoic acid (2-6p). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6p (0.67 g, 74%) as 
a white solid. 1H NMR (500 MHz, CDCl3) δ 2.34 (t, J = 7.5 Hz, 2H), 1.66 – 
1.60 (m, 2H), 1.37 – 1.22 (m, 26H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 
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MHz, CDCl3) δ 180.13, 34.06, 31.93, 29.69, 29.66, 29.66, 29.64, 29.59, 29.43, 
29.36, 29.23, 29.06, 24.68, 22.68, 14.09. HRMS (ESI, M - H): calcd. for 
C17H33O2 269.2486 ; found 269.2494. 
 
icosanoic acid (2-6q). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-6q (0.72 g, 69%) as 
a white solid. 1H NMR (500 MHz, CDCl3) δ 2.35 (t, J = 7.5 Hz, 2H), 1.68 – 
1.58 (m, 2H), 1.37 – 1.23 (m, 32H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 180.17, 34.06, 31.93, 29.70, 29.66, 29.64, 29.59, 29.43, 29.36, 
29.24, 29.06, 24.67, 22.69, 14.10. HRMS (ESI, M - H): calcd. for C20H39O2 
311.2956 ; found 311.2965. 
 
Synthesis of (R)-4-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolane (2-
25). To a solution of 2-9 (0.20 g, 1.50 mmol) in anhydrous 
dimethylformamide (30 mL) were added sodium hydride (60%; 0.07 g, 1.66 
mmol) portionwise followed by addition of benzyl bromide (0.20 mL, 1.66 
mmol). The reaction mixture was then stirred at room temperature for 1 h. 
After that, the reaction mixture was quenched with ice water and diluted with 
diethyl ether. The organic layer was washed with water and brine and 
subsequently dried over MgSO4, filtered and concentrated. The crude mixture 
was purified by flash chromatography (ethyl acetate : hexane = 1 : 30 to 1 : 
15) to give 2-25 (0.27 g, 80%) as a colorless oil. 1H NMR (500 MHz, CDCl3) 
δ 7.38 – 7.33 (m, 4H), 7.31 – 7.27 (m, 1H), 4.58 (q, J = 12.1 Hz, 2H), 4.31 
(dd, J = 12.0, 6.0 Hz, 1H), 4.06 (dd, J = 8.3, 6.4 Hz, 1H), 3.75 (dd, J = 8.3, 6.3 
Hz, 1H), 3.56 (dd, J = 9.8, 5.7 Hz, 1H), 3.48 (dd, J = 9.8, 5.5 Hz, 1H), 1.43 (s, 
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3H), 1.37 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 137.90, 128.34, 127.67, 
127.66, 109.33, 74.68, 73.45, 71.02, 66.81, 26.71, 25.33. HRMS (ESI, M + 
Na): calcd. for C13H18NaO3 245.1148 ; found 245.1155. 
 
Synthesis of (S)-3-(benzyloxy)propane-1,2-diol (2-5). To a solution of 2-
25  (0.25 g, 1.12 mmol) in acetonitrile (4 mL) was added HCl (3M; 0.80 mL, 
2.40 mmol). The reaction mixture was stirred at room temperature for 30 min. 
After that, the reaction mixture was quenched by addition of sat NaHCO3. The 
aqueous layer was then extracted with ethyl acetate (3x). The combined 
organic layers were dried over MgSO4, filtered and concentrated to give 2-5 
(0.19 g, 94%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.28 (m, 
5H), 4.54 (s, 2H), 3.92 – 3.84 (m, 1H), 3.67 (dd, J = 11.5, 3.7 Hz, 1H), 3.59 
(dd, J = 11.5, 5.8 Hz, 1H), 3.53 (qd, J = 9.7, 5.2 Hz, 2H), 3.12 (s, 1H), 2.72 (s, 
1H). 13C NMR (126 MHz, CDCl3) δ 137.63, 128.45, 127.85, 127.75, 73.51, 
71.68, 70.67, 63.97. HRMS (ESI, M + Na): calcd. for C10H14NaO3 205.0835 ; 
found 205.0836. 
 
Synthesis of (R)-3-(benzyloxy)-2-hydroxypropyl 15-
methylhexadecanoate (2-26). To a solution of 2-5 (0.61g, 3.37 mmol) in 
dichloromethane: dimethylformamide (5 : 1; 24 mL) was added 2-6d (0.73 g, 
2.70 mmol). The reaction mixture was cooled down to 0oC followed by the 
addition of DCC (1.16 g, 5.65 mmol) and DMAP (0.03 g, 0.27 mmol). The 
reaction mixture was stirred at 0oC for 30 min before warming up to room 
temperature and further stirred for 12 h. After that, the reaction mixture was 
concentrated and the crude mixture was purified by flash chromatography 
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(ethyl acetate : hexane = 1 : 6) to give 2-26 (0.70 g, 60%) as a white solid. 1H 
NMR (300 MHz, CDCl3) δ 7.38 – 7.28 (m, 5H), 4.55 (s, 2H), 4.21 – 4.12 (m, 
2H), 4.01 (dd, J = 10.9, 5.2 Hz, 1H), 3.51 (qd, J = 9.6, 5.2 Hz, 2H), 2.31 (t, J = 
7.5 Hz, 2H), 1.63 – 1.47 (m, 3H), 1.26 (s, 20H), 1.15 (dd, J = 12.4, 6.1 Hz, 
2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 173.87, 137.62, 
128.39, 127.79, 127.67, 73.42, 70.84, 68.82, 65.28, 38.99, 34.08, 29.88, 29.65, 
29.62, 29.58, 29.54, 29.39, 29.19, 29.06, 27.89, 27.35, 24.83, 22.59. HRMS 
(ESI, M + Na): calcd. for C27H46NaO4 457.3294 ; found 457.3299. 
 
General procedure for the synthesis of 2-27 
To a solution of 2-26 (0.35 mmol) in dichloromethane (3.50 mL) were added 
2-6 (0.41 mmol), DCC (0.7 mmol) and DMAP (0.07 mmol). The reaction 
mixture was stirred room temperature for 12 h. After that, the reaction mixture 
was concentrated and the crude mixture was purified by flash chromatography 
to give 2-27. 
 
(R)-3-(benzyloxy)-2-(13-methyltetradecanoyloxy)propyl  
15-methylhexadecanoate (2-27a). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 20) to give 2-27a (0.18 g, 77%) 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.32 (td, J = 14.2, 7.3 Hz, 5H), 
5.31 – 5.19 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.35 (dd, J = 11.9, 3.8 Hz, 1H), 
4.20 (d, J = 6.4 Hz, 1H), 3.59 (dd, J = 5.1, 1.5 Hz, 2H), 2.34 – 2.26 (m, 4H), 
1.61 (dd, J = 17.3, 10.3 Hz, 4H), 1.52 (dt, J = 13.3, 6.6 Hz, 2H), 1.26 (s, 36H), 
1.19 – 1.12 (m, 4H), 0.86 (d, J = 6.6 Hz, 12H).13C NMR (126 MHz, CDCl3) δ 
173.38, 173.08, 137.72, 128.40, 127.76, 127.61, 73.30, 70.00, 68.27, 62.64, 
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39.05, 34.32, 34.11, 29.94, 29.70, 29.68, 29.65, 29.62, 29.47, 29.28, 29.12, 
29.08, 27.95, 27.41, 24.95, 24.87, 22.64. HRMS (ESI, 2M + Na): calcd. for 
C84H148NaO10 1340.0970 ; found 1340.0978. 
 
(R)-3-(benzyloxy)-2-(14-methylpentadecanoyloxy)propyl  
15-methylhexadecanoate (2-27b). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 20) to give 2-27b (0.19 g, 79%) 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.28 (m, 5H), 5.25 (dd, 
J = 10.8, 4.5 Hz, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.35 (dd, J = 11.9, 3.8 Hz, 
1H), 4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.59 (dd, J = 5.2, 1.6 Hz, 2H), 2.34 – 2.27 
(m, 4H), 1.59 (d, J = 6.7 Hz, 4H), 1.51 (dt, J = 13.3, 6.6 Hz, 2H), 1.25 (s, 
38H), 1.15 (dd, J = 13.7, 6.6 Hz, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR 
(126 MHz, CDCl3) δ 173.39, 173.09, 137.70, 128.40, 127.76, 127.61, 73.29, 
69.99, 68.25, 62.64, 39.05, 34.32, 34.10, 29.93, 29.71, 29.68, 29.65, 29.62, 
29.47, 29.27, 29.11, 29.08, 27.95, 27.41, 24.94, 24.87, 22.64. HRMS (ESI, 2M 
+ Na): calcd. for C86H152NaO10 1368.1278 ; found 1368.1286. 
 
(R)-3-(benzyloxy)propane-1,2-diyl bis(15-methylhexadecanoate)  
(2-27c). The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 1 : 20) to give 2-27c (0.20 g, 83%) as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.39 – 7.26 (m, 5H), 5.27 – 5.22 (m, 1H), 4.54 (q, 
J = 12.1 Hz, 2H), 4.35 (dd, J = 11.8, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 
1H), 3.62 – 3.57 (m, 2H), 2.30 (dt, J = 21.4, 7.5 Hz, 4H), 1.65 – 1.57 (m, 4H), 
1.51 (dt, J = 13.2, 6.6 Hz, 2H), 1.25 (s, 40H), 1.19 – 1.12 (m, 4H), 0.86 (d, J = 
6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 173.39, 173.09, 137.69, 128.40, 
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127.75, 127.60, 73.29, 69.98, 68.24, 62.63, 39.04, 34.31, 34.10, 29.94, 29.72, 
29.68, 29.65, 29.62, 29.47, 29.28, 29.11, 29.08, 27.95, 27.41, 24.94, 24.86, 




15-methylhexadecanoate (2-27d). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 20) to give 2-27d (0.18 g, 81%) 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.27 (m, 5H), 5.24 (dt, J 
= 10.2, 5.2 Hz, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.34 (dd, J = 11.9, 3.8 Hz, 1H), 
4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.59 (dd, J = 5.1, 1.6 Hz, 2H), 2.30 (dt, J = 
22.1, 7.6 Hz, 4H), 1.61 (dd, J = 14.4, 7.1 Hz, 4H), 1.51 (dd, J = 13.3, 6.6 Hz, 
1H), 1.25 (s, 32H), 1.18 – 1.11 (m, 4H), 0.86 (t, J = 3.3 Hz, 15H). 13C NMR 
(126 MHz, CDCl3) δ 173.40, 173.11, 137.71, 128.41, 127.77, 127.61, 73.30, 
69.99, 68.26, 62.64, 44.26, 39.05, 34.32, 34.11, 30.61, 30.26, 29.94, 29.72, 
29.68, 29.65, 29.62, 29.50, 29.48, 29.41, 29.30, 29.28, 29.12, 29.08, 27.96, 
27.41, 24.95, 24.87, 24.56, 22.65. HRMS (ESI, 2M + Na): calcd. for 
C82H144NaO10 1312.0657 ; found 1312.0665. 
 
(R)-3-(benzyloxy)-2-(12,12-dimethyltridecanoyloxy)propyl  
15-methylhexadecanoate (2-27e). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 20) to give 2-27e (0.18 g, 80%) 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.32 (td, J = 14.0, 7.1 Hz, 5H), 
5.28 – 5.21 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.35 (dd, J = 11.9, 3.8 Hz, 1H), 
4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.59 (dd, J = 5.1, 1.5 Hz, 2H), 2.30 (dt, J = 
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21.7, 7.5 Hz, 4H), 1.60 (dt, J = 13.9, 7.0 Hz, 4H), 1.51 (dt, J = 13.2, 6.6 Hz, 
1H), 1.26 (s, 34H), 1.15 (d, J = 4.9 Hz, 4H), 0.86 (t, J = 3.3 Hz, 15H). 13C 
NMR (126 MHz, CDCl3) δ 173.39, 173.09, 137.71, 128.40, 127.76, 127.61, 
73.30, 69.99, 68.26, 62.64, 44.27, 39.05, 34.32, 34.11, 30.63, 30.26, 29.94, 
29.71, 29.68, 29.65, 29.62, 29.47, 29.41, 29.27, 29.11, 29.08, 27.95, 27.41, 
24.95, 24.87, 24.56, 22.65. HRMS (ESI, 2M + Na): calcd. for C84H148NaO10 
1340.0970 ; found 1340.0978. 
 
(R)-3-(benzyloxy)-2-(13,13-dimethyltetradecanoyloxy)propyl  
15-methylhexadecanoate (2-27f). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 20) to give 2-27f (0.20 g, 85%) 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.32 (td, J = 13.9, 7.6 Hz, 5H), 
5.28 – 5.22 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.34 (dd, J = 11.9, 3.8 Hz, 1H), 
4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.59 (dd, J = 5.2, 1.6 Hz, 2H), 2.30 (dt, J = 
21.6, 7.6 Hz, 4H), 1.64 – 1.57 (m, 4H), 1.51 (dd, J = 13.3, 6.6 Hz, 1H), 1.25 
(s, 36H), 1.18 – 1.13 (m, 4H), 0.86 (t, J = 3.3 Hz, 15H). 13C NMR (126 MHz, 
CDCl3) δ 173.39, 173.10, 137.70, 128.40, 127.76, 127.61, 73.29, 69.99, 68.25, 
62.64, 44.26, 39.05, 34.32, 34.10, 30.64, 30.25, 29.93, 29.73, 29.71, 29.67, 
29.65, 29.63, 29.62, 29.47, 29.41, 29.27, 29.11, 29.08, 27.95, 27.41, 24.94, 
24.87, 24.56, 22.64. HRMS (ESI, 2M + Na): calcd. for C86H152NaO10 
1368.1283 ; found 1368.1289. 
 
(2R)-3-(benzyloxy)-2-(11-methyltridecanoyloxy)propyl  
15-methylhexadecanoate (2-27g). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 20) to give 2-27g (0.17 g, 76%) 
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as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.27 (m, 5H), 5.24 (dt, J 
= 10.4, 5.1 Hz, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.34 (dd, J = 11.9, 3.8 Hz, 1H), 
4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.59 (dd, J = 5.1, 1.5 Hz, 2H), 2.30 (dt, J = 
21.8, 7.5 Hz, 4H), 1.66 – 1.57 (m, 4H), 1.51 (td, J = 13.3, 6.6 Hz, 1H), 1.25 (s, 
35H), 1.14 (dd, J = 11.7, 6.5 Hz, 4H), 0.93 – 0.82 (m, 12H). 13C NMR (126 
MHz, CDCl3) δ 173.40, 173.10, 137.69, 128.40, 127.76, 127.61, 73.29, 69.98, 
68.24, 62.63, 39.04, 36.62, 34.37, 34.31, 34.10, 29.98, 29.93, 29.71, 29.68, 
29.65, 29.61, 29.47, 29.28, 29.27, 29.11, 29.07, 27.95, 27.41, 27.09, 24.94, 
24.86, 22.64, 19.20, 11.39. HRMS (ESI, 2M + Na): calcd. for C82H144NaO10 
1312.0657 ; found 1312.0664. 
 
(2R)-3-(benzyloxy)-2-(12-methyltetradecanoyloxy)propyl  
15-methylhexadecanoate (2-27h). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 20) to give 2-27h (0.18 g, 79%) 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.27 (m, 5H), 5.28 – 
5.20 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.34 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 
(dd, J = 11.9, 6.4 Hz, 1H), 3.59 (dd, J = 5.1, 1.6 Hz, 2H), 2.30 (dt, J = 21.6, 7.6 
Hz, 4H), 1.63 – 1.56 (m, 4H), 1.51 (dt, J = 13.3, 6.6 Hz, 1H), 1.25 (s, 37H), 
1.13 (dd, J = 18.1, 7.1 Hz, 4H), 0.88 – 0.83 (m, 12H). 13C NMR (126 MHz, 
CDCl3) δ 173.39, 173.10, 137.69, 128.40, 127.76, 127.60, 73.29, 69.98, 68.24, 
62.63, 39.04, 36.62, 34.38, 34.32, 34.10, 30.01, 29.93, 29.71, 29.68, 29.65, 
29.62, 29.48, 29.27, 29.11, 29.08, 27.95, 27.41, 27.10, 24.94, 24.86, 22.64, 






15-methylhexadecanoate (2-27i). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 20) to give 2-27i (0.18 g, 75%) 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.31 (dt, J = 22.0, 7.8 Hz, 5H), 
5.28 – 5.21 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.35 (dd, J = 11.9, 3.8 Hz, 1H), 
4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.59 (dd, J = 5.2, 1.6 Hz, 2H), 2.30 (dt, J = 
21.2, 7.6 Hz, 4H), 1.63 – 1.57 (m, 4H), 1.51 (dt, J = 13.3, 6.6 Hz, 1H), 1.25 (s, 
39H), 1.16 – 1.04 (m, 4H), 0.89 – 0.81 (m, 12H). 13C NMR (126 MHz, 
CDCl3) δ 173.39, 173.09, 137.72, 128.41, 127.76, 127.61, 73.30, 70.00, 68.27, 
62.65, 39.05, 36.64, 34.39, 34.33, 34.11, 30.03, 29.94, 29.72, 29.69, 29.66, 
29.63, 29.48, 29.28, 29.12, 29.09, 27.96, 27.41, 27.11, 24.95, 24.87, 22.64, 




27j). The crude mixture was purified by flash chromatography (ethyl acetate : 
hexane = 1 : 20) to give 2-27j (0.16 g, 80%) as a white solid. 1H NMR (500 
MHz, CDCl3) δ 7.36 – 7.26 (m, 5H), 5.24 (td, J = 9.3, 5.1 Hz, 1H), 4.54 (q, J = 
12.1 Hz, 2H), 4.34 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 1H), 
3.59 (dd, J = 5.1, 1.5 Hz, 2H), 2.30 (dt, J = 21.7, 7.5 Hz, 4H), 1.64 – 1.57 (m, 
4H), 1.51 (dt, J = 13.2, 6.6 Hz, 1H), 1.25 (s, 32H), 1.17 – 1.11 (m, 2H), 0.87 
(dd, J = 12.0, 6.7 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 173.41, 173.10, 
137.69, 128.40, 127.76, 127.61, 73.29, 69.98, 68.24, 62.64, 39.04, 34.31, 
34.10, 31.85, 29.93, 29.71, 29.68, 29.64, 29.61, 29.47, 29.41, 29.26, 29.11, 
29.07, 27.95, 27.40, 24.94, 24.86, 22.64, 14.08. HRMS (ESI, 2M + Na): calcd. 
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for C74H128NaO10 1199.9405 ; found 1199.9409. 
 
(R)-3-(benzyloxy)-2-(dodecanoyloxy)propyl 15-methylhexadecanoate 
(2-27k). The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 1 : 20) to give 2-27k (0.17 g, 81%) as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.37 – 7.27 (m, 5H), 5.24 (dt, J = 10.7, 5.1 Hz, 
1H), 4.54 (q, J = 12.1 Hz, 2H), 4.34 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 
11.9, 6.4 Hz, 1H), 3.59 (dd, J = 5.1, 1.5 Hz, 2H), 2.34 – 2.26 (m, 4H), 1.61 
(dd, J = 13.9, 7.0 Hz, 4H), 1.51 (dd, J = 13.3, 6.6 Hz, 1H), 1.25 (s, 36H), 1.18 
– 1.12 (m, 2H), 0.87 (dd, J = 12.7, 6.6 Hz, 9H). 13C NMR (126 MHz, CDCl3) 
δ 173.40, 173.10, 137.69, 128.40, 127.76, 127.61, 73.29, 69.98, 68.24, 62.63, 
39.04, 34.32, 34.10, 31.90, 29.93, 29.71, 29.68, 29.65, 29.61, 29.47, 29.33, 
29.27, 29.11, 29.07, 27.95, 27.41, 24.94, 24.86, 22.67, 22.64, 14.09. HRMS 
(ESI, 2M + Na): calcd. for C78H136NaO10 1256.0031 ; found 1256.0040 
 
(R)-3-(benzyloxy)-2-(tetradecanoyloxy)propyl 15-methylhexadecanoate 
(2-27l). The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 1 : 20) to give 2-27l (0.19 g, 82%) as a white solid. 1H 
NMR (300 MHz, CDCl3) δ 7.38 – 7.27 (m, 5H), 5.29 – 5.20 (m, 1H), 4.60 – 
4.48 (m, 2H), 4.35 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 1H), 
3.59 (d, J = 5.2 Hz, 2H), 2.30 (dt, J = 12.8, 7.5 Hz, 4H), 1.64 – 1.57 (m, 4H), 
1.50 (dd, J = 13.2, 6.6 Hz, 1H), 1.25 (s, 40H), 1.15 (d, J = 6.4 Hz, 2H), 0.88 
(dd, J = 8.9, 6.5 Hz, 9H). 13C NMR (75 MHz, CDCl3) δ 173.42, 173.12, 
137.70, 128.41, 127.77, 127.61, 73.29, 69.99, 68.25, 62.64, 39.05, 34.32, 
34.11, 31.91, 29.94, 29.68, 29.65, 29.62, 29.47, 29.34, 29.28, 29.11, 29.08, 
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27.95, 27.41, 24.94, 24.87, 22.64, 14.10. HRMS (ESI, 2M + Na): calcd. for 
C82H144NaO10 1312.0657 ; found 1312.0665. 
 
(R)-1-(benzyloxy)-3-(15-methylhexadecanoyloxy)propan-2-yl 
icosanoate (2-27m). The crude mixture was purified by flash chromatography 
(ethyl acetate : hexane = 1 : 20) to give 2-27m (0.22 g, 85%) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.27 (m, 5H), 5.25 (dt, J = 7.5, 2.6 Hz, 
1H), 4.54 (q, J = 12.1 Hz, 2H), 4.34 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 
11.9, 6.5 Hz, 1H), 3.59 (dd, J = 5.2, 1.7 Hz, 2H), 2.30 (dt, J = 21.3, 7.6 Hz, 
4H), 1.68 – 1.57 (m, 4H), 1.51 (dt, J = 13.3, 6.6 Hz, 1H), 1.25 (s, 52H), 1.18 – 
1.10 (m, 2H), 0.87 (dd, J = 12.7, 6.7 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 
173.40, 173.10, 137.69, 128.40, 127.76, 127.61, 73.29, 69.98, 68.24, 62.64, 
39.05, 34.32, 34.10, 31.91, 29.94, 29.72, 29.69, 29.65, 29.62, 29.48, 29.35, 
29.28, 29.11, 29.08, 27.95, 27.41, 24.94, 24.87, 22.67, 22.64, 14.10. HRMS 
(ESI, 2M + Na): calcd. for C94H168NaO10 1480.2535 ; found 1480.2540. 
 
(R)-3-(benzyloxy)propane-1,2-diyl bis(12-methyltridecanoate) (2-27n). 
The crude mixture was purified by flash chromatography (ethyl acetate : 
hexane = 1 : 20) to give 2-27n (0.18 g, 85%) as a white solid. 1H NMR (500 
MHz, CDCl3) δ 7.37 – 7.26 (m, 5H), 5.27 – 5.22 (m, 1H), 4.54 (q, J = 12.1 Hz, 
2H), 4.35 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.59 (dd, 
J = 5.1, 1.1 Hz, 2H), 2.30 (dt, J = 20.7, 7.5 Hz, 4H), 1.64 – 1.57 (m, 4H), 1.52 
(dt, J = 13.2, 6.6 Hz, 2H), 1.26 (s, 28H), 1.18 – 1.13 (m, 4H), 0.86 (d, J = 6.6 
Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 173.36, 173.06, 137.71, 128.39, 
127.74, 127.59, 73.29, 70.00, 68.27, 62.63, 39.04, 34.31, 34.10, 29.91, 29.66, 
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29.60, 29.46, 29.26, 29.10, 29.07, 27.94, 27.39, 24.94, 24.86, 22.62. HRMS 
(ESI, 2M + Na): calcd. for C76H132NaO10 1227.9713 ; found 1227.9719. 
 
(R)-3-(benzyloxy)propane-1,2-diyl bis(13-methyltetradecanoate)  
(2-27o). The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 1 : 20) to give 2-27o (0.18 g, 83%) as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.37 – 7.27 (m, 5H), 5.25 (dq, J = 10.2, 5.1 Hz, 
1H), 4.54 (q, J = 12.1 Hz, 2H), 4.35 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 
11.9, 6.4 Hz, 1H), 3.59 (dd, J = 5.2, 1.6 Hz, 2H), 2.30 (dt, J = 21.4, 7.6 Hz, 
4H), 1.61 (dd, J = 13.9, 6.8 Hz, 4H), 1.51 (dd, J = 13.3, 6.6 Hz, 2H), 1.26 (s, 
32H), 1.18 – 1.12 (m, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, 
CDCl3) δ 173.36, 173.06, 137.67, 128.37, 127.73, 127.57, 73.26, 69.95, 68.22, 
62.60, 39.01, 34.29, 34.07, 29.90, 29.67, 29.62, 29.59, 29.44, 29.24, 29.08, 
29.04, 27.92, 27.37, 24.91, 24.83, 22.61. HRMS (ESI, 2M + Na): calcd. for 
C80H140NaO10 1284.0344 ; found 1284.0354. 
 
(R)-3-(benzyloxy)propane-1,2-diyl bis(14-methylpentadecanoate) 
 (2-27p). The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 1 : 20) to give 2-27p (0.19 g, 81%) as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.38 – 7.26 (m, 5H), 5.27 – 5.21 (m, 1H), 4.54 (q, 
J = 12.1 Hz, 2H), 4.34 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 
1H), 3.62 – 3.56 (m, 2H), 2.30 (dt, J = 21.3, 7.5 Hz, 4H), 1.67 – 1.57 (m, 4H), 
1.51 (dt, J = 13.3, 6.6 Hz, 2H), 1.25 (s, 36H), 1.18 – 1.11 (m, 4H), 0.86 (d, J = 
6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 173.39, 173.09, 137.69, 128.40, 
127.76, 127.60, 73.29, 69.98, 68.24, 62.63, 39.04, 34.31, 34.10, 29.93, 29.71, 
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29.67, 29.65, 29.61, 29.47, 29.27, 29.11, 29.07, 27.95, 27.40, 24.94, 24.86, 
22.64. HRMS (ESI, 2M + Na): calcd. for C84H148NaO10 1340.0965 ; found 
1340.0973. 
 
(R)-3-(benzyloxy)propane-1,2-diyl dioctanoate (2-27q). The crude 
mixture was purified by flash chromatography (ethyl acetate : hexane = 1 : 20) 
to give 2-27q (0.13 g, 84%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.31 (tq, J = 14.0, 7.0 Hz, 5H), 5.28 – 5.21 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 
4.34 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.65 – 3.54 
(m, 2H), 2.30 (dt, J = 21.8, 7.5 Hz, 4H), 1.60 (dt, J = 14.0, 7.1 Hz, 4H), 1.29 – 
1.26 (m, 16H), 0.87 (t, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
173.38, 173.08, 137.64, 128.37, 127.73, 127.58, 73.24, 69.94, 68.18, 62.60, 
34.27, 34.05, 31.60, 29.00, 28.97, 28.88, 24.89, 24.81, 22.55, 14.01. HRMS 
(ESI, M + Na): calcd. for C26H42NaO5 457.2924 ; found 457.2934. 
 
(R)-3-(benzyloxy)propane-1,2-diyl didodecanoate (2-27r). The crude 
mixture was purified by flash chromatography (ethyl acetate : hexane = 1 : 20) 
to give 2-27r (0.15 g, 79%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.32 (td, J = 14.2, 7.3 Hz, 5H), 5.27 – 5.22 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 
4.35 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.59 (dd, J = 
5.1, 1.6 Hz, 2H), 2.30 (dt, J = 21.3, 7.6 Hz, 4H), 1.65 – 1.56 (m, 4H), 1.26 (s, 
32H), 0.88 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 173.37, 173.07, 
137.69, 128.39, 127.74, 127.59, 73.28, 69.98, 68.24, 62.62, 34.30, 34.09, 
31.88, 29.59, 29.45, 29.31, 29.26, 29.09, 29.06, 24.93, 24.85, 22.65, 14.07. 





(R)-3-(benzyloxy)propane-1,2-diyl ditetradecanoate (2-27s). The crude 
mixture was purified by flash chromatography (ethyl acetate : hexane = 1 : 20) 
to give 2-27s (0.17 g, 80%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.32 (td, J = 14.1, 7.2 Hz, 5H), 5.29 – 5.19 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 
4.35 (dd, J = 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.65 – 3.53 
(m, 2H), 2.30 (dt, J = 21.2, 7.6 Hz, 4H), 1.25 (s, 40H), 0.88 (t, J = 6.9 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 173.39, 173.09, 137.69, 128.39, 127.75, 
127.60, 73.29, 69.98, 68.25, 62.63, 34.31, 34.10, 31.90, 29.66, 29.64, 29.61, 
29.46, 29.33, 29.27, 29.10, 29.07, 24.94, 24.86, 22.66, 14.08. HRMS (ESI, 2M 
+ Na): calcd. for C76H132NaO10 1227.9713 ; found 1227.9718. 
 
(R)-3-(benzyloxy)propane-1,2-diyl dipalmitate (2-27t). The crude 
mixture was purified by flash chromatography (ethyl acetate : hexane = 1 : 20) 
to give 2-27t (0.20 g, 85%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.37 – 7.27 (m, 5H), 5.28 – 5.20 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.35 (dd, J 
= 11.9, 3.7 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.64 – 3.54 (m, 2H), 2.30 
(dt, J = 21.3, 7.5 Hz, 4H), 1.65 – 1.55 (m, 4H), 1.26 (s, 48H), 0.88 (t, J = 6.8 
Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 173.39, 173.09, 137.71, 128.40, 
127.76, 127.60, 73.29, 69.99, 68.26, 62.64, 34.32, 34.11, 31.91, 29.68, 29.65, 
29.62, 29.47, 29.35, 29.28, 29.11, 29.08, 24.94, 24.87, 22.67, 14.09. HRMS 





(R)-3-(benzyloxy)propane-1,2-diyl diheptadecanoate (2-27u). The crude 
mixture was purified by flash chromatography (ethyl acetate : hexane = 1 : 20) 
to give 2-27u (0.19 g, 81%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
7.36 – 7.27 (m, 5H), 5.27 – 5.19 (m, 1H), 4.54 (q, J = 12.1 Hz, 2H), 4.35 (dd, J 
= 11.9, 3.8 Hz, 1H), 4.19 (dd, J = 11.9, 6.4 Hz, 1H), 3.64 – 3.55 (m, 2H), 2.35 
– 2.25 (m, 4H), 1.65 – 1.55 (m, 4H), 1.26 (s, 52H), 0.88 (t, J = 7.0 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 173.37, 173.07, 137.73, 128.40, 127.76, 
127.61, 73.31, 70.02, 68.29, 62.65, 34.33, 34.11, 31.91, 29.69, 29.65, 29.62, 
29.48, 29.34, 29.27, 29.12, 29.09, 24.95, 24.88, 22.67, 14.08. HRMS (ESI, 2M 
+ Na): calcd. for C88H156NaO10 1396.1596 ; found 1396.1603. 
 
General procedure for the synthesis of 2-28. To a solution of 2-27  (0.20 
g) in ethanol : acetic acid (13 : 1; 4.30 mL) was added palladium on charcoal 
(Pd/C) (0.02 g, 10% Pd content). The reaction mixture was stirred at room 
temperature under an atmosphere of hydrogen for 12 h before being filtered 
through a pad of celite. The filtrate was then concentrated to give 2-28. 
 
(R)-3-hydroxy-2-(13-methyltetradecanoyloxy)propyl  
15-methylhexadecanoate (2-28a). 2-28a (0.15 g, 87%) was obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.12 – 5.01 (m, 1H), 4.30 (d, J = 
4.5 Hz, 1H), 4.24 (d, J = 5.7 Hz, 1H), 3.76 – 3.68 (m, 2H), 2.33 (dt, J = 11.5, 
7.5 Hz, 4H), 1.61 (dd, J = 14.3, 7.2 Hz, 4H), 1.51 (dt, J = 13.2, 6.6 Hz, 2H), 
1.25 (s, 36H), 1.17 – 1.11 (m, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR (126 
MHz, CDCl3) δ 173.76, 173.42, 72.11, 62.01, 61.54, 39.05, 34.28, 34.10, 
29.93, 29.70, 29.68, 29.64, 29.60, 29.46, 29.25, 29.11, 29.08, 27.95, 27.40, 
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24.93, 24.88, 22.64. HRMS (ESI, 2M + Na): calcd. for C70H136NaO10 
1160.0031 ; found 1160.0039. 
 
(R)-3-hydroxy-2-(14-methylpentadecanoyloxy)propyl  
15-methylhexadecanoate (2-28b). 2-28b (0.15 g, 89%) was obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.12 – 5.04 (m, 1H), 4.32 (dd, J = 
11.9, 4.4 Hz, 1H), 4.23 (dd, J = 11.9, 5.7 Hz, 1H), 3.72 (d, J = 4.6 Hz, 2H), 
2.37 – 2.30 (m, 4H), 1.61 (d, J = 7.2 Hz, 4H), 1.53 – 1.48 (m, 2H), 1.25 (s, 
38H), 1.14 (d, J = 7.0 Hz, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, 
CDCl3) δ 173.78, 173.43, 72.10, 62.00, 61.53, 39.05, 34.28, 34.09, 29.93, 
29.71, 29.67, 29.64, 29.60, 29.46, 29.25, 29.11, 29.08, 27.95, 27.41, 24.93, 
24.87, 22.64. HRMS (ESI, 2M + Na): calcd. for C72H140NaO10 1188.0339 ; 
found 1188.0349. 
 
(R)-3-hydroxypropane-1,2-diyl bis(15-methylhexadecanoate) (2-28c). 2-
28c (0.14 g, 83%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3) 
δ 5.10 – 5.04 (m, 1H), 4.32 (dd, J = 11.9, 4.5 Hz, 1H), 4.23 (dd, J = 11.9, 5.7 
Hz, 1H), 3.72 (dd, J = 5.0, 1.2 Hz, 2H), 2.33 (dt, J = 11.3, 7.6 Hz, 4H), 1.62 
(dt, J = 14.4, 7.3 Hz, 4H), 1.51 (dt, J = 13.3, 6.6 Hz, 2H), 1.25 (s, 40H), 1.17 – 
1.11 (m, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 
173.78, 173.43, 72.10, 62.00, 61.54, 39.05, 34.28, 34.10, 29.94, 29.71, 29.68, 
29.64, 29.61, 29.46, 29.26, 29.11, 29.08, 27.95, 27.41, 24.93, 24.88, 22.64. 






15-methylhexadecanoate (2-28d). 2-28d (0.16 g, 91%) was obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.11 – 5.02 (m, 1H), 4.31 (dd, J = 
11.9, 4.3 Hz, 1H), 4.22 (dd, J = 11.9, 5.8 Hz, 1H), 3.71 (d, J = 4.8 Hz, 2H), 
2.35 – 2.29 (m, 4H), 1.61 (dd, J = 14.3, 7.1 Hz, 4H), 1.50 (dt, J = 13.2, 6.6 Hz, 
1H), 1.24 (s, 32H), 1.14 (d, J = 4.8 Hz, 4H), 0.85 (t, J = 3.1 Hz, 15H). 13C 
NMR (126 MHz, CDCl3) δ 173.75, 173.42, 72.07, 62.04, 61.45, 44.23, 39.03, 
34.26, 34.07, 30.57, 30.23, 29.91, 29.69, 29.65, 29.62, 29.59, 29.47, 29.44, 
29.39, 29.25, 29.24, 29.09, 29.05, 27.93, 27.39, 24.90, 24.85, 24.52, 




15-methylhexadecanoate (2-28e). 2-28e (0.16 g, 90%) was obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.10 – 5.06 (m, 1H), 4.32 (dd, J = 
11.9, 4.5 Hz, 1H), 4.23 (dd, J = 11.9, 5.7 Hz, 1H), 3.73 (dd, J = 5.0, 1.3 Hz, 
2H), 2.33 (dt, J = 11.8, 7.6 Hz, 4H), 1.67 – 1.58 (m, 4H), 1.51 (dt, J = 13.3, 6.6 
Hz, 1H), 1.25 (s, 34H), 1.17 – 1.12 (m, 4H), 0.86 (t, J = 3.3 Hz, 15H). 13C 
NMR (126 MHz, CDCl3) δ 173.77, 173.42, 72.10, 62.00, 61.55, 44.26, 39.05, 
34.28, 34.10, 30.62, 30.26, 29.94, 29.71, 29.69, 29.68, 29.64, 29.63, 29.61, 
29.47, 29.46, 29.41, 29.25, 29.11, 29.08, 27.95, 27.41, 24.93, 24.88, 24.56, 







15-methylhexadecanoate (2-28f). 2-28f (0.16 g, 95%) was obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.14 – 5.02 (m, 1H), 4.31 (dd, J = 
11.9, 4.4 Hz, 1H), 4.23 (dd, J = 11.9, 5.7 Hz, 1H), 3.72 (dd, J = 5.0, 1.2 Hz, 
2H), 2.33 (dt, J = 11.6, 7.6 Hz, 4H), 1.66 – 1.56 (m, 4H), 1.50 (td, J = 13.3, 6.6 
Hz, 1H), 1.25 (s, 36H), 1.16 – 1.10 (m, 4H), 0.85 (t, J = 3.3 Hz, 15H). 13C 
NMR (126 MHz, CDCl3) δ 173.78, 173.43, 72.10, 62.01, 61.52, 44.26, 39.05, 
34.28, 34.09, 30.63, 30.25, 29.93, 29.72, 29.71, 29.67, 29.67, 29.64, 29.61, 
29.60, 29.46, 29.41, 29.25, 29.11, 29.08, 27.95, 27.40, 24.92, 24.87, 24.55, 




15-methylhexadecanoate (2-28g). 2-28g (0.15 g, 88%) was obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.10 – 5.03 (m, 1H), 4.31 (dd, J = 
11.9, 4.3 Hz, 1H), 4.21 (dd, J = 11.9, 5.8 Hz, 1H), 3.71 (d, J = 4.8 Hz, 2H), 
2.31 (dt, J = 11.8, 7.5 Hz, 4H), 1.60 (dd, J = 14.2, 7.1 Hz, 4H), 1.50 (dt, J = 
13.2, 6.6 Hz, 1H), 1.24 (s, 35H), 1.12 (dd, J = 18.8, 6.6 Hz, 4H), 0.89 – 0.77 
(m, 12H). 13C NMR (126 MHz, CDCl3) δ 173.74, 173.42, 72.07, 62.05, 61.42, 
39.02, 36.60, 34.35, 34.25, 34.06, 29.96, 29.91, 29.69, 29.65, 29.62, 29.58, 
29.45, 29.23, 29.08, 29.05, 27.92, 27.38, 27.06, 24.90, 24.84, 22.61, 19.17, 







15-methylhexadecanoate (2-28h). 2-28h (0.15 g, 87%) was obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.11 – 5.05 (m, 1H), 4.36 – 4.28 
(m, 1H), 4.23 (dd, J = 11.9, 5.7 Hz, 1H), 3.72 (d, J = 4.7 Hz, 2H), 2.33 (dt, J = 
11.6, 7.6 Hz, 4H), 1.61 (dd, J = 14.2, 7.1 Hz, 4H), 1.50 (dd, J = 13.3, 6.6 Hz, 
1H), 1.25 (s, 37H), 1.17 – 1.05 (m, 4H), 0.94 – 0.81 (m, 12H). 13C NMR (126 
MHz, CDCl3) δ 173.78, 173.43, 72.08, 61.99, 61.52, 39.04, 36.62, 34.38, 
34.27, 34.09, 30.00, 29.93, 29.71, 29.68, 29.64, 29.61, 29.47, 29.25, 29.11, 
29.07, 27.95, 27.40, 27.09, 24.92, 24.87, 22.64, 19.20, 11.39. HRMS (ESI, 2M 
+ Na): calcd. for C70H136NaO10 1160.0026 ; found 1160.0035. 
 
(2R)-3-hydroxy-2-(13-methylpentadecanoyloxy)propyl  
15-methylhexadecanoate (2-28i). 2-28i (0.15 g, 85%) was obtained as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.09 – 5.02 (m, 1H), 4.31 (dd, J = 
11.9, 4.2 Hz, 1H), 4.21 (dd, J = 11.9, 5.8 Hz, 1H), 3.71 (d, J = 4.5 Hz, 2H), 
2.31 (dt, J = 11.5, 7.5 Hz, 4H), 1.60 (dd, J = 13.6, 6.7 Hz, 4H), 1.50 (dt, J = 
13.2, 6.6 Hz, 1H), 1.24 (s, 39H), 1.16 – 1.05 (m, 4H), 0.89 – 0.77 (m, 12H). 
13C NMR (126 MHz, CDCl3) δ 173.73, 173.41, 72.07, 62.06, 61.40, 39.02, 
36.60, 34.35, 34.24, 34.06, 29.99, 29.91, 29.68, 29.65, 29.62, 29.58, 29.44, 
29.23, 29.08, 29.05, 27.92, 27.38, 27.07, 24.89, 24.84, 22.60, 19.16, 11.35. 







(R)-2-(decanoyloxy)-3-hydroxypropyl 15-methylhexadecanoate (2-28j). 
2-28j (0.15 g, 88%) was obtained as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 5.10 – 5.01 (m, 1H), 4.30 (dd, J = 11.9, 4.3 Hz, 1H), 4.20 (dd, J = 
11.9, 5.9 Hz, 1H), 3.70 (d, J = 4.9 Hz, 2H), 2.30 (dt, J = 11.8, 7.6 Hz, 4H), 
1.59 (dd, J = 14.2, 7.1 Hz, 4H), 1.49 (dt, J = 13.2, 6.6 Hz, 1H), 1.23 (s, 32H), 
1.16 – 1.09 (m, 2H), 0.85 (dd, J = 12.6, 6.7 Hz, 9H). 13C NMR (126 MHz, 
CDCl3) δ 173.72, 173.41, 72.05, 62.08, 61.35, 39.00, 34.23, 34.04, 31.80, 
29.89, 29.66, 29.63, 29.59, 29.56, 29.42, 29.37, 29.21, 29.06, 29.02, 27.90, 
27.36, 24.87, 24.82, 22.58, 14.02. HRMS (ESI, 2M + Na): calcd. for 
C60H116NaO10 1019.8466 ; found 1019.8475. 
 
(R)-2-(dodecanoyloxy)-3-hydroxypropyl 15-methylhexadecanoate (2-
28k). 2-28k (0.16 g, 91%) was obtained as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 5.13 – 5.03 (m, 1H), 4.32 (dd, J = 11.9, 4.4 Hz, 1H), 4.23 (dd, J = 
11.9, 5.7 Hz, 1H), 3.72 (d, J = 5.3 Hz, 2H), 2.33 (dt, J = 11.4, 7.6 Hz, 4H), 
1.61 (dd, J = 14.2, 7.1 Hz, 4H), 1.51 (dt, J = 13.3, 6.6 Hz, 1H), 1.25 (s, 36H), 
1.18 – 1.11 (m, 2H), 0.87 (dd, J = 12.9, 6.6 Hz, 9H). 13C NMR (126 MHz, 
CDCl3) δ 173.79, 173.44, 72.09, 62.00, 61.52, 39.04, 34.28, 34.09, 31.89, 
29.93, 29.71, 29.68, 29.64, 29.60, 29.45, 29.32, 29.25, 29.11, 29.07, 27.95, 
27.40, 24.92, 24.87, 22.66, 22.64, 14.09. HRMS (ESI, 2M + Na): calcd. for 
C64H124NaO10 1075.9092 ; found 1075.9099. 
 
(R)-3-hydroxy-2-(tetradecanoyloxy)propyl 15-methylhexadecanoate (2-
28l). 2-28l (0.16 g, 92%) was obtained as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 5.08 (dd, J = 10.1, 5.1 Hz, 1H), 4.32 (dd, J = 11.9, 4.5 Hz, 1H), 4.23 
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(dd, J = 11.9, 5.7 Hz, 1H), 3.73 (dd, J = 5.0, 1.3 Hz, 2H), 2.33 (dt, J = 11.4, 7.6 
Hz, 4H), 1.62 (dq, J = 14.4, 7.3 Hz, 4H), 1.51 (dt, J = 13.3, 6.6 Hz, 1H), 1.25 
(s, 40H), 1.18 – 1.10 (m, 2H), 0.87 (dd, J = 12.8, 6.7 Hz, 9H). 13C NMR (126 
MHz, CDCl3) δ 173.76, 173.41, 72.12, 62.01, 61.56, 39.06, 34.29, 34.10, 
31.91, 29.94, 29.71, 29.67, 29.64, 29.60, 29.46, 29.34, 29.26, 29.12, 29.08, 
27.96, 27.41, 24.94, 24.88, 22.67, 22.64, 14.09. HRMS (ESI, 2M + Na): calcd. 
for C68H132NaO10 1131.9718 ; found 1131.9726. 
 
(R)-1-hydroxy-3-(15-methylhexadecanoyloxy)propan-2-yl icosanoate 
(2-28m). 2-28m (0.15 g, 85%) was obtained as a white solid. 1H NMR (500 
MHz, CDCl3) δ 5.08 (q, J = 5.0 Hz, 1H), 4.32 (dd, J = 11.9, 4.5 Hz, 1H), 4.23 
(dd, J = 11.9, 5.7 Hz, 1H), 3.72 (d, J = 4.6 Hz, 2H), 2.33 (dt, J = 11.2, 7.6 Hz, 
4H), 1.61 (dd, J = 14.2, 7.1 Hz, 4H), 1.51 (dt, J = 13.3, 6.6 Hz, 1H), 1.25 (s, 
52H), 1.18 – 1.11 (m, 2H), 0.87 (dd, J = 12.7, 6.7 Hz, 9H). 13C NMR (126 
MHz, CDCl3) δ 173.78, 173.43, 72.09, 62.00, 61.53, 39.05, 34.28, 34.10, 
31.91, 29.94, 29.72, 29.69, 29.65, 29.61, 29.47, 29.35, 29.26, 29.11, 29.08, 
27.95, 27.41, 24.93, 24.88, 22.67, 22.64, 14.10. HRMS (ESI, 2M + Na): calcd. 
for C80H156NaO10 1300.1596 ; found 1300.1601. 
 
(R)-3-hydroxypropane-1,2-diyl bis(12-methyltridecanoate) (2-28n). 2-
28n (0.14 g, 85%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3) 
δ 5.12 – 5.01 (m, 1H), 4.31 (dd, J = 11.9, 4.4 Hz, 1H), 4.22 (dd, J = 11.9, 5.8 
Hz, 1H), 3.71 (d, J = 4.6 Hz, 2H), 2.36 – 2.30 (m, 4H), 1.61 (dd, J = 14.2, 7.1 
Hz, 4H), 1.51 (dd, J = 13.3, 6.6 Hz, 2H), 1.25 (s, 28H), 1.17 – 1.11 (m, 4H), 
0.85 (d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 173.78, 173.44, 
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72.07, 62.03, 61.46, 39.02, 34.26, 34.08, 29.90, 29.65, 29.59, 29.45, 29.24, 
29.09, 29.06, 27.93, 27.38, 24.90, 24.85, 22.62. HRMS (ESI, 2M + Na): calcd. 
for C62H120NaO10 1047.8774 ; found 1047.8782. 
 
(R)-3-hydroxypropane-1,2-diyl bis(13-methyltetradecanoate) (2-28o). 
2-28o (0.15 g, 89%) was obtained as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 5.11 – 5.05 (m, 1H), 4.31 (dd, J = 11.9, 4.4 Hz, 1H), 4.25 – 4.20 (m, 
1H), 3.72 (d, J = 4.5 Hz, 2H), 2.32 (dt, J = 11.3, 7.6 Hz, 4H), 1.65 – 1.57 (m, 
4H), 1.50 (td, J = 13.2, 6.6 Hz, 2H), 1.25 (s, 32H), 1.18 – 1.10 (m, 4H), 0.85 
(d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 173.77, 173.44, 72.08, 
62.02, 61.48, 39.03, 34.27, 34.08, 29.92, 29.69, 29.63, 29.60, 29.45, 29.25, 
29.10, 29.07, 27.94, 27.39, 24.91, 24.86, 22.63. HRMS (ESI, 2M + Na): calcd. 
for C66H128NaO10 1103.9400 ; found 1103.9405. 
 
(R)-3-hydroxypropane-1,2-diyl bis(14-methylpentadecanoate) (2-28p). 
2-28p (0.16 g, 94%) was obtained as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 5.14 – 5.04 (m, 1H), 4.32 (dd, J = 11.9, 4.3 Hz, 1H), 4.23 (dd, J = 
11.9, 5.7 Hz, 1H), 3.72 (d, J = 4.7 Hz, 2H), 2.33 (dt, J = 11.1, 7.6 Hz, 4H), 
1.61 (dd, J = 13.7, 6.8 Hz, 4H), 1.51 (dt, J = 13.2, 6.6 Hz, 2H), 1.25 (s, 36H), 
1.14 (d, J = 6.1 Hz, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, 
CDCl3) δ 173.78, 173.43, 72.10, 62.00, 61.53, 39.05, 34.28, 34.09, 29.93, 
29.71, 29.67, 29.64, 29.60, 29.46, 29.25, 29.11, 29.08, 27.95, 27.40, 24.93, 





(R)-3-hydroxypropane-1,2-diyl dioctanoate (2-28q). 2-28q (0.15 g, 93%) 
was obtained as a white solid. 1H NMR (300 MHz, CDCl3) δ 5.11 – 4.99 (m, 
1H), 4.31 (dd, J = 11.9, 4.4 Hz, 1H), 4.21 (dd, J = 11.9, 5.8 Hz, 1H), 3.71 (d, J 
= 5.0 Hz, 2H), 2.32 (dd, J = 14.6, 7.3 Hz, 4H), 1.61 (d, J = 3.8 Hz, 4H), 1.27 
(s, 16H), 0.87 (t, J = 6.6 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 173.79, 
173.46, 72.06, 62.04, 61.43, 34.24, 34.06, 31.60, 28.98, 28.86, 24.88, 24.83, 
22.54, 14.00. HRMS (ESI, M + Na): calcd. for C19H36NaO5 367.2455 ; found 
367.2462. 
 
(R)-3-hydroxypropane-1,2-diyl didodecanoate (2-28r). 2-28r (0.16 g, 
95%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.12 – 5.03 
(m, 1H), 4.31 (dd, J = 11.9, 4.4 Hz, 1H), 4.22 (dd, J = 11.9, 5.7 Hz, 1H), 3.72 
(d, J = 4.5 Hz, 2H), 2.32 (dt, J = 11.2, 7.6 Hz, 4H), 1.61 (dd, J = 14.2, 7.1 Hz, 
4H), 1.34 – 1.22 (m, 32H), 0.87 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) δ 173.77, 173.43, 72.08, 62.01, 61.50, 34.27, 34.08, 31.88, 29.58, 
29.44, 29.31, 29.24, 29.09, 29.06, 24.91, 24.86, 22.65, 14.07. HRMS (ESI, 2M 
+ Na): calcd. for C54H104NaO10 935.7527 ; found 935.7535. 
 
(R)-3-hydroxypropane-1,2-diyl ditetradecanoate (2-28s). 2-28s (0.16 g, 
93%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.10 – 5.05 
(m, 1H), 4.31 (dd, J = 11.9, 4.3 Hz, 1H), 4.23 (dd, J = 11.9, 5.7 Hz, 1H), 3.72 
(d, J = 4.6 Hz, 2H), 2.32 (dt, J = 11.2, 7.6 Hz, 4H), 1.61 (dd, J = 13.7, 6.8 Hz, 
4H), 1.25 (s, 40H), 0.87 (t, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
173.78, 173.44, 72.09, 62.01, 61.51, 34.27, 34.09, 31.90, 29.66, 29.63, 29.59, 
29.45, 29.33, 29.25, 29.10, 29.07, 24.92, 24.87, 22.66, 14.08. HRMS (ESI, 2M 
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+ Na): calcd. for C62H120NaO10 1047.8779 ; found 1047.8787. 
 
(R)-3-hydroxypropane-1,2-diyl dipalmitate (2-28t). 2-28t (0.16 g, 88%) 
was obtained as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.08 (p, J = 4.9 
Hz, 1H), 4.31 (dd, J = 11.9, 4.3 Hz, 1H), 4.23 (dd, J = 11.9, 5.7 Hz, 1H), 3.72 
(d, J = 4.9 Hz, 2H), 2.32 (dt, J = 11.2, 7.6 Hz, 4H), 1.60 (dd, J = 14.1, 7.0 Hz, 
4H), 1.25 (s, 48H), 0.87 (t, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
173.77, 173.42, 72.09, 62.01, 61.52, 34.27, 34.09, 31.90, 29.68, 29.64, 29.60, 
29.46, 29.34, 29.25, 29.11, 29.07, 24.92, 24.87, 22.67, 14.08. HRMS (ESI, 2M 
+ Na): calcd. for C70H136NaO10 1160.0031 ; found 1160.0040. 
 
(R)-3-hydroxypropane-1,2-diyl diheptadecanoate (2-28u). 2-28u (0.16 g, 
90%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.12 – 5.05 
(m, 1H), 4.32 (dd, J = 11.9, 4.4 Hz, 1H), 4.23 (dd, J = 11.9, 5.7 Hz, 1H), 3.72 
(d, J = 4.5 Hz, 2H), 2.32 (dt, J = 11.3, 7.6 Hz, 4H), 1.66 – 1.57 (m, 4H), 1.25 
(s, 52H), 0.87 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 173.75, 
173.42, 72.12, 62.02, 61.54, 34.28, 34.10, 31.91, 29.68, 29.64, 29.60, 29.46, 
29.34, 29.25, 29.11, 29.08, 24.93, 24.88, 22.67, 14.08. HRMS (ESI, 2M + 
Na): calcd. for C74H144NaO10 1216.0657 ; found 1216.0663. 
 
General procedure for the synthesis of 2-2. Imidazole (11.56 mmol) was 
dissolved in toluene (9 mL), and the solution was cooled to 0oC. PCl3 (2.55 
mmol) in toluene (2.50 mL) and then triethylamine (6.60 mmol) were added, 
and the reaction mixture was stirred for 30 min before being cooled to -10oC. 
A solution of 2-29 (0.5 mmol) in a mixture of toluene (7 mL) and 
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dichloromethane (2.50 mL) was then added dropwise to the reaction mixture. 
After the addition, the reaction mixture was allowed to stir for a further 1h at 
10oC before being quenched by addition of water : triehtylamine (1: 4; 14 
mL). The aqueous layer was extracted with dichloromethane (3x). The 
combined organic layers were dried over MgSO4, filtered and concentrated. 
The crude mixture was purified by flash chromatography to give 2-2. 
 
triethylammonium (S)-3-(15-methylhexadecanoyloxy)-2-(13-
methyltetradecanoyloxy)propyl phosphonate (2-2a). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 1% 
v/v triethylamine) to give 2-2a (0.25 g, 68%) as a white gum. 1H NMR (500 
MHz, CDCl3) δ 5.23 – 5.16 (m, 1H), 4.35 (dd, J = 11.9, 3.7 Hz, 1H), 4.15 (dd, 
J = 11.9, 6.3 Hz, 1H), 4.01 (dd, J = 8.1, 5.2 Hz, 2H), 3.18 – 2.98 (m, 5H), 2.28 
(dd, J = 16.3, 8.5 Hz, 4H), 1.58 (dd, J = 12.2, 6.4 Hz, 4H), 1.49 (dt, J = 13.3, 
6.6 Hz, 2H), 1.32 (t, J = 7.3 Hz, 9H), 1.23 (s, 36H), 1.16 – 1.10 (m, 4H), 0.84 
(d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 173.33, 172.94, 70.16, 
70.11, 62.30, 62.20, 62.17, 45.60, 39.02, 34.23, 34.04, 29.91, 29.69, 29.66, 
29.63, 29.61, 29.46, 29.26, 29.10, 29.08, 27.92, 27.38, 24.83, 22.61, 8.50. 31P 
NMR (202 MHz, CDCl3) δ 5.22. HRMS (ESI, M - H): calcd. for C35H68O7P 
631.4708 ; found 631.4714. 
 
triethylammonium (S)-3-(15-methylhexadecanoyloxy)-2-(14-
methylpentadecanoyloxy)propyl phosphonate (2-2b). The crude mixture 
was purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 
1% v/v triethylamine) to give 2-2b (0.26 g, 70%) as a white gum. 1H NMR 
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(500 MHz, CDCl3) δ 5.17 – 5.11 (m, 1H), 4.30 (dd, J = 11.9, 3.6 Hz, 1H), 4.10 
(dd, J = 11.9, 6.4 Hz, 1H), 3.93 (dd, J = 7.9, 5.3 Hz, 2H), 3.01 (q, J = 7.3 Hz, 
6H), 2.22 (dd, J = 15.6, 8.0 Hz, 4H), 1.52 (dd, J = 12.2, 6.5 Hz, 4H), 1.44 (dt, J 
= 13.3, 6.6 Hz, 2H), 1.27 (t, J = 7.3 Hz, 9H), 1.18 (s, 38H), 1.08 (d, J = 7.0 Hz, 
4H), 0.79 (d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 173.21, 172.82, 
70.25, 70.19, 62.33, 61.85, 61.82, 45.43, 38.89, 34.13, 33.93, 29.78, 29.56, 
29.53, 29.51, 29.47, 29.33, 29.14, 28.97, 28.95, 27.79, 27.25, 24.73, 24.71, 
22.49, 8.39. 31P NMR (202 MHz, CDCl3) δ 5.01. HRMS (ESI, M - H): calcd. 
for C36H70O7P 645.4865 ; found 645.4870. 
 
(2S)-3-(hydroxyhydrophosphoryloxy)propane-1,2-diyl bis(15-
methylhexadecanoate), triethylammonium salt (2-2c). The crude mixture 
was purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 
1% v/v triethylamine) to give 2-2c (0.28 g, 73%) as a white gum. 1H NMR 
(500 MHz, CDCl3) δ 5.18 – 5.13 (m, 1H), 4.31 (dd, J = 11.9, 3.6 Hz, 1H), 4.11 
(dd, J = 11.9, 6.4 Hz, 1H), 3.94 (dd, J = 7.9, 5.3 Hz, 2H), 3.02 (q, J = 7.2 Hz, 
6H), 2.23 (dd, J = 15.7, 7.9 Hz, 4H), 1.57 – 1.50 (m, 4H), 1.45 (dt, J = 13.3, 
6.6 Hz, 2H), 1.28 (t, J = 7.3 Hz, 9H), 1.19 (s, 40H), 1.11 – 1.06 (m, 4H), 0.80 
(d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 173.25, 172.85, 70.27, 
70.21, 62.35, 61.86, 61.83, 45.43, 38.91, 34.15, 33.95, 29.80, 29.58, 29.55, 
29.52, 29.50, 29.35, 29.16, 29.15, 28.99, 28.97, 27.81, 27.27, 24.75, 24.73, 
22.51, 8.40. 31P NMR (202 MHz, CDCl3) δ 5.07.  HRMS (ESI, M - H): calcd. 






methylhexadecanoyloxy)propyl phosphonate (2-2d). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 1% 
v/v triethylamine) to give 2-2d (0.26 g, 72%) as a white gum. 1H NMR (500 
MHz, CDCl3) δ 5.18 – 5.11 (m, 1H), 4.30 (dd, J = 11.9, 3.6 Hz, 1H), 4.10 (dd, 
J = 11.9, 6.4 Hz, 1H), 3.94 (dd, J = 7.9, 5.3 Hz, 2H), 3.01 (dd, J = 13.5, 6.4 
Hz, 6H), 2.23 (dd, J = 16.7, 7.8 Hz, 4H), 1.52 (d, J = 12.8 Hz, 4H), 1.44 (dt, J 
= 13.2, 6.6 Hz, 1H), 1.27 (t, J = 7.3 Hz, 9H), 1.18 (s, 32H), 1.08 (d, J = 4.3 Hz, 
4H), 0.79 (t, J = 3.2 Hz, 15H). 13C NMR (126 MHz, CDCl3) δ 173.19, 172.80, 
70.15, 70.09, 62.24, 61.94, 61.91, 45.45, 44.10, 38.89, 34.11, 33.91, 30.45, 
30.09, 29.77, 29.55, 29.52, 29.49, 29.46, 29.35, 29.32, 29.26, 29.15, 29.13, 
28.97, 28.94, 27.78, 27.25, 24.72, 24.70, 24.40, 22.49, 8.39. 31P NMR (202 




methylhexadecanoyloxy)propyl phosphonate (2-2e). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 1% 
v/v triethylamine) to give 2-2e (0.25 g, 67%) as a white gum. 1H NMR (500 
MHz, CDCl3) δ 5.19 – 5.12 (m, 1H), 4.31 (dd, J = 11.9, 3.6 Hz, 1H), 4.11 (dd, 
J = 11.9, 6.3 Hz, 1H), 3.97 (dd, J = 7.9, 5.3 Hz, 2H), 3.11 – 2.97 (m, 6H), 2.24 
(dd, J = 17.2, 7.7 Hz, 4H), 1.58 – 1.50 (m, 4H), 1.46 (dt, J = 13.2, 6.6 Hz, 1H), 
1.29 (t, J = 7.3 Hz, 9H), 1.20 (s, 34H), 1.09 (d, J = 4.0 Hz, 4H), 0.80 (t, J = 3.2 
Hz, 15H). 13C NMR (126 MHz, CDCl3) δ 173.23, 172.83, 70.10, 70.04, 62.22, 
62.08, 62.05, 45.56, 44.14, 38.93, 34.14, 33.95, 30.51, 30.13, 29.82, 29.60, 
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29.57, 29.54, 29.51, 29.37, 29.30, 29.17, 29.01, 28.98, 27.83, 27.29, 24.74, 
24.44, 22.53, 8.44. 31P NMR (202 MHz, CDCl3) δ 4.96. HRMS (ESI, M - H): 
calcd. for C35H68O7P 631.4708 ; found 631.4708. 
 
triethylammonium (S)-2-(13,13-dimethyltetradecanoyloxy)-3-(15-
methylhexadecanoyloxy)propyl phosphonate (2-2f). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 1% 
v/v triethylamine) to give 2-2f (0.24 g, 65%) as a white gum. 1H NMR (500 
MHz, CDCl3) δ 5.20 – 5.12 (m, 1H), 4.31 (dd, J = 11.9, 3.6 Hz, 1H), 4.11 (dd, 
J = 11.9, 6.4 Hz, 1H), 3.95 (dd, J = 8.0, 5.2 Hz, 2H), 3.03 (q, J = 7.0 Hz, 5H), 
2.24 (dd, J = 16.3, 7.9 Hz, 4H), 1.58 – 1.50 (m, 4H), 1.45 (dd, J = 13.3, 6.6 
Hz, 1H), 1.28 (t, J = 7.3 Hz, 9H), 1.20 (s, 36H), 1.09 (s, 4H), 0.80 (t, J = 3.3 
Hz, 15H). 13C NMR (126 MHz, CDCl3) δ 173.25, 172.86, 70.20, 70.14, 62.30, 
61.96, 61.93, 45.46, 44.14, 38.92, 34.15, 33.95, 30.52, 30.13, 29.81, 29.61, 
29.59, 29.56, 29.53, 29.50, 29.36, 29.30, 29.18, 29.16, 29.00, 28.98, 27.82, 
27.28, 24.76, 24.74, 24.44, 22.53, 8.41. 31P NMR (202 MHz, CDCl3) δ 5.06. 
HRMS (ESI, M - H): calcd. for C36H70O7P 645.4865 ; found 645.4870. 
 
triethylammonium (2S)-3-(15-methylhexadecanoyloxy)-2-(11-
methyltridecanoyloxy)propyl phosphonate (2-2g). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 1% 
v/v triethylamine) to give 2-2g (0.24 g, 66%) as a white gum. 1H NMR (500 
MHz, CDCl3) δ 5.19 – 5.10 (m, 1H), 4.30 (dd, J = 11.9, 3.6 Hz, 1H), 4.10 (dd, 
J = 11.9, 6.4 Hz, 1H), 3.94 (dd, J = 8.0, 5.3 Hz, 2H), 3.01 (q, J = 7.2 Hz, 6H), 
2.23 (dd, J = 16.1, 8.0 Hz, 4H), 1.52 (dd, J = 12.7, 6.5 Hz, 4H), 1.44 (dt, J = 
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13.3, 6.6 Hz, 1H), 1.18 (s, 35H), 1.07 (dd, J = 11.6, 7.0 Hz, 4H), 0.80 – 0.75 
(m, 12H). 13C NMR (126 MHz, CDCl3) δ 173.22, 172.83, 70.24, 70.18, 62.32, 
61.88, 61.84, 45.39, 38.90, 36.48, 34.23, 34.14, 33.94, 29.85, 29.79, 29.57, 
29.53, 29.48, 29.33, 29.15, 29.14, 28.98, 28.95, 27.80, 27.26, 26.95, 24.74, 
24.72, 22.50, 19.06, 11.24, 8.38. 31P NMR (202 MHz, CDCl3) δ 5.07. HRMS 
(ESI, M - H): calcd. for C34H66O7P 617.4552 ; found 617.4561. 
 
triethylammonium (2S)-3-(15-methylhexadecanoyloxy)-2-(12-
methyltetradecanoyloxy)propyl phosphonate (2-2h). The crude mixture 
was purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 
1% v/v triethylamine) to give 2-2h (0.27 g, 73%) as a white gum. 1H NMR 
(500 MHz, CDCl3) δ 4.57 (dt, J = 10.6, 5.3 Hz, 1H), 4.23 – 4.12 (m, 4H), 3.03 
(td, J = 7.2, 3.8 Hz, 5H), 2.27 (t, J = 7.6 Hz, 4H), 1.59 – 1.52 (m, 4H), 1.47 (dt, 
J = 13.3, 6.6 Hz, 1H), 1.29 (t, J = 7.3 Hz, 9H), 1.21 (s, 37H), 1.12 – 1.02 (m, 
4H), 0.83 – 0.78 (m, 12H). 13C NMR (126 MHz, CDCl3) δ 173.27, 69.79, 
69.75, 63.65, 63.62, 45.47, 38.95, 36.53, 34.28, 34.00, 29.91, 29.84, 29.62, 
29.59, 29.55, 29.52, 29.38, 29.18, 29.06, 27.85, 27.31, 27.00, 24.74, 22.55, 
19.11, 11.29, 8.44. 31P NMR (202 MHz, CDCl3) δ 4.29. HRMS (ESI, M - H): 
calcd. for C35H68O7P 631.4708 ; found 631.4817. 
 
triethylammonium (2S)-3-(15-methylhexadecanoyloxy)-2-(13-
methylpentadecanoyloxy)propyl phosphonate (2-2i). The crude mixture 
was purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 
1% v/v triethylamine) to give 2-2i (0.28 g, 75%) as a white gum. 1H NMR 
(500 MHz, CDCl3) δ 5.22 – 5.13 (m, 1H), 4.32 (dd, J = 11.9, 3.7 Hz, 1H), 4.12 
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(dd, J = 11.9, 6.4 Hz, 1H), 3.98 (dd, J = 8.0, 5.2 Hz, 2H), 3.14 – 2.95 (m, 5H), 
2.25 (dd, J = 17.0, 7.7 Hz, 4H), 1.59 – 1.51 (m, 4H), 1.46 (dt, J = 13.2, 6.6 Hz, 
1H), 1.30 (t, J = 7.3 Hz, 9H), 1.21 (s, 39H), 1.13 – 1.02 (m, 4H), 0.85 – 0.77 
(m, 12H). 13C NMR (126 MHz, CDCl3) δ 173.26, 172.86, 70.09, 70.03, 62.22, 
62.12, 62.08, 45.58, 38.94, 36.53, 34.27, 34.15, 33.96, 29.93, 29.84, 29.62, 
29.59, 29.54, 29.39, 29.38, 29.19, 29.03, 29.00, 27.84, 27.31, 27.00, 24.77, 
24.76, 22.54, 19.11, 11.29, 8.45. 31P NMR (202 MHz, CDCl3) δ 5.13. HRMS 
(ESI, M - H): calcd. for C36H70O7P 645.4865 ; found 645.4873. 
 
triethylammonium (S)-2-(decanoyloxy)-3-(15-
methylhexadecanoyloxy)propyl phosphonate (2-2j). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 1% 
v/v triethylamine) to give 2-2j (0.22 g, 65%) as a white gum. 1H NMR (500 
MHz, CDCl3) δ 5.19 – 5.12 (m, 1H), 4.31 (dd, J = 11.9, 3.7 Hz, 1H), 4.11 (dd, 
J = 11.9, 6.4 Hz, 1H), 3.96 (dd, J = 8.1, 5.2 Hz, 2H), 3.03 (q, J = 6.9 Hz, 6H), 
2.24 (dd, J = 16.6, 7.8 Hz, 4H), 1.54 (dd, J = 13.0, 6.6 Hz, 4H), 1.46 (dt, J = 
13.3, 6.6 Hz, 1H), 1.28 (t, J = 7.3 Hz, 9H), 1.20 (s, 32H), 1.08 (d, J = 6.8 Hz, 
2H), 0.81 (dd, J = 12.3, 6.7 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 173.22, 
172.82, 70.19, 70.14, 62.28, 62.01, 61.97, 45.53, 38.93, 34.15, 33.96, 31.73, 
29.81, 29.58, 29.55, 29.52, 29.49, 29.35, 29.30, 29.15, 29.01, 28.97, 27.82, 
27.28, 24.75, 22.52, 13.95, 8.42. 31P NMR (202 MHz, CDCl3) δ 5.00. HRMS 







methylhexadecanoyloxy)propyl phosphonate (2-2k). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 1% 
v/v triethylamine) to give 2-2k (0.24 g, 68%) as a white gum. 1H NMR (500 
MHz, CDCl3) δ 5.11 (dd, J = 10.6, 4.5 Hz, 1H), 4.28 (dd, J = 11.9, 3.6 Hz, 
1H), 4.07 (dd, J = 11.9, 6.4 Hz, 1H), 3.91 (dd, J = 8.0, 5.2 Hz, 2H), 2.99 (q, J = 
7.2 Hz, 6H), 2.20 (dd, J = 15.8, 8.0 Hz, 4H), 1.53 – 1.47 (m, 4H), 1.42 (dt, J = 
13.3, 6.6 Hz, 1H), 1.25 (t, J = 7.3 Hz, 9H), 1.16 (s, 36H), 1.08 – 1.03 (m, 2H), 
0.77 (t, J = 6.3 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 173.14, 172.75, 70.16, 
70.10, 62.23, 61.82, 61.79, 45.43, 38.83, 34.06, 33.87, 31.68, 29.72, 29.50, 
29.47, 29.44, 29.41, 29.39, 29.26, 29.11, 29.07, 28.91, 28.88, 27.73, 27.19, 
24.67, 24.65, 22.43, 13.88, 8.35. 31P NMR (202 MHz, CDCl3) δ 4.89. HRMS 
(ESI, M - H): calcd. for C32H62O7P 589.4239 ; found 589.4241. 
 
triethylammonium (S)-3-(15-methylhexadecanoyloxy)-2-
(tetradecanoyloxy)propyl phosphonate (2-2l). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 1% 
v/v triethylamine) to give 2-2l (0.24 g, 67%) as a white gum. 1H NMR (500 
MHz, CDCl3) δ 5.16 – 5.09 (m, 1H), 4.29 (dd, J = 11.9, 3.5 Hz, 1H), 4.08 (dd, 
J = 11.9, 6.4 Hz, 1H), 3.90 (dd, J = 7.9, 5.3 Hz, 2H), 2.99 (q, J = 7.3 Hz, 6H), 
2.20 (dd, J = 15.4, 7.8 Hz, 4H), 1.50 (dd, J = 12.1, 6.4 Hz, 4H), 1.42 (dt, J = 
13.3, 6.6 Hz, 1H), 1.25 (t, J = 7.3 Hz, 9H), 1.16 (s, 40H), 1.08 – 1.02 (m, 2H), 
0.78 (dd, J = 12.6, 6.7 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 173.18, 
172.79, 70.28, 70.22, 62.33, 61.73, 61.70, 45.35, 38.85, 34.10, 33.89, 31.71, 
29.74, 29.51, 29.48, 29.45, 29.43, 29.28, 29.14, 29.08, 28.92, 28.90, 27.74, 
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27.21, 24.69, 24.67, 22.47, 22.45, 13.90, 8.34. 31P NMR (202 MHz, CDCl3) δ 
4.99. HRMS (ESI, M - H): calcd. for C34H66O7P 617.4552 ; found 617.4560. 
 
triethylammonium (S)-2-(icosanoyloxy)-3-(15-
methylhexadecanoyloxy)propyl phosphonate (2-2m). The crude mixture 
was purified by flash chromatography (dichloromethane : methanol = 20 : 1 + 
1% v/v triethylamine) to give 2-2m (0.28 g, 70%) as a white gum. 1H NMR 
(500 MHz, CDCl3) δ 5.24 – 5.15 (m, 1H), 4.39 – 4.30 (m, 1H), 4.15 (dd, J = 
11.9, 6.4 Hz, 1H), 3.99 (dd, J = 7.5, 5.5 Hz, 2H), 3.06 (d, J = 5.3 Hz, 5H), 2.27 
(dd, J = 15.9, 8.0 Hz, 4H), 1.57 (d, J = 5.2 Hz, 4H), 1.49 (dt, J = 13.2, 6.6 Hz, 
1H), 1.32 (t, J = 7.3 Hz, 9H), 1.23 (s, 52H), 1.12 (d, J = 5.9 Hz, 2H), 0.85 (dd, 
J = 12.4, 6.5 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 173.34, 172.94, 70.26, 
70.20, 62.37, 62.09, 62.06, 45.55, 39.01, 34.24, 34.04, 31.87, 29.90, 29.65, 
29.60, 29.45, 29.30, 29.25, 29.09, 29.07, 27.91, 27.37, 24.84, 24.82, 22.63, 
22.60, 14.05, 8.48. 31P NMR (202 MHz, CDCl3) δ 5.16. HRMS (ESI, M - H): 
calcd. for C40H78O7P 701.5491 ; found 701.5492. 
 
triethylammonium (S)-2,3-bis(12-methyltridecanoyloxy)propyl 
phosphonate (2-2n). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 20 : 1 + 1% v/v triethylamine) to give 2-2n 
(0.25 g, 73%) as a white gum. 1H NMR (500 MHz, CDCl3) δ 4.61 (dt, J = 
10.6, 5.3 Hz, 1H), 4.20 (qd, J = 11.6, 5.3 Hz, 4H), 3.19 – 2.96 (m, 5H), 2.29 (t, 
J = 7.6 Hz, 4H), 1.57 (dd, J = 14.4, 7.2 Hz, 4H), 1.49 (dt, J = 13.3, 6.6 Hz, 
2H), 1.32 (t, J = 7.3 Hz, 9H), 1.23 (s, 28H), 1.16 – 1.10 (m, 4H), 0.84 (d, J = 
6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 173.31, 70.21, 70.17, 63.55, 
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63.52, 45.62, 39.00, 34.02, 29.88, 29.64, 29.57, 29.43, 29.23, 29.11, 27.91, 
27.36, 24.78, 22.60, 8.50. 31P NMR (202 MHz, CDCl3) δ 4.32. HRMS (ESI, 
M - H): calcd. for C31H60O7P 575.4082 ; found 575.4088. 
 
triethylammonium (S)-2,3-bis(13-methyltetradecanoyloxy)propyl 
phosphonate (2-2o). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 20 : 1 + 1% v/v triethylamine) to give 2-2o. 1H 
NMR (500 MHz, CDCl3) δ 4.60 (dt, J = 10.6, 5.2 Hz, 1H), 4.19 (qd, J = 11.6, 
5.3 Hz, 4H), 3.16 – 2.98 (m, 5H), 2.28 (t, J = 7.6 Hz, 4H), 1.56 (dd, J = 14.2, 
7.1 Hz, 4H), 1.48 (dt, J = 13.2, 6.6 Hz, 2H), 1.30 (t, J = 7.3 Hz, 9H), 1.22 (s, 
32H), 1.15 – 1.09 (m, 4H), 0.83 (d, J = 6.6 Hz, 12H). 13C NMR (126 MHz, 
CDCl3) δ 173.29, 70.08, 70.05, 63.56, 63.53, 45.56, 38.98, 34.00, 29.86, 
29.64, 29.59, 29.55, 29.40, 29.21, 29.08, 27.88, 27.34, 24.75, 22.58, 8.47. 31P 
NMR (202 MHz, CDCl3) δ 4.26. HRMS (ESI, M - H): calcd. for C33H64O7P 
603.4395 ; found 603.4384. 
 
triethylammonium (S)-2,3-bis(14-methylpentadecanoyloxy)propyl 
phosphonate (2-2p). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 20 : 1 + 1% v/v triethylamine) to give 2-2p 
(0.25 g, 69%) as a white gum. 1H NMR (500 MHz, CDCl3) δ 5.14 (td, J = 8.9, 
5.2 Hz, 1H), 4.30 (dd, J = 11.9, 3.6 Hz, 1H), 4.10 (dd, J = 11.9, 6.4 Hz, 1H), 
3.93 (dd, J = 8.0, 5.3 Hz, 2H), 3.01 (q, J = 7.3 Hz, 6H), 2.22 (dd, J = 15.6, 8.0 
Hz, 4H), 1.56 – 1.49 (m, 4H), 1.44 (dt, J = 13.3, 6.6 Hz, 2H), 1.27 (t, J = 7.3 
Hz, 9H), 1.18 (s, 36H), 1.10 – 1.05 (m, 4H), 0.79 (d, J = 6.6 Hz, 12H). 13C 
NMR (126 MHz, CDCl3) δ 173.21, 172.82, 70.25, 70.19, 62.32, 61.85, 61.82, 
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45.45, 38.89, 34.13, 33.93, 29.78, 29.56, 29.52, 29.50, 29.47, 29.33, 29.14, 
29.12, 28.97, 28.95, 27.79, 27.25, 24.73, 24.71, 22.49, 8.39. 31P NMR (202 
MHz, CDCl3) δ 5.01. HRMS (ESI, M - H): calcd. for C35H68O7P 631.4708 ; 
found 631.4716. 
 
triethylammonium (S)-2,3-bis(octanoyloxy)propyl phosphonate (2-2q). 
The crude mixture was purified by flash chromatography (dichloromethane : 
methanol = 20 : 1 + 1% v/v triethylamine) to give 2-2q (0.19 g, 75%) as a 
white gum. 1H NMR (500 MHz, CDCl3) δ 5.20 – 5.13 (m, 1H), 4.32 (dd, J = 
11.9, 3.7 Hz, 1H), 4.12 (dd, J = 11.9, 6.3 Hz, 1H), 3.97 (dd, J = 8.0, 5.2 Hz, 
2H), 3.08 – 2.95 (m, 6H), 2.28 – 2.23 (m, 4H), 1.55 (dd, J = 11.8, 6.9 Hz, 4H), 
1.29 (t, J = 7.3 Hz, 9H), 1.23 (s, 16H), 0.83 (t, J = 6.8 Hz, 6H). 13C NMR (126 
MHz, CDCl3) δ 173.28, 172.87, 70.22, 70.16, 62.31, 62.00, 61.97, 45.44, 
34.16, 33.99, 33.97, 31.53, 28.97, 28.95, 28.92, 28.80, 24.76, 24.74, 24.72, 
22.47, 13.93, 8.43. 31P NMR (202 MHz, CDCl3) δ 5.05. HRMS (ESI, M - H): 
calcd. for C19H36O7P 407.2204 ; found 407.2213. 
 
(2S)-3-(hydroxyhydrophosphoryloxy)propane-1,2-diyl didodecanoate, 
triethylammonium salt (2-2r). The crude mixture was purified by flash 
chromatography (dichloromethane : methanol = 20 : 1 + 1% v/v triethylamine) 
to give 2-2r (0.23 g, 75%) as a white gum. 1H NMR (500 MHz, CDCl3) δ 5.19 
– 5.13 (m, 1H), 4.31 (dd, J = 11.9, 3.5 Hz, 1H), 4.11 (dd, J = 11.9, 6.4 Hz, 
1H), 3.97 – 3.93 (m, 2H), 3.09 – 2.96 (m, 6H), 2.24 (dd, J = 15.8, 8.0 Hz, 4H), 
1.53 (d, J = 5.6 Hz, 4H), 1.27 (t, J = 7.3 Hz, 9H), 1.19 (s, 32H), 0.82 (t, J = 6.8 
Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 173.25, 172.85, 70.20, 70.14, 62.29, 
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61.95, 61.92, 45.43, 34.14, 33.95, 31.76, 29.47, 29.34, 29.19, 29.16, 28.99, 
28.96, 24.75, 24.73, 22.53, 13.96, 8.40. 31P NMR (202 MHz, CDCl3) δ 5.06. 
HRMS (ESI, M - H): calcd. for C27H52O7P 519.3456 ; found 519.3459. 
 
triethylammonium (S)-2,3-bis(tetradecanoyloxy)propyl phosphonate 
(2-2s). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 20 : 1 + 1% v/v triethylamine) to give 2-2s 
(0.25 g, 73%) as a white gum. 1H NMR (500 MHz, CDCl3) δ 5.22 – 5.16 (m, 
1H), 4.35 (dd, J = 11.9, 3.6 Hz, 1H), 4.15 (dd, J = 11.9, 6.4 Hz, 1H), 3.97 (dd, 
J = 8.0, 5.3 Hz, 2H), 3.05 (dd, J = 14.5, 7.2 Hz, 6H), 2.29 – 2.24 (m, 4H), 1.62 
– 1.54 (m, 4H), 1.30 (d, J = 7.4 Hz, 9H), 1.23 (s, 40H), 0.85 (t, J = 6.9 Hz, 
6H). 13C NMR (126 MHz, CDCl3) δ 173.34, 172.95, 70.38, 70.32, 62.45, 
61.96, 61.93, 45.49, 34.25, 34.04, 31.85, 29.62, 29.58, 29.43, 29.28, 29.24, 
29.07, 29.05, 24.84, 24.81, 22.61, 14.03, 8.46. 31P NMR (202 MHz, CDCl3) δ 
5.17. HRMS (ESI, M - H): calcd. for C31H60O7P 575.4082 ; found 575.4081 
 
triethylammonium (S)-2,3-bis(palmitoyloxy)propyl phosphonate (2-2t). 
The crude mixture was purified by flash chromatography (dichloromethane : 
methanol = 20 : 1 + 1% v/v triethylamine) to give 2-2t (0.26 g, 72%) as a 
white gum. 1H NMR (500 MHz, CDCl3) δ 5.23 – 5.16 (m, 1H), 4.35 (dd, J = 
11.9, 3.6 Hz, 1H), 4.15 (dd, J = 11.9, 6.4 Hz, 1H), 3.99 (dd, J = 8.0, 5.2 Hz, 
2H), 3.06 (dd, J = 7.0, 2.5 Hz, 6H), 2.28 (dd, J = 16.1, 8.0 Hz, 4H), 1.57 (dd, J 
= 12.0, 6.5 Hz, 4H), 1.32 (t, J = 7.3 Hz, 9H), 1.23 (s, 48H), 0.86 (t, J = 6.9 Hz, 
6H). 13C NMR (126 MHz, CDCl3) δ 173.37, 172.98, 70.28, 70.22, 62.39, 
62.08, 62.05, 45.52, 34.25, 34.05, 31.88, 29.66, 29.63, 29.61, 29.46, 29.31, 
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29.26, 29.10, 29.08, 24.85, 24.83, 22.64, 14.06, 8.48. 31P NMR (121 MHz, 
CDCl3) δ 5.28. HRMS (ESI, M - H): calcd. for C35H68O7P 631.4708 ; found 
631.4705. 
 
triethylammonium (S)-2,3-bis(heptadecanoyloxy)propyl phosphonate 
(2-2u). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 20 : 1 + 1% v/v triethylamine) to give 2-2u 
(0.28 g, 74%) as a white gum. 1H NMR (500 MHz, CDCl3) δ 5.19 (td, J = 9.0, 
5.3 Hz, 1H), 4.35 (dd, J = 11.9, 3.6 Hz, 1H), 4.15 (dd, J = 11.9, 6.4 Hz, 1H), 
3.97 (dd, J = 7.9, 5.3 Hz, 2H), 3.05 (q, J = 7.3 Hz, 6H), 2.27 (dd, J = 15.4, 7.8 
Hz, 4H), 1.55 (dd, J = 13.2, 6.3 Hz, 4H), 1.33 (t, J = 7.3 Hz, 9H), 1.23 (s, 
52H), 0.85 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 173.37, 172.98, 
70.45, 70.39, 62.52, 61.88, 61.85, 45.52, 34.26, 34.06, 31.86, 29.64, 29.59, 
29.44, 29.30, 29.25, 29.24, 29.09, 29.07, 24.85, 24.82, 22.62, 14.04, 8.49. 31P 
NMR (202 MHz, CDCl3) δ 5.19. HRMS (ESI, M - H): calcd. for C37H72O7P 




(2-30). To a solution of 2-3b  (1.56 g, 2.46 mmol) in anhydrous 
dichloromethane (40 mL) were added 2-9 (0.65 g, 4.91 mmol) and 4Å 
molecular sieves. The reaction mixture was cooled down to 0oC followed by 
dropwise addition of TMSOTf (89 L, 0.49 mmol) in dichloromethane (40 
mL). The reaction mixture was then stirred at 0oC for 12 h. After that, the 
reaction mixture was diluted with dichloromethane and washed with sat 
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NaHCO3, water and brine. The organic layer was dried over MgSO4, filtered 
and concentrated. The crude mixture was purified by flash chromatography 
(ethyl acetate : hexane = 2 : 1) to give 2-30 (0.60g, 40%) as a white solid. 1H 
NMR (300 MHz, CDCl3) δ 7.37 – 7.22 (m, 13H), 7.22 – 7.16 (m, 2H), 5.66 (d, 
J = 7.9 Hz, 1H), 4.80 (dd, J = 12.9, 8.9 Hz, 3H), 4.71 – 4.63 (m, 1H), 4.56 (t, J 
= 11.4 Hz, 3H), 4.36 – 4.20 (m, 1H), 4.03 (dd, J = 16.3, 8.0 Hz, 2H), 3.80 (dd, 
J = 10.5, 5.5 Hz, 1H), 3.75 – 3.66 (m, 3H), 3.65 – 3.54 (m, 2H), 3.47 (dd, J = 
17.5, 7.9 Hz, 1H), 1.86 (s, 3H), 1.40 (s, 3H), 1.34 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 170.34, 138.38, 138.06, 137.97, 128.41, 128.37, 128.32, 127.94, 
127.81, 127.73, 127.58, 109.43, 100.26, 80.52, 78.41, 74.85, 74.69, 74.53, 
73.41, 70.49, 68.88, 66.71, 56.54, 26.78, 25.38, 23.48. HRMS (ESI, M + Na): 
calcd. for C35H43NNaO8 628.2886; found 628.2892.  
 
Synthesis of N-(4,5-bis(benzyloxy)-6-(benzyloxymethyl)-2-((S)-2,3-
dihydroxypropoxy)tetrahydro-2H-pyran-3-yl)acetamide(2-31). To a 
solution of 2-30  (0.16 g, 0.27 mmol) in acetonitrile (10 mL) was added HCl 
(3M; 0.27 mL, 0.80 mmol). The reaction mixture was stirred at room 
temperature for 1 h. After that, the reaction mixture was quenched by addition 
of sat NaHCO3. The aqueous layer was then extracted with ethyl acetate (3x). 
The combined organic layers were dried over MgSO4, filtered, concentrated 
and purified by flash chromatography (dichloromethane : methanol = 95 : 5) 
to give 2-31 (0.13 g, 83%) as a white solid. 1H NMR (500 MHz, MeOD) δ 
7.36 – 7.24 (m, 13H), 7.19 – 7.15 (m, 2H), 4.75 (dd, J = 15.3, 11.2 Hz, 2H), 
4.67 (d, J = 11.3 Hz, 1H), 4.55 (dt, J = 14.7, 12.1 Hz, 3H), 4.47 (d, J = 8.4 Hz, 
1H), 3.89 – 3.81 (m, 2H), 3.76 – 3.63 (m, 4H), 3.60 – 3.48 (m, 5H), 1.90 (s, 
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3H). 13C NMR (126 MHz, MeOD) δ 174.46, 140.73, 140.40, 140.25, 130.29, 
130.21, 130.21, 129.96, 129.88, 129.69, 129.64, 129.62, 129.52, 103.85, 
84.98, 80.52, 76.95, 76.69, 75.31, 73.08, 72.87, 70.83, 65.12, 57.60, 23.91. 




32). To a solution of 2-31  (0.22 g, 0.39 mmol) in tetrahydrofuran (2 mL) were 
added TrCl (0.13 g, 0.47 mmol), DMAP (5 mg, 0.04 mmol) and triethylamine 
(0.22 mL, 1.56 mmol). The reaction mixture was then refluxed for 12 h. After 
that, the reaction mixture was diluted with ethyl acetate and washed with 
brine. The organic layer was dried over MgSO4, filtered and concentrated. The 
crude mixture was purified by flash chromatography (ethyl acetate : hexane = 
1 : 1) to give 2-32 (0.20 g, 63%) as a white solid. 1H NMR (500 MHz, CDCl3) 
δ 7.43 (d, J = 7.8 Hz, 7H), 7.35 – 7.28 (m, 17H), 7.21 (dd, J = 15.8, 7.6 Hz, 
6H), 5.38 (d, J = 7.9 Hz, 1H), 4.80 (dd, J = 23.3, 11.3 Hz, 2H), 4.71 (d, J = 7.9 
Hz, 1H), 4.65 (d, J = 11.6 Hz, 1H), 4.58 (t, J = 10.4 Hz, 2H), 4.52 (d, J = 12.2 
Hz, 1H), 3.91 (dd, J = 18.7, 9.3 Hz, 3H), 3.75 – 3.61 (m, 4H), 3.57 – 3.47 (m, 
2H), 3.19 (dd, J = 9.1, 5.2 Hz, 1H), 3.10 (dd, J = 9.1, 6.0 Hz, 1H), 2.98 (d, J = 
5.0 Hz, 1H), 1.78 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.48, 143.81, 
138.31, 137.93, 137.87, 128.65, 128.50, 128.41, 128.34, 128.02, 127.88, 
127.79, 127.60, 127.01, 101.01, 86.56, 80.60, 78.53, 74.74, 74.64, 74.51, 
73.43, 71.89, 69.86, 68.75, 64.14, 56.57, 23.51. HRMS (ESI, M + Na): calcd. 






acetate (2-33). To a solution of 2-32  (195 mg, 0.24 mmol) in 
dichloromethane (8 mL) were added triethylamine (101 L, 0.72 mmol), 
DMAP (8 mg, 0.07 mmol) and acetic anhydride (40 L, 0.42 mmol). The 
reaction mixture was then stirred at room temperature for 1 h. After that, the 
reaction mixture was diluted with dichloromethane and washed with brine. 
The organic layer was dried over MgSO4, filtered and concentrated. The crude 
mixture was purified by flash chromatography (ethyl acetate : hexane = 1 : 3 
to 1 : 1) to give 2-33 (0.17 g, 84%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 7.41 (d, J = 7.7 Hz, 7H), 7.29 (d, J = 7.1 Hz, 16H), 7.21 (dd, J = 
15.2, 11.1 Hz, 7H), 5.39 (d, J = 7.9 Hz, 1H), 5.18 (dd, J = 7.5, 3.7 Hz, 1H), 
4.83 – 4.77 (m, 3H), 4.67 – 4.56 (m, 4H), 4.51 (d, J = 12.2 Hz, 1H), 4.12 – 
4.06 (m, 1H), 4.00 (dd, J = 11.4, 3.5 Hz, 1H), 3.77 (dd, J = 11.4, 6.8 Hz, 1H), 
3.72 (d, J = 3.4 Hz, 2H), 3.63 (t, J = 8.8 Hz, 1H), 3.55 (dt, J = 9.1, 3.2 Hz, 1H), 
3.38 – 3.32 (m, 1H), 3.20 (d, J = 4.8 Hz, 2H), 2.08 (s, 3H), 1.75 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 170.41, 170.14, 143.66, 138.46, 138.09, 138.01, 
128.60, 128.42, 128.38, 128.31, 127.86, 127.82, 127.73, 127.69, 127.55, 
127.07, 99.90, 86.52, 80.09, 78.48, 74.74, 74.50, 73.42, 72.19, 68.84, 67.92, 
62.41, 56.82, 23.42, 21.14. HRMS (ESI, M + Na): calcd. for C53H55NNaO9 









(2-34). The oxidant solution was prepared by dissolving CrO3 (2 mg, 0.03 
mmol) and H5IO6 (1 g, 4.39 mmol) in acetonitrile : water ( 133 : 1; 10 mL). 
Compound    2-33 (0.18 g, 0.21 mmol) was dissolved in acetonitrile : water ( 
133 : 1; 0.6 mL). The oxidant solution (165 L) was added in 5 min interval 
over the course of 30 min. After the addition, the reaction mixture was further 
stirred at room temperature for 1 h. After that, the reaction mixture was 
filtered through celite and the filtrate was dried over MgSO4, filtered and 
concentrated. The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 1 : 1 to dichloromethane : methanol 8 : 1) to give 2-34 (13 
mg, 10%) as a white solid. 1H NMR (300 MHz, MeOD) δ 7.29 (ddd, J = 9.1, 
6.9, 4.3 Hz, 13H), 7.17 (dd, J = 7.0, 2.5 Hz, 2H), 5.06 (dd, J = 6.4, 2.2 Hz, 
1H), 4.74 (dd, J = 22.2, 10.1 Hz, 3H), 4.60 (dd, J = 16.2, 6.9 Hz, 2H), 4.55 – 
4.45 (m, 2H), 4.18 (dd, J = 10.8, 2.2 Hz, 1H), 3.91 – 3.78 (m, 2H), 3.75 – 3.70 
(m, 2H), 3.69 – 3.56 (m, 2H), 3.50 (t, J = 5.9 Hz, 1H), 2.10 (s, 3H), 1.94 (s, 
3H). 13C NMR (75 MHz, MeOD) δ 174.95, 173.37, 140.71, 140.42, 140.31, 
130.29, 130.22, 129.93, 129.84, 129.68, 129.62, 129.55, 107.26, 103.90, 
84.62, 80.45, 76.99, 76.69, 75.31, 71.73, 70.70, 57.64, 24.03, 21.95. HRMS 




oxopropan-2-yl acetate (2-35). To a solution of 2-34  (24 mg, 0.04 mmol) in 
dichloromethane (0.40 mL) were added EDC.HCl (11 mg, 0.06 mmol), HOBt 
168 
 
(8 mg, 0.06 mmol) and 2-7a (11 mg, 0.06 mmol). The reaction mixture was 
then stirred at room temperature for 12 h. After that, the reaction mixture was 
diluted with dichloromethane and washed with sat NaHCO3 and brine. The 
organic layer was dried over MgSO4, filtered and concentrated. The crude 
mixture was purified by flash chromatography (dichloromethane : methanol = 
40 : 1) to give 2-35 (28 mg, 93%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 7.34 – 7.28 (m, 13H), 7.19 (dd, J = 7.3, 1.7 Hz, 2H), 6.41 (t, J = 5.6 
Hz, 1H), 5.55 (d, J = 8.2 Hz, 1H), 5.26 – 5.19 (m, 1H), 4.79 (t, J = 11.6 Hz, 
2H), 4.65 (d, J = 11.6 Hz, 1H), 4.60 – 4.50 (m, 4H), 4.09 (dd, J = 11.2, 3.5 Hz, 
1H), 3.89 (dd, J = 11.2, 4.8 Hz, 1H), 3.86 – 3.79 (m, 1H), 3.72 – 3.61 (m, 4H), 
3.57 – 3.51 (m, 1H), 3.26 (ddd, J = 23.0, 13.3, 6.9 Hz, 2H), 3.11 (dt, J = 13.1, 
6.4 Hz, 1H), 2.14 (s, 3H), 1.83 (s, 3H), 1.50 – 1.46 (m, 2H), 1.25 (s, 18H), 
0.88 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.35, 169.62, 167.38, 138.25, 
137.89, 137.86, 128.49, 128.42, 128.40, 128.08, 127.89, 127.83, 127.78, 
127.70, 100.99, 80.75, 78.30, 74.91, 74.65, 74.44, 73.48, 73.09, 68.86, 68.44, 
55.61, 39.43, 31.88, 29.63, 29.61, 29.58, 29.54, 29.51, 29.40, 29.32, 29.25, 
26.86, 23.48, 22.65, 20.93, 14.08. HRMS (ESI, M - H): calcd. for C46H63N2O9 
787.4539 ; found 787.4533. 
 
Synthesis of 1H-imidazole-1-sulfonyl azide(2-36). NaN3 (1 g, 15.4 mmol) 
in acetonitrile (15 mL) was cooled down to 0oC. SO2Cl2 (12 mL, 14.8 mmol) 
was then added dropwise to the mixture. The reaction mixture was then 
warmed up to room temperature and stirred for 12 h. After that, the mixture 
was cooled down to 0oC followed by addition of imidazole (2 g, 29.4 mmol) 
portionwise. After the addition, the reaction mixture was warmed up to room 
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temperature and stirred for 2 h. Subsequently, the reaction mixture was diluted 
with ethyl acetate and washed with sat NaHCO3 and water. The organic layer 
was dried over MgSO4, filtered and concentrated. The crude mixture was 
purified by flash chromatography (ethyl acetate : hexane = 1 : 2) to give 2-36 
(1.90 g, 71%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.01 (s, 1H), 
7.37 (s, 1H), 7.21 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 136.63, 131.93, 
117.64. HRMS (ESI, M + H): calcd. for C3H4N5O2S 174.0080 ; found 
174.0080. 
 
Synthesis of 6-(acetoxymethyl)-3-azidotetrahydro-2H-pyran-2,4,5-triyl 
triacetate (2-38). To a solution of 2-37  (1.9 g, 8.58 mmol) in methanol (36 
mL) were added diazo transfer reagent 3-36 (1.8 g, 10.30 mmol), K2CO3 (1.8 
g, 12.90 mmol) and CuSO4.5H2O (0.02 g, 0.09 mmol). The reaction mixture 
was stirred at room temperature for 2 h. Following that, the solvent was 
removed under vacuum and the residue was co-evaporated with toluene (2x). 
Pyridine (42.90 mL) and acetic anhydride (6.5 mL, 69.20 mmol) were 
subsequently added and the reaction mixture was stirred at room temperature 
for 3 h. After that, the reaction mixture was diluted with ethyl acetate and 
washed with 5M HCl and sat NaHCO3. The organic layer was dried over 
MgSO4, filtered and concentrated. The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 3) to give 2-38 (1.70 g, 55%) as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 5.53 (d, J = 8.6 Hz, 1H), 5.11 – 
4.96 (m, 2H), 4.27 (dd, J = 12.5, 4.5 Hz, 1H), 4.03 (dd, J = 14.0, 12.1 Hz, 2H), 
3.78 (ddd, J = 9.8, 4.5, 2.1 Hz, 1H), 3.67 – 3.60 (m, 1H), 2.15 (s, 3H), 2.06 (s, 
3H), 2.04 (s, 3H), 1.99 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.39, 169.64, 
170 
 
169.49, 168.43, 92.46, 89.87, 72.60, 67.73, 62.50, 61.32, 20.74, 20.55, 20.49, 




pyran-3,4-diyl diacetate (2-39). To a solution of 2-38 (0.87 g, 2.33 mmol) in 
dichloromethane (5 mL) were added BF3.OEt2 (0.37 mL, 3.02 mmol) and 
PhSH (0.71 mL, 6.98 mmol). The reaction mixture was then microwave 
irradiated at 110oC for 20 min (Warning! Pressure more than 5 bars was 
generated). After that, the reaction mixture was diluted with dichloromethane 
and washed with sat NaHCO3 and brine. The organic layer was dried over 
MgSO4, filtered and concentrated. The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 6) to give 2-39 (0.56 g, 57%) as a 
brownish solid. 1H NMR (300 MHz, CDCl3) δ 7.49 (dd, J = 4.8, 3.1 Hz, 2H), 
7.36 – 7.29 (m, 4H), 5.63 (d, J = 5.6 Hz, 1H), 5.38 – 5.27 (m, 1H), 5.01 (d, J = 
10.1 Hz, 1H), 4.58 (ddd, J = 10.2, 5.1, 2.1 Hz, 1H), 4.28 (dd, J = 12.4, 5.1 Hz, 
1H), 4.19 (dd, J = 8.7, 3.6 Hz, 1H), 4.11 – 4.04 (m, 1H), 4.04 (d, J = 1.9 Hz, 
1H), 2.09 (s, 3H), 2.04 (s, 3H), 2.01 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 
170.39, 169.70, 134.05, 132.14, 129.15, 128.01, 86.41, 71.94, 68.64, 68.44, 
61.83, 61.53, 20.63, 20.57, 20.52. HRMS (ESI, M + Na): calcd. for 
C18H21N3NaO7S 446.0992 ; found 446.0993. 
 
Synthesis of 5-azido-2-(hydroxymethyl)-6-(phenylthio)tetrahydro-2H-
pyran-3,4-diol (2-40). To a solution of 2-39 (0.27 g, 0.63 mmol) in methanol 
(3.5 mL) was added NaOMe (0.01 g, 0.19 mmol). The reaction mixture was 
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stirred at room temperature for 30 min. After that, the reaction mixture was 
concentrated and the crude mixture was purified by flash chromatography 
(ethyl acetate : hexane = 1 : 3 to dichloromethane : methanol = 95 : 5) to give 
2-40 (0.15 g, 80%) as a faint yellowish solid. 1H NMR (500 MHz, CDCl3) δ 
7.47 – 7.45 (m, 1H), 7.31 – 7.26 (m, 4H), 5.52 (d, J = 5.1 Hz, 1H), 4.16 (d, J = 
9.7 Hz, 1H), 3.95 (d, J = 12.4 Hz, 1H), 3.83 (dt, J = 42.1, 12.2 Hz, 4H), 3.72 
(t, J = 9.2 Hz, 1H), 3.34 (dd, J = 28.6, 9.6 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ 133.09, 132.39, 129.14, 127.94, 87.51, 73.40, 72.40, 69.93, 63.48, 




(phenylthio)tetrahydro-2H-pyran (2-41). To a solution of 2-40 (0.07 g, 0.24 
mmol) in anhydrous dimethylformamide (1.2 mL) were added sodium hydride 
(60%; 0.03 g, 0.78 mmol) portionwise followed by addition of benzyl bromide 
(92 L, 0.78 mmol). The reaction mixture was then stirred at room 
temperature for 2 h. After that, the reaction mixture was quenched with ice 
water and diluted with diethyl ether. The organic layer was washed with water 
and brine and subsequently dried over MgSO4, filtered and concentrated. The 
crude mixture was purified by flash chromatography (ethyl acetate : hexane = 
1 : 12) to give 2-41 (0.11 g, 80%) as a white solid. 1H NMR (300 MHz, 
CDCl3) δ 7.53 (dd, J = 6.3, 3.3 Hz, 2H), 7.33 (ddd, J = 12.5, 8.0, 3.8 Hz, 18H), 
5.64 (d, J = 5.3 Hz, 1H), 4.93 (d, J = 3.7 Hz, 2H), 4.85 (d, J = 11.6 Hz, 2H), 
4.59 (dd, J = 15.3, 8.1 Hz, 3H), 4.49 – 4.36 (m, 2H), 3.98 (dd, J = 9.9, 5.3 Hz, 
1H), 3.80 (d, J = 9.6 Hz, 2H), 3.66 (dd, J = 10.8, 1.9 Hz, 1H). 13C NMR (75 
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MHz, CDCl3) δ 137.80, 137.73, 137.62, 133.60, 132.02, 129.01, 128.94, 
128.47, 128.43, 128.34, 128.16, 128.10, 127.93, 127.82, 127.71, 127.59, 
127.53, 87.21, 81.79, 78.21, 75.70, 75.05, 73.40, 71.76, 68.25, 64.06. HRMS 
(ESI, M + Na): calcd. for C33H33N3NaO4S 590.2084 ; found 590.2090. 
 
General procedure for the synthesis of 2-42 
To a solution of 2-41  (0.20 mmol) in anhydrous diethyl ether (2.5 mL) were 
added 2-4 (0.18 mmol), NIS (0.33 mmol) and 4Å molecular sieves. The 
reaction mixture was stirred at room temperature for 1 h before being cooled 
down to 0oC followed by dropwise addition TfOH (0.11 mmol) in diethyl 
ether (2.5 mL). The reaction mixture was then warmed up to room temperature 
and stirred for 1 h. After that, the reaction mixture was quenched by 
triethylamine, diluted with diethyl ether and washed with 10% aqueous 
Na2S2O3, sat NaHCO3 and brine. The organic layer was dried over MgSO4, 
filtered and concentrated. The crude mixture was purified by flash 
chromatography to give 2-42. 
 
(2R)-3-(3-azido-4,5-bis(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-
pyran-2-yloxy)-N-hexadecyl-2-hydroxypropanamide (2-42a). The crude 
mixture was purified by flash chromatography (ethyl acetate: hexane : diethyl 
ether = 1 : 2 : 1) to give 2-42a (0.05g, 42%) as white solid. 1H NMR (500 
MHz, CDCl3) δ 7.38 – 7.25 (m, 13H), 7.19 – 7.16 (m, 2H), 6.83 (t, J = 5.7 Hz, 
1H), 4.93 (d, J = 3.6 Hz, 1H), 4.86 (q, J = 10.7 Hz, 2H), 4.80 (d, J = 11.0 Hz, 
1H), 4.62 (d, J = 12.0 Hz, 1H), 4.54 (d, J = 11.0 Hz, 1H), 4.49 (d, J = 11.9 Hz, 
1H), 4.20 (q, J = 4.8 Hz, 1H), 3.99 – 3.93 (m, 1H), 3.91 (d, J = 9.4 Hz, 1H), 
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3.85 (dd, J = 10.0, 3.2 Hz, 1H), 3.80 – 3.71 (m, 4H), 3.70 – 3.66 (m, 1H), 3.49 
(dd, J = 10.2, 3.6 Hz, 1H), 3.33 – 3.21 (m, 2H), 1.55 – 1.49 (m, 2H), 1.27 (s, 
26H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.88, 137.76, 
137.61, 137.54, 128.43, 128.38, 128.37, 128.01, 127.92, 127.78, 127.64, 
98.23, 80.42, 78.05, 75.47, 74.93, 73.52, 71.08, 70.70, 70.27, 68.09, 63.64, 
39.36, 31.87, 29.64, 29.60, 29.56, 29.54, 29.53, 29.31, 29.27, 26.88, 22.64, 





The crude mixture was purified by flash chromatography (ethyl acetate: 
hexane : diethyl ether = 1 : 2 : 1) to give 2-42b (0.05g, 42%) as white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.38 – 7.26 (m, 13H), 7.16 (d, J = 9.2 Hz, 2H), 
6.82 (t, J = 5.6 Hz, 1H), 4.92 (d, J = 3.6 Hz, 1H), 4.86 (q, J = 10.6 Hz, 2H), 
4.79 (d, J = 10.9 Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 4.50 (dd, J = 23.3, 11.4 
Hz, 2H), 4.19 (t, J = 5.2 Hz, 1H), 3.98 – 3.92 (m, 1H), 3.90 (d, J = 9.9 Hz, 
1H), 3.84 (d, J = 9.9 Hz, 1H), 3.77 (dd, J = 10.4, 5.1 Hz, 1H), 3.74 – 3.70 (m, 
2H), 3.67 (t, J = 9.3 Hz, 1H), 3.49 (dd, J = 10.2, 3.6 Hz, 1H), 3.33 – 3.20 (m, 
2H), 1.56 – 1.48 (m, 3H), 1.25 (s, 22H), 1.19 – 1.13 (m, 2H), 0.87 (d, J = 6.6 
Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 170.87, 137.77, 137.62, 137.55, 
128.46, 128.41, 128.39, 128.04, 127.95, 127.82, 127.81, 127.67, 98.26, 80.45, 
78.07, 75.50, 74.96, 73.55, 71.12, 70.75, 70.26, 68.11, 63.67, 39.39, 39.04, 
29.92, 29.70, 29.66, 29.63, 29.59, 29.56, 29.29, 27.94, 27.40, 26.90, 22.64. 
HRMS (ESI, M - H): calcd. for C47H67N4O7 799.5015 ; found 799.5020. 
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General procedure for the synthesis of 2-1. To a solution of 2-42 (0.09 
mmol) in dichloromethane : pyridine (1 : 1; 3 mL) was added AcSH (1.5 mL). 
The reaction mixture was stirred at room temperature for 12 h. The reaction 
mixture was then warmed up to room temperature and stirred for 1 h. After 
that, the reaction mixture was diluted with dichloromethane and washed with 
1M HCl, sat NaHCO3, water and brine. The organic layer was dried over 
MgSO4, filtered and concentrated. The crude mixture was purified by flash 




hydroxypropanamide (2-1a). The crude mixture was purified by flash 
chromatography (ethyl acetate: methanol = 95 : 5 ) to give 2-1a (0.05g, 68%) 
as white solid. 1H NMR (500 MHz, CDCl3) δ 7.28 (ddt, J = 17.6, 13.3, 6.5 Hz, 
12H), 7.20 – 7.16 (m, 1H), 7.13 – 7.06 (m, 1H), 6.81 (t, J = 5.8 Hz, 1H), 6.09 
(d, J = 9.1 Hz, 1H), 4.85 (d, J = 3.7 Hz, 1H), 4.80 (t, J = 10.8 Hz, 1H), 4.67 (t, 
J = 12.5 Hz, 1H), 4.61 – 4.55 (m, 2H), 4.53 – 4.45 (m, 2H), 4.29 – 4.19 (m, 
1H), 4.02 (dd, J = 11.5, 2.7 Hz, 1H), 3.89 (dd, J = 7.9, 3.4 Hz, 1H), 3.79 – 3.58 
(m, 5H), 3.26 – 3.15 (m, 2H), 1.87 (s, 3H), 1.48 (d, J = 17.9 Hz, 2H), 1.27 (s, 
26H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.72, 170.29, 
138.23, 137.83, 137.56, 128.39, 128.31, 128.28, 128.12, 128.02, 127.94, 
127.84, 127.82, 127.72, 127.67, 127.59, 127.26, 98.81, 80.27, 78.30, 74.84, 
73.47, 73.41, 71.67, 71.19, 68.77, 52.69, 39.14, 31.83, 29.61, 29.57, 29.53, 
29.49, 29.27, 29.22, 26.86, 23.19, 22.64, 14.04. HRMS (ESI, M - H): calcd. 






methylhexadecyl)propanamide (2-1b). The crude mixture was purified by 
flash chromatography (ethyl acetate: methanol = 95 : 5 ) to give 2-1b (0.05g, 
68%) as white solid.1H NMR (500 MHz, CDCl3) δ 7.31 (dd, J = 15.6, 5.6 Hz, 
11H), 7.25 – 7.21 (m, 2H), 7.20 – 7.17 (m, 2H), 7.08 (d, J = 3.6 Hz, 1H), 4.82 
(dd, J = 23.5, 11.8 Hz, 3H), 4.66 – 4.55 (m, 2H), 4.51 – 4.45 (m, 2H), 4.22 (s, 
2H), 4.09 (d, J = 16.3 Hz, 1H), 3.87 (s, 1H), 3.68 (dd, J = 38.0, 29.3 Hz, 6H), 
3.20 (s, 2H), 1.86 (s, 3H), 1.54 – 1.44 (m, 3H), 1.25 (s, 22H), 1.16 (s, 4H), 
0.86 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 171.53, 170.48, 
138.22, 137.80, 137.53, 128.50, 128.40, 128.36, 128.20, 128.10, 128.07, 
127.92, 127.91, 127.84, 127.76, 127.70, 127.35, 98.86, 81.83, 80.07, 78.39, 
74.92, 73.50, 73.16, 71.70, 71.26, 70.86, 68.82, 52.82, 39.22, 39.02, 29.91, 
29.69, 29.66, 29.63, 29.58, 29.54, 29.26, 27.93, 27.38, 26.90, 22.63. HRMS 
(ESI, M + H): calcd. for C49H73N2O8 817.5361 ; found 817.5363. 
 
General procedure for the synthesis of 2-43. To a solution of 2-1 (0.02 
mmol) in pyridine (0.25 mL) were added 2-2 (0.03 mmol) and CCl3CN (0.25 
mL). The reaction mixture was microwave irradiated at 90oC for 1 h 15 min. 
Iodine (0.14 mmol) in a mixture of pyridine : water (19 : 1; 0.2 mL) was added 
and the resulting mixture was stirred at room temperature for 6 h. After that, 
the reaction mixture was diluted with dichloromethane, washed with 10% 
aqueous Na2S2O3 and 1 M CuSO4. The organic layer was dried over MgSO4, 
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filtered and concentrated. The crude mixture was purified by flash 





2-(13-methyltetradecanoyloxy)propyl phosphate (2-43a). The crude 
mixture was purified by flash chromatography (dichloromethane : methanol = 
15 : 1 + 1% v/v triethylamine) to give 2-43a (22 mg, 71%) as a yellowish 
solid. 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.22 (m, 13H), 7.15 – 7.11 (m, 
2H), 6.75 (t, J = 15.8 Hz, 1H), 5.26 – 5.18 (m, 1H), 4.84 – 4.80 (m, 1H), 4.77 
– 4.67 (m, 3H), 4.60 (s, 1H), 4.48 (d, J = 12.7 Hz, 2H), 4.34 (dd, J = 12.0, 3.3 
Hz, 2H), 4.15 – 4.05 (m, 2H), 3.99 (s, 2H), 3.84 (dd, J = 11.0, 3.2 Hz, 1H), 
3.76 (s, 1H), 3.74 (s, 2H), 3.68 – 3.61 (m, 1H), 3.27 (dt, J = 21.0, 6.9 Hz, 1H), 
3.19 – 3.10 (m, 1H), 3.02 (dt, J = 14.5, 7.3 Hz, 6H), 2.25 (dd, J = 14.5, 7.1 Hz, 
4H), 1.98 (s, 3H), 1.52 (dd, J = 18.2, 11.5 Hz, 9H), 1.29 (d, J = 7.3 Hz, 9H), 
1.24 (s, 58H), 1.14 (d, J = 6.9 Hz, 6H), 0.85 (d, J = 6.6 Hz, 18H). 13C NMR 
(126 MHz, CDCl3) δ 173.34, 173.00, 170.82, 168.96, 163.42, 138.62, 138.44, 
138.09, 128.34, 128.27, 128.18, 127.88, 127.74, 127.73, 127.50, 127.46, 
127.43, 98.62, 92.12, 81.31, 77.76, 75.26, 74.77, 74.72, 73.33, 71.14, 70.10, 
68.70, 68.54, 64.01, 62.39, 53.38, 52.64, 45.72, 39.38, 39.03, 34.16, 34.00, 
29.93, 29.70, 29.64, 29.50, 29.33, 29.12, 29.10, 27.93, 27.39, 27.02, 24.87, 
24.81, 23.10, 22.62, 8.50. 31P NMR (202 MHz, CDCl3) δ -1.12. . HRMS (ESI, 







2-(14-methylpentadecanoyloxy)propyl phosphate (2-43b). The crude 
mixture was purified by flash chromatography (dichloromethane : methanol = 
15 : 1 + 1% v/v triethylamine) to give 2-43b (23 mg, 73%) as a yellowish 
solid. 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.23 (m, 13H), 7.17 – 7.10 (m, 
2H), 5.23 (s, 1H), 4.82 (d, J = 3.4 Hz, 1H), 4.78 – 4.66 (m, 3H), 4.61 (d, J = 
12.1 Hz, 1H), 4.47 (t, J = 12.2 Hz, 2H), 4.34 (dd, J = 11.9, 3.1 Hz, 2H), 4.10 
(dd, J = 19.5, 7.5 Hz, 1H), 3.99 (d, J = 2.2 Hz, 2H), 3.85 – 3.79 (m, 1H), 3.74 
(dd, J = 12.3, 9.7 Hz, 3H), 3.65 (d, J = 10.2 Hz, 1H), 3.27 (dd, J = 24.2, 10.1 
Hz, 1H), 3.15 (t, J = 12.9 Hz, 1H), 3.06 – 2.99 (m, 6H), 2.33 – 2.21 (m, 5H), 
1.98 (s, 3H), 1.58 – 1.48 (m, 9H), 1.30 (d, J = 7.3 Hz, 9H), 1.24 (s, 60H), 1.15 
– 1.09 (m, 6H), 0.85 (d, J = 6.6 Hz, 18H). 13C NMR (126 MHz, CDCl3) δ 
173.35, 173.00, 170.84, 168.94, 163.41, 138.63, 138.43, 138.08, 128.27, 
128.18, 127.88, 127.75, 127.73, 127.50, 127.46, 127.43, 98.59, 81.27, 77.78, 
74.78, 74.72, 73.33, 71.13, 70.15, 68.55, 64.02, 62.38, 52.66, 45.75, 39.39, 
39.03, 34.16, 34.00, 29.93, 29.70, 29.51, 29.33, 29.30, 29.13, 29.10, 27.93, 
27.39, 27.03, 24.87, 24.81, 23.09, 22.62, 8.51. 31P NMR (202 MHz, CDCl3) δ 








methylhexadecanoyloxy)propyl phosphate (2-43c). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 15 : 1 + 1% 
v/v triethylamine) to give 2-43c (22 mg, 70%) as a yellowish solid. 1H NMR 
(500 MHz, CDCl3) δ 7.31 (dt, J = 17.0, 7.7 Hz, 13H), 7.16 (s, 2H), 6.71 (d, J = 
21.4 Hz, 1H), 6.26 (s, 1H), 5.26 (s, 1H), 4.89 (dd, J = 19.0, 3.6 Hz, 1H), 4.85 – 
4.74 (m, 2H), 4.73 – 4.68 (m, 1H), 4.69 (d, J = 8.3 Hz, 1H), 4.58 – 4.48 (m, 
2H), 4.40 – 4.20 (m, 3H), 4.14 (ddd, J = 21.0, 10.5, 5.1 Hz, 2H), 4.04 (dd, J = 
13.9, 5.0 Hz, 1H), 3.85 – 3.74 (m, 3H), 3.65 (ddd, J = 18.4, 14.9, 8.5 Hz, 2H), 
3.35 – 3.14 (m, 2H), 3.07 (dd, J = 7.3, 4.7 Hz, 5H), 2.33 – 2.26 (m, 4H), 1.88 
(s, 3H), 1.54 (dt, J = 19.9, 6.7 Hz, 9H), 1.34 (t, J = 7.3 Hz, 9H), 1.27 (s, 62H), 
1.19 – 1.15 (m, 6H), 0.88 (d, J = 6.6 Hz, 18H). 13C NMR (126 MHz, CDCl3) δ 
173.34, 173.00, 171.04, 168.67, 163.39, 138.59, 138.38, 138.05, 128.46, 
128.36, 128.34, 128.29, 128.20, 128.16, 128.11, 127.89, 127.75, 127.53, 
127.49, 81.12, 80.19, 78.28, 77.80, 74.82, 74.74, 73.47, 73.34, 71.87, 71.11, 
69.97, 68.52, 64.19, 62.28, 52.71, 45.81, 39.44, 39.22, 39.03, 34.14, 33.99, 
31.88, 29.93, 29.71, 29.66, 29.52, 29.50, 29.34, 29.31, 29.13, 29.10, 27.93, 
27.40, 27.03, 26.92, 24.86, 24.81, 23.26, 23.06, 22.63, 17.53, 14.08, 8.53. 31P 
NMR (202 MHz, CDCl3) δ -1.29. . HRMS (ESI, M - H): calcd. for 






(2-43d). The crude mixture was purified by flash chromatography 
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(dichloromethane : methanol = 15 : 1 + 1% v/v triethylamine) to give 2-43d 
(22 mg, 72%) as a yellowish solid. 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.24 
(m, 13H), 7.15 (d, J = 7.3 Hz, 2H), 6.88 (s, 1H), 6.81 (s, 1H), 5.25 (s, 1H), 
4.85 (s, 1H), 4.76 (dd, J = 23.1, 12.9 Hz, 3H), 4.64 (d, J = 12.1 Hz, 1H), 4.50 
(t, J = 12.5 Hz, 2H), 4.37 (d, J = 8.8 Hz, 1H), 4.14 (d, J = 11.0 Hz, 2H), 4.01 
(s, 2H), 3.87 (s, 1H), 3.77 (d, J = 6.3 Hz, 3H), 3.68 (d, J = 10.1 Hz, 2H), 3.30 
(d, J = 12.4 Hz, 1H), 3.19 (d, J = 5.4 Hz, 1H), 3.06 (s, 6H), 2.28 (dd, J = 14.7, 
7.2 Hz, 4H), 2.02 (s, 3H), 1.63 – 1.49 (m, 9H), 1.32 (d, J = 6.0 Hz, 9H), 1.27 
(s, 54H), 1.17 (d, J = 5.8 Hz, 6H), 0.90 – 0.86 (m, 21H). 13C NMR (126 MHz, 
CDCl3) δ 173.35, 173.00, 170.85, 169.11, 163.48, 138.60, 138.42, 138.06, 
128.43, 128.32, 128.26, 128.23, 128.17, 128.07, 127.96, 127.86, 127.72, 
127.67, 127.49, 127.43, 98.61, 92.15, 81.33, 77.77, 74.87, 74.71, 73.31, 71.11, 
70.16, 69.28, 68.74, 68.53, 63.90, 62.41, 52.67, 45.76, 44.23, 39.39, 39.01, 
34.15, 33.99, 33.84, 31.87, 30.59, 30.21, 29.91, 29.68, 29.64, 29.52, 29.47, 
29.38, 29.32, 29.28, 29.11, 29.08, 27.91, 27.37, 27.02, 26.91, 24.86, 24.80, 
24.53, 22.61, 14.06, 8.51. 31P NMR (202 MHz, CDCl3) δ -1.18. HRMS (ESI, 






(2-43e). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 15 : 1 + 1% v/v triethylamine) to give 2-43e 
(23 mg, 73%) as a yellowish solid. 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.25 
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(m, 13H), 7.16 (d, J = 2.1 Hz, 2H), 6.85 (s, 1H), 6.78 (s, 1H), 5.26 (s, 1H), 
4.85 (dd, J = 9.0, 3.4 Hz, 1H), 4.78 (dd, J = 21.1, 9.9 Hz, 3H), 4.64 (d, J = 12.1 
Hz, 1H), 4.51 (dd, J = 23.6, 11.1 Hz, 2H), 4.37 (dd, J = 11.9, 3.2 Hz, 2H), 4.25 
(dd, J = 13.5, 4.6 Hz, 1H), 4.14 (dd, J = 12.0, 6.9 Hz, 1H), 4.02 (dd, J = 11.0, 
5.1 Hz, 2H), 3.86 (dd, J = 10.9, 3.1 Hz, 1H), 3.76 (dd, J = 10.2, 5.5 Hz, 4H), 
3.67 (t, J = 10.0 Hz, 1H), 3.32 (s, 0H), 3.29 (d, J = 6.7 Hz, 1H), 3.26 – 3.16 
(m, 1H), 3.09 – 3.02 (m, 7H), 2.28 (dd, J = 14.6, 7.1 Hz, 4H), 2.01 (s, 3H), 
1.54 (td, J = 13.4, 6.7 Hz, 8H), 1.32 (d, J = 7.4 Hz, 9H), 1.27 (s, 56H), 1.17 (d, 
J = 6.1 Hz, 6H), 0.90 – 0.87 (m, 21H). 13C NMR (126 MHz, CDCl3) δ 173.34, 
172.99, 170.79, 163.45, 138.61, 138.44, 138.08, 128.45, 128.33, 128.27, 
128.17, 128.08, 127.87, 127.72, 127.50, 127.45, 98.62, 92.13, 81.32, 77.76, 
74.80, 74.71, 73.45, 73.32, 71.14, 70.11, 68.76, 68.54, 63.95, 62.39, 52.66, 
45.73, 44.24, 39.38, 39.02, 34.15, 33.99, 30.62, 30.22, 29.92, 29.69, 29.51, 
29.48, 29.39, 29.32, 29.29, 29.12, 29.09, 27.92, 27.38, 27.02, 24.86, 24.81, 
24.55, 23.11, 22.62, 14.07, 8.50. 31P NMR (202 MHz, CDCl3) δ -1.09. HRMS 






phosphate (2-43f). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 15 : 1 + 1% v/v triethylamine) to give 2-43f 
(23 mg, 72%) as a yellowish solid. 1H NMR (500 MHz, CDCl3) δ 7.30 (ddd, J 
= 18.9, 14.6, 7.0 Hz, 13H), 7.15 (d, J = 7.5 Hz, 2H), 5.25 (s, 1H), 4.85 (s, 1H), 
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4.81 – 4.70 (m, 3H), 4.64 (d, J = 12.1 Hz, 1H), 4.50 (t, J = 12.5 Hz, 2H), 4.37 
(dd, J = 11.9, 3.0 Hz, 2H), 4.14 (dd, J = 12.0, 6.9 Hz, 1H), 4.07 – 3.98 (m, 
2H), 3.86 (d, J = 10.7 Hz, 1H), 3.81 – 3.73 (m, 3H), 3.68 (d, J = 9.7 Hz, 1H), 
3.34 – 3.25 (m, 1H), 3.18 (d, J = 7.6 Hz, 1H), 3.08 – 3.02 (m, 6H), 2.28 (t, J = 
10.7 Hz, 4H), 2.01 (s, 3H), 1.62 – 1.49 (m, 8H), 1.27 (s, 58H), 1.17 (d, J = 6.3 
Hz, 6H), 0.88 (t, J = 3.3 Hz, 21H). 13C NMR (126 MHz, CDCl3) δ 173.35, 
173.00, 170.83, 169.08, 163.45, 138.63, 138.43, 138.08, 128.26, 128.17, 
127.86, 127.72, 127.49, 127.44, 127.42, 98.57, 81.27, 77.79, 74.76, 74.71, 
73.32, 71.10, 70.13, 68.70, 68.54, 63.94, 62.41, 52.65, 45.74, 44.24, 39.37, 
39.02, 34.15, 33.99, 31.87, 30.62, 30.22, 29.91, 29.68, 29.64, 29.49, 29.38, 
29.32, 29.11, 29.09, 27.92, 27.38, 27.01, 24.86, 24.80, 24.54, 23.09, 22.61, 
8.49. 31P NMR (202 MHz, CDCl3) δ -1.04. HRMS (ESI, M - H): calcd. for 





2-(11-methyltridecanoyloxy)propyl phosphate (2-43g). The crude mixture 
was purified by flash chromatography (dichloromethane : methanol = 15 : 1 + 
1% v/v triethylamine) to give 2-43g (22 mg, 73%) as a yellowish solid. 1H 
NMR (500 MHz, CDCl3) δ 7.36 – 7.26 (m, 13H), 7.19 – 7.12 (m, 2H), 5.25 (s, 
1H), 4.85 (d, J = 3.0 Hz, 1H), 4.80 – 4.70 (m, 3H), 4.64 (d, J = 12.1 Hz, 1H), 
4.56 – 4.47 (m, 2H), 4.41 – 4.33 (m, 2H), 4.14 (dd, J = 12.0, 6.9 Hz, 1H), 4.01 
(d, J = 5.3 Hz, 2H), 3.90 – 3.83 (m, 1H), 3.77 (dd, J = 8.7, 5.5 Hz, 4H), 3.68 
(d, J = 10.2 Hz, 1H), 3.36 – 3.26 (m, 1H), 3.24 – 3.15 (m, 1H), 3.06 (dd, J = 
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7.2, 4.7 Hz, 6H), 2.28 (dd, J = 15.0, 7.4 Hz, 4H), 2.01 (s, 3H), 1.63 – 1.49 (m, 
9H), 1.34 (d, J = 7.3 Hz, 9H), 1.27 (s, 57H), 1.19 – 1.13 (m, 6H), 0.87 (dd, J = 
10.4, 4.8 Hz, 18H). 13C NMR (126 MHz, CDCl3) δ 173.33, 172.98, 170.85, 
168.89, 163.39, 138.63, 138.45, 138.10, 128.36, 128.28, 128.18, 127.89, 
127.73, 127.50, 127.43, 98.63, 92.09, 81.33, 77.75, 75.28, 74.80, 74.71, 73.33, 
71.17, 70.06, 68.55, 64.06, 62.36, 52.68, 45.76, 39.39, 39.03, 36.62, 34.37, 
34.15, 34.00, 30.00, 29.93, 29.70, 29.66, 29.49, 29.46, 29.34, 29.30, 29.13, 
29.10, 27.93, 27.39, 27.09, 27.03, 24.87, 24.82, 23.10, 22.63, 19.18, 14.07, 
11.37, 8.52. 31P NMR (202 MHz, CDCl3) δ -1.23. HRMS (ESI, M - H): calcd. 





2-(12-methyltetradecanoyloxy)propyl phosphate (2-43h). The crude 
mixture was purified by flash chromatography (dichloromethane : methanol = 
15 : 1 + 1% v/v triethylamine) to give 2-43h (23 mg, 74%) as a yellowish 
solid. 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.27 (m, 13H), 7.19 – 7.14 (m, 
2H), 4.85 (d, J = 3.4 Hz, 1H), 4.76 (dd, J = 24.5, 13.5 Hz, 4H), 4.62 (dd, J = 
16.2, 8.7 Hz, 2H), 4.50 (dd, J = 13.8, 11.6 Hz, 2H), 4.36 (d, J = 8.2 Hz, 1H), 
4.27 (dt, J = 15.0, 7.5 Hz, 4H), 4.02 (dd, J = 11.0, 5.4 Hz, 1H), 3.89 (s, 1H), 
3.83 – 3.73 (m, 4H), 3.67 (d, J = 10.0 Hz, 1H), 3.29 (dt, J = 13.4, 7.1 Hz, 1H), 
3.18 (dd, J = 13.6, 6.2 Hz, 1H), 3.08 – 3.03 (m, 6H), 2.29 (t, J = 8.5 Hz, 4H), 
2.00 (s, 3H), 1.62 – 1.48 (m, 9H), 1.33 (d, J = 7.3 Hz, 9H), 1.26 (s, 59H), 1.17 
(dd, J = 13.4, 6.6 Hz, 6H), 0.87 (dd, J = 12.0, 6.5 Hz, 18H). 13C NMR (126 
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MHz, CDCl3) δ 173.42, 173.37, 170.97, 168.89, 163.42, 138.62, 138.40, 
138.07, 128.45, 128.35, 128.28, 128.19, 128.10, 127.89, 127.77, 127.73, 
127.51, 127.48, 127.44, 98.52, 81.23, 77.82, 75.31, 74.83, 74.75, 73.46, 73.34, 
71.45, 71.10, 68.54, 62.90, 52.70, 45.73, 39.41, 39.03, 36.61, 34.36, 33.98, 
30.00, 29.92, 29.70, 29.65, 29.62, 29.49, 29.46, 29.34, 29.31, 29.30, 29.14, 
27.93, 27.39, 27.08, 27.03, 24.81, 24.79, 23.04, 22.62, 19.18, 11.37, 8.51. 31P 
NMR (202 MHz, CDCl3) δ -1.55. HRMS (ESI, M - H): calcd. for 





2-(13-methylpentadecanoyloxy)propyl phosphate (2-43i). The crude 
mixture was purified by flash chromatography (dichloromethane : methanol = 
15 : 1 + 1% v/v triethylamine) to give 2-43i (23 mg, 73%) as a yellowish 
solid. 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.23 (m, 13H), 7.15 – 7.11 (m, 
2H), 5.23 (s, 1H), 4.82 (s, 1H), 4.73 (dd, J = 24.4, 13.4 Hz, 4H), 4.61 (d, J = 
12.1 Hz, 1H), 4.53 – 4.43 (m, 2H), 4.34 (dd, J = 11.9, 3.2 Hz, 2H), 4.11 (dd, J 
= 12.0, 6.9 Hz, 1H), 4.00 (d, J = 5.8 Hz, 2H), 3.86 – 3.79 (m, 1H), 3.80 – 3.71 
(m, 4H), 3.65 (d, J = 9.9 Hz, 2H), 3.29 – 3.22 (m, 1H), 3.15 (d, J = 13.0 Hz, 
1H), 3.02 (dt, J = 11.8, 5.9 Hz, 6H), 2.25 (dd, J = 14.8, 7.1 Hz, 5H), 1.99 (s, 
3H), 1.59 – 1.46 (m, 9H), 1.30 (s, 9H), 1.24 (s, 61H), 1.13 (dd, J = 12.4, 5.6 
Hz, 6H), 0.84 (dd, J = 10.2, 4.9 Hz, 18H). 13C NMR (126 MHz, CDCl3) δ 
173.33, 172.99, 170.84, 168.94, 163.40, 138.62, 138.45, 138.09, 128.48, 
128.34, 128.28, 128.19, 128.13, 127.89, 127.73, 127.51, 127.44, 98.64, 92.08, 
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81.33, 77.76, 75.28, 74.80, 74.72, 73.33, 71.16, 70.08, 68.55, 64.04, 62.37, 
52.68, 45.74, 39.39, 39.03, 36.63, 34.37, 34.16, 34.00, 30.03, 29.93, 29.71, 
29.69, 29.66, 29.52, 29.50, 29.46, 29.34, 29.30, 29.13, 29.11, 27.93, 27.40, 
27.10, 27.03, 26.92, 24.87, 24.82, 23.11, 22.63, 19.19, 14.08, 11.37, 8.51. 31P 
NMR (202 MHz, CDCl3) δ -1.19. HRMS (ESI, M - H): calcd. for 





methylhexadecanoyloxy)propyl phosphate (2-43j). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 15 : 1 + 1% 
v/v triethylamine) to give 2-43j (22 mg, 75%) as a yellowish solid. 1H NMR 
(500 MHz, CDCl3) δ 7.33 – 7.23 (m, 13H), 7.16 – 7.10 (m, 2H), 5.25 – 5.16 
(m, 1H), 4.81 (t, J = 13.5 Hz, 1H), 4.71 (dd, J = 29.3, 11.1 Hz, 3H), 4.61 (d, J 
= 12.1 Hz, 1H), 4.47 (t, J = 12.0 Hz, 2H), 4.34 (dd, J = 11.9, 3.2 Hz, 2H), 4.11 
(dd, J = 11.9, 6.9 Hz, 2H), 4.04 – 3.95 (m, 3H), 3.84 (dd, J = 11.0, 2.9 Hz, 
1H), 3.74 (dd, J = 8.7, 5.1 Hz, 4H), 3.68 – 3.61 (m, 2H), 3.26 (dt, J = 13.2, 6.4 
Hz, 1H), 3.20 – 3.13 (m, 1H), 3.04 – 2.98 (m, 6H), 2.26 (dd, J = 14.3, 7.0 Hz, 
5H), 1.98 (s, 3H), 1.59 – 1.49 (m, 8H), 1.24 (s, 54H), 1.17 – 1.10 (m, 6H), 
0.86 (t, J = 5.7 Hz, 15H). 13C NMR (126 MHz, CDCl3) δ 173.36, 173.01, 
170.79, 169.07, 163.42, 138.64, 138.45, 138.10, 128.48, 128.38, 128.35, 
128.28, 128.18, 128.15, 127.89, 127.76, 127.73, 127.50, 127.46, 127.43, 
98.64, 81.30, 77.78, 74.84, 74.73, 73.49, 73.33, 71.14, 70.20, 70.14, 68.73, 
68.55, 63.97, 62.41, 52.63, 45.73, 39.37, 39.03, 34.16, 34.00, 31.84, 29.92, 
185 
 
29.70, 29.65, 29.49, 29.43, 29.33, 29.30, 29.27, 29.13, 29.08, 27.93, 27.39, 
27.02, 26.91, 24.86, 24.82, 23.11, 22.63, 14.07, 8.50. 31P NMR (202 MHz, 






methylhexadecanoyloxy)propyl phosphate (2-43k). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 15 : 1 + 1% 
v/v triethylamine) to give 2-43k (21 mg, 71%) as a yellowish solid. 1H NMR 
(500 MHz, CDCl3) δ 7.29 (ddd, J = 13.1, 10.3, 4.4 Hz, 13H), 7.16 (dd, J = 7.2, 
1.8 Hz, 2H), 5.24 (s, 1H), 4.85 (d, J = 3.1 Hz, 1H), 4.81 – 4.68 (m, 3H), 4.64 
(d, J = 12.1 Hz, 1H), 4.50 (dd, J = 14.5, 11.6 Hz, 2H), 4.36 (dd, J = 11.9, 3.3 
Hz, 2H), 4.14 (dd, J = 12.0, 6.8 Hz, 1H), 4.02 (dd, J = 13.6, 6.4 Hz, 2H), 3.87 
(dd, J = 11.0, 2.9 Hz, 1H), 3.82 – 3.74 (m, 3H), 3.68 (d, J = 9.7 Hz, 1H), 3.30 
(dt, J = 13.2, 7.0 Hz, 1H), 3.19 (dt, J = 12.5, 6.2 Hz, 1H), 3.10 – 3.02 (m, 6H), 
2.28 (dd, J = 15.2, 7.5 Hz, 5H), 2.01 (s, 3H), 1.54 (dt, J = 19.8, 11.2 Hz, 8H), 
1.33 (t, J = 7.3 Hz, 9H), 1.27 (s, 58H), 1.20 – 1.14 (m, 6H), 0.89 (dd, J = 12.5, 
6.7 Hz, 15H). 13C NMR (126 MHz, CDCl3) δ 173.36, 173.02, 170.99, 168.83, 
163.42, 138.60, 138.39, 138.06, 128.28, 128.19, 127.75, 127.52, 127.48, 
98.42, 81.15, 77.82, 75.36, 74.81, 74.74, 73.33, 71.10, 70.09, 68.53, 64.13, 
62.33, 52.70, 45.77, 39.43, 39.03, 34.15, 33.99, 31.88, 29.92, 29.70, 29.68, 
29.65, 29.63, 29.60, 29.49, 29.32, 29.13, 29.09, 27.93, 27.39, 27.03, 24.86, 
24.81, 23.05, 22.64, 22.62, 14.07, 8.51. 31P NMR (202 MHz, CDCl3) δ -1.32. 
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2-(tetradecanoyloxy)propyl phosphate (2-43l). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 15 : 1 + 1% 
v/v triethylamine) to give 2-43l (21 mg, 73%) as a yellowish solid. 1H NMR 
(500 MHz, CDCl3) δ 7.36 – 7.27 (m, 13H), 7.18 – 7.13 (m, 2H), 5.24 (s, 1H), 
4.87 – 4.83 (m, 1H), 4.80 – 4.69 (m, 3H), 4.64 (d, J = 12.1 Hz, 1H), 4.55 – 
4.47 (m, 2H), 4.37 (dd, J = 11.9, 3.2 Hz, 2H), 4.18 – 4.11 (m, 1H), 4.06 – 4.00 
(m, 3H), 3.88 (d, J = 6.8 Hz, 1H), 3.77 (dd, J = 8.4, 5.6 Hz, 4H), 3.68 (d, J = 
10.4 Hz, 2H), 3.29 (dt, J = 13.4, 6.5 Hz, 1H), 3.24 – 3.15 (m, 1H), 3.04 (dt, J = 
11.5, 5.8 Hz, 6H), 2.28 (dd, J = 14.3, 7.1 Hz, 4H), 2.01 (s, 3H), 1.61 – 1.51 
(m, 8H), 1.27 (s, 62H), 1.20 – 1.14 (m, 6H), 0.89 (t, J = 6.2 Hz, 15H). 13C 
NMR (126 MHz, CDCl3) δ 173.36, 173.01, 170.89, 169.02, 138.61, 138.41, 
138.07, 128.43, 128.32, 128.27, 128.17, 128.07, 127.87, 127.74, 127.73, 
127.50, 127.46, 98.50, 81.21, 77.80, 74.72, 73.44, 73.32, 71.10, 70.15, 68.54, 
63.99, 62.38, 52.65, 45.73, 39.39, 39.02, 34.15, 33.99, 31.88, 29.92, 29.69, 
29.49, 29.32, 29.12, 29.08, 28.89, 27.92, 27.38, 27.02, 24.86, 24.80, 24.00, 
23.07, 22.64, 22.61, 19.75, 14.06, 9.81, 8.49, 0.75. 31P NMR (202 MHz, 









methylhexadecanoyloxy)propyl phosphate (2-43m). The crude mixture was 
purified by flash chromatography (dichloromethane : methanol = 15 : 1 + 1% 
v/v triethylamine) to give 2-43m (19 mg, 72%) as a yellowish solid. 1H NMR 
(500 MHz, CDCl3) δ 7.31 (dd, J = 21.3, 7.0 Hz, 13H), 7.18 (d, J = 11.9 Hz, 
2H), 5.25 (s, 1H), 4.89 – 4.68 (m, 5H), 4.63 (q, J = 7.6 Hz, 1H), 4.56 – 4.48 
(m, 2H), 4.37 (dd, J = 11.9, 3.2 Hz, 2H), 4.28 – 4.21 (m, 1H), 4.14 (dd, J = 
12.0, 6.9 Hz, 1H), 4.06 – 3.96 (m, 3H), 3.88 – 3.63 (m, 7H), 3.30 (dt, J = 13.5, 
7.2 Hz, 1H), 3.20 (dt, J = 13.4, 5.9 Hz, 1H), 3.05 (dd, J = 7.1, 3.4 Hz, 6H), 
2.29 (dt, J = 7.5, 5.9 Hz, 6H), 2.01 (s, 3H), 1.54 (dt, J = 19.9, 12.3 Hz, 8H), 
1.31 (s, 9H), 1.27 (s, 74H), 1.19 – 1.14 (m, 6H), 0.89 (t, J = 6.1 Hz, 15H). 13C 
NMR (126 MHz, CDCl3) δ 173.40, 173.06, 170.85, 169.33, 163.60, 138.57, 
138.40, 138.04, 128.45, 128.35, 128.28, 128.18, 128.08, 127.90, 127.75, 
127.73, 127.52, 127.46, 98.54, 92.12, 81.29, 77.84, 75.12, 74.88, 74.73, 73.46, 
73.32, 71.19, 71.09, 70.27, 68.69, 68.56, 63.76, 62.47, 52.69, 45.74, 39.02, 
34.17, 34.00, 31.87, 29.91, 29.67, 29.62, 29.50, 29.47, 29.31, 29.11, 29.09, 
27.92, 27.38, 27.02, 26.91, 24.86, 24.80, 23.08, 22.61, 14.05, 8.48. 31P NMR 
(202 MHz, CDCl3) δ -1.06. HRMS (ESI, M - H): calcd. for C89H148N2O15P 









oxopropan-2-yl 2,3-bis(12-methyltridecanoyloxy)propyl phosphate (2-
43n). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 15 : 1 + 1% v/v triethylamine) to give 3-43n 
(21 mg, 72%) as a yellowish solid. 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.26 
(m, 13H), 7.18 – 7.13 (m, 2H), 5.25 (s, 1H), 4.85 – 4.67 (m, 5H), 4.63 (dd, J = 
12.1, 5.8 Hz, 1H), 4.58 – 4.45 (m, 3H), 4.37 (ddd, J = 15.8, 13.7, 4.0 Hz, 2H), 
4.26 – 4.11 (m, 2H), 4.01 (dt, J = 12.8, 6.3 Hz, 2H), 3.86 – 3.64 (m, 7H), 3.56 
(d, J = 2.3 Hz, 1H), 3.30 (dd, J = 14.0, 7.4 Hz, 1H), 3.20 (dd, J = 13.7, 6.9 Hz, 
1H), 3.07 (dd, J = 7.2, 4.5 Hz, 6H), 2.39 – 2.24 (m, 5H), 2.05 (s, 3H), 1.56 
(ddd, J = 19.8, 18.2, 7.0 Hz, 8H), 1.27 (s, 54H), 1.19 – 1.14 (m, 6H), 0.88 (t, J 
= 6.5 Hz, 15H). 13C NMR (126 MHz, CDCl3) δ 173.37, 173.01, 171.26, 
170.81, 163.47, 138.76, 138.61, 138.52, 128.27, 128.23, 128.17, 128.11, 
127.74, 127.72, 127.70, 127.64, 127.59, 127.49, 127.45, 127.42, 127.32, 
127.26, 98.99, 92.16, 81.70, 81.27, 78.23, 77.80, 77.70, 74.58, 73.31, 73.19, 
71.09, 70.95, 68.58, 63.85, 62.44, 52.82, 52.64, 45.71, 39.36, 39.00, 34.15, 
34.06, 33.99, 31.87, 29.90, 29.74, 29.66, 29.61, 29.56, 29.48, 29.46, 29.38, 
29.31, 29.26, 29.10, 29.08, 27.91, 27.37, 27.30, 27.00, 24.85, 24.79, 23.08, 
22.70, 22.63, 22.60, 14.06, 8.50. 31P NMR (202 MHz, CDCl3) δ -1.06. HRMS 









oxopropan-2-yl 2,3-bis(13-methyltetradecanoyloxy)propyl phosphate (2-
43o). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 15 : 1 + 1% v/v triethylamine) to give 2-43o 
(21 mg, 71%) as a yellowish solid. 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.24 
(m, 13H), 7.19 – 7.13 (m, 2H), 6.74 (s, 1H), 6.50 (s, 1H), 4.85 (s, 1H), 4.82 – 
4.73 (m, 2H), 4.74 – 4.67 (m, 1H), 4.64 (d, J = 12.1 Hz, 1H), 4.50 (dd, J = 
15.2, 11.5 Hz, 2H), 4.31 – 4.21 (m, 4H), 4.03 (dd, J = 11.0, 5.2 Hz, 1H), 3.90 
(dd, J = 10.7, 2.6 Hz, 1H), 3.82 – 3.73 (m, 3H), 3.68 (d, J = 9.3 Hz, 1H), 3.29 
(dt, J = 21.1, 7.0 Hz, 1H), 3.22 – 3.14 (m, 1H), 3.11 – 3.04 (m, 6H), 2.42 – 
2.27 (m, 9H), 1.99 (s, 3H), 1.62 – 1.50 (m, 8H), 1.34 (d, J = 7.3 Hz, 9H), 1.27 
(s, 58H), 1.20 – 1.14 (m, 6H), 0.89 (t, J = 6.4 Hz, 15H). 13C NMR (126 MHz, 
CDCl3) δ 173.45, 173.41, 170.95, 169.14, 163.43, 138.62, 138.43, 138.08, 
128.29, 128.20, 127.76, 127.75, 127.66, 127.52, 127.47, 92.02, 81.28, 77.83, 
74.87, 74.75, 73.34, 71.31, 71.10, 68.56, 65.01, 62.97, 52.72, 45.75, 45.74, 
39.41, 39.03, 34.08, 34.00, 31.89, 29.93, 29.70, 29.65, 29.49, 29.41, 29.33, 
29.21, 29.14, 29.09, 27.94, 27.39, 27.04, 24.86, 24.81, 23.07, 22.64, 22.62, 
14.10, 14.08, 8.52. 31P NMR (202 MHz, CDCl3) δ -1.49. HRMS (ESI, M - H): 










oxopropan-2-yl 2,3-bis(14-methylpentadecanoyloxy)propyl phosphate (2-
43p). The crude mixture was purified by flash chromatography 
(dichloromethane : methanol = 15 : 1 + 1% v/v triethylamine) to give 3-43p 
(21 mg, 70%) as a yellowish solid. 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.25 
(m, 13H), 7.15 (d, J = 7.5 Hz, 2H), 5.25 (s, 1H), 4.78 (dd, J = 11.0, 7.6 Hz, 
3H), 4.70 (dd, J = 10.9, 5.1 Hz, 2H), 4.65 (s, 1H), 4.62 (d, J = 2.4 Hz, 1H), 
4.49 (dt, J = 9.9, 8.2 Hz, 2H), 4.35 (dd, J = 9.9, 5.3 Hz, 2H), 4.26 – 4.09 (m, 
2H), 4.03 (d, J = 5.7 Hz, 2H), 3.77 (d, J = 8.2 Hz, 3H), 3.67 (dd, J = 18.5, 8.7 
Hz, 2H), 3.35 – 3.27 (m, 1H), 3.19 (dd, J = 13.4, 6.8 Hz, 1H), 3.08 (s, 6H), 
2.29 (dd, J = 15.0, 7.4 Hz, 4H), 2.00 (s, 3H), 1.62 – 1.49 (m, 8H), 1.35 – 1.32 
(m, 9H), 1.27 (s, 62H), 1.19 – 1.14 (m, 6H), 0.89 (dd, J = 13.1, 6.6 Hz, 14H). 
13C NMR (126 MHz, CDCl3) δ 173.37, 173.02, 171.57, 169.30, 163.42, 
138.57, 138.38, 138.03, 132.15, 128.30, 128.26, 128.20, 128.14, 127.75, 
127.66, 127.61, 127.54, 127.48, 102.32, 93.35, 81.41, 80.60, 77.73, 77.57, 
75.75, 75.13, 74.80, 74.74, 74.68, 73.82, 73.33, 73.28, 72.27, 68.96, 65.04, 
63.28, 53.67, 45.79, 39.28, 39.03, 34.14, 33.99, 31.90, 29.93, 29.70, 29.65, 
29.52, 29.50, 29.34, 29.30, 29.13, 29.10, 27.93, 27.40, 27.03, 25.66, 24.86, 
24.81, 24.01, 22.89, 22.66, 22.63, 19.40, 14.09, 8.52, 6.51. 31P NMR (202 
MHz, CDCl3) δ -1.08. HRMS (ESI, M - H): calcd. for C83H136N2O15P 








oxopropan-2-yl 2,3-bis(octanoyloxy)propyl phosphate (2-43q). The crude 
mixture was purified by flash chromatography (dichloromethane : methanol = 
15 : 1 + 1% v/v triethylamine) to give 2-43q (20 mg, 75%) as a yellowish 
solid. 1H NMR (500 MHz, CDCl3) δ 7.29 (ddd, J = 14.4, 12.8, 7.0 Hz, 13H), 
7.17 – 7.14 (m, 2H), 6.80 (d, J = 15.7 Hz, 2H), 5.24 (s, 1H), 4.84 (s, 1H), 4.76 
(dd, J = 23.5, 12.7 Hz, 4H), 4.63 (d, J = 12.1 Hz, 1H), 4.55 – 4.46 (m, 2H), 
4.36 (d, J = 11.9 Hz, 2H), 4.13 (dd, J = 12.0, 6.8 Hz, 1H), 4.03 (dd, J = 10.6, 
4.9 Hz, 3H), 3.85 (d, J = 13.6 Hz, 1H), 3.76 (dd, J = 8.5, 5.5 Hz, 4H), 3.67 (d, 
J = 10.3 Hz, 1H), 3.34 – 3.26 (m, 1H), 3.22 – 3.16 (m, 1H), 3.11 – 3.07 (m, 
6H), 2.28 (dd, J = 14.4, 7.1 Hz, 4H), 2.01 (s, 3H), 1.64 – 1.48 (m, 6H), 1.35 (s, 
9H), 1.27 (s, 42H), 0.93 – 0.87 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 
173.34, 173.00, 171.04, 168.69, 163.47, 138.55, 138.37, 138.02, 128.42, 
128.28, 128.19, 127.87, 127.73, 127.72, 127.64, 127.52, 127.47, 98.42, 92.06, 
81.19, 77.78, 75.36, 74.93, 74.72, 73.31, 71.10, 69.96, 68.49, 64.16, 62.26, 
52.75, 45.82, 39.45, 34.12, 33.96, 31.87, 31.62, 29.73, 29.67, 29.63, 29.62, 
29.32, 29.02, 28.99, 28.91, 28.89, 27.02, 24.82, 24.78, 23.05, 22.64, 22.55, 
14.07, 14.01, 8.54. 31P NMR (202 MHz, CDCl3) δ -1.28. HRMS (ESI, M - H): 










oxopropan-2-yl 2,3-bis(dodecanoyloxy)propyl phosphate (2-43r). The 
crude mixture was purified by flash chromatography (dichloromethane : 
methanol = 15 : 1 + 1% v/v triethylamine) to give 2-43r (21 mg, 75%) as a 
yellowish solid. 1H NMR (500 MHz, CDCl3) δ 7.30 (ddd, J = 11.5, 10.9, 5.3 
Hz, 13H), 7.15 (dd, J = 7.3, 1.9 Hz, 2H), 6.74 (d, J = 22.0 Hz, 2H), 5.29 – 5.20 
(m, 1H), 4.85 (d, J = 3.2 Hz, 1H), 4.79 – 4.70 (m, 4H), 4.64 (d, J = 12.1 Hz, 
1H), 4.50 (dd, J = 14.4, 11.6 Hz, 2H), 4.36 (dd, J = 11.9, 3.2 Hz, 2H), 4.14 
(dd, J = 12.0, 6.9 Hz, 1H), 4.02 (dd, J = 10.9, 5.1 Hz, 3H), 3.86 (dd, J = 11.0, 
3.1 Hz, 1H), 3.81 – 3.73 (m, 4H), 3.68 (d, J = 9.6 Hz, 2H), 3.29 (dt, J = 13.4, 
6.5 Hz, 1H), 3.22 – 3.14 (m, 1H), 3.06 (dd, J = 7.3, 4.6 Hz, 6H), 2.33 – 2.26 
(m, 4H), 2.01 (s, 3H), 1.59 – 1.50 (m, 6H), 1.33 (s, 9H), 1.27 (s, 58H), 0.90 (t, 
J = 6.9 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 173.32, 172.98, 171.09, 
168.57, 163.44, 138.57, 138.39, 138.05, 128.28, 128.19, 127.87, 127.74, 
127.72, 127.63, 127.52, 127.47, 98.42, 92.08, 81.18, 77.79, 75.41, 74.89, 
74.72, 73.33, 71.14, 69.93, 68.52, 64.24, 62.26, 52.77, 45.81, 39.45, 34.13, 
33.98, 31.87, 29.69, 29.65, 29.63, 29.60, 29.49, 29.47, 29.31, 29.28, 29.11, 
29.09, 27.04, 24.85, 24.80, 23.02, 22.64, 14.06, 8.53. 31P NMR (202 MHz, 










oxopropan-2-yl 2,3-bis(tetradecanoyloxy)propyl phosphate (2-43s). The 
crude mixture was purified by flash chromatography (dichloromethane : 
methanol = 15 : 1 + 1% v/v triethylamine) to give 2-43s (22 mg, 73%) as a 
yellowish solid. 1H NMR (500 MHz, CDCl3) δ 7.27 (ddd, J = 12.2, 10.1, 6.0 
Hz, 13H), 7.16 – 7.11 (m, 2H), 6.67 (s, 1H), 6.27 (s, 1H), 5.22 (s, 1H), 4.85 (s, 
1H), 4.75 (dd, J = 11.0, 6.7 Hz, 2H), 4.68 (d, J = 11.2 Hz, 1H), 4.60 (d, J = 
12.1 Hz, 1H), 4.48 (dd, J = 16.7, 11.6 Hz, 2H), 4.32 (dd, J = 11.9, 3.2 Hz, 2H), 
4.12 (dd, J = 11.9, 6.7 Hz, 1H), 4.06 – 3.97 (m, 2H), 3.88 – 3.83 (m, 1H), 3.75 
(dd, J = 9.0, 7.1 Hz, 3H), 3.65 (d, J = 9.6 Hz, 1H), 3.27 (dt, J = 13.3, 6.3 Hz, 
1H), 3.21 – 3.12 (m, 1H), 3.07 (dd, J = 7.1, 4.6 Hz, 6H), 2.26 (dd, J = 15.8, 8.2 
Hz, 4H), 1.97 (s, 3H), 1.53 (dd, J = 32.2, 6.9 Hz, 6H), 1.36 (d, J = 7.3 Hz, 9H), 
1.25 (s, 66H), 0.87 (t, J = 6.9 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 173.37, 
173.03, 168.75, 163.49, 138.56, 138.35, 138.03, 128.29, 128.19, 127.75, 
127.53, 127.49, 104.96, 98.33, 92.07, 81.08, 77.86, 74.90, 74.74, 73.33, 71.09, 
70.04, 68.55, 64.15, 62.29, 52.76, 45.86, 39.48, 34.14, 33.99, 31.87, 29.68, 
29.64, 29.49, 29.31, 29.11, 29.08, 27.03, 24.85, 24.80, 23.02, 22.63, 14.07, 
14.05, 8.54. 31P NMR (202 MHz, CDCl3) δ -1.47. HRMS (ESI, M - H): calcd. 










oxopropan-2-yl 2,3-bis(palmitoyloxy)propyl phosphate (2-43t). The crude 
mixture was purified by flash chromatography (dichloromethane : methanol = 
15 : 1 + 1% v/v triethylamine) to give 2-43t (23 mg, 74%) as a yellowish 
solid. 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.19 (m, 12H), 7.12 (d, J = 7.5 Hz, 
2H), 6.97 (s, 1H), 6.83 (s, 1H), 5.21 (s, 1H), 4.81 (d, J = 3.2 Hz, 1H), 4.73 (dd, 
J = 22.1, 12.7 Hz, 3H), 4.60 (d, J = 12.0 Hz, 1H), 4.51 – 4.43 (m, 1H), 4.34 
(td, J = 12.2, 3.3 Hz, 2H), 4.11 (ddd, J = 15.7, 12.0, 6.7 Hz, 1H), 4.00 (dd, J = 
10.9, 4.8 Hz, 2H), 3.80 (dd, J = 10.4, 2.7 Hz, 1H), 3.72 (dd, J = 13.0, 5.3 Hz, 
3H), 3.65 (t, J = 7.9 Hz, 1H), 3.27 (dt, J = 13.4, 7.1 Hz, 1H), 3.15 (dd, J = 
13.5, 7.1 Hz, 1H), 3.06 (dd, J = 6.7, 4.5 Hz, 6H), 2.26 (dt, J = 15.1, 7.6 Hz, 
4H), 1.97 (s, 2H), 1.59 – 1.47 (m, 6H), 1.32 (s, 8H), 1.24 (s, 74H), 0.86 (t, J = 
6.9 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 173.34, 173.04, 170.98, 169.03, 
163.57, 138.54, 138.36, 138.00, 128.38, 128.26, 128.16, 128.00, 127.85, 
127.73, 127.72, 127.51, 127.45, 98.39, 92.13, 81.17, 77.81, 75.24, 74.91, 
74.71, 73.29, 71.03, 70.06, 68.50, 63.94, 62.36, 52.70, 45.78, 39.43, 34.16, 
34.13, 33.99, 33.97, 31.86, 29.65, 29.60, 29.49, 29.47, 29.30, 29.27, 29.10, 
29.07, 27.02, 24.84, 24.80, 24.78, 23.04, 22.62, 14.05, 8.51. 31P NMR (202 
MHz, CDCl3) δ -1.43. HRMS (ESI, M - H): calcd. for C79H128N2O15P 










oxopropan-2-yl 2,3-bis(heptadecanoyloxy)propyl phosphate (2-43u). The 
crude mixture was purified by flash chromatography (dichloromethane : 
methanol = 15 : 1 + 1% v/v triethylamine) to give 2-43u (23 mg, 72%) as a 
yellowish solid. 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.25 (m, 13H), 7.19 – 
7.12 (m, 2H), 6.83 (s, 2H), 5.25 (s, 1H), 4.84 (d, J = 3.1 Hz, 1H), 4.76 (dd, J = 
22.9, 12.3 Hz, 3H), 4.62 (d, J = 19.3 Hz, 1H), 4.49 (dd, J = 14.8, 11.6 Hz, 2H), 
4.36 (dd, J = 11.9, 3.0 Hz, 2H), 4.13 (dd, J = 12.0, 6.9 Hz, 1H), 4.07 – 3.97 
(m, 3H), 3.84 (d, J = 10.5 Hz, 1H), 3.76 (d, J = 13.1 Hz, 3H), 3.67 (d, J = 10.1 
Hz, 1H), 3.34 – 3.26 (m, 1H), 3.21 – 3.15 (m, 1H), 3.09 – 3.06 (m, 6H), 2.29 
(dt, J = 21.8, 7.3 Hz, 4H), 2.01 (s, 3H), 1.62 – 1.51 (m, 6H), 1.33 (d, J = 7.4 
Hz, 9H), 1.27 (s, 78H), 0.89 (t, J = 6.7 Hz, 9H). 13C NMR (126 MHz, CDCl3) 
δ 173.38, 173.04, 170.90, 169.17, 163.58, 138.55, 138.39, 138.02, 128.27, 
128.17, 127.97, 127.86, 127.73, 127.72, 127.71, 127.51, 127.45, 98.50, 92.13, 
81.27, 77.81, 75.14, 74.92, 74.71, 73.31, 71.07, 70.12, 68.53, 63.87, 62.40, 
52.72, 45.76, 39.42, 34.15, 33.99, 31.87, 29.74, 29.66, 29.61, 29.49, 29.47, 
29.31, 29.27, 29.10, 29.08, 27.02, 24.85, 24.80, 23.07, 22.63, 14.06, 8.50. 31P 
NMR (202 MHz, CDCl3) δ -1.32. HRMS (ESI, M - H): calcd. for 







General procedure for the synthesis of PGL1. A solution of 2-43  (0.020 
g) in chloroform : methanol (1 : 1; 3 mL) was stirred in the presence of Dowex 
50W X 4 (Na+) resin for 3 h, filtered, then concentrated under reduced 
pressure. The residue was dissolved in dichloromethane : methanol (1 : 4; 3 
mL) with Pd/C (0.05 g, 10% Pd content) and stirred under an atmosphere of 
hydrogen for 12 h. The reaction mixture was filtered through a pad of celite 






2-(13-methyltetradecanoyloxy)propyl phosphate (PGL1a). PGL1a (14.70 
mg, 89%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD 
= 1 :1) δ 5.22 (s, 1H), 4.40 (dd, J = 12.0, 3.1 Hz, 1H), 4.25 – 4.11 (m, 1H), 
4.06 – 3.75 (m, 6H), 3.72 – 3.55 (m, 3H), 3.16 (dd, J = 14.9, 7.6 Hz, 3H), 2.38 
– 2.27 (m, 4H), 2.02 (s, 3H), 1.63 – 1.48 (m, 8H), 1.25 (s, 58H), 1.14 (s, 6H), 
0.84 (d, J = 6.6 Hz, 18H). 13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 
174.75, 174.35, 173.75, 170.87, 98.33, 76.12, 73.18, 72.89, 71.88, 71.28, 
69.08, 64.52, 63.40, 62.30, 54.65, 47.45, 40.26, 39.90, 34.97, 34.86, 30.75, 
30.51, 30.37, 30.34, 30.20, 30.15, 29.97, 28.78, 28.23, 27.87, 25.73, 25.70, 
23.14, 22.99, 9.24. 31P NMR (202 MHz, CDCl3 : MeOD = 1 :1) δ -0.57. 









2-(14-methylpentadecanoyloxy)propyl phosphate (PGL1b). PGL1b (14.90 
mg, 90%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD 
= 1 :1) δ 5.22 (s, 1H), 4.78 (s, 1H), 4.40 (d, J = 9.2 Hz, 1H), 4.16 (dd, J = 11.9, 
6.7 Hz, 1H), 3.99 (s, 1H), 3.92 (d, J = 6.3 Hz, 2H), 3.84 – 3.74 (m, 2H), 3.75 – 
3.51 (m, 4H), 3.39 – 3.34 (m, 1H), 3.17 (dd, J = 15.3, 8.5 Hz, 2H), 2.37 – 2.26 
(m, 3H), 2.02 (s, 3H), 1.67 – 1.44 (m, 9H), 1.25 (s, 60H), 1.14 (d, J = 5.9 Hz, 
6H), 0.85 (d, J = 6.6 Hz, 18H). 13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 
174.82, 174.42, 173.84, 171.05, 98.46, 76.22, 73.34, 72.98, 72.03, 71.47, 
69.16, 64.65, 63.49, 62.42, 54.82, 47.62, 40.36, 40.00, 35.05, 34.93, 32.81, 
30.84, 30.61, 30.59, 30.55, 30.43, 30.29, 30.24, 30.22, 30.13, 30.06, 28.87, 
28.32, 27.96, 27.85, 26.65, 25.83, 25.80, 23.51, 23.17, 23.02, 14.54. 31P NMR 
(202 MHz, CDCl3 : MeOD = 1 :1) δ -0.58. HRMS (ESI, M - H): calcd. for 





methylhexadecanoyloxy)propyl phosphate (PGL1c). PGL1c (14.42 mg, 
87%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD = 1 
:1) δ 5.21 (s, 1H), 4.76 (d, J = 3.1 Hz, 1H), 4.39 (dd, J = 12.0, 3.0 Hz, 1H), 
4.20 – 4.13 (m, 1H), 4.02 – 3.88 (m, 3H), 3.82 (dd, J = 19.2, 12.2 Hz, 2H), 
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3.71 – 3.56 (m, 4H), 3.26 – 3.13 (m, 2H), 2.36 – 2.25 (m, 4H), 2.01 (s, 3H), 
1.52 (ddd, J = 21.8, 19.9, 6.2 Hz, 9H), 1.24 (s, 62H), 1.16 – 1.10 (m, 6H), 0.83 
(d, J = 6.6 Hz, 18H). 13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 174.70, 
174.29, 173.67, 170.76, 98.22, 76.02, 73.06, 72.78, 71.84, 71.26, 70.06, 69.00, 
63.34, 62.27, 54.56, 40.19, 39.82, 34.92, 34.80, 32.65, 30.68, 30.44, 30.39, 
30.27, 30.12, 30.08, 29.90, 28.70, 28.16, 27.79, 27.69, 25.66, 25.63, 23.36, 
23.11, 22.97, 14.50. 31P NMR (202 MHz, CDCl3 : MeOD = 1 :1) δ -0.53. 






(PGL1d). PGL1d (14.50 mg, 88%) was obtained as a white solid. 1H NMR 
(500 MHz, CDCl3 : MeOD = 1 :1) δ 5.21 (s, 1H), 4.76 (d, J = 3.2 Hz, 1H), 
4.39 (dd, J = 12.0, 3.0 Hz, 1H), 4.16 (dd, J = 12.0, 6.8 Hz, 1H), 4.00 – 3.91 
(m, 3H), 3.82 (ddd, J = 30.8, 16.9, 7.6 Hz, 3H), 3.67 (ddd, J = 23.1, 10.0, 4.4 
Hz, 4H), 3.21 (dd, J = 20.9, 4.7 Hz, 2H), 2.38 – 2.27 (m, 4H), 2.02 (s, 3H), 
1.58 (d, J = 6.0 Hz, 4H), 1.56 – 1.45 (m, 5H), 1.24 (s, 54H), 1.13 (d, J = 5.8 
Hz, 6H), 0.91 – 0.78 (m, 21H). 13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 
174.75, 174.34, 173.72, 170.84, 98.29, 76.10, 73.13, 72.86, 71.87, 71.32, 
71.25, 69.04, 63.38, 62.28, 54.61, 45.09, 40.23, 39.87, 34.96, 34.84, 31.45, 
30.90, 30.71, 30.48, 30.46, 30.43, 30.37, 30.31, 30.17, 30.12, 29.93, 28.74, 
28.20, 27.84, 25.70, 25.68, 25.38, 23.12, 23.11, 22.98. 31P NMR (202 MHz, 
CDCl3 : MeOD = 1 :1) δ -0.47. HRMS (ESI, M - H): calcd. for C62H118N2O15P 
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(PGL1e). PGL1e (14.70 mg, 89%) was obtained as a white solid. 1H NMR 
(500 MHz CDCl3 : MeOD = 1 :1) δ 5.21 (s, 1H), 4.79 – 4.70 (m, 2H), 4.39 
(dd, J = 11.9, 3.0 Hz, 1H), 4.15 (dd, J = 12.0, 6.8 Hz, 1H), 4.01 – 3.89 (m, 
3H), 3.81 (ddd, J = 22.3, 14.4, 9.1 Hz, 4H), 3.67 (ddd, J = 16.5, 10.6, 5.4 Hz, 
4H), 2.29 (dd, J = 16.9, 7.6 Hz, 4H), 2.02 (s, 3H), 1.58 (d, J = 6.4 Hz, 4H), 
1.53 – 1.44 (m, 5H), 1.24 (s, 56H), 1.12 (d, J = 6.4 Hz, 6H), 0.85 – 0.81 (m, 
21H). 13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 174.70, 174.29, 173.25, 
170.85, 98.20, 76.04, 73.08, 72.78, 71.86, 71.26, 68.96, 64.49, 63.34, 62.29, 
54.61, 47.41, 40.21, 39.83, 34.93, 34.81, 31.42, 30.88, 30.69, 30.46, 30.44, 
30.40, 30.32, 30.28, 30.14, 30.09, 29.92, 28.71, 28.17, 27.81, 27.70, 25.67, 
25.64, 25.35, 23.37, 23.11, 22.98. 31P NMR (202 MHz, CDCl3 : MeOD = 1 







phosphate (PGL1f). PGL1f (14.56 mg, 88%) was obtained as a white solid. 
1H NMR (500 MHz, CDCl3 : MeOD = 1 :1) δ 5.20 (s, 0H), 4.78 (s, 1H), 4.40 
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(d, J = 11.9 Hz, 1H), 4.16 (dd, J = 11.9, 6.8 Hz, 1H), 4.01 – 3.85 (m, 3H), 3.79 
(dd, J = 15.5, 8.7 Hz, 2H), 3.72 – 3.59 (m, 3H), 3.19 (ddd, J = 21.8, 14.0, 7.1 
Hz, 2H), 2.30 (dd, J = 16.7, 7.9 Hz, 4H), 2.02 (s, 3H), 1.58 (d, J = 5.5 Hz, 4H), 
1.55 – 1.44 (m, 4H), 1.24 (s, 56H), 1.13 (d, J = 5.9 Hz, 6H), 0.90 – 0.76 (m, 
21H). 13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 174.72, 174.32, 173.34, 
170.99, 98.24, 76.08, 73.12, 72.82, 71.90, 71.31, 69.00, 64.50, 63.37, 62.34, 
54.66, 47.45, 45.09, 40.36, 39.87, 34.95, 34.83, 31.46, 30.90, 30.72, 30.49, 
30.47, 30.44, 30.35, 30.32, 30.17, 30.12, 29.93, 28.75, 28.20, 27.84, 25.71, 
25.68, 25.37, 23.13, 22.98. 31P NMR (202 MHz, , CDCl3 : MeOD = 1 :1) δ -






2-(11-methyltridecanoyloxy)propyl phosphate (PGL1g). PGL1g (14.01 
mg, 85%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD 
= 1 :1) δ 5.21 (s, 1H), 4.77 (s, 1H), 4.39 (dd, J = 12.0, 2.9 Hz, 1H), 4.19 – 4.14 
(m, 1H), 3.99 (s, 1H), 3.94 – 3.87 (m, 2H), 3.86 (dd, J = 9.7, 6.9 Hz, 1H), 3.83 
– 3.74 (m, 2H), 3.73 – 3.57 (m, 4H), 3.25 – 3.19 (m, 1H), 2.30 (dd, J = 16.9, 
7.8 Hz, 4H), 2.02 (s, 3H), 1.58 (d, J = 5.1 Hz, 4H), 1.50 (dd, J = 13.3, 6.6 Hz, 
4H), 1.24 (s, 57H), 1.13 (d, J = 6.5 Hz, 6H), 0.83 (dd, J = 11.0, 4.7 Hz, 18H). 
13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 174.74, 174.34, 173.71, 
170.60, 98.29, 76.09, 73.15, 72.86, 71.90, 71.32, 69.03, 64.51, 63.38, 62.32, 
54.65, 39.88, 37.47, 35.25, 34.96, 34.84, 32.70, 30.82, 30.72, 30.49, 30.47, 
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30.44, 30.36, 30.31, 30.27, 30.18, 30.13, 29.95, 28.75, 28.21, 27.91, 27.85, 
25.71, 25.68, 23.12, 22.98, 19.72, 11.85. 31P NMR (202 MHz, CDCl3 : MeOD 






2-(12-methyltetradecanoyloxy)propyl phosphate (PGL1h). PGL1h (14.04 
mg, 85%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD 
= 1 :1) δ 4.77 (d, J = 3.0 Hz, 1H), 4.27 – 4.19 (m, 3H), 3.91 (dd, J = 10.1, 3.4 
Hz, 2H), 3.87 – 3.83 (m, 1H), 3.79 (d, J = 11.9 Hz, 2H), 3.74 – 3.68 (m, 2H), 
3.64 (s, 1H), 3.38 – 3.33 (m, 1H), 3.27 – 3.18 (m, 2H), 2.32 (dd, J = 13.8, 6.3 
Hz, 4H), 2.02 (s, 3H), 1.62 – 1.56 (m, 4H), 1.54 – 1.46 (m, 4H), 1.25 (s, 59H), 
1.13 (d, J = 6.7 Hz, 6H), 0.88 – 0.81 (m, 18H). 13C NMR (126 MHz, CDCl3 : 
MeOD = 1 :1) δ 174.77, 174.75, 173.79, 170.90, 98.32, 76.09, 73.13, 72.90, 
71.97, 71.91, 69.05, 63.92, 62.30, 54.66, 47.47, 39.88, 37.45, 35.24, 34.78, 
30.80, 30.72, 30.48, 30.43, 30.30, 30.26, 30.17, 30.13, 29.95, 28.75, 28.20, 
27.89, 27.84, 25.66, 23.12, 22.99, 19.72, 11.84. 31P NMR (202 MHz, , CDCl3 
: MeOD = 1 :1) δ -1.19. HRMS (ESI, M - H): calcd. for C63H120N2O15P 










2-(13-methylpentadecanoyloxy)propyl phosphate (PGL1i). PGL1i (14.23 
mg, 86%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD 
= 1 :1) δ 5.21 (s, 1H), 4.77 (s, 1H), 4.39 (dd, J = 12.0, 3.0 Hz, 1H), 4.17 – 4.12 
(m, 1H), 3.98 (s, 2H), 3.88 (ddd, J = 16.9, 10.5, 5.1 Hz, 3H), 3.78 (t, J = 11.3 
Hz, 2H), 3.72 – 3.60 (m, 4H), 3.27 – 3.21 (m, 1H), 2.30 (dd, J = 16.9, 7.8 Hz, 
4H), 2.02 (s, 3H), 1.58 (d, J = 5.6 Hz, 4H), 1.50 (dd, J = 13.2, 6.6 Hz, 4H), 
1.25 (s, 61H), 1.13 (d, J = 6.5 Hz, 6H), 0.83 (dd, J = 11.6, 4.7 Hz, 18H). 13C 
NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 174.73, 174.33, 173.74, 170.86, 
98.29, 76.09, 73.15, 72.86, 71.89, 71.32, 69.04, 64.53, 63.39, 62.32, 54.64, 
47.45, 40.24, 39.88, 37.46, 35.25, 34.96, 34.84, 30.83, 30.73, 30.50, 30.48, 
30.45, 30.35, 30.32, 30.27, 30.18, 30.13, 29.95, 28.76, 28.21, 27.91, 27.85, 
27.75, 25.72, 25.69, 23.13, 22.99, 19.72, 14.52, 11.85. 31P NMR (202 MHz, 
CDCl3 : MeOD = 1 :1) δ -0.57. HRMS (ESI, M - H): calcd. for C64H122N2O15P 





methylhexadecanoyloxy)propyl phosphate (PGL1j). PGL1j (14.22 mg, 
87%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD = 1 
:1) δ 5.21 (s, 1H), 4.76 (d, J = 3.2 Hz, 1H), 4.39 (dd, J = 12.0, 3.0 Hz, 1H), 
4.18 – 4.13 (m, 1H), 3.99 (dd, J = 8.9, 5.4 Hz, 2H), 3.91 (dd, J = 10.4, 3.3 Hz, 
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1H), 3.88 – 3.82 (m, 1H), 3.78 (t, J = 11.8 Hz, 2H), 3.71 (d, J = 5.1 Hz, 2H), 
3.65 (t, J = 7.2 Hz, 2H), 3.26 – 3.15 (m, 2H), 2.30 (dd, J = 16.6, 7.9 Hz, 4H), 
2.02 (s, 3H), 1.58 (d, J = 5.1 Hz, 4H), 1.50 (dd, J = 13.2, 6.6 Hz, 4H), 1.24 (s, 
54H), 1.17 – 1.07 (m, 6H), 0.84 (t, J = 7.4 Hz, 15H). 13C NMR (126 MHz, 
CDCl3 : MeOD = 1 :1) δ 174.75, 174.33, 173.71, 170.85, 98.29, 76.11, 73.14, 
72.86, 71.88, 71.25, 69.05, 64.45, 63.37, 62.30, 54.62, 40.22, 39.86, 34.94, 
34.83, 32.69, 30.71, 30.48, 30.46, 30.43, 30.28, 30.15, 30.11, 29.92, 28.74, 
28.19, 27.83, 25.67, 23.42, 23.12, 22.98, 14.54. 31P NMR (202 MHz, CDCl3 : 
MeOD = 1 :1) δ -0.49. HRMS (ESI, M - H): calcd. for C58H110N2O15P 





methylhexadecanoyloxy)propyl phosphate (PGL1k).b PGL1k (14.61 mg, 
89%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD = 1 
:1) δ 5.21 (s, 1H), 4.76 (d, J = 3.1 Hz, 1H), 4.39 (dd, J = 11.9, 2.9 Hz, 1H), 
4.16 (dd, J = 12.0, 6.8 Hz, 1H), 4.03 – 3.89 (m, 3H), 3.84 (d, J = 6.7 Hz, 1H), 
3.78 (t, J = 12.3 Hz, 2H), 3.70 (dd, J = 12.2, 5.3 Hz, 2H), 3.64 (t, J = 8.0 Hz, 
2H), 3.26 – 3.14 (m, 2H), 2.31 (dt, J = 16.8, 8.5 Hz, 4H), 2.02 (s, 3H), 1.58 (d, 
J = 4.8 Hz, 4H), 1.50 (td, J = 13.1, 6.5 Hz, 4H), 1.24 (s, 58H), 1.13 (d, J = 6.0 
Hz, 4H), 0.84 (t, J = 6.9 Hz, 15H). 31P NMR (202 MHz, CDCl3 : MeOD = 1 








2-(tetradecanoyloxy)propyl phosphate (PGL1l). PGL1l (15.54 mg, 88%) 
was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD = 1 :1) δ 
5.20 (t, J = 7.4 Hz, 1H), 4.76 (d, J = 3.2 Hz, 1H), 4.39 (dd, J = 12.0, 3.1 Hz, 
1H), 4.15 (dd, J = 12.0, 6.8 Hz, 1H), 3.98 (dd, J = 8.8, 5.7 Hz, 1H), 3.91 (dd, J 
= 10.9, 4.2 Hz, 2H), 3.85 (dd, J = 10.6, 6.9 Hz, 1H), 3.78 (t, J = 12.8 Hz, 2H), 
3.69 (dd, J = 11.5, 5.0 Hz, 2H), 3.64 (t, J = 7.3 Hz, 2H), 3.16 (dd, J = 14.7, 7.4 
Hz, 2H), 2.30 (dd, J = 17.0, 7.7 Hz, 4H), 2.02 (s, 3H), 1.62 – 1.56 (m, 4H), 
1.50 (dd, J = 13.3, 6.6 Hz, 4H), 1.24 (s, 62H), 1.15 – 1.10 (m, 4H), 0.85 (dd, J 
= 13.5, 6.6 Hz, 15H). 13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 174.71, 
174.31, 173.69, 170.81, 98.25, 73.10, 72.83, 71.89, 71.22, 70.08, 69.03, 64.44, 
63.35, 62.31, 54.61, 47.42, 40.33, 40.21, 40.01, 39.85, 34.93, 34.82, 32.70, 
30.70, 30.47, 30.45, 30.42, 30.32, 30.29, 30.14, 30.10, 29.92, 28.73, 28.18, 
27.82, 27.71, 25.68, 25.65, 23.41, 23.11, 22.97, 14.53.  31P NMR (202 MHz, 
CDCl3 : MeOD = 1 :1) δ -0.56. HRMS (ESI, M - H): calcd. for C62H118N2O15P 





methylhexadecanoyloxy)propyl phosphate (PGL1m).b PGL1m (17.40 mg, 
87%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD = 1 
:1) δ 4.26 (s, 1H), 4.09 (d, J = 5.0 Hz, 1H), 3.92 (d, J = 13.6 Hz, 2H), 3.80 (d, J 
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= 10.9 Hz, 2H), 3.69 (d, J = 11.8 Hz, 2H), 3.67 – 3.52 (m, 4H), 3.44 – 3.34 (m, 
2H), 2.35 – 2.24 (m, 4H), 1.96 (s, 3H), 1.58 (s, 4H), 1.52 – 1.44 (m, 4H), 1.23 
(s, 74H), 1.12 (d, J = 5.6 Hz, 6H), 0.84 (t, J = 6.2 Hz, 15H). 31P NMR (202 
MHz, CDCl3 : MeOD = 1 :1) δ -0.61. HRMS (ESI, M - H): calcd. for 




oxopropan-2-yl 2,3-bis(12-methyltridecanoyloxy)propyl phosphate 
(PGL1n).b PGL1n (14.22 mg, 87%) was obtained as a white solid. 1H NMR 
(500 MHz, CDCl3 : MeOD = 1 :1) δ 5.22 (s, 1H), 4.05 – 3.96 (m, 2H), 3.92 (d, 
J = 6.0 Hz, 2H), 3.79 (s, 3H), 3.72 – 3.63 (m, 3H), 3.60 (d, J = 10.3 Hz, 2H), 
3.19 (s, 3H), 2.33 (dd, J = 17.1, 9.1 Hz, 4H), 2.03 (s, 3H), 1.60 (s, 4H), 1.51 
(dd, J = 13.4, 6.7 Hz, 4H), 1.26 (s, 54H), 1.15 (d, J = 6.5 Hz, 4H), 0.87 (dd, J = 
12.2, 6.6 Hz, 15H). 31P NMR (202 MHz, CDCl3 : MeOD = 1 :1) δ -0.62. . 




oxopropan-2-yl 2,3-bis(13-methyltetradecanoyloxy)propyl phosphate 
(PGL1o).b PGL1o (14.11 mg, 86%) was obtained as a white solid. 1H NMR 
(500 MHz, CDCl3 : MeOD = 1 :1) δ 4.27 (d, J = 11.2 Hz, 4H), 3.93 (s, 2H), 
3.85 – 3.80 (m, 2H), 3.70 (s, 4H), 3.37 (d, J = 8.5 Hz, 2H), 2.35 – 2.31 (m, 
4H), 2.01 (d, J = 7.0 Hz, 3H), 1.60 (d, J = 4.2 Hz, 4H), 1.50 (d, J = 6.7 Hz, 
4H), 1.25 (s, 58H), 1.13 (d, J = 6.3 Hz, 6H), 0.85 (t, J = 6.3 Hz, 15H). 31P 
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NMR (202 MHz, CDCl3 : MeOD = 1 :1) δ -1.23. HRMS (ESI, M - H): calcd. 




oxopropan-2-yl 2,3-bis(14-methylpentadecanoyloxy)propyl phosphate 
(PGL1p).b PGL1p (14.01 mg, 85%) was obtained as a white solid. 1H NMR 
(500 MHz, CDCl3 : MeOD = 1 :1) δ 4.86 (s, 1H), 4.40 (d, J = 11.2 Hz, 1H), 
4.21 – 4.09 (m, 2H), 3.95 (dd, J = 29.2, 11.8 Hz, 3H), 3.81 (d, J = 9.3 Hz, 2H), 
3.71 – 3.66 (m, 2H), 3.60 (d, J = 6.9 Hz, 2H), 3.26 (d, J = 6.3 Hz, 2H), 2.35 – 
2.29 (m, 4H), 2.04 (s, 3H), 1.59 (s, 4H), 1.51 (dd, J = 13.4, 6.7 Hz, 5H), 1.26 
(s, 62H), 1.15 (d, J = 6.2 Hz, 6H), 0.87 (dd, J = 12.3, 6.5 Hz, 18H). 31P NMR 
(202 MHz, CDCl3 : MeOD = 1 :1) δ -0.64. HRMS (ESI, M - H): calcd. for 




oxopropan-2-yl 2,3-bis(octanoyloxy)propyl phosphate (PGL1q). PGL1q 
(14.28 mg, 90%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : 
MeOD = 1 :1) δ 5.21 (s, 1H), 4.85 (d, J = 3.2 Hz, 1H), 4.38 (dd, J = 12.0, 3.1 
Hz, 1H), 4.15 (dd, J = 12.0, 6.9 Hz, 1H), 4.02 – 3.97 (m, 2H), 3.89 (dd, J = 
10.2, 2.7 Hz, 2H), 3.79 (t, J = 8.9 Hz, 2H), 3.70 (dd, J = 19.3, 7.1 Hz, 2H), 
3.64 – 3.58 (m, 2H), 3.36 (d, J = 9.4 Hz, 1H), 3.26 – 3.17 (m, 2H), 2.35 – 2.28 
(m, 4H), 2.03 (s, 3H), 1.58 (d, J = 4.5 Hz, 5H), 1.55 – 1.49 (m, 3H), 1.26 (d, J 
= 19.2 Hz, 42H), 0.86 (dd, J = 10.5, 6.7 Hz, 9H). 13C NMR (126 MHz, CDCl3 
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: MeOD = 1 :1) δ 174.78, 174.38, 173.86, 170.96, 98.11, 75.97, 73.14, 72.67, 
71.89, 71.34, 68.77, 64.63, 63.40, 62.32, 54.80, 40.32, 34.95, 34.83, 32.75, 
32.55, 32.53, 30.51, 30.17, 29.90, 29.84, 29.80, 27.89, 25.72, 25.69, 23.46, 
23.42, 23.41, 23.02, 14.54, 1.58. 31P NMR (202 MHz, CDCl3 : MeOD = 1 :1) 





oxopropan-2-yl 2,3-bis(dodecanoyloxy)propyl phosphate (PGL1r). PGL1r 
(14.09 mg, 87%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : 
MeOD = 1 :1) δ 5.21 (dd, J = 4.3, 2.3 Hz, 1H), 4.84 (d, J = 3.1 Hz, 1H), 4.38 
(dd, J = 12.0, 3.1 Hz, 1H), 4.15 (dd, J = 12.0, 6.9 Hz, 1H), 3.98 (dd, J = 11.1, 
6.1 Hz, 2H), 3.92 – 3.86 (m, 2H), 3.82 – 3.76 (m, 2H), 3.73 – 3.60 (m, 4H), 
3.35 (dd, J = 11.1, 7.8 Hz, 1H), 3.19 – 3.13 (m, 2H), 2.30 (dd, J = 15.8, 7.9 
Hz, 4H), 2.03 (s, 3H), 1.58 (d, J = 6.0 Hz, 4H), 1.54 – 1.49 (m, 2H), 1.24 (s, 
58H), 0.86 (t, J = 6.7 Hz, 9H). 13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 
174.74, 174.34, 173.84, 170.86, 98.08, 75.98, 73.08, 72.67, 71.85, 71.30, 
68.77, 64.60, 63.39, 62.29, 54.74, 40.29, 34.95, 34.83, 32.72, 30.50, 30.48, 
30.45, 30.35, 30.32, 30.18, 30.14, 29.96, 29.94, 27.87, 25.72, 25.68, 23.43, 
23.01, 22.30, 14.54. 31P NMR (202 MHz, CDCl3 : MeOD = 1 :1) δ -1.67. 








bis(tetradecanoyloxy)propyl phosphate (PGL1s).b PGL1s (14.39 mg, 88%) 
was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : MeOD = 1 :1) δ 
4.97 (s, 1H), 4.38 (d, J = 10.4 Hz, 1H), 4.17 – 4.09 (m, 1H), 3.99 (d, J = 6.8 
Hz, 1H), 3.92 (d, J = 6.4 Hz, 1H), 3.83 (dd, J = 25.3, 11.3 Hz, 3H), 3.68 (dd, J 
= 20.2, 11.9 Hz, 3H), 3.60 (s, 1H), 3.40 – 3.34 (m, 2H), 2.30 (dd, J = 14.3, 7.0 
Hz, 4H), 1.95 (s, 3H), 1.58 (d, J = 3.9 Hz, 4H), 1.52 (s, 3H), 1.24 (s, 66H), 
0.86 (t, J = 6.8 Hz, 9H). 31P NMR (202 MHz, CDCl3 : MeOD = 1 :1) δ -3.13. 




oxopropan-2-yl 2,3-bis(palmitoyloxy)propyl phosphate (PGL1t). PGL1t 
(14.34 mg, 87%) was obtained as a white solid. 1H NMR (500 MHz, CDCl3 : 
MeOD = 1 :1) δ 5.21 (s, 1H), 4.95 (s, 1H), 4.37 (dd, J = 11.9, 2.8 Hz, 1H), 
4.19 – 4.12 (m, 1H), 3.98 (d, J = 5.5 Hz, 1H), 3.91 (dd, J = 11.1, 4.4 Hz, 2H), 
3.85 – 3.79 (m, 2H), 3.73 – 3.66 (m, 2H), 3.63 – 3.56 (m, 2H), 3.37 (d, J = 9.1 
Hz, 2H), 3.21 – 3.12 (m, 3H), 2.29 (dd, J = 14.7, 7.3 Hz, 4H), 2.03 (s, 3H), 
1.58 (d, J = 4.5 Hz, 4H), 1.52 (d, J = 10.5 Hz, 2H), 1.24 (s, 74H), 0.86 (t, J = 
6.9 Hz, 9H). 13C NMR (126 MHz, CDCl3 : MeOD = 1 :1) δ 174.74, 174.35, 
173.38, 170.97, 97.80, 73.00, 72.39, 71.84, 71.27, 68.34, 64.70, 63.42, 62.29, 
54.87, 40.37, 34.96, 34.85, 32.73, 30.51, 30.46, 30.38, 30.35, 30.20, 30.16, 
29.98, 27.89, 25.74, 25.70, 23.44, 23.04, 22.31, 14.54. 31P NMR (202 MHz, 
CDCl3 : MeOD = 1 :1) δ -3.10. HRMS (ESI, M - H): calcd. for C62H118N2O15P 
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oxopropan-2-yl 2,3-bis(heptadecanoyloxy)propyl phosphate (PGL1u).b 
PGL1u (14.72 mg, 89%) was obtained as a white solid. . 1H NMR (500 MHz, 
CDCl3 : MeOD = 1 :1) δ 4.37 (dd, J = 11.9, 2.7 Hz, 1H), 4.13 (dd, J = 12.0, 
7.2 Hz, 1H), 4.00 – 3.91 (m, 2H), 3.88 – 3.78 (m, 2H), 3.74 – 3.65 (m, 2H), 
3.62 – 3.56 (m, 1H), 3.39 – 3.33 (m, 1H), 3.18 (dd, J = 13.6, 6.7 Hz, 4H), 2.34 
– 2.26 (m, 3H), 2.05 (s, 3H), 1.61 – 1.50 (m, 6H), 1.24 (s, 78H), 0.86 (t, J = 
6.9 Hz, 9H). 31P NMR (202 MHz, CDCl3 : MeOD = 1 :1) δ -4.15.HRMS (ESI, 
M - H): calcd. for C64H122N2O15P 1189.8588 ; found 1189.8596. 
 





Appendix B. Experimental Procedures and Data Characterization for 
Compounds 3 
 
General Procedures. All chemical reagents and solvents were obtained from 
Sigma Aldrich, Merck, Alfa Aesar, or Fluka and were used without further 
purification. The microwave-assisted reactions were performed using the 
Biotage Initiator microwave synthesizer. Analytical TLC was carried out on 
precoated silica plates (Merck silica gel 60, F254) and visualized with UV 
light or stained with phosphomolybdic acid (PMA) stain. Flash column 
chromatography was performed with silica (Merck, 70-230 mesh). 1H NMR 
and 13C NMR spectra were measured on a Bruker ACF 300 or AMX 500 
Fourier transform spectrometer. Chemical shifts were reported in parts per 
million (δ) relative to the internal standard of tetramethylsilane (TMS). The 
signals observed were described as follows: s (singlet), d (doublet), t (triplet), 
q (quartet), dd (doublet of doublets), m (multiplet). The number of protons (n) 
for a given resonance was indicated as nH. Mass spectra were performed on a 
Finnigan/MAT LCQ mass spectrometer under electron spray ionization (ESI) 




yl)ethylidene)dihydrofuran-2(3H)-one (3-1). A stirred mixture of 
andrographolide AP (0.5 g, 1.43 mmol), tetrahydrofuran (10 ml), p-
toluenesulfonic acid (0.025g, 0.143 mmol) and 2,2-dimethoxypropane  (3.51 
ml,  28.53 mmol) was microwave irradiated at 80oC for 11 min. The reaction 
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mixture was then concentrated and purified by flash chromatography (ethyl 
acetate/hexane 1:3 to 1:2) to obtain compound 3-1 as a white solid (85%). 1H 
NMR (500 MHz, CDCl3) 6.92 (t, J = 6.5 Hz, 1H), 5.01 (t, J = 5.7 Hz, 1H), 
4.89 (s, 1H), 4.61 (s, 1H), 4.43 (dd, J = 10.4, 6.1 Hz, 1H), 4.24 (dd, J = 10.4, 
1.6 Hz, 1H), 3.95 (d, J = 11.6 Hz, 1H), 3.48 (dd, J = 8.6, 3.4 Hz, 1H), 3.17 (d, 
J = 11.6 Hz, 1H), 2.98 (d, J = 7.1 Hz, 1H), 2.56 (t, J = 6.5 Hz, 2H), 2.41 (d, J 
= 13.5 Hz, 1H), 2.01 - 1.93 (m, 2H), 1.87 - 1.67 (m, 4H), 1.40 (s, 3H), 1.35 (s, 
3H), 1.32 - 1.22 (m, 3H), 1.19 (s, 3H), 0.94 (s, 3H). 13C NMR (125 MHz, 
CDCl3) 170.29, 149.05, 146.93, 127.94, 108.91, 99.11, 76.23, 74.44, 66.01, 
63.83, 55.95, 52.17, 38.37, 37.84, 37.60, 34.50, 27.04, 26.07, 25.28, 24.95, 






2). To a solution of 3-1 (50 mg, 0.13 mmol) in anhydrous DMF (0.2 mL) was 
added imidazole (44 mg, 0.64 mmol) and TBDMSCl (48 mg, 0.32 mmol). The 
resulting mixture was stirred at room temperature for 30 min. The reaction 
mixture was then diluted with diethyl ether and washed with water (2x) and 
brine (2x). The organic layer was dried over MgSO4, filtered and the crude 
mixture was purified by flash chromatography (ethyl acetate : hexane = 1 : 5 
to 1 : 4) to afford compound 3-2 as a white solid (77%). 1H NMR (500 MHz, 
CDCl3) 6.83 (t, J = 6.3 Hz, 1H), 5.05 (s, 1H), 4.87 (s, 1H), 4.59 (s, 1H), 4.41 
(dd, J = 9.8, 6.4 Hz, 1H), 4.08 (dd, J = 9.8, 2.9 Hz, 1H), 3.95 (d, J = 11.6 Hz, 
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1H), 3.50 (dd, J = 8.2, 3.8 Hz, 1H), 3.17 (d, J = 11.6 Hz, 1H), 2.63 - 2.56 (m, 
1H), 2.44 - 2.39 (m, 2H), 1.98 – 1.94 (m, 2H), 1.85 (d, J = 11.2 Hz, 1H), 1.82 
- 1.77 (m, 1H), 1.69 - 1.66(m, 2H), 1.41 (s, 3H), 1.36 (s, 3H), 1.29 - 1.25 (m, 
3H), 1.19 (s, 3H), 0.95 (s, 3H), 0.91 (s, 9H), 0.16 (s, 3H), 0.11 (s, 3H). 13C 
NMR (126 MHz, CDCl3) 169.94, 148.19, 146.71, 127.38, 109.73, 99.20, 
75.94, 73.91, 66.95, 63.99, 56.09, 51.91, 38.16, 37.95, 37.54, 34.48, 26.82, 
26.07, 25.59, 25.21, 24.83, 24.79, 23.10, 17.81, 16.51, -4.21, -4.67. HRMS 





(3-3). To a solution of 3-2 (80 mg, 0.16 mmol) in THF : H2O (4 : 1, 0.84 mL) 
at 0C was added trifluoroacetic acid (29L, 0.38 mmol). The resulting 
mixture was then warmed up to room temperature and stirred for 1 h. 
Thereafter, sat NaHCO3 was added to neutralize the acid. The aqueous layer 
was then extracted with ethyl acetate (4x) and the combined organic layer was 
dried over MgSO4, filtered and concentrated to yield compound 3-3 as a white 
solid (94%). 1H NMR (500 MHz, CDCl3) 6.78 (t, J = 5.7 Hz, 1H), 5.03 (s, 
1H), 4.83 (s, 1H), 4.54 (s, 1H), 4.40 (dd, J = 9.7, 6.4 Hz, 1H), 4.16 (d, J = 11.1 
Hz, 1H), 4.06 (dd, J = 9.8, 2.9 Hz, 1H), 3.47 - 3.44 (m, 1H), 3.31 (d, J = 11.0 
Hz, 1H), 2.57 - 2.50 (m 1H), 2.38 (d, J = 13.6 Hz, 2H), 1.95 (t, J = 9.9 Hz, 
1H), 1.83 - 1.78 (m, 4H), 1.68 (d, J = 13.0 Hz, 1H), 1.30 - 1.17 (m, 6H), 0.89 
(s, 9H), 0.65 (s, 3H), 0.14 (s, 3H), 0.10 (s, 3H). 13C NMR (125 MHz, CDCl3) 
170.05, 148.24, 146.32, 127.22, 109.67, 80.23, 73.93, 66.90, 63.98, 55.95, 
213 
 
55.06, 42.67, 38.59, 37.58, 37.12, 27.96, 25.54, 24.64, 23.56, 22.68, 17.75, 






yl)ethylidene)dihydrofuran-2(3H)-one (3-4). To a solution of 3-3 (852 mg, 
1.8 mmol) in pyridine (13 mL) was added TBDMSCl (3.2 g, 21 mmol). The 
resulting mixture was stirred at room temperature for 1 h. Ethyl acetate was 
then added to dilute the reaction mixture and the organic layer was 
subsequently washed with 1M CuSO4 solution (4x), dried over MgSO4, 
filtered and concentrated. The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 5 to 1 : 4) to afford compound 3-
4 as a white solid (78%). 1H NMR (500 MHz, CDCl3) 6.83 - 6.79 (m, 1H), 
5.05 - 5.04 (m, 1H), 4.84 (s, 1H), 4.55 (s, 1H), 4.41 (dd, J = 9.8, 6.4 Hz, 1H), 
4.34 (d, J = 7.2 Hz, 1H), 4.19 (d, J = 10.0 Hz, 1H), 4.07 (dd, J = 9.8, 3.0 Hz, 
1H), 3.38 (d, J = 10.0 Hz, 1H), 3.34 - 3.28 (m, 1H), 2.57 – 2.50 (m, 1H), 2.43 
- 2.36 (m, 2H),1.99 - 1.79 (m, 4H), 1.74 - 1.65 (m, 3H), 1.28 - 1.25 (m 2H), 
1.22 (s, 3H), 0.90 (s, 9H), 0.88 (s, 9H), 0.68 (s, 3H), 0.15 (s, 3H), 0.11 (s, 3H), 
0.06 (s, 3H), 0.05 (s, 3H). 13C NMR (125 MHz, CDCl3)  169.89, 148.07, 
146.36, 127.31, 109.59, 80.04, 73.88, 66.96, 65.18, 56.10, 55.13, 42.48, 38.72, 
37.66, 37.31, 28.57, 25.75, 25.59, 24.55, 23.72, 23.08, 18.05, 17.79, 15.71, -
4.21, -4.71, -5.78, -5.83. HRMS (ESI, M + 1) calcd. for  C32H59O5Si2, 






methylenedecahydronaphthalen-2-yl hex-5-ynoate (3-5). To a solution of 
3-4 (300 mg, 0.5 mmol) in dichloromethane (5 mL) were added 5-hexynoic 
acid (192 L, 1.55 mmol), coupling reagent DCC (352 mg, 1.71 mmol) and 
DMAP (19 mg, 0.16 mmol). The resulting mixture was stirred at room 
temperature for 4 h. The suspension was then filtered and the crude mixture 
was purified by flash chromatography (ethyl acetate : hexane = 1 : 10 to 1 : 8) 
to afford compound 3-5 as a white solid (97%). 1H NMR (500 MHz, CDCl3) 
6.85 - 6.82 (m, 1H), 5.04 - 5.03 (m, 1H), 4.86 (s, 1H), 4.59 (dd, J = 10.8, 5.3 
Hz, 1H), 4.55 (s, 1H), 4.40 (dd, J = 9.8, 6.3 Hz, 1H), 4.08 (m, 1H), 3.83 (d, J = 
10.5 Hz, 1H), 3.61 (d, J = 10.5 Hz, 1H), 2.58 - 2.51 (ddd, J = 17.9, 11.4, 7.0 
Hz, 1H), 2.44 (td, J = 7.4, 2.1 Hz, 2H), 2.39 – 2.36 (m, 1H), 2.25 (td, J = 6.9, 
2.6 Hz, 2H), 1.96 (t, J = 2.6 Hz, 1H), 1.93 - 1.61 (m, 10H), 1.35 - 1.25 (m, 
2H), 0.94 (s, 3H), 0.90 (s, 9H), 0.88 (s, 9H), 0.80 (s, 3H), 0.15 (s, 3H), 0.11 (s, 
3H), 0.02 (s, 6H). 13C NMR (125 MHz, CDCl3) 172.64, 169.89, 148.10, 
146.80, 127.35, 109.19, 83.15, 80.15, 73.89, 69.10, 66.95, 63.65, 56.18, 55.41, 
42.48, 38.87, 38.16, 37.51, 33.25, 25.86, 25.58, 25.24, 24.59, 24.36, 23.72, 
23.18, 18.22, 17.83, 17.80, 14.55, -4.21, -4.70, -5.64, -5.72. HRMS (ESI, M + 








methylenedecahydronaphthalen-1-yl)methyl hex-5-ynoate (AP1). To a 
solution of 3-5 (20 mg, 0.03 mmol) in methanol (0.2 mL) was added ceric 
ammonium nitrate (20 mg, 0.036 mmol). The resulting mixture was stirred at 
room temperature for 12 h. Therafter, the crude reaction mixture was purified 
by flash chromatography (ethyl acetate : hexane = 1 : 1 to 2 : 1) to afford AP1 
as a white solid ( 15%). 1H NMR (500 MHz, CDCl3) 6.95 (t, J = 6.7 Hz, 1H), 
5.03 (d, J = 5.7 Hz, 1H), 4.91 (s, 1H), 4.60 (s, 1H), 4.46 (dd, J = 10.5, 6.1 Hz, 
1H), 4.36 (d, J = 11.7 Hz, 1H), 4.26 (dd, J = 10.3, 1.6 Hz, 1H), 4.12 (d, J = 
11.6 Hz, 1H), 3.33 (dd, J = 11.9, 4.0 Hz, 1H), 2.55 (t, J = 6.7 Hz, 2H), 2.47 - 
2.43 (m, 3H), 2.27 (dt, J = 6.9, 3.4 Hz, 2H), 2.00 - 1.95 (m, 2H), 1.86 -1.79 
(m, 6H), 1.74 - 1.69 (m, 1H), 1.46 (dd, J = 13.0, 4.1 Hz, 1H), 1.29 - 1.23 (m, 
4H), 1.16 (s, 3H), 0.73 (s, 3H). 13C NMR (125 MHz, CDCl3) 173.04, 169.78, 
148.75, 146.46, 128.01, 108.91, 83.10, 78.76, 74.23, 69.27, 66.24, 64.82, 
55.96, 55.30, 42.51, 39.06, 37.77, 37.28, 33.00, 27.75, 24.77, 24.24, 23.51, 





6-methylenedecahydronaphthalen-2-yl hex-5-ynoate (AP2). Same as AP1. 
The crude reaction mixture was subsequently purified by flash 
chromatography (ethyl acetate : hexane = 1 : 1) to afford AP2 as a white solid 
( 15%). 1H NMR (500 MHz, CDCl3)  6.97 - 6.94 (m, 1H), 5.02 (s, 1H), 4.91 
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(s, 1H), 4.67 (dd, J = 11.9, 4.2 Hz, 1H), 4.60 (s, 1H), 4.45 (dd, J = 10.5, 6.1 
Hz, 1H), 4.25 (dd, J = 10.5, 2.0 Hz, 1H), 4.12 (d, J = 11.9 Hz, 1H), 3.39 (t, J = 
10.6 Hz, 1H), 2.55 - 2.52(m, 2H), 2.48 (t, J = 7.4 Hz, 2H), 2.44 (d, J = 13.0 
Hz, 1H), 2.35 (d, J = 6.7 Hz, 1H), 2.27 (td, J = 6.9, 2.6 Hz, 2H), 1.99 (t, J = 
2.6 Hz, 2H), 1.88 - 1.73 (m, 8H), 1.44 - 1.31 (m, 3H), 1.08 (s, 3H), 0.72 (s, 
3H).13C NMR (125 MHz, CDCl3) 172.01, 169.80, 148.55, 146.32, 128.11, 
109.03, 82.83, 82.36, 74.27, 69.53, 66.22, 63.48, 55.84, 55.49, 42.64, 38.83, 
37.67, 36.92, 33.12, 24.73, 24.21, 23.95, 23.55, 22.43, 17.71, 14.93.HRMS 




yl)ethylidene)tetrahydrofuran-3-yl hex-5-ynoate (3-6). To a solution of 3-1 
(40 mg, 0.1 mmol) in dichloromethane (0.3 mL) was added 5-hexynoic acid 
(35L, 0.3 mmol) and coupling reagent DCC (69 mg, 0.33 mmol). The 
resulting mixture was stirred at room temperature for 4 days. The suspension 
was then filtered and the crude mixture was purified by flash chromatography 
(ethyl acetate : hexane = 1 : 4 to 1 : 2) to afford 5-6 as a white solid (50%). 1H 
NMR (500 MHz, CDCl3) 7.02 (td, J = 6.8, 1.7 Hz, 1H), 5.94 (d, J = 6.1 Hz, 
1H), 4.89 (s, 1H), 4.55 (dd, J = 11.2, 6.2 Hz, 1H), 4.52 (s, 1H), 4.23 (dd, J = 
11.2, 1.9 Hz, 1H), 3.95 (d, J = 11.6 Hz, 1H), 3.49 (dd, J = 8.6, 4.0 Hz, 1H), 
3.17 (d, J = 11.6 Hz, 1H), 2.52 (t, J = 7.4 Hz, 2H), 2.46 - 2.39 (m, 3H), 2.28 
(td, J = 6.9, 2.6 Hz, 2H), 1.98 (t, J = 2.7 Hz, 2H), 1.86 (t, J = 7.1 Hz, 3H), 1.82 
- 1.75 (m, 1H), 1.72 - 1.67 (m, 2H), 1.40 (s, 3H), 1.36 (s, 3H), 1.29 - 1.23 (m, 
4H), 1.19 (s, 3H), 0.93 (s, 3H). 13C NMR (125 MHz, CDCl3) 172.60, 169.02, 
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150.66, 147.01, 123.75, 108.90, 99.13, 82.65, 76.10, 71.58, 69.58, 67.80, 
63.89, 55.85, 52.13, 38.32, 37.88, 37.55, 34.48, 32.53, 26.99, 26.10, 25.45, 
25.27, 24.89, 23.33, 23.10, 17.74, 16.14. HRMS (ESI, 2M + Na) calcd. for  




yl)ethylidene)-5-oxotetrahydrofuran-3-yl hex-5-ynoate (AP3). 3-6 (20 mg, 
0.04 mmol) was added to a mixture of acetic acid and water (7 : 3; 0.52 mL : 
0.22 mL). The resulting mixture was stirred at room temperature for 30 min. 
Sat NaHCO3 was then added to neutralize the acid. The aqueous layer was 
extracted with ethyl acetate (4x) and the combined organic layer was dried 
over MgSO4, filtered and the crude product obtained was purified by flash 
chromatography (ethyl acetate: hexane = 1 : 2 to 1 : 1) to obtain AP3 as a 
white solid (82%). 1H NMR (500 MHz, CDCl3) 7.00 (t, J = 6.8 Hz, 1H), 5.93 
(d, J = 5.6 Hz, 1H), 4.87 (s, 1H), 4.55 (dd, J = 10.9, 6.5 Hz, 1H), 4.48 (s, 1H), 
4.23 (d, J = 11.3 Hz, 1H), 4.17 (d, J = 11.1 Hz, 1H), 3.49 - 3.46 (m, 1H), 3.31 
(d, J = 10.8 Hz, 1H), 2.58 (s, 2H), 2.51 (t, J = 7.4 Hz, 2H), 2.47 - 2.33(m, 3H), 
2.27 (td, J = 6.7, 2.5 Hz, 2H), 1.98 - 1.93 (m, 2H), 1.88 - 1.79 (m, 6H), 1.72 
(dt, J = 12.6, 3.1 Hz, 1H), 1.33 - 1.26 (m, 2H), 1.24 (s, 3H), 1.20 - 1.17 (m, 
1H), 0.66 (s, 3H). 13C NMR (125 MHz, CDCl3) 172.64, 169.03, 150.55, 
146.63, 123.77, 108.83, 82.63, 80.34, 71.58, 69.59, 67.74, 64.06, 55.76, 55.13, 
42.83, 38.78, 37.65, 36.96, 32.51, 28.12, 25.29, 23.64, 23.31, 22.68, 17.73, 






yl)ethyl)dihydrofuran-2(3H)-one (5-7). To a solution of 3-1 (100 mg, 0.26 
mmol) in anhydrous methanol (1 mL) was sodium borohydride (12 mg, 0.31 
mmol). The resulting mixture was stirred at room temperature for one hour. 
The crude mixture was directly purified by flash chromatography (ethyl 
acetate : hexane = 1 : 2 to 2 : 3) to afford compound 3-7 as a white solid 
(50%).1H NMR (500 MHz, CDCl3) 4.84 (s, 1H), 4.63 (s, 1H), 4.58 - 4.56 (m, 
1H), 4.30 - 4.24 (m, 2H), 3.95 (d, J = 11.6 Hz, 1H), 3.48 (dd, J = 8.6, 3.6 Hz, 
1H), 3.15 (d, J = 11.6 Hz, 1H), 2.47 - 2.44 (m, 1H), 2.40 - 2.36 (m, 2H), 2.03 - 
1.99 (m, 2H), 1.85 - 1.69 (m, 4H), 1.65 - 1.55 (m, 4H), 1.40 (s, 3H), 1.35 (s, 
3H), 1.31 - 1.21 (m, 3H), 1.18 (s, 3H), 0.89 (s, 3H).13C NMR (126 MHz, 
CDCl3) 177.75, 147.57, 107.29, 99.07, 76.39, 74.44, 69.12, 63.93, 56.65, 
52.30, 45.65, 38.53, 38.06, 37.88, 34.44, 27.10, 26.08, 25.29, 25.00, 23.45, 





1H-naphtho[2,1-d][1,3]dioxin-7-yl)ethyl)dihydrofuran-2(3H)-one (3-8). To 
a solution of 3-7 (80 mg, 0.20 mmol) in anhydrous DMF (0.3 mL) was added 
imidazole (68 mg, 1.00 mmol) and TBDMSCl (77 mg, 0.50 mmol). The 
resulting mixture was heated to 80oC and stirred for 30 min. The reaction 
mixture was then diluted with diethyl ether and washed with water (2x) and 
brine (2x). The organic layer was dried over MgSO4, filtered and the crude 
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mixture was purified by flash chromatography (ethyl acetate : hexane = 1 : 6 
to 1 : 4) to afford compound 3-8 as a white solid (72%).1H NMR (500 MHz, 
CDCl3) 4.84 (s, 1H), 4.55 (s, 1H), 4.51 - 4.49 (m, 1H), 4.22 (dd, J = 9.9, 3.6 
Hz, 1H), 4.11 (d, J = 9.9 Hz, 1H), 3.95 (d, J = 11.6 Hz, 1H), 3.47 (dd, J = 8.6, 
3.6 Hz, 1H), 3.15 (d, J = 11.6 Hz, 1H), 2.38 (d, J = 10.4 Hz, 2H), 2.01 - 1.90 
(m, 2H), 1.85 - 1.67 (m, 4H), 1.62 - 1.52 (m, 4H), 1.39 (s, 3H), 1.35 (s, 3H), 
1.27 - 1.23 (m, 3H), 1.18 (s, 3H), 0.88 (s, 3H), 0.87 (s, 9H), 0.07 (s, 6H).13C 
NMR (126 MHz, CDCl3) 177.81, 147.30, 107.57, 98.97, 76.38, 74.02, 69.92, 
63.88, 56.35, 52.29, 45.84, 38.47, 37.95, 37.83, 34.55, 27.15, 26.04, 25.57, 
25.20, 24.99, 23.39, 22.77, 21.89, 17.90, 16.26, -4.56, -4.86. . HRMS (ESI, 





To a solution of 3-8 (50 mg, 0.16 mmol) in THF : H2O (4 : 1, 0.50 mL) at 0C 
was added trifluoroacetic acid (18L, 0.23 mmol). The resulting mixture was 
then warmed up to room temperature and stirred for 1 h. Thereafter, sat 
NaHCO3 was added to neutralize the acid. The aqueous layer was then 
extracted with ethyl acetate (4x) and the combined organic layer was dried 
over MgSO4, filtered and concentrated to yield compound 3-9 as a white solid 
(99%).1H NMR (500 MHz, CDCl3) 4.82 (s, 1H), 4.51 (s, 1H), 4.49 - 4.47 (m, 
1H), 4.21 (dd, J = 9.9, 3.6 Hz, 1H), 4.15 (d, J = 10.8 Hz, 1H), 4.10 (d, J = 9.9 
Hz, 1H), 3.45 - 3.42 (m, 1H), 3.28 (d, J = 10.8 Hz, 1H), 2.36 (t, J = 10.9 Hz, 
2H), 1.95 - 1.90 (m, 1H), 1.80 - 1.77 (m, 4H), 1.64 - 1.42 (m, 4H), 1.28 - 1.23 
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(m, 2H), 1.21 (s, 3H), 1.19 - 1.16 (m, 2H), 0.86 (s, 9H), 0.61 (s, 3H), 0.07 (s, 
3H), 0.06 (s, 3H). 13C NMR (126 MHz, CDCl3)177.97, 146.98, 107.34, 80.44, 
74.07, 69.97, 64.12, 56.47, 55.23, 45.99, 42.71, 38.96, 38.07, 36.95, 28.14, 
25.57, 23.92, 22.81, 22.70, 21.77, 17.90, 15.19, -4.59, -4.86. HRMS (ESI, 2M 





10). To a solution of 3-9 (50 mg, 0.11 mmol) in dichloromethane (1.2 mL) 
were added 5-hexynoic acid (15L, 0.13 mmol), coupling reagent DCC (29 
mg, 1.32 mmol) and DMAP (2 mg, 0.01 mmol). The resulting mixture was 
stirred at room temperature for 2 h. The suspension was then filtered and the 
crude mixture was purified by flash chromatography (ethyl acetate : hexane = 
1 : 4 to 1 : 2) to afford compound 3-10 as a white solid (50%). 1H NMR (500 
MHz, DMSO) 4.82 (s, 1H), 4.68 (d, J = 4.5 Hz, 1H), 4.58 - 4.56 (m, 1H), 4.53 
(s, 1H), 4.27 (dd, J = 10.0, 2.9 Hz, 1H), 4.17 (d, J = 11.6 Hz, 1H), 4.07 (d, J = 
11.7 Hz, 1H), 4.02 (d, J = 10.0 Hz, 1H), 3.19 - 3.15 (m, 1H), 2.78 (t, J = 2.3 
Hz, 1H), 2.68 - 2.64 (m, 1H), 2.35 (t, J = 7.3 Hz, 2H), 2.18 (td, J = 7.1, 2.5 Hz, 
2H), 1.91 - 1.79 (m, 2H), 1.72 - 1.63 (m, 5H), 1.57 - 1.50 (m, 3H), 1.45 - 1.33 
(m, 2H), 1.23 (t, J = 14.3 Hz, 3H), 1.03 (s, 3H), 0.84 (s, 9H), 0.63 (s, 3H), 0.09 
(s, 3H), 0.07 (s, 3H).13C NMR (126 MHz, DMSO) 177.93, 172.32, 147.62, 
106.67, 83.59, 76.55, 73.98, 71.60, 69.86, 65.13, 55.37, 54.10, 44.90, 41.71, 
38.06, 36.72, 33.32, 32.62, 27.60, 25.53, 25.05, 23.45, 22.74, 22.00, 20.76, 
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17.60, 17.09, 14.13, -4.66, -5.05. HRMS (ESI, M + Na) calcd. for  




methylenedecahydronaphthalen-1-yl)methyl hex-5-ynoate (NC1). To a 
solution of 3-10 (30 mg, 0.05 mmol) in methanol (0.3 mL) was added ceric 
ammonium nitrate (35 mg, 0.06 mmol). The resulting mixture was stirred at 
room temperature for 12 h. The crude reaction mixture was subsequently 
purified by flash chromatography (ethyl acetate : hexane = 1 : 1 to 1 : 2) to 
afford NC1 as a white solid ( 17%). 1H NMR (500 MHz, CDCl3) 4.84 (s, 1H), 
4.62 (s, 1H), 4.56 - 4.55 (m, 1H), 4.34 (d, J = 11.7 Hz, 1H), 4.30 - 4.24 (m, 
2H), 4.09 (d, J = 11.7 Hz, 1H), 3.31 (dd, J = 11.8, 3.8 Hz, 1H), 2.56 (s, 1H), 
2.45 - 2.41 (m, 3H), 2.39 (s, 1H), 2.24 (td, J = 6.9, 2.5 Hz, 2H), 1.97 (t, J = 2.3 
Hz, 1H), 1.92 (dd, J = 12.8, 4.6 Hz, 1H), 1.85 - 1.78 (m, 6H), 1.68 - 1.49 (m, 
6H), 1.46 - 1.37 (m, 1H), 1.25 - 1.20 (m, 2H), 1.13 (s, 3H), 0.66 (s, 3H).13C 
NMR (126 MHz, CDCl3)178.00, 173.16, 146.84, 107.32, 83.08, 78.81, 74.59, 
69.24, 68.93, 64.97, 56.50, 55.26, 45.59, 42.39, 39.11, 38.16, 37.07, 32.96, 
27.71, 24.42, 23.43, 22.67, 22.39, 21.84, 17.71, 14.78. HRMS (ESI, M + Na) 











ylcarbamate (3-11a). To a solution of 7-amino-4methylcoumarin (28 mg, 
0.16 mmol) in dichloromethane (2 mL) was added sat NaHCO3 (2 mL). The 
biphasic mixture was stirred at room temperature for 5 min and then the 
stirring was stopped so that a solution of triphosgene (29 mg, 0.097 mmol) in 
dichloromethane could be added into the dichloromethane layer. After the 
addition, stirring was resumed for another 10-30  minutes before the 
dichloromethane layer was removed via a syringe, dried over MgSO4 and 
concentrated to afford the corresponding crude isocyanate, which was used 
without further purification. The crude isocyanate and 3-1 (43 mg, 0.11 mmol) 
were dissolved in dichloromethane (4 mL) followed by the addition of TEA 
(34 µL, 0.243 mmol). The reaction mixture was stirred at room temperature 
for 2.5 h. The crude reaction mixture was purified by flash chromatography 
(ethyl acetate : hexane = 2:3 to 1:1) to afford 3-11a as white solid (72%). 1H 
NMR (500 MHz, DMSO) δ 10.42 (s, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.55 (s, 
1H), 7.42 (d, J = 8.7 Hz, 1H), 6.91 (t, J = 6.9 Hz, 1H), 6.27 (s, 1H), 6.09 (d, J 
= 5.2 Hz, 1H), 4.85 (s, 1H), 4.62 (dd, J = 11.1, 5.7 Hz, 1H), 4.55 (s, 1H), 4.45 
(d, J = 11.1 Hz, 1H), 3.85 (d, J = 11.6 Hz, 1H), 3.09 (d, J = 11.6 Hz, 1H), 2.40 
(s, 3H), 2.34 (d, J = 12.8 Hz, 1H), 2.13 – 1.83 (m, 3H), 1.68 (m, 3H), 1.28 (m, 
9H), 1.12 (s, 3H), 0.83 (s, 3H). HRMS (ESI) [M+ Na]+: calcd for 







ylcarbamate (3-11b). Same as 3-11a. 6-acetyl-2-naphthylamine was used as 
starting material. After reaction, the precipitated product was filtered and 
washed with methanol : dichloromethane (2 : 98) to afford 3-11b as white 
solid (58%). 1H NMR (500 MHz, DMSO) δ 10.33 (s, 1H), 8.58 (s, 1H), 8.15 
(s, 1H), 8.08 (d, J = 8.9 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.6 Hz, 
1H), 7.65 (d, J = 8.6 Hz, 1H), 6.92 (t, J = 6.6 Hz, 1H), 6.09 (d, J = 5.3 Hz, 
1H), 4.85 (s, 1H), 4.65 (dd, J = 11.0, 5.8 Hz, 1H), 4.57 (s, 1H), 4.46 (d, J = 
10.9 Hz, 1H), 3.84 (d, J = 11.6 Hz, 1H), 3.38 (dd, J = 8.9, 3.1 Hz, 1H), 3.08 
(d, J = 11.6 Hz, 1H), 2.68 (s, 3H), 2.59 (d, J = 6.9 Hz, 1H), 2.33 (d, J = 12.6 
Hz, 1H), 2.03 – 1.85 (m, 3H), 1.67 (t, J = 10.1 Hz, 3H), 1.36 – 1.16 (m, 9H), 
1.11 (s, 3H), 0.83 (s, 3H). 13C NMR (125 MHz, DMSO) δ 197.46, 168.99, 
152.70, 149.21, 147.68, 138.88, 135.79, 132.77, 130.50, 130.13, 128.39, 
127.42, 124.82, 124.17, 120.01, 113.45, 108.24, 98.12, 75.73, 71.59, 68.10, 
62.72, 54.85, 51.41, 38.03, 37.12, 36.92, 33.94, 27.41, 26.57, 25.73, 25.16, 
24.86, 24.81, 22.61, 15.57. HRMS (ESI) [M – H]–: calcd for C36H42NO7, 











ylcarbamate (APCM). To a solution of 3-11a (47mg, 0.08mmol) in THF : 
H2O (7 : 3, 3.2 mL) at 0 °C was added trifluoroacetic acid (230 µL, 3 mmol). 
The resulting mixture was then warmed up to room temperature and stirred for 
1 h. Thereafter, the mixture was again cooled to 0 °C, neutralized with sat 
NaHCO3 and extracted with ethyl acetate (4x). The combined organic layer 
was dried over MgSO4, concentrated and the crude product obtained was 
purified by flash chromatography (dichloromethane : methanol = 100 : 0 to  98 
: 2) to afford APCM as white solid (91%). 1H NMR (500 MHz, DMSO) δ 
10.40 (s, 1H), 7.81 – 7.68 (m, 1H), 7.54 (s, 1H), 7.41 (dd, J = 8.7, 1.6 Hz, 1H), 
6.90 (t, J = 6.6 Hz, 1H), 6.26 (s, 1H), 6.07 (d, J = 5.5 Hz, 1H), 4.80 (s, 1H), 
4.61 (dd, J = 11.1, 5.8 Hz, 1H), 4.49 (s, 1H), 4.44 (d, J = 10.6 Hz, 1H), 3.80 
(d, J = 11.0 Hz, 1H), 3.27 – 3.15 (m, 2H), 2.46 – 2.37 (m, 5H), 2.35 – 2.24 (m, 
1H), 2.01 – 1.85 (m, 2H), 1.79 – 1.52 (m, 4H), 1.41 – 1.14 (m, 4H), 1.06 (s, 
3H), 0.61 (s, 3H).13C NMR (125 MHz, DMSO) δ 168.99, 159.97, 153.77, 
153.13, 152.51, 149.58, 147.81, 142.30, 126.07, 124.69, 114.64, 114.39, 
112.11, 107.75, 104.66, 78.41, 71.56, 68.26, 62.59, 55.16, 54.33, 42.23, 38.63, 
37.35, 36.44, 27.87, 24.72, 23.90, 23.02, 17.97, 14.55. HRMS (ESI) [M+Na]+: 









ylcarbamate (APNP). Same as APCM. the crude product obtained was 
purified by flash chromatography (dichloromethane : methanol = 100 : 0 to  98 
: 2) to afford APNP as white solid (88%) 1H NMR (500 MHz, CDCl3) δ 8.45 
(s, 1H), 8.06 (d, J = 8.6 Hz, 2H), 7.97 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 8.6 Hz, 
1H), 7.51 (d, J = 8.9 Hz, 1H), 7.16 (s, 1H), 7.11 (t, J = 6.9 Hz, 1H), 6.06 (d, J 
= 5.6 Hz, 1H), 4.90 (s, 1H), 4.63 (dd, J = 11.5, 5.8 Hz, 1H), 4.54 (s, 1H), 4.45 
(d, J = 11.4 Hz, 1H), 4.18 (d, J = 11.3 Hz, 1H), 3.57 – 3.43 (m, 1H), 3.33 (d, J 
= 10.8 Hz, 1H), 2.54 (m, 4H), 2.05 – 1.96 (m, 1H), 1.93 – 1.75 (m, 6H), 1.36 – 
1.19 (m, 8H), 0.68 (s, 3H).  13C NMR (125 MHz, DMSO) δ 197.99, 169.51, 
153.23, 149.87, 148.28, 139.38, 136.30, 133.28, 131.01, 130.65, 128.90, 
127.94, 125.27, 124.70, 120.53, 108.26, 78.88, 72.10, 68.60, 63.05, 55.62, 
54.82, 42.72, 39.12, 37.84, 36.94, 28.35, 27.09, 25.17, 24.38, 23.51, 15.05. 





1-yl)methyl hex-5-ynoate (AP1CM). To a solution of 7-amino-
4methylcoumarin (28 mg, 0.16 mmol) in dichloromethane (2 mL) was added 
sat NaHCO3 (2 mL). The biphasic mixture was stirred at room temperature for 
5 min and then the stirring was stopped so that a solution of triphosgene (29 
mg, 0.097 mmol) in dichloromethane could be added into the dichloromethane 
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layer. After the addition, stirring was resumed for another 10-30  minutes 
before the dichloromethane layer was removed via a syringe, dried over  
MgSO4 and concentrated to afford the corresponding crude isocyanate, which 
was used without further purification. The crude isocyanate and AP1 (49 mg, 
0.11 mmol) were dissolved in dichloromethane (4 mL) followed by the 
addition of TEA (34 µL, 0.243 mmol). The reaction mixture was stirred at 
room temperature for 2.5 h. The crude reaction mixture was purified by flash 
chromatography (ethyl acetate : hexane = 2:3 to 1:1) to afford AP1CM as 
white solid (65%). 1H NMR (500 MHz, DMSO) δ 10.39 (s, 1H), 7.71 (d, J = 
8.7 Hz, 1H), 7.53 (s, 1H), 7.41 (dd, J = 8.6, 1.3 Hz, 1H), 6.91 (t, J = 6.7 Hz, 
1H), 6.25 (s, 1H), 6.07 (d, J = 5.5 Hz, 1H), 4.82 (s, 1H), 4.70 (d, J = 4.7 Hz, 
1H), 4.61 (dd, J = 11.0, 5.8 Hz, 1H), 4.51 (s, 1H), 4.44 (d, J = 11.1 Hz, 1H), 
4.16 (d, J = 11.7 Hz, 1H), 4.05 (d, J = 11.7 Hz, 1H), 3.22 – 3.09 (m, 1H), 2.76 
(t, J = 2.5 Hz, 1H), 2.66 – 2.55 (m, 1H), 2.48 – 2.41 (m, 1H), 2.39 (s, 3H), 
2.32 (m, 2H), 2.16 (m, 2H), 2.00 – 1.88 (m, 2H), 1.79 (d, J = 13.3 Hz, 1H), 
1.74 – 1.60 (m, 3H), 1.57 – 1.38 (m, 3H), 1.24 (m, 3H), 1.01 (s, 3H), 0.64 (s, 
3H).  13C NMR (125 MHz, DMSO) δ 172.33, 168.97, 159.95, 153.76, 153.13, 
152.50, 149.52, 147.75, 142.28, 126.09, 124.70, 114.65, 114.38, 112.11, 
107.75, 104.67, 83.60, 76.51, 71.61, 71.54, 68.27, 65.07, 55.19, 53.90, 41.68, 
38.79, 37.51, 36.52, 32.58, 27.55, 24.74, 24.58, 23.42, 22.73, 17.96, 17.06, 









ynoate (AP1NP). Same as AP1CM. 6-acetyl-2-naphthylamine was used as 
starting material. After reaction, the precipitated product was filtered and 
washed with methanol : dichloromethane (2 : 98) to afford AP1NP as white 
solid (36%). 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.13 – 8.01 (m, 2H), 
7.96 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.52 (d, J = 8.5 Hz, 1H), 
7.20 (s, 1H), 7.11 (t, J = 6.6 Hz, 1H), 6.06 (d, J = 5.5 Hz, 1H), 4.92 (s, 1H), 
4.63 (dd, J = 11.3, 5.9 Hz, 1H), 4.55 (s, 1H), 4.45 (d, J = 11.4 Hz, 1H), 4.36 
(d, J = 11.7 Hz, 1H), 4.13 (d, J = 11.8 Hz, 1H), 3.40 – 3.27 (m, 1H), 2.74 (s, 
3H), 2.67 – 2.36 (m, 5H), 2.27 (m, 2H), 2.01 (m, 3H), 1.94 – 1.78 (m, 5H), 
1.76 – 1.67 (m, 1H), 1.53 – 1.39 (m, 1H), 1.37 – 1.24 (m, 3H), 1.17 (s, 3H), 
0.72 (s, 3H). 13C NMR (125 MHz, DMSO) δ 197.50, 172.34, 169.03, 152.75, 
149.36, 147.73, 138.89, 135.82, 132.79, 130.53, 130.16, 128.41, 127.45, 
124.81, 124.20, 120.05, 113.51, 113.49, 107.81, 83.60, 76.51, 71.60, 68.14, 
65.07, 59.74, 55.18, 53.91, 41.69, 37.52, 36.53, 32.58, 27.55, 26.59, 24.75, 
24.58, 23.41, 22.73, 17.06, 13.85. HRMS (ESI) [M – H]–: calcd for 





2(3H)-one (3-12). To a stirred solution of andrographolide AP (1.0 g, 2.85 
mmol) in pyridine (15 mL) was added TBDMSCl (2.58 g, 17.1 mmol) at room 
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temperature. The resulting mixture was stirred at room temperature for 1 h. 
The reaction mixture was then diluted with ethyl acetate (20 mL) and poured 
into 1M CuSO4 (150 mL) solution and extracted with ethyl acetate (3x20 mL). 
The combined organic layer was washed with brine (20 mL), dried over 
MgSO4, filtered and concentrated. The residue was purified by column 
chromatography (ethyl acetate : hexane = 1 : 1) to afford 3-12 as a white solid 
(90%). 1H NMR (500 MHz, CDCl3) δ 6.96 (t, J = 6.5 Hz, 1H), 5.02 (t, J = 6.1 
Hz, 1H), 4.88 (s, 1H), 4.59 (s, 1H), 4.49 – 4.41 (m, 2H), 4.25 (dd, J = 10.4, 1.9 
Hz, 1H), 4.19 (d, J = 10.0 Hz, 1H), 3.38 (d, J = 10.1 Hz, 1H), 3.31 (m, 1H), 
2.67 – 2.47 (m, 3H), 2.41 (dd, J = 13.2, 3.3 Hz, 1H), 2.01 – 1.69 (m, 6H), 1.24 
(d, J = 13.6 Hz, 6H), 0.89 (s, 9H), 0.70 (s, 3H), 0.06 (d, J = 3.6 Hz, 6H). 13C 
NMR (125 MHz, CDCl3) δ 170.45, 149.26, 147.14, 128.59, 109.25, 80.68, 
74.84, 66.70, 65.74, 56.63, 55.80, 43.03, 39.51, 38.31, 37.71, 29.12, 26.30, 
25.23, 24.39, 23.70, 18.59, 16.01, -5.20, -5.28. HRMS (ESI, M - 1) calcd. for  





pyran-2-yloxy)dihydrofuran-2(3H)-one (3-13). To a stirred solution of 3-12 
(0.8 g, 1.72 mmol) and dihydropyran (235 µL, 2.58 mmol) in dichloromethane 
(30 mL) at room temperature was added p-toiuenesulfonic acid (0.144 g, 0.76 
mmol). The resulting mixture was stirred at room temperature for 40 min. The 
crude reaction mixture was then purified by flash chromatography (ethyl 
acetate : hexane = 3 : 7) to afford 3-13 as a white solid (78%). The 
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ylidene)ethyl)decahydronaphthalen-2-yl hex-5-ynoate (3-14). To a solution 
of 3-13 (700 mg, 1.28 mmol) in dichloromethane (15 mL) were added 5-
hexynoic acid (722 L, 6.38 mmol), coupling reagent DCC (1.45 g, 7.02 
mmol) and DMAP (78 mg, 0.64 mmol). The resulting mixture was stirred at 
room temperature for 10 h. The suspension was then filtered and the crude 
mixture was purified by flash chromatography (ethyl acetate : hexane = 1 : 10 
to 1 : 8) to afford 3-14 as a white solid (94%). The diastereomeric mixture was 





methylenedecahydronaphthalen-2-yl hex-5-ynoate (3-15). To a solution 3-
14 (85 mg, 0.13 mmol) in dichloromethane (1.2 mL) containing 5% (v/v) of 1, 
2-ethanedithiol at -40 °C was slowly added Lewis acid BF3.Et2O (8 µL, 0.07 
mmol) and the resulting mixture was stirred at -40 °C for 30 min. The reaction 
mixture was then poured into sat NaHCO3 and extracted with dichloromethane 
(4x). The combine organic extract was dried over MgSO4, filtered and 
concentrated. The crude product was purified by flash column 
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chromatography (ethyl acetate : hexane = 3:7 to 2:6) to afford compound 3-15 
as white solid (73%). 1H NMR (500 MHz, CDCl3) δ 6.99 (t, J = 6.4 Hz, 1H), 
5.03 (s, 1H), 4.90 (s, 1H), 4.58 (dd, J = 10.2, 6.0 Hz, 2H), 4.45 (dd, J = 10.4, 
6.1 Hz, 1H), 4.26 (dd, J = 10.5, 1.8 Hz, 1H), 3.84 (d, J = 10.5 Hz, 1H), 3.60 
(d, J = 10.5 Hz, 1H), 2.62 – 2.48 (m, 2H), 2.48 – 2.36 (m, 3H), 2.26 (m, 3H), 
1.97 (t, J = 2.5 Hz, 1H), 1.94 – 1.78 (m, 6H), 1.78 – 1.66 (m, 3H), 1.38 – 1.21 
(m, 2H), 0.94 (s, 3H), 0.88 (s, 9H), 0.84 (s, 3H), 0.03 (s, 6H). 13C NMR (125 
MHz, CDCl3) δ 173.03, 170.16, 149.27, 147.43, 128.27, 108.65, 83.45, 80.50, 
74.55, 69.43, 66.51, 64.04, 56.51, 55.83, 42.78, 39.41, 38.58, 37.66, 33.57, 
26.17, 25.70, 25.03, 24.66, 24.02, 23.54, 18.52, 18.15, 14.66, -5.33, -5.42. 






16a). To a solution of 7-amino-4methylcoumarin (56 mg, 0.32 mmol) in 
dichloromethane (4 mL) was added sat NaHCO3 (4 mL). The biphasic mixture 
was stirred at room temperature for 5 min and then the stirring was stopped so 
that a solution of triphosgene (58 mg, 0.19 mmol) in dichloromethane could be 
added into the dichloromethane layer. After the addition, stirring was resumed 
for another 10-30  min before the dichloromethane layer was removed via a 
syringe, dried over  MgSO4 and concentrated to afford the corresponding 
crude isocyanate. The crude isocyanate and 3-15 (85 mg, 0.15 mmol) were 
dissolved in dichloromethane (4 mL) and stirred at -20 °C for 4-5 min 
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followed by the addition of TEA (68 µL, 0.49 mmol). The reaction mixture 
was stirred at -20 °C for 2.5 h. The crude reaction mixture was purified by 
flash chromatography (ethyl acetate : hexane = 2:3 to 1:1) to afford 3-16a as 
white solid (60%). 1H NMR (500 MHz, CDCl3) δ 7.81 (s, 1H), 7.61 – 7.51 (m, 
2H), 7.42 (d, J = 8.5 Hz, 1H), 7.08 (t, J = 6.5 Hz, 1H), 6.20 (s, 1H), 6.01 (d, J 
= 5.3 Hz, 1H), 4.85 (s, 1H), 4.58 (m, 2H), 4.48 (s, 1H), 4.40 (d, J = 11.3 Hz, 
1H), 3.83 (d, J = 10.5 Hz, 1H), 3.58 (d, J = 10.5 Hz, 1H), 2.58 (m, 1H), 2.51 – 
2.32 (m, 6H), 2.25 (td, J = 6.9, 2.6 Hz, 2H), 1.96 (t, J = 2.5 Hz, 1H), 1.93 – 
1.77 (m, 6H), 1.75 – 1.56 (m, 3H), 1.38 – 1.20 (m, 3H), 0.93 (s, 3H), 0.86 (s, 
9H), 0.80 (s, 3H), 0.00 (d, J = 3.0 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 
172.96, 169.79, 161.38, 154.67, 152.60, 152.50, 151.77, 147.60, 141.38, 
125.69, 124.17, 116.09, 114.87, 113.58, 108.55, 106.52, 83.45, 80.39, 72.16, 
69.43, 68.92, 64.05, 56.35, 55.80, 42.76, 39.45, 38.54, 37.65, 33.55, 26.15, 
25.77, 25.65, 24.67, 24.01, 23.52, 18.85, 18.50, 18.14, 14.63, -5.35, -5.44. 





methylenedecahydronaphthalen-2-yl hex-5-ynoate (3-16b). Same as 3-16a. 
6-acetyl-2-naphthylamine was used as starting material. The crude reaction 
mixture was purified by flash chromatography (ethyl acetate : hexane = 2:3 to 
1:1) to afford 3-16b as white solid (68%). 1H NMR (500 MHz, CDCl3) δ 8.41 
(s, 1H), 8.14 – 7.98 (m, 2H), 7.93 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H), 
7.50 (dd, J = 8.8, 1.6 Hz, 1H), 7.10 (dd, J = 6.7, 5.9 Hz, 1H), 6.04 (d, J = 5.6 
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Hz, 1H), 4.88 (s, 1H), 4.60 (m, 2H), 4.51 (s, 1H), 4.42 (dd, J = 11.4, 0.9 Hz, 
1H), 3.82 (d, J = 10.6 Hz, 1H), 3.57 (d, J = 10.5 Hz, 1H), 2.72 (s, 3H), 2.63 – 
2.54 (m, 1H), 2.53 – 2.34 (m, 4H), 2.26 (m, 2H), 1.96 (t, J = 2.6 Hz, 1H), 1.94 
– 1.77 (m, 6H), 1.76 – 1.63 (m, 3H), 1.42 – 1.20 (m, 3H), 0.93 (s, 3H), 0.86 (s, 
9H), 0.80 (s, 3H), -0.00 (d, J = 3.9 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 
197.85, 172.68, 169.31, 152.46, 151.24, 147.37, 137.17, 136.34, 133.74, 
130.87, 129.90, 129.33, 127.92, 124.92, 123.90, 119.72, 114.7, 108.30, 83.18, 
80.10, 71.85, 69.16, 68.74, 63.80, 56.07, 55.54, 42.48, 39.15, 38.28, 37.38, 
33.28, 26.63, 25.88, 25.45, 25.38, 24.40, 23.75, 23.28, 18.23, 17.87, 14.37, -






2-yl hex-5-ynoate (AP2CM). To a solution of 3-16a (23 mg, 0.03 mmol) in 
methanol : dichloromethane (3 mL, 2 : 1) was added ceric ammonium nitrate 
(74 mg, 0.135 mmol). The resulting mixture was stirred at room temperature 
for 20 h. The crude reaction mixture was subsequently preparative TLC (ethyl 
acetate : hexane = 1 : 1) to afford AP2CM as white solid (34%). 1H NMR 
(500 MHz, CDCl3) δ 7.69 – 7.51 (m, 3H), 7.47 – 7.35 (m, 1H), 7.09 (t, J = 6.6 
Hz, 1H), 6.23 (s, 1H), 6.04 (d, J = 5.4 Hz, 1H), 4.90 (s, 1H), 4.70 (dd, J = 
11.8, 4.1 Hz, 1H), 4.60 (dd, J = 11.3, 5.7 Hz, 1H), 4.52 (s, 1H), 4.43 (d, J = 
11.3 Hz, 1H), 4.14 (d, J = 11.8 Hz, 1H), 3.47 – 3.34 (m, 1H), 2.59 (m, 1H), 
2.54 – 2.36 (m, 6H), 2.29 (m, 2H), 2.06 – 1.94 (m, 2H), 1.92 – 1.75 (m, 6H), 
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1.46 – 1.20 (m, 6H), 1.09 (s, 3H), 0.71 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 
172.26, 169.57, 161.28, 154.69, 152.52, 152.39, 151.21, 146.78, 141.14, 
125.74, 124.36, 116.21, 114.82, 113.71, 109.18, 106.55, 83.13, 82.53, 72.04, 
69.82, 68.93, 63.74, 55.93, 55.73, 42.90, 39.16, 37.90, 37.15, 33.38, 26.16, 
25.70, 24.50, 24.16, 23.82, 22.71, 18.86, 17.99, 15.18. HRMS (ESI, M - 1) 





hex-5-ynoate (AP2NP). Same as AP2CM. The crude reaction mixture was 
subsequently preparative TLC (ethyl acetate : hexane = 1 : 1) to afford 
AP2NP as brown solid (48%). 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 
8.04 (dd, J = 8.5, 1.5 Hz, 2H), 7.94 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.7 Hz, 
1H), 7.48 (d, J = 8.3 Hz, 1H), 7.08 (t, J = 7.3 Hz, 1H), 6.99 (s, 1H), 6.03 (d, J 
= 5.6 Hz, 1H), 4.90 (s, 1H), 4.68 (dd, J = 11.6, 4.2 Hz, 1H), 4.60 (dd, J = 11.4, 
5.8 Hz, 1H), 4.53 (s, 1H), 4.43 (dd, J = 11.4, 1.0 Hz, 1H), 4.11 (m, 2H), 3.36 
(t, J = 11.2 Hz, 1H), 2.72 (s, 3H), 2.57 (m, 1H), 2.52 – 2.38 (m, 3H), 2.27 (m, 
2H), 2.02 – 1.92 (m, 2H), 1.91 – 1.70 (m, 6H), 1.36 (m, 3H), 1.26 (m, 3H), 
1.07 (s, 3H), 0.69 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 198.10, 172.24, 
169.50, 152.70, 151.00, 146.79, 137.38, 136.59, 134.04, 131.17, 130.16, 
129.61, 128.17, 125.22, 124.39, 119.95, 115.01, 109.19, 83.11, 82.53, 72.09, 
69.82, 68.90, 63.73, 55.93, 55.73, 42.90, 39.13, 37.90, 37.15, 33.38, 26.89, 
25.66, 24.49, 24.16, 23.82, 22.71, 17.98, 15.17. HRMS (ESI, M + Na) calcd. 
for  C39H45NNaO8; 678.3037; found 678.3047.  
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Appendix C. Experimental Procedures and Characterization Data for 
Compounds 4 
General Procedures. All chemical reagents and solvents were obtained from 
Sigma Aldrich, Merck, Alfa Aesar, or Fluka and were used without further 
purification. The microwave-assisted reactions were performed using the 
Biotage Initiator microwave synthesizer. Analytical TLC was carried out on 
precoated silica plates (Merck silica gel 60, F254) and visualized with UV 
light or stained with phosphomolybdic acid (PMA) stain. Flash column 
chromatography was performed with silica (Merck, 70-230 mesh). The 
purities of the compounds were determined via HPLC using a Shimadzhu 
LCMS-ITTOF system with a Phenomenex Luma C18 column (50 mm Å~ 3.0 
mm, 5 μm). Compounds used in the biological assays have purities of at least 
95%. 1H and 13C NMR spectra were measured on a Bruker ACF 300 or AMX 
500 Fourier transform spectrometer. Chemical shifts were reported in parts per 
million (δ) relative to the internal standard of tetramethylsilane (TMS). The 
signals observed were described as follows: s (singlet), d (doublet), t (triplet), 
q (quartet), dd (doublet of doublets), m (multiplet). The number of protons (n) 
for a given resonance was indicated as nH. Mass spectra were performed on a 
Finnigan/MAT LCQ mass spectrometer under electron spray ionization (ESI) 
or electron impact (EI) techniques. 
 
Synthesis of 2-((4aR,6aR,7S,10bR)-3,3,6a,10b-tetramethyl-8-
oxodecahydro-1H-naphtho[2,1-d][1,3]dioxin-7-yl)acetaldehyde (4-1a). A 
mixture of compound 4-1 (1 g, 2.56 mmol), dichloromethane (20 mL) and 
pyridine (3 mL) was cooled to -78oC and then bubbled with O3 until 
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completion of reaction (monitored by TLC). The reaction mixture was 
warmed to room temperature, diluted with dichloromethane and extracted with 
aqueous copper sulfate (1 M). The organic layer was dried over magnesium 
sulfate, concentrated and purified by column chromatography (ethyl acetate : 
hexane 1 : 3) to obtain compound 4-1a as a white solid (42%). 1H NMR (300 
MHz, CDCl3) δ 9.82 (s, 1H), 3.95 (d, J = 11.6 Hz, 1H), 3.55 (dd, J = 8.5, 3.9 
Hz, 1H), 3.22 (d, J = 11.6 Hz, 1H), 3.01 (dd, J = 17.6, 9.7 Hz, 1H), 2.84 (d, J 
= 10.9 Hz, 1H), 2.55 – 2.15 (m, 3H), 2.08 – 1.50 (m, 6H), 1.39 (s, 3H), 1.36 
(s, 3H), 1.28 (s, 3H), 0.94 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 209.36, 
200.89, 99.23, 75.85, 63.59, 57.55, 50.72, 41.08, 39.96, 37.85, 37.33, 34.20, 
26.86, 26.19, 25.24, 24.49, 22.10, 17.42. HRMS (FAB, M + 1): calcd. for 
C18H29O4, 309.2060; found 309.2060. 
 
Synthesis of 2-(3,3,6a,10b-tetramethyl-8-methylenedecahydro-1H-
naphtho[2,1-d][1,3]dioxin-7-yl)acetaldehyde (4-1b). Compound 4-1b was 
synthesized using the procedure used for the synthesis of compound 4-1a. The 
crude mixture was purified by flash chromatography (ethyl acetate : hexane  = 
6 : 1) to afford 4-1b as white solid (16%). 1H NMR (500 MHz, CDCl3) δ 9.65 
(d, J = 2.6 Hz, 1H), 4.84 (s, 1H), 4.43 (s, 1H), 3.97 (d, J = 11.6 Hz, 1H), 3.50 
(dd, J = 8.8, 4.1 Hz, 1H), 3.18 (d, J = 11.6 Hz, 1H), 2.57 (ddd, J = 17.0, 11.0, 
3.1 Hz, 1H), 2.47 – 2.39 (m, 2H), 2.34 (d, J = 10.8 Hz, 1H), 2.11 – 1.95 (m, 
2H), 1.85 – 1.70 (m, 2H), 1.63 (ddd, J = 12.9, 7.4, 5.3 Hz, 1H), 1.40 (s, 3H), 
1.36 (s, 3H), 1.34 – 1.24 (m, 3H), 1.21 (s, 3H), 0.92 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 202.78, 147.67, 108.83, 99.09, 76.40, 63.85, 52.25, 50.52, 
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40.02, 37.84, 37.32, 34.61, 27.19, 26.17, 25.35, 25.02, 22.97, 16.46. HRMS 
(FAB, M + 1): calcd. for C19H31O3, 307.2273; found 307.2275. 
 
General procedure for the synthesis of 4-3a to 4-3c.  The corresponding 
-bromo ester (1.0 mmol), triphenylphosphine (1.05 mmol) and 
tetrahydrofuran (2.5 mL) were microwave irradiated at 110C for 1 h. The 
resulting precipitate was filtered and wash with diethylether to obtain the 
Wittig salt. The salt was then dissolved in methanol (10 mL) and 10% aqueous 
sodium hydroxide (30 mL) was added to the solution. The precipitate formed 
was filtered, dried in the vacuum oven for 12 h and used without further 
purification. 
 
General procedure for the synthesis of 4-4a to 4-4e. To a solution of 4-1 
(0.16 mmol) in anhydrous dichloromethane (1.6 mL) was added the 
corresponding ylide 4-3 (0.32 mmol). The mixture was then stirred at room 





d][1,3]dioxin-8(4aH)-one (4-4a). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1: 2 to 1 : 1) to afford 4-4a as a 
white solid (83%). 1H NMR (500 MHz, CDCl3) δ 6.48 (qd, J = 6.1, 2.8 Hz, 
1H), 4.35 (t, J = 7.5 Hz, 2H), 3.92 (d, J = 11.6 Hz, 1H), 3.54 (dd, J = 8.3, 3.7 
Hz, 1H), 3.20 (d, J = 11.6 Hz, 1H), 3.15 – 3.04 (m, 1H), 2.90 – 2.78 (m, 1H), 
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2.63 (dt, J = 14.5, 9.2 Hz, 1H), 2.41 (dd, J = 11.8, 4.4 Hz, 1H), 2.32 – 2.22 (m, 
2H), 2.08 – 2.01 (m, 2H), 2.00 – 1.94 (m, 1H), 1.86 – 1.70 (m, 3H), 1.67 – 
1.56 (m, 2H), 1.45 – 1.41 (m, 1H), 1.38 (s, 3H), 1.35 (s, 3H), 1.25 (s, 3H), 
0.96 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 209.42, 171.29, 139.64, 125.98, 
99.35, 75.62, 65.47, 63.72, 63.12, 50.97, 41.89, 41.39, 38.06, 34.31, 26.65, 
26.21, 25.25, 25.13, 24.50, 23.78, 22.61, 16.99. HRMS (ESI, M + Na) calcd. 




The crude mixture was purified by flash chromatography (ethyl acetate : 
hexane = 1 : 4) to afford 4-4b as a white solid (83%). 1H NMR (500 MHz, 
CDCl3) δ 6.71 – 6.67 (m, 1H), 4.85 (s, 1H), 4.44 (s, 1H), 4.37 (t, J = 7.6 Hz, 
2H), 3.96 (d, J = 11.4 Hz, 1H), 3.50 (dd, J = 8.5, 3.8 Hz, 1H), 3.18 (d, J = 12 
Hz, 1H), 2.88 (dt, J = 7.3, 2.5 Hz, 2H), 2.33 – 2.27 (m, 3H), 1.99 – 1.93 (m, 
1H), 1.86 – 1.70 (m, 4H), 1.41 (s, 3H), 1.36 (s, 3H), 1.31 – 1.23 (m, 4H), 1.20 
(s, 3H), 0.95 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.20, 147.25, 141.69, 
124.76, 108.31, 99.12, 76.21, 65.23, 63.94, 55.94, 52.19, 38.33, 37.91, 37.62, 
34.52, 27.01, 26.13, 25.82, 25.31, 25.25, 24.97, 23.19, 16.19. HRMS (ESI, 2M 




The crude mixture was purified by flash chromatography (ethyl acetate : 
hexane = 1 : 4 to 1 : 3) to afford 4-4c as a white solid (96%). 1H NMR (500 
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MHz, CDCl3) δ 6.47 – 6.42 (m, 1H), 4.64 – 4.62 (m, 1H), 3.91 (d, J = 11.4 
Hz, 1H), 3.53 (dd, J = 8.2, 3.8 Hz, 1H), 3.19 (d, J = 12 Hz, 1H), 2.62 – 2.56 
(m, 2H), 2.42 – 2.38 (m, 2H), 2.28 – 2.22 (m, 2H), 2.03 – 1.95 (m, 4H), 1.85 -
1.58 (m, 4H), 1.39 (d, J = 6.3 Hz, 3H), 1.37 (s, 3H), 1.34 (s, 3H), 0.1.24 (s, 
3H), 0.94 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 209.43, 170.88, 139.37, 
127.38, 99.27, 75.57, 74.08, 63.64, 63.01, 50.85, 41.82, 41.32, 37.97, 34.20, 
32.99, 26.62, 26.60, 26.13, 25.17, 24.42, 23.65, 22.55, 22.18, 16.90. HRMS 




yl)ethylidene)dihydrofuran-2(3H)-one (4-4d). The crude mixture was 
purified by flash chromatography (ethyl acetate : hexane = 1 : 8) to afford 4-
4d as a white solid (80%). 1H NMR (500 MHz, CDCl3) δ 6.65 (dd, J = 12.7, 
6.7 Hz, 1H), 4.85 (s, 1H), 4.71 – 4.60 (m, 1H), 4.43 (s, 1H), 3.96 (d, J = 11.6 
Hz, 1H), 3.49 (dd, J = 8.6, 3.9 Hz, 1H), 3.17 (d, J = 11.6 Hz, 1H), 3.04 – 2.97  
(m, 1H), 2.45 – 2.38  (m, 2H), 2.34 – 2.20 (m, 2H), 2.01 – 1.92 (m, 2H), 1.87 
– 1.68 (m, 4H), 1.43 – 1.39 (m, 6H), 1.36 (s, 3H), 1.31 – 1.26 (m, 3H), 1.19 (s, 
3H), 0.94 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.82, 147.24, 141.45, 
126.13, 108.29, 99.10, 76.21, 73.84, 63.92, 55.94, 55.89, 52.18, 38.32, 37.89, 
37.61, 34.51, 33.09, 27.01, 26.12, 25.75, 25.31, 24.96, 23.18, 22.31, 16.16. 






oxodecahydro-1H-naphtho[2,1-d][1,3]dioxin-7-yl)but-2-enoate (4-4e). The 
crude mixture was purified by flash chromatography (ethyl acetate : hexane = 
1 : 6) to afford 4-4e as a white solid (98%). 1H NMR (300 MHz, CDCl3) δ 
6.94 – 6.75 (m, 1H), 5.79 (d, J = 15.7 Hz, 1H), 3.94 (d, J = 11.6 Hz, 1H), 3.68 
(s, 3H), 3.54 (dd, J = 8.3, 3.5 Hz, 1H), 3.21 (d, J = 11.6 Hz, 1H), 2.76 – 2.64 
(m, 1H), 2.50 – 2.39 (m, 1H), 2.33 – 2.17 (m, 2H), 2.11 – 1.95 (m, 3H), 1.87 – 
1.58 (m, 5H), 1.40 (s, 3H), 1.36 (s, 3H), 1.26 (s, 3H), 0.95 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ 209.46, 166.94, 148.75, 121.69, 99.29, 75.73, 63.65, 
62.96, 51.34, 51.04, 41.93, 41.44, 38.00, 34.23, 26.78, 26.19, 25.44, 25.19, 
24.49, 22.58, 16.97. HRMS (ESI, M + 1) calcd. for  C21H33O5, 365.2323; 
found 365.2329. 
 
General procedure for the synthesis of 4-5a to 4-5e, 4-7a to 4-7c and 4-
11.  To the corresponding compound 4-4, 4-6 or 4-10 (50 mg) in methanol 
(1.5 mL) was added Amberlyst 15 (H+) (60 mg). The mixture was agitated 
with a mechanical shaker for 12 h. The acidic resin was then filtered off and 




2(3H)-one (4-5a) The crude mixture was purified by flash chromatography 
(ethyl acetate/hexane 2:1) to afford compound 4-5a as a white solid (60%). 1H 
NMR (300 MHz, DMSO-d6) δ 6.40 (dt, J = 6.6, 3.0 Hz, 1H), 5.07 (s, 1H), 
4.31 (t, J = 7.4 Hz, 2H), 4.21 (s, 1H), 3.80 (d, J = 11.0 Hz, 1H), 2.92 – 2.80 
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(m, 2H), 2.40 – 2.32(m, 3H), 2.24 – 2.15 (m, 1H), 2.06 – 1.98 (m, 2H), 1.72 - 
1.60 (m, 5H), 1.37 – 1.35 (m, 1H), 1.14 (s, 3H), 0.67 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 210.44, 170.74, 139.52, 125.93, 78.15, 65.35, 62.43, 61.76, 
52.75, 42.35, 41.56, 41.47, 36.37, 27.48, 24.53, 23.41, 23.14, 23.05, 14.86. 




yl)ethylidene)dihydrofuran-2(3H)-one (4-5b). The crude mixture was 
purified by flash chromatography (ethyl acetate : hexane = 1 : 1) to afford 4-
5b as a white solid (70%). 1H NMR (500 MHz, DMSO-d6) δ 6.48 – 6.42 (m, 
1H), 5.04 (d, J = 4.9 Hz, 1H), 4.80 (s, 1H), 4.43 (s, 1H), 4.32 (t, J = 7.4 Hz, 
2H), 4.12 (dd, J = 7.5, 2.8 Hz, 1H), 3.84 (dd, J = 11.0, 2.7 Hz, 1H), 3.28 – 
3.22 (m, 2H), 2.86 (t, J = 6.9 Hz, 2H), 2.32 (d, J = 12.4 Hz, 2H), 2.24 – 2.14 
(m, 1H), 1.93 (td, J = 12.8, 4.6 Hz, 1H), 1.85 (d, J = 10.4 Hz, 1H), 1.75- 1.69  
(m, 2H), 1.65 – 1.60 (m, 2H), 1.35 (td, J = 13.1, 9.0 Hz, 1H), 1.23 – 1.19 (m, 
2H), 1.09 (s, 3H), 0.66 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 170.63, 
147.77, 140.27, 125.60, 107.41, 78.38, 65.25, 62.59, 55.25, 54.31, 42.23, 
38.57, 37.44, 36.44, 27.85, 24.91, 24.58, 23.91, 23.01, 14.65. HRMS (ESI, M 




methyldihydrofuran-2(3H)-one (4-5c). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 2: 1) to afford 4-5c as a white 
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solid (80%). 1H NMR (500 MHz, CDCl3) δ 6.40 (td, J = 7.0, 3.2 Hz, 1H), 5.04 
(s, 1H), 4.76 – 4.50 (m, 1H), 4.19 (s, 1H), 3.82 (d, J = 11.1 Hz, 1H), 3.06 
(ddd, J = 43.3, 16.9, 7.2 Hz, 1H), 2.42 – 2.34 (m, 4H), 2.25 – 2.16 (m, 1H), 
2.05 – 2.00  (m, 2H), 1.72 – 1.62 (m, 5H), 1.41 – 1.33 (m, 1H), 1.32 (d, J = 3.7 
Hz, 3H), 1.16 (s, 3H), 0.68 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 211.32, 
171.11, 140.41, 128.03, 79.11, 74.75, 63.38, 62.70, 53.70, 43.31, 42.51, 42.43, 
37.33, 33.17, 28.45, 24.36, 24.08, 24.00, 22.92, 15.80. HRMS (ESI, M - 1) 




methyldihydrofuran-2(3H)-one (4-5d). The crude mixture was purified by 
flash chromatography (ethyl acetate : hexane = 1 : 1) to afford 4-5d as a white 
solid (70%). 1H NMR (500 MHz, DMSO-d6) δ 6.44 (dd, J = 9.8, 3.8 Hz, 1H), 
5.03 (d, J = 4.8 Hz, 1H), 4.80 (s, 1H), 4.70 – 4.59 (m, 1H), 4.43 (s, 1H), 4.12 
(dd, J = 7.5, 2.7 Hz, 1H), 3.84 (dd, J = 11.0, 2.6 Hz, 1H), 3.28 – 3.19 (m, 2H), 
3.08 – 2.99 (m, 1H), 2.47 – 2.38 (m, 1H), 2.33 – 2.29  m, 2H), 2.22 – 2.13 (m, 
1H), 1.92 (td, J = 12.7, 4.5 Hz, 1H), 1.84 (d, J = 10.5 Hz, 1H), 1.77 – 1.61 (m, 
4H), 1.31 (d, J = 6.2 Hz, 3H), 1.23 (d, J = 9.7 Hz, 2H), 1.08 (s, 3H), 0.65 (s, 
3H). 13C NMR (126 MHz, DMSO-d6) δ 170.09, 147.77, 140.28, 126.72, 
107.42, 78.37, 73.71, 62.59, 55.22, 54.29, 42.23, 38.58, 37.44, 36.44, 32.25, 
27.85, 24.87, 23.92, 23.00, 21.93, 14.65. HRMS (ESI, M - 1) calcd. for  





dimethyl-2-oxodecahydronaphthalen-1-yl)but-2-enoate (4-5e). The crude 
mixture was purified by flash chromatography (ethyl acetate : hexane = 3 : 2 
to 2 : 1) to afford 4-5e as a white solid (72%). 1H NMR (500 MHz, DMSO-d6) 
δ 6.83 – 6.73 (m, 1H), 5.81 (d, J = 15.7 Hz, 1H), 5.01 (d, J = 5.0 Hz, 1H), 4.17 
(dd, J = 7.2, 3.1 Hz, 1H), 3.80 (dd, J = 11.1, 3.1 Hz, 1H), 3.61 (s, 3H), 3.35 
(dd, J = 11.0, 7.2 Hz, 1H), 2.47 – 2.35 (m, 3H), 2.19 (dd, J = 13.2, 4.1 Hz, 
1H), 2.09 (dd, J = 14.0, 7.4 Hz, 1H), 2.00 (dd, J = 12.0, 6.4 Hz, 1H), 1.75 – 
1.58 (m, 5H), 1.31 (td, J = 12.3, 5.9 Hz, 1H), 1.15 (s, 3H), 0.65 (s, 3H). 13C 
NMR (126 MHz, DMSO-d6) δ 210.11, 166.05, 149.61, 120.78, 78.08, 62.33, 
61.34, 52.70, 50.99, 42.26, 41.52, 41.51, 36.32, 27.38, 24.66, 23.37, 23.02, 
14.78. HRMS (ESI, M - 1) calcd. for  C18H27O5 323.1864; found 323.1870 
 
General procedure for the synthesis of 6-6a to 6-6c. To the solution of 4-
1a (0.16 mmol) in anhydrous toluene (1.5 mL) were added rhodanine, 
thiazolidinedione or oxindole (0.19 mmol) and piperidine (0.016 mmol). The 
mixture was heated to 80C and stirred at this temperature for 4 h. The crude 




thioxothiazolidin-4-one (4-6a). The crude mixture was purified by flash 
chromatography (ethyl acetate : hexane = 1 : 3 to 1 : 2) to afford 4-6a as a 
yellow solid (68%). 1H NMR (300 MHz, CDCl3) δ 10.17 (s, 1H), 6.78 (t, J = 
7.7 Hz, 1H), 3.95 (d, J = 11.6 Hz, 1H), 3.57 (dd, J = 8.3, 3.4 Hz, 1H), 3.25 (d, 
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J = 11.6 Hz, 1H), 2.72 – 2.61 (m, 1H), 2.53 – 2.42 (m, 1H), 2.35 – 2.23 (m, 
2H), 2.09 – 1.96 (m, 3H), 1.89 – 1.57 (m, 5H), 1.41 (s, 3H), 1.38 (s, 3H), 1.27 
(s, 3H), 0.97 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 209.20, 193.74, 167.13, 
138.01, 129.55, 99.46, 75.60, 63.57, 62.87, 50.88, 41.61, 41.32, 37.98, 34.38, 
26.70, 26.19, 25.76, 25.24, 24.48, 22.34, 16.94. HRMS (ESI, M - 1) calcd. for  




2,4-dione (4-6b). The crude mixture was purified by flash chromatography 
(ethyl acetate : hexane = 1 : 4 to 1 : 2 ) to afford 4-6b as a yellow solid (78%). 
1H NMR (500 MHz, CDCl3) δ 9.33 (s, 1H), 6.92 (t, J = 7.6 Hz, 1H), 3.98 (d, J 
= 11.6 Hz, 1H), 3.59 (dd, J = 8.6, 3.8 Hz, 1H), 3.27 (d, J = 11.6 Hz, 1H), 2.68 
(ddd, J = 14.6, 9.9, 7.6 Hz, 1H), 2.54 – 2.46 (m, 1H), 2.36 – 2.26 (m, 2H), 
2.11 – 1.99 (m, 3H), 1.90 - 1.84 (m, 1H), 1.81 – 1.74 (m, 1H), 1.71 – 1.60 (m, 
2H), 1.49 – 1.45 (m, 1H), 1.43 (s, 3H), 1.40 (s, 3H), 1.30 (s, 3H), 0.99 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 209.37, 167.16, 165.58, 138.62, 126.61, 99.42, 
75.71, 63.53, 62.77, 50.88, 41.60, 41.28, 37.93, 34.36, 26.78, 26.15, 25.43, 
25.22, 24.50, 22.35, 16.89. HRMS (ESI, M - 1) calcd. for  C21H28NO5S, 




(4-6c). The crude mixture was purified by flash chromatography (ethyl acetate 
: hexane = 1 : 2 to 1 : 1 ) to afford 4-6c as a yellow solid (55%). 1H NMR (500 
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MHz, CDCl3) δ 8.93 (s, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.20 (t, J = 7.7 Hz, 1H), 
7.02 (t, J = 7.6 Hz, 1H), 6.87 (d, J = 7.7 Hz, 1H), 6.81 (t, J = 7.4 Hz, 1H), 3.98 
(d, J = 11.6 Hz, 1H), 3.56 (dd, J = 8.8, 3.4 Hz, 1H), 3.25 (d, J = 11.6 Hz, 1H), 
3.20 – 3.12 (m, 1H), 2.57 (ddd, J = 16.2, 7.6, 3.0 Hz, 1H), 2.51 – 2.41 (m, 
2H), 2.32 (td, J = 13.2, 6.9 Hz, 1H), 2.06 – 1.99 (m, 2H), 1.87 – 1.78 (m, 2H), 
1.71 – 1.61 (m, 2H), 1.51 – 1.45 (m, 1H), 1.41 (s, 3H), 1.38 (s, 3H), 1.29 (s, 
3H), 1.04 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 209.49, 169.80, 141.97, 
141.04, 128.88, 127.79, 123.88, 122.63, 122.07, 110.08, 99.22, 76.02, 63.61, 
63.59, 51.21, 41.72, 41.41, 37.91, 34.63, 27.00, 26.25, 25.32, 24.70, 23.04, 





7a). The crude mixture was purified by flash chromatography (ethyl acetate : 
hexane = 2 : 1) to give compound 4-7a as a yellow solid (74%). 1H NMR (500 
MHz, DMSO-d6) δ 13.56 (s, 1H), 6.65 (t, J = 7.6 Hz, 1H), 5.07 (s, 1H), 4.20 
(s, 1H), 3.80 (d, J = 11.0 Hz, 1H), 2.44 – 2.35 (m, 2H), 2.24 – 2.19 (m, 1H), 
2.09 – 1.97 (m, 2H), 1.78 – 1.60 (m, 5H), 1.39 – 1.32 (m, 1H), 1.15 (s, 3H), 
0.68 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 210.19, 196.17, 167.82, 
138.01, 128.85, 78.06, 62.39, 61.49, 52.67, 42.35, 41.45, 41.38, 36.35, 27.44, 
25.39, 23.29, 23.16, 14.86. HRMS (ESI, M + Na) calcd. for C18H25NNaO4S2, 






dione (4-7b). The crude mixture was purified by flash chromatography (ethyl 
acetate : hexane = 2 : 1 to 1 : 0 ) to afford 4-7b as a yellow solid (80%). 1H 
NMR (500 MHz, DMSO-d6) δ 12.32 (s, 1H), 6.74 (t, J = 7.4 Hz, 1H), 5.06 (d, 
J = 4.7 Hz, 1H), 4.19 (d, J = 4.3 Hz, 1H), 3.79 (d, J = 10.9 Hz, 1H), 3.37 (d, J 
= 6.7 Hz, 1H), 3.31 – 3.27 (m, 1H), 2.48 (d, J = 2.0 Hz, 1H), 2.42 – 2.33 (m, 
2H), 2.20 (dd, J = 12.4, 3.5 Hz, 1H), 2.06 – 1.99 (m, 2H), 1.71 (dd, J = 13.1, 
4.5 Hz, 1H), 1.67 – 1.60 (m, 4H), 1.39 – 1.29 (m, 1H), 1.14 (s, 3H), 0.66 (s, 
3H). 13C NMR (126 MHz, DMSO-d6) δ 210.17, 167.74, 166.15, 137.56, 
126.45, 78.04, 62.37, 61.43, 52.66, 42.33, 41.39, 36.33, 27.42, 24.93, 23.30, 





The crude mixture was purified by flash chromatography (ethyl acetate : 
hexane = 4 : 1 to 8 : 1 ) to afford 4-7c as a yellow solid (92%). 1H NMR (500 
MHz, DMSO-d6) δ 10.35 (s, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.21 (t, J = 7.7 Hz, 
1H), 6.99 (t, J = 7.6 Hz, 1H), 6.84 (d, J = 7.7 Hz, 1H), 6.60 (t, J = 7.1 Hz, 1H), 
5.04 (d, J = 4.9 Hz, 1H), 4.19 (dd, J = 7.1, 2.9 Hz, 1H), 3.83 (dd, J = 11.0, 2.6 
Hz, 1H), 3.38 (dd, J = 11.0, 7.2 Hz, 1H), 2.93 – 2.76 (m, 1H), 2.60 (dd, J = 
9.4, 2.5 Hz, 1H), 2.53 (dd, J = 7.2, 3.0 Hz, 1H), 2.47 – 2.40 (m, 1H), 2.25 – 
2.21 (m, 1H), 2.08 – 2.00 (m, 1H), 1.81 – 1.56 (m, 5H), 1.39 (td, J = 12.7, 4.6 
Hz, 1H), 1.16 (s, 3H), 0.76 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 210.48, 
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168.01, 141.94, 141.39, 128.77, 127.27, 123.73, 122.13, 121.29, 109.57, 
78.10, 62.40, 62.29, 52.68, 42.30, 41.47, 41.44, 36.41, 27.45, 23.36, 23.06, 
22.42, 14.90. . HRMS (ESI, M - 1) calcd. for  C23H28NO4, 382.2024; found 
382.2034. 
 
Synthesis of 1-methyl-3-(methyldiphenylsilyl)pyrrolidin-2-one (4-9). To 
a solution of N-methyl-2-pyrrolidone (145 L, 1.5 mmol) in anhydrous 
tetrahydrofuran (3 mL) at -78oC was added lithium diisopropylamide (LDA; 
0.9 mL, 1.8 mmol) dropwise. The reaction mixture was stirred at -78oC for 30 
min. Subsequently chlorodiphenylmethylsilane (0.32 mL, 1.5 mmol) was 
added dropwise and the reaction mixture was further stirred at -78oC for 1 h. 
After that the reaction mixture was warmed up to room temperature and stirred 
for an additional 1 h. The reaction mixture was then diluted with hexane and 
washed with saturated NH4Cl and water. The organic layer was dried over 
MgSO4, concentrated and purified by flash chromatography (ethyl acetate : 
hexane = 1 : 2 to 1 : 1) to afford 4-9 as a colorless liquid (67%). 1H NMR (300 
MHz, CDCl3) δ 7.60 (ddd, J = 9.3, 7.4, 1.8 Hz, 4H), 7.43 – 7.25 (m, 6H), 3.09 
(td, J = 9.3, 3.9 Hz, 1H), 2.65 (s, 3H), 2.55 (dd, J = 10.4, 4.7 Hz, 1H), 2.30 – 
2.10 (m, 1H), 1.94 (ddd, J = 12.8, 8.6, 4.3 Hz, 1H), 1.23 (t, J = 7.1 Hz, 1H), 
0.69 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 175.89, 134.62, 129.29, 127.59, 
127.50, 48.35, 30.90, 29.12, 20.42, -4.62. HRMS (ESI, M + Na) calcd. for  







yl)ethylidene)pyrrolidin-2-one (4-10). To the solution of 4-1b (60 mg, 0.19 
mmol) in anhydrous tetrahydrofuran (1 mL) at -78oC was added lithium 
diisopropylamide (LDA; 0.14 mL, 0.27 mmol) dropwise. The reaction mixture 
was stirred at -78oC for 30 min. Subsequently 4-9 (60 mg, 0.23 mmol) in 
anhydrous tetrahydrofuran (1 mL) was added to the reaction mixture at -78oC. 
The reaction mixture was warmed up to room temperature and stirred for 3.5 
h.  The reaction mixture was then diluted with ethyl acetate and washed with 
saturated NH4Cl and water. The organic layer was dried over MgSO4, 
concentrated and purified by flash chromatography (ethyl acetate : hexane = 2 
: 1) to afford 4-10 as a white solid (14%). 1H NMR (500 MHz, CDCl3) δ 6.05 
– 5.93 (m, 1H), 3.99 (d, J = 11.6 Hz, 1H), 3.56 – 3.46 (m, 1H), 3.41 – 3.34 (m, 
1H), 3.29 (dd, J = 13.8, 6.8 Hz, 2H), 3.20 (d, J = 11.5 Hz, 1H), 2.85 (s, 3H), 
2.58 (s, 2H), 2.37 (dd, J = 13.4, 2.6 Hz, 1H), 2.32 – 2.18 (m, 3H), 2.02 – 1.98 
(m, 3H), 1.89 – 1.81 (m, 2H), 1.66 - 1.54 (m, 3H), 1.39 (s, 3H), 1.34 (s, 3H), 
1.26 (s, 3H), 0.90 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 211.63, 168.70, 
135.48, 129.32, 98.70, 77.07, 64.65, 63.33, 51.70, 46.46, 42.17, 41.62, 37.54, 
34.22, 29.83, 27.94, 26.24, 25.40, 25.33, 25.22, 22.64, 20.10, 16.37. HRMS 









methylpyrrolidin-2-one (4-11). The crude mixture was purified by flash 
chromatography (dichloromethane : methanol = 97 : 3 to 95 : 5) to afford 4-11 
as a white solid (70%). 1H NMR (500 MHz, DMSO-d6) δ 5.73 (ddd, J = 7.7, 
5.9, 2.1 Hz, 1H), 5.02 (d, J = 5.0 Hz, 1H), 4.17 (dd, J = 7.2, 3.1 Hz, 1H), 3.81 
(dd, J = 11.0, 3.1 Hz, 1H), 3.34 (dd, J = 10.6, 7.7 Hz, 1H), 3.29 – 3.25 (m, 
2H), 3.24 – 3.16 (m, 1H), 2.75 (s, 3H), 2.57 – 2.52 (m, 2H), 2.34 (td, J = 13.0, 
6.9 Hz, 1H), 2.27 – 2.14 (m, 3H), 2.02 – 1.93 (m, 1H), 1.71 – 1.57 (m, 5H), 
1.40 – 1.32 (m, 1H), 1.14 (s, 3H), 0.65 (s, 3H). 13C NMR (126 MHz, DMSO-
d6) δ 210.91, 167.51, 134.50, 129.37, 78.19, 63.35, 62.39, 52.93, 45.56, 42.28, 
41.74, 41.64, 36.39, 29.34, 27.47, 24.90, 23.48, 23.05, 19.30, 14.87. HRMS 




(4-12). A reaction mixture of andrographolide (0.19 g, 0.54 mmol) in pyridine 
(2 ml) and acetic anhydride (1 mL) was stirred at room temperature for 12 h. 
The reaction mixture was then diluted with ethyl acetate and washed with 
copper sulfate solution (1 M). The organic layer was then concentrated and 
purified by flash column chromatography (ethyl acetate/hexane 1:4) to give 
compound 4-12 as a white solid (46%). 1H NMR (300 MHz, CDCl3) δ 6.99 (s, 
1H), 6.69 (t, J = 7.6 Hz, 1H), 6.15 (d, J = 3.5Hz, 1H), 4.86 (s, 1H), 4.59 (dd, J 
= 11.4, 4.7 Hz, 1H), 4.43 (s, 1H), 4.37 (d, J = 11.7 Hz, 1H), 4.10 (d, J = 11.7 
Hz,1H), 2.51 – 2.33 (m, 3H), 2.03 (s, 6H), 1.94 – 1.32 (m, 9H), 1.02 (s, 3H), 
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0.77 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.88, 170.50, 167.87, 146.44, 
145.44, 143.88, 125.84, 108.77, 104.91, 79.66, 64.63, 56.00, 55.19, 41.22, 
39.04, 37.82, 37.01, 25.86, 24.54, 24.17, 22.62, 21.13, 21.04, 14.55. HRMS 





X-ray crystal data of 4-10 
Identification code  yl229 
Empirical formula  C23 H35 N O4 
Formula weight  389.52 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 7.1095(6) Å = 90°. 
 b = 11.5528(10) Å = 94.766(2)°. 
 c = 12.9169(11) Å  = 90°. 
Volume 1057.26(16) Å3 
Z 2 
Density (calculated) 1.224 Mg/m3 
Absorption coefficient 0.082 mm-1 
F(000) 424 
Crystal size 0.50 x 0.20 x 0.16 mm3 
Theta range for data collection 1.58 to 27.49°. 
Index ranges -9<=h<=9, -15<=k<=14, -16<=l<=12 
Reflections collected 7502 
Independent reflections 4376 [R(int) = 0.0513] 
Completeness to theta = 27.49° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9869 and 0.9599 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4376 / 1 / 258 
Goodness-of-fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.0687, wR2 = 0.1486 
R indices (all data) R1 = 0.0988, wR2 = 0.1660 
Absolute structure parameter 1.4(18) 










Appendix D. NMR Spectra of Some Intermediates and Analogues1 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          295.8 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off















































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :             53
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          296.2 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577970 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



































































































































































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          296.7 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :            122
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          297.2 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577934 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off


























































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          295.5 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



















































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :             52
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          296.3 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577990 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off








































































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
TD :          32768
TE :          298.0 K
*** Processing Parameters ***
LB :           0.10 Hz
SF :    500.2300090 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :             55
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          295.8 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577950 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off


















































































































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          296.5 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



























































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :             52
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          297.0 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577950 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off


















































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :             10
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          298.0 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



























































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :           1527
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          298.4 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577910 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off






















































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          299.9 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off




























































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :           1502
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          300.0 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577907 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off









































































































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          295.7 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    500.1300140 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off







































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :            205
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          296.6 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577950 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off






































































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :              8
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
TE :          294.8 K
*** Processing Parameters ***
LB :           0.30 Hz
SF :    500.1300130 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



























































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :            202
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          295.8 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577950 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         22.409 degree

































































































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            649
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : DMSO
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        171.605 degree
PHC1 :          2.064 degree
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